Prevention of colorectal cancer in Scotland: strategies for those at increased genetic risk by Mitchell, Rory J.
Prevention of Colorectal Cancer in Scotland: Strategies for
those at Increased Genetic Risk
Rory J. Mitchell





(i) That this thesis is composed by myself
(ii) That the work presented within this thesis is my own unless
otherwise stated






Many thanks to Harry Campbell, Mary Porteous and Malcolm Dunlop, for their
supervision and support over the course ofmy studentship.
I would like to acknowledge the following people for their contribution to the research
presented in this thesis:
Susan Farrington for her help in assessing pathogenicity ofmismatch repair gene
variants. Norma Brown and Alison Fordyce for their work in conducting interviews and
constructing pedigree files during the initial construction of the family history data set.
David Brewster and the Staff at ISD for organising the record linkage process, and for
making me welcome at the ISD HQ. Jeff Lloyd for programming the computer model,
and Gus Ferguson for his collaboration and advice throughout the computer modelling
project.
Thanks also to Robin Mitchell and Richard Storton for help with proofreading my
thesis, and extra thanks to Helen Rice for proofreading and providing support,
encouragement and lasagne during my write-up.
A special thank-you to Rosa Bissett, who knows everything and was always willing to
help me out. Thanks also to Rachel, Maureen and the rest of the SOCCS team.
Finally, I'd like to acknowledge Helen Eborall, Lisa Hanna, Lorna Sibbett, Igor Rudan,
and the rest ofmy "PhD peers", for all their support.
111
Abbreviations
CI = Confidence Interval
COGS = Colorectal Cancer Genetic Susceptibility Study Programme
CSO = Chief Scientist Office
FAP = Familial Adenomatous Polyposis
FDR = First Degree relative
FOBT = Faecal Occult Blood Test
GUI = Graphical User Interface
HNPCC = Hereditary Non-Polyposis Colorectal Cancer
ISD = Information and Statistics Division
MMR = Mismatch Repair
MSI = Microsatellite Instability
NYSIIS = New York State Intelligence Information System
OR = Odds Ratio
ORmh = Mantel Haenszel estimator for the Odds Ratio
RR = Relative Risk
SCR = Scottish Cancer Registry
SDR = Second Degree Relative
UML = Unified Modelling Language
IV
Abstract
The identification ofpeople at increased genetic risk of colorectal cancer and the
provision of appropriate clinical screening represents one approach to the prevention of
colorectal cancer in the Scottish population. This thesis aims to contribute to current
knowledge regarding the available tools for identifying those at increased genetic risk
in a population, namely genetic testing and family history assessment.
Key issues relating to the use of family history in this context were addressed through
the analysis of a unique data set, comprising family history information reported by a
colorectal cancer case or control subject at interview and the results of record linkage
of this data to the Scottish Cancer Registry. Retrospective family history case-control
analysis showed that individuals with an affected first-degree relative were at an
increased risk of developing colorectal cancer (ORimh 2.14, 95% CI = 1.11, 4.14).
Prevalence of such a family history in control subjects was 9.4% (95% CI = 4.9, 13.9).
Substantial under-reporting of family history was evident, with sensitivity of interview
as a means of determining a history of colorectal cancer in a first-degree relative being
approximately 0.55 for both cases and controls. These studies illustrate the potential
advantages of targeting people with a family history, but also highlight some of the
limitations of such an approach.
The genetic epidemiology of the mismatch repair genes hMLH 1 and hMSH2 and their
association with colorectal cancer was considered in a systematic literature review.
Although conventional epidemiological studies are lacking, there is compelling
evidence to implicate mutations in these genes in the aetiology of a sub-set of
colorectal cancers, with penetrance of approximately 80% in males and 40% in
females. A total of 550 different published gene variants were identified, and this high
degree of heterogeneity was illustrated in a unique database. This review indicates that
carriers ofmismatch repair gene mutations merit particular consideration in the context
of colorectal cancer prevention through targeting people at increased genetic risk.
Accordingly, the challenge of identifying asymptomatic mismatch repair gene mutation
carriers in Scotland was addressed through the development of a computer model of
cascade genetic testing, a strategy in which a mutation is identified in one family
v
member and systematically traced through a pedigree. The model predicts that
application of cascade genetic testing to colorectal cancer cases < 55 years of age over
a twenty- year period would involve testing 7142 patients and 849 relatives of known
carriers, and would identify 321.2 (95%CI = 305.3, 337.1) asymptomatic mutation
carriers, representing approximately 27% of the estimated 1209 carriers in Scotland.
Model outcomes were highly sensitive to the prevalence and penetrance of mutations,
and the participation rates of those offered testing. Overall, outcomes from this
computer model suggest that cascade genetic testing is potentially a useful means of
identifying asymptomatic mismatch repair gene mutation carriers in Scotland. Follow-
up work should ensure that it is also of practical importance as a tool for planning
research and health policy.
Identification and screening ofmismatch repair gene mutation carriers is an important
approach to colorectal cancer prevention, but is only relevant to a minority of people at
increased genetic risk. Hence, despite inherent limitations, family history remains a
crucial tool for genetic risk assessment in a population. An integrated approach to the
prevention of colorectal cancer through targeting people at increased genetic risk can
potentially provide substantial health benefits to a sub-group of the population, and thus
contribute to the overall prevention of colorectal cancer in Scotland.
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1.1 Genetics of Colorectal Cancer: A Public Health Perspective
Many common complex diseases have a hereditary genetic component to their aetiology,
and hence a proportion of healthy individuals in a population are at increased genetic risk
of developing a specific condition. At present, there is considerable interest in
understanding the genetic basis of disease susceptibility, driven both by the desire to further
scientific knowledge, and by the hope that this knowledge may lead to novel treatments and
prevention strategies. One strategy for disease prevention is to identify people at increased
genetic risk and thus provide an opportunity for intervention, either to reduce the absolute
risk of disease to that individual or to identify and treat the disease at an early stage.
Previously, people at increased genetic risk were identified solely on the basis of their
family history, but recent advances in understanding of molecular genetics have provided
the potential for more accurate risk assessment.
Colorectal cancer provides a paradigm for the use of genetic information to reduce the
burden of a common complex disease. It is a significant public health problem, and a
proportion of cases are directly attributable to genetic predisposition. The molecular basis
of this predisposition is now understood to some extent, although clinically, most "high-
risk" individuals are identified through their family history. Furthermore, clinical
intervention strategies, considered in detail later, are available for prevention or early
detection of colorectal tumours, and these can be targeted to the sub-group of the
population at increased genetic risk.
2
Currently, devising and implementing strategies for preventing colorectal cancer through
targeting people at increased genetic risk provides a major challenge and a significant
opportunity for the scientific and medical community. Rapidly advancing knowledge of the
molecular genetics involved offers huge potential in this regard, but genuine health benefits
will only result if such knowledge is applied accurately, appropriately, and in a manner that
is complementary to existing strategies based on familial aggregation. Conversely, the
relevance and application of family history information must be further evaluated, and
considered in the context of genetic testing.
1.2 Descriptive Epidemiology of Colorectal Cancer
Worldwide, colorectal cancer is a major public health problem, with a current annual
incidence approaching 950,000 cases (118). The incidence rate of colorectal cancer
increases with advancing age, and the disease is more common in males than in females.
Globally, incidence rates are variable and are about four times higher in developed
countries than in developing countries (119).
These trends are reflected in the cancer statistics for Scotland, where the annual number of
colorectal cancer registrations currently exceeds 1800 cases in males, and 1600 cases in
females, making this the third most common malignancy in both sexes (123). Over the ten-
year period up to 1998. incidence rates have increased by 22.8% in males and 2.4% in
females (123), an observation that may be partly due to the ageing population in Scotland.
Incidence increases with age in both sexes, being exceedingly rare in people under thirty
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years of age, and increasing rapidly beyond age 50 (102). Overall, lifetime risks of
developing colorectal cancer are 5.2% and 4.6% in males and females respectively, and
annual mortality over the last five years for which data are available (1997-2001) averaged
856 deaths in males and 780 deaths in females (123).
Colorectal cancer therefore presents a significant public health problem both globally and
within Scotland, and consequently much research has been conducted with the aim of
identifying and optimizing strategies for prevention of this disease.
1.3 Clinical Characteristics of Colorectal Cancer
The development of most colorectal cancers is considered to follow an adenoma-
adenocarcinoma sequence (108). Broadly speaking, tumorigenesis follows the "two-hit"
principle originally proposed by Knudson (144). The earliest detectable lesion is a
disruption of the normal micro-architecture of the colon to form Aberrant Crypt Foci,
which in turn may develop into adenomatous or non-adenomatous polyps. Adenomatous
polyps occur quite frequently in the general population (311), and in many cases do not
develop further. However, such lesions have the potential to undergo malignant
transformation, thus completing the sequential development of colorectal carcinoma.
The process of colorectal cancer tumorigenesis is a slow one, with the timeframe for the
adenoma-carcinoma sequence being in the region of 10-15 years. However, symptoms
often do not develop until the process is well advanced. These factors provide a rationale
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for prevention of colorectal cancer through screening for early lesions, which is considered
in detail later.
In the absence of screening, patients first present to their general practitioners with
symptoms suggestive of colorectal cancer, and are referred to secondary care for a full
diagnostic work-up and treatment. The principal treatment method for colorectal cancer is
surgical excision, and this may be supplemented with radiotherapy and/or chemotherapy.
As with all cancerous lesions, the key to optimal treatment is early detection. To some
extent, early diagnosis may be achieved by raising public awareness of the symptoms and
risks of colorectal cancer. Providing rapid diagnosis and immediate treatment is, of course,
also beneficial. Unfortunately, due to the late onset and non-specific nature of colorectal
cancer symptoms, the majority of cases are not diagnosed until they reach an advanced
stage, by which time metastasis may have taken place and removal of the primary tumour
may be difficult or impossible. Overall, five-year survival following a diagnosis of
colorectal cancer in Scotland is approximately 45% (123), with the major factor
determining the success of treatment being stage at diagnosis.
1.4 Environmental Factors Influencing Colorectal Cancer Risk
While incidence rates are subject to geographical variation (119), and may also vary
according to ethnicity (9), and there is compelling evidence that the observed differences
are primarily due to the role of environmental factors. This hypothesis is supported by the
rising incidence of colorectal cancer in populations undergoing rapid economic
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development, with associated "westernization" of diet and lifestyle (118, 251). Further
evidence for a strong environmental influence comes from migrant data; despite the
relatively low incidence of colorectal cancer in Japan, incidence rates in Hawaiian Japanese
are among the highest in the world (217). Accordingly, considerable effort and resources
have been expended with the aim of elucidating the precise dietary and other variables
responsible for the observed environmental influences on colorectal cancer incidence.
A report commissioned by the World Cancer Research Fund and the American Institute for
Cancer Research concluded that evidence was sufficient to suggest that adherence to a diet
high in vegetables and low in meat, together with regular physical activity and avoidance of
alcohol, could substantially reduce colorectal cancer risk (314). Other reviews (223) and
publications by the International Agency for Research on Cancer (124-126) have reached
similar conclusions, although direct evidence supporting the hypothesis that dietary
modification can prevent colorectal cancer is not available. Clinical intervention studies (8,
247) and observational cohort studies (79), as well as studies utilizing animal models (234,
281), have shown no evidence of polyp prevention related to diet. Nonetheless, polyp
prevention may not be the best endpoint, so results of further clinical studies with cancer
prevention as the endpoint are awaited.
In addition to dietary factors, an association between hormone replacement therapy and
colorectal cancer has been reported by a number of case-control and cohort studies, with
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the majority of these providing evidence in favor of a protective effect (223). The weight of
evidence also suggests that smoking may be a significant risk factor (88).
Physical activity has consistently been associated with reduction of colorectal cancer risk
(24, 61, 90, 101, 193, 208, 255, 273), although precise data relating to the type and duration
of exercise required and the magnitude of the effect on risk remains comparatively scarce.
Accumulating evidence also implicates obesity as a risk factor for colorectal cancer (85,
252), and a positive association may exist between colorectal cancer and diabetes (155,
156). It has been hypothesized that hyperinsulinaemia may be an important risk factor for
colorectal cancer, and that this association may explain the observed effects of obesity,
exercise and diabetes on colorectal cancer risk (87, 89, 143, 208).
1.5 Genetic Susceptibility to Colorectal Cancer
Colorectal cancer is a multifactorial condition, and while environmental factors are clearly
important in the aetiology of the disease, there is a significant input from genetic factors.
Twin studies have provided classic epidemiological evidence for genetic susceptibility to
colorectal cancer (106, 168), with a recent large-scale twin study suggesting that about 35
percent of all colorectal cancer cases have a genetic component to their aetiology (168).
The most compelling evidence of genetic susceptibility, however, comes from observations
of familial aggregation and molecular genetic studies.
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1.5.1 Familial Aggregation
The genetic factors involved in colorectal cancer are poorly understood and may include
dominant genes, recessive genes, pathogenic mutations of low penetrance, and complex
gene-gene and gene-environment interactions. Recently, research has begun to unravel
some of these factors, particularly those that confer genetic susceptibility in an autosomal
dominant manner. From an historical perspective, however, it is the tendency for familial
aggregation of colorectal cancer that has formed the basis of our understanding of the
genetic nature of the disease. The observed patterns of familial aggregation, and the
associations between this aggregation and other clinical features, have traditionally
provided a means of classification for hereditary cancer syndromes, and have informed
genetic risk assessment and clinical practice. Although new understanding regarding the
molecular genetic factors involved has prompted some revision of previous classification
and clinical management, familial aggregation continues to be the mainstay of clinical
genetics, providing a simple means of identifying people at increased genetic risk and
evaluating their risk.
1.5.1.1 Rare Hereditary Colorectal Cancer Syndromes
Several "cancer family syndromes" can be clearly defined on the basis of their clinical
characteristics. The most common of these syndromes is Familial Adenomatous Polyposis
(FAP), which is characterized by a very early development of multiple adenomas, ranging
up to several thousand in number. FAP is inherited in an autosomal dominant fashion.
Penetrance approaches 100%, and the average age at onset of cancer is around 44 years.
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Other rare syndromes which confer an increased risk of colorectal cancer include Peutz-
Jeghers syndrome, characterized by mucocutaneous pigmentation and hamartomatous
polyps of the large bowel, and Juvenile Polyposis, in which hamartomatous polyps occur
during childhood.
Collectively, these syndromes account for approximately 0.1% of colorectal cancer cases
(223). They are thus of limited importance from a wider public health perspective, and
affected families have been extensively studied on account of the relative ease of clinical
diagnosis. Consequently, this thesis is not concerned with the above syndromes, and
focuses instead on the more common Hereditary Non-Polyposis Colorectal Cancer
syndrome (HNPCC), and the wider aspects of familial aggregation and genetic risk of
colorectal cancer.
1.5.1.2 Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
As the name suggests. Hereditary Non-Polyposis Colorectal Cancer syndrome is a term
applied to colorectal cancer cases that are apparently hereditary in origin but do not exhibit
extensive polyposis and are thus not considered to have one of the above syndromes. In the
HNPCC syndrome, affected kindreds have an unusually high occurrence of colorectal and
certain extracolonic cancers, with a relatively early age of onset. Historically, the first
documented HNPCC kindred was identified by the pathologist Alfred Warthin in 1913
(298), who was alerted to the presence of the affected family by the prediction of his
seamstress, based on her family history, that she would die of cancer. The study of this
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family was re-visited by Lynch and colleagues in the 1960's and 70's (183, 185). Henry T.
Lynch is credited with characterizing the HNPCC syndrome; hence the term "Lynch
Syndrome' which is used to describe the condition in some publications.
The most common extracolonic malignancy that occurs as part of the HNPCC spectrum is
endometrial cancer, and other tumours that occur more rarely include those of the ovary,
stomach, hepatobiliary tract, brain, skin, renal pelvis and ureter. Other clinical and
pathological features have been associated with colorectal tumours occurring in people with
HNPCC, as opposed to ostensibly 'sporadic' colorectal cancer. These include poor
differentiation, an excess of signet-cell and mucoid features, infiltrating leukocytes and a
propensity for the right-sided colon. However, none of these features are pathognomic, and
hence HNPCC has traditionally been diagnosed and defined exclusively on the basis of
family history.
The limitations of family history as a means of diagnosing or defining a clinical condition
are well recognized, and are considered in more detail later. Essentially, the number of
cases within a family will depend upon chance and family size, as well as the extent of
familial risk. Definitions of familial risk are thus open to interpretation, and consequently
various criteria have been used in the past to define people at high risk, or to diagnose
people with HNPCC. In 1991 a set of criteria were proposed by the International
Collaborative Group on HNPCC, with a view to standardizing criteria used for
epidemiological studies, and thus facilitating unbiased comparisons (283). The Amsterdam
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Criteria, as these proposed criteria became known, have become widely accepted as the
basis for a diagnosis of empirically defined HNPCC. Subsequently, revised criteria,
referred to as the Modified Amsterdam Criteria, or Amsterdam II, have been published with
a view to including families that exhibit extracolonic cancers as part of the HNPCC
syndrome (15). Slightly different criteria have been used in several studies in Asia
(Japanese Criteria)(82), and the less stringent "Bethesda" criteria have also been suggested
to include a larger proportion of the spectrum of people at increased genetic risk (236).
These criteria are presented in table 1.1.
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Three relatives with colorectal cancer, one of which is a first-degree relative of
the other two; colorectal cancer affecting more than one generation; at least one
colorectal cancer case diagnosed before age 50 years
Two colorectal cancer cases in first-degree relatives in very small families that
cannot be expanded further; colorectal cancer affecting more than one generation;
at least one colorectal cancer case diagnosed before age 55 years
Two first-degree relatives affected by colorectal cancer, plus a third relative with
an unusually early-onset neoplasm or endometrial cancer
Three or more colorectal cancer cases among first-degree relatives
Two or more colorectal cancers among first-degree relatives and any of the
following: diagnosis before age 50 years; right colon involvement; synchronous
or metachronous multiple colorectal cancers; association with extracolonic
malignancy
Individuals from families that fulfill the Amsterdam criteria
Individuals with two HNPCC-related cancers, including synchronous and
metachronous colorectal cancers or associated extracolonic cancers
Individuals with colorectal cancer, plus colorectal cancer and/or HNPCC-related
extracolonic cancer and/or colorectal adenoma in a first-degree relative; at least
one of the cancers diagnosed before age 45 years and the adenoma diagnosed
before age 40 years
Individuals with colorectal or endometrial cancer diagnosed before age 45 years
Individuals with right-sided colorectal cancer with an undifferentiated
histopathologic pattern (solid/cribiform) diagnosed before age 45 years
Individuals with signet-ring cell type colorectal cancer diagnosed before age 45
years
Individuals with colorectal adenomas diagnosed before age 40 years
* Fulfillment of any of the criteria listed is sufficient, t Cases can be classified as fulfilling either the first set
of criteria or the second set and can be diagnosed with hereditary nonpolyposis colorectal cancer if they fulfill






For research purposes, the Amsterdam criteria are the most widely used, and by this
definition of HNPCC, the syndrome may account for 1-5 percent of all colorectal cancer
cases (49, 138, 195).
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The lifetime risk of colorectal cancer for an individual with HNPCC defined solely on the
basis of meeting the empirical Amsterdam family history criteria is approximately 40%
(291), and the average age of onset is approximately 44 years. In relative terms, the risk of
colorectal cancer for an individual with HNPCC, as compared to the general population,
will decline with age. Voskuil et al., found that the cumulative incidence ratio in HNPCC
family members compared to the general population decreased from 148 at age 40 to 11 by
age 75 (291). In reality, where the cause of HNPCC in a family is a gene defect inherited in
a true autosomal dominant fashion, the family will comprise a mixture of people at an
extremely high risk, and people without the defect, who will have an actual risk no greater
than the rest of the general population. As discussed later, the ability to make this
distinction is one of the major advantages of genetic testing.
1.5.1.3 Familial Risk In People Not Meeting Empirical Criteria For HNPCC
The complex molecular basis of genetic susceptibility is likely to involve numerous genes,
which may be expressed in a recessive or dominant manner with varying penetrance. These
genes may interact with each other, or with environmental risk factors. The extent of the
genetic contribution to the aetiology of colorectal cancer, and the precise nature of that
contribution, will therefore vary considerably between different cases. Accordingly, a
spectrum of genetic risk is evident in a given population, and thus individuals with a family
history of colorectal cancer that does not meet the specified criteria for HNPCC may still be
at increased genetic risk of colorectal cancer. Quantifying the extent of genetic risk
associated with a specific family history presents a major challenge both in the research and
clinical context, and a body of published evidence addressing this issue is now available.
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Numerous studies have suggested that a relatively high number of colorectal cancer patients
have a family history of the disease, as opposed to controls, and such observations suggest
a degree of heritability (153, 157). Better quality evidence is now available from case-
control (22, 25, 70, 141, 149, 153, 157, 160, 205, 206, 222, 239, 256, 260, 272) and cohort
studies (39, 78, 92, 136, 179), which have directly compared the colorectal cancer
experience of relatives of cases with relatives of controls, or with the general population,
thus quantifying the magnitude of the relative risk. A systematic review and meta-analysis
of such studies, conducted by Johns et alproduced an estimate of relative risk for a first-
degree relative of a colorectal cancer case of 2.25 (95% CI = 2.00, 2.53) (134). The same
meta-analysis showed that individuals with more than one affected first-degree relative
have a relative risk of 4.25 (95% CI = 2.40, 6.22), and that people with a first-degree
relative diagnosed at less than 45 years of age have a relative risk of 3.87 (95% CI = 2.40,
6.22) (134).
Broadly speaking, familial risk increases with extent of family history, i.e. the number of
affected relatives and the degree of relationship with the person in question, and the risk is
also greater when the affected relative(s) were diagnosed at a young age. Although the
above studies have provided information on the relative risk relating to various sub-groups
of the population with a family history of colorectal cancer, assessment of the absolute risk




Recent advances in understanding of genetics, and in the available technology for research
in the field of genetic epidemiology, have made the definition of the molecular changes that
underlie genetic susceptibility to complex disease a realistic goal.
Polymorphisms in genes coding for enzymes involved in carcinogen metabolism have been
implicated in modification of colorectal cancer risk. Several carcinogens, including dietary
heterocyclic amines, act as substrates for the N-acetyltransferase enzymes NAT1 and
NAT2, providing a clear rationale for an association between polymorphisms in these genes
and risk of colorectal cancer. However, evidence in support of this hypothesis is
inconclusive, with recent literature reviews and meta-analyses concluding that no consistent
association between N-acetyltransferase and colorectal cancer risk has been demonstrated
(28. 48, 320) and that further studies in this area are required. Similarly, the role of the
glutatione S-transferase family of enzymes in the metabolism of a range of carcinogens has
prompted the investigation of the role of polymorphisms in susceptibility to colorectal
cancer. Again, results have been inconsistent, and a systematic literature review (43) and a
recent meta-analysis (321) provided no support to the hypothesis that polymorphisms in
these genes influence colorectal cancer risk. Polymorphisms in various other genes,
including Methyltetrahydrofolate reductase, Apolipoprotein E and Tumour Necrosis
Factor-a have also been implicated in colorectal cancer susceptibility.
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Whilst identification of polymorphisms that modify colorectal cancer risk is important from
the broad perspective of understanding the genetic epidemiology of colorectal cancer, the
effects are generally small or moderate, and are not well understood. Consequently, the
genes considered above are not currently of clinical relevance, and the role ofmolecular
genetics in current strategies for prevention of colorectal cancer focuses on autosomal
dominant colorectal cancer syndromes.
Families exhibiting an autosomal dominant colorectal cancer syndrome are amenable to
linkage analysis, which provides a useful method of determining the chromosomal location
of the gene responsible. This technique was used to localize the gene for Familial
Adenomatous Polyposis (18, 163), facilitating the subsequent identification of mutations in
the adenomatous polyposis coli gene as the cause of this syndrome (95). Progress has also
been made in understanding the genetic basis of other rare cancer family syndromes.
Pathogenic mutations in the STK11 gene are evident in a large proportion of families with
Peutz-Jehers syndrome (107, 303, 322), although this gene has been excluded as a cause in
some families, suggesting a degree of genetic heterogeneity (17). Similarly, approximately
50% of families exhibiting the Juvenile Polyposis Syndrome have mutations in the SMAD4
gene, although the BMPR1A gene has also been implicated in some such families, and in
others the genetic basis remains unknown (1 13, 238, 313).
From a public health perspective, the most important hereditary colorectal cancer syndrome
is HNPCC, and consequently the genetic basis of this syndrome has been the subject of
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much research. Recently, it has been established that a large proportion of families
diagnosed with HNPCC harbor potentially pathogenic mutations in mismatch repair genes.
This group of genes code for a complex of proteins that play an integral role in the
recognition and repair of errors in DNA replication.
The originally identified, and best understood, mismatch repair system has been described
in the bacterium, Escherichia coli. Human homologues of the mismatch repair genes
present in this organism have since been identified. This process is reflected in the
nomenclature, with human mismatch repair genes being classified according to their
homology with the genes that comprise the bacterial system, as shown in table 1.2.
Table 1.2 Classification and Nomenclature of Human Mismatch Repair Genes
Bacterial Gene Human Homologues
MutS human MutS Homologue 2 (hMSH2)
human MutS Homologue 3 (hMSH3)
human MutS Homologue 6 (hMSH6)
human MutL Homologue 1 (hMLHl)
Post Meiotic Segregation Increased 1 (PMS1)
Post Meiotic Segregation Increased 2 (PMS2)
Proliferating Cell Nuclear Antigen (PCNA)
Methyl-CpG-Binding Endonuclease
human MutY Homologue 1 (hMYH)
The precise mechanisms involved in the human mismatch repair system have yet to be





interactions with other genes may also have a role. However, a broad model for the
function of the system has been established.
The primary role of the three MutS homologues is in the recognition and binding of any
emors that may have occurred during DNA replication. hMSH2 can bind with one of two
other mismatch repair proteins creating heterodimers comprising either hMSH2/hMSH6 or
hMSH2/hMSH3. The former complex, sometimes referred to as hMutSa, preferentially
recognizes mismatches involving only one base pair, whereas the hMSH2/hMSH3
complex, also known as hMutSP, binds to larger DNA mismatches, typically involving 2-4
bases (147). In either case, a larger heterodimer formed by hMLH 1 and hPMS2 is then
recruited to excise the incorrect daughter sequence and replace it with the correct sequence,
using the parental strand as a template. The hMLHl protein has no known enzymatic
activity itself and probably acts as a "molecular matchmaker," in that it recruits other DNA
repair proteins to the mismatch repair complex. The protein product of hMYH is involved
in the repair of oxidative DNA damage (259). At present the function of hPMSl is largely
unknown, and the role of other mismatch repair genes, including the putative MutH
homologues remains to be characterized.
Of the pathogenic mutations identified so far in mismatch repair genes, the vast majority
occur in hMLHl and hMSH2, an observation that may reflect their central role in the
mismatch repair process. Other mismatch repair genes that have been implicated as causes
of colorectal cancer are hMSH6, hMYH, PMS1 and PMS2.
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As discussed in detail in chapter 3, mutations in mismatch repair genes were originally
implicated as the genetic defect underlying the HNPCC syndrome. However, the
relationship between these genes and empirically defined HNPCC is not straightforward.
Such mutations have been found only in a proportion of families that meet the Amsterdam
family history criteria. Conversely, pathogenic mutations in hMLHl or hMSH2 have also
been identified in kindreds that do not meet the traditional criteria for diagnosis of HNPCC.
This observation may be due to the inherent misclassification bias involved in diagnosing a
condition on the basis of family history alone, particularly in small families. It is also
possible that some mismatch repair gene mutations are not detected during analysis for
technical reasons. Equally, the incomplete correlation between empirically defined HNPCC
and known mismatch repair genes may be indicative of genetic heterogeneity. Kindreds
exhibiting the HNPCC syndrome may harbour pathogenic mutations in other, as yet
unidentified, mismatch repair genes, in other genes involved in the same biological
pathway, or in genes unconnected with mismatch repair.
The association between mismatch repair genes and colorectal cancer is further
complicated by the apparent role of microsatellite instability (MSI). MSI, characterized by
instability of microsatellite repeats during cell replication, can occur as a consequence of
mismatch repair deficiency (264) and is a feature of a large proportion of colorectal
tumours occurring as part of the HNPCC syndrome (19). However, ostensibly pathogenic
MMR gene mutations have been identified in the absence of MSI, and conversely MSI
occurs in a minority of "sporadic" colorectal cancers (19). Thus, microsatellite instability
and family history are both associated with the sub-set of colorectal cancers caused by
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mismatch repair gene mutations, but are not consistent nor pathognomic featuies of
mismatch repair deficiency.
This complexity and uncertainty is reflected in the current terminology. Strictly speaking,
the term HNPCC refers to people meeting the empirical Amsterdam criteria, but since the
identification of mismatch repair gene mutations as the causal factor in a proportion of such
people, the term has also become synonymous with these mutations. An attempt to address
this situation has been made, by suggesting that the term "Hereditary Mismatch Repair
Deficiency Syndrome" be used to describe cases in which the cause is known to be a
germline mutation in a mismatch repair gene (132). However, this term is not in widespread
use, and the somewhat confusing terminology remains.
Since their identification, knowledge and understanding of mismatch repair genes and their
role in colorectal cancer has advanced rapidly, but it remains limited in many respects. The
mismatch repair genes hMLHl and hMSH2 are highly heterogeneous, with more than 200
allelic variants identified in each. This factor introduces substantial obstacles to obtaining a
clear understanding of the association between mismatch repair gene mutations and
colorectal cancer. Complete mutation analysis of these genes is required to determine the
known or suspected defects in the individual in question. This is both technically difficult
and time-consuming. Consequently, for largely economic and practical reasons, mutation
analysis has been carried out almost exclusively among colorectal disease patients,
particularly those identified as being at high risk of harboring mutations. Lack of control
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data, coupled with the heterogeneous nature of the gene variants concerned, makes the
pathogenicity of each variant difficult to establish. Indeed, pathogenicity may vary
according to the nature and location of the gene variant involved. Identification of the
causal defect is therefore subject to interpretation based on clinical and molecular data that
is often insufficient for such purposes.
Despite the above limitations, however, the identification of mismatch repair genes and
their role in the aetiology of a subset of colorectal cancer cases provides the potential for
improving genetic risk assessment, and as such offers new opportunities for prevention of
colorectal cancer through targeting people at increased genetic risk.
1.6 Principles of Colorectal Cancer Prevention
There are several possible approaches to the challenge of reducing the burden of colorectal
cancer in the Scottish population, and these can be broadly categorized as primary
prevention, chemoprevention and secondary prevention:
1.6.1 Primary Prevention
Primary prevention centers on the reduction of colorectal cancer risk through the avoidance
of known risk factors, and the adoption of a healthier lifestyle and diet. Although evidence
from intervention studies is limited, it is reasonable, on the basis of the known relative risks
of various factors, to suppose that primary prevention could theoretically play a major role
in reducing colorectal cancer incidence and mortality. However, the difficulties inherent in
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achieving significant lifestyle changes are well recognized, and whilst primary pievention
is ultimately the most desirable method of reducing the burden of disease it may not be
feasible to achieve a substantial effect in the near future.
1.6.2 Chemoprevention
Chemoprevention using Non-Steroidal Anti Inflammatory Drugs (NSAlDs) is another
promising area of research, with the potential to reduce colorectal cancer incidence (13, 16,
63, 94, 103, 120, 176, 233, 244). Both epidemiologic evidence and experiments utilizing
murine models have suggested that nonsteroidal antiinflammatory drugs have antitumour
properties that may prevent colorectal cancer. Sulindac has been shown to inhibit tumour
growth in experimental systems and to reduce adenoma counts in humans with familial
adenomatous polyposis (86), as has a recent study of the specific cyclo-oxygenase-2
inhibitor, celecoxib (262). Two recent randomized controlled studies have demonstrated
that aspirin reduces the risk of adenoma development or recurrence in people with a
personal history of adenomas or colorectal cancer (13, 244). Although such studies provide
compelling proof of the chemopreventive properties of NSAIDs, further clinical trials are
required to determine if the benefits of this approach outweigh the inherent risks of long-
term use. Thus, whilst chemoprevention may have a role as part of future strategies for
colorectal cancer prevention it is at present largely confined to the research context.
1.6.3 Secondary Prevention
The adenoma-carcinoma sequence of colorectal cancer development provides a lengthy
latent period of tumorigenesis before a symptomatic tumour becomes evident. During this
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stage pre-neoplastic lesions and early-stage cancers may be detected. Colorectal cancer is
thus an ideal candidate condition for screening, adequately meeting the criteria prepared by
the UK National Screening Committee (279), which are in turn based on the principles of
screening first outlined by the WHO (309). There is a clear rationale for 'secondary
prevention' of colorectal cancer, through screening procedures designed to facilitate the
identification and removal of preneoplastic lesions, and the early detection and treatment of
existing tumours.
Screening has considerable potential as a means of reducing the disease burden of
colorectal cancer, but the appropriate application of screening depends on the techniques
involved, their effectiveness and their disadvantages. Several methods are available, that
may be used alone, or in combination:
(i) Faecal Occult Blood Test (FOBT)
Intermittent bleeding is a common feature of colorectal adenomas and carcinomas, and may
occur relatively early in cancer progression, before the tumour becomes symptomatic. The
faecal occult blood test relies on the pseudoperoxidase activity of haemoglobin to test for
occult blood in a stool sample. Positive FOBT results can be followed-up using more
stringent diagnostic techniques.
The test is non-invasive and therefore has no risks directly associated with it. It is also
fairly easy to use. relatively inexpensive, and can be sent through the post. Consequently,
FOBT is relatively acceptable to the target population, and can potentially be used for
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screening large numbers of people. However, the intermittent nature of bleeding means that
FOBT may miss a significant proportion of cancers and precancerous lesions. The
sensitivity of a one-time faecal occult blood test is in the region of 30-70%. and varies
depending on the setting (at home or in medical practice) and the exact test and protocol
used (169, 190, 226, 318). Perhaps more significantly, the FOBT also lacks specificity,
since various other conditions can produce faecal blood, and the results can also be
influenced by diet and medication. Individuals with a false positive result may be offered
more invasive screening and diagnostic procedures unnecessarily, ultimately leading to
increased costs and health risks.
(ii) Colonoscopy
Colonoscopy is usually considered to represent the 'gold-standard' for detection of early
colorectal tumours and pre-neoplastic lesions. It is an invasive procedure requiring a skilled
operator, and permits the visualisation of the majority of the colon. Colonoscopy has an
estimated sensitivity of over 90% for detecting cancers and large adenomas (231). Biopsy
and polypectomy can be performed at the time of examination. The technique is associated
with a small but significant complication rate itself, and the necessity of sedation introduces
additional risks. Nonetheless, colonoscopy constitutes the mainstay of secondary
prevention of colorectal cancer, particularly in people deemed to be at a particularly high
risk of the disease, as considered later.
(iii) Flexible Sigmoidoscopy
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Flexible sigmoidoscopy is an invasive procedure used to visualise the descending (sigmoid)
colon, and the main disadvantage of this technique is an inability to detect more proximal
cancers. Compared to colonoscopy, flexible sigmoidoscopy is associated with fewer
complications but is also less effective. The sensitivity of flexible sigmoidoscopy has been
estimated at approximately 68-78% (121, 169). Again, biopsies can be taken at the time of
examination.
(iv) Double Contrast Barium Enema
This technique provides an alternative, and non-invasive means of visualising the colon, but
compares unfavourably with colonoscopy in terms of sensitivity and specificity, and
obviously does not facilitate biopsy or polypectomy at the same time as visualization.
Consequently, double contrast barium enema is primarily used as a complementary
technique or when there are technical difficulties with performing colonoscopy.
(v) Virtual Colonoscopy
Virtual colonoscopy is a relatively new technique that uses helical computed tomography to
generate images of the large bowel. The minimally invasive nature of the technique and the
associated low complication rate offer considerable advantages over conventional
colonoscopy. Virtual colonoscopy has been shown to have broadly comparable sensitivity
to conventional colonoscopy in terms of identifying polyps over 6mm in size (64), but
detection rates for smaller adenomas compare less favourably (64, 99, 232). At present
virtual colonoscopy is expensive and largely limited to the research context, but it remains
a promising technique that may form an aspect of future screening programmes (20, 310).
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* * * * *
For each individual who may be offered screening, the objective is to apply a tailored
screening protocol that will maximize the benefits and minimize the associated costs, health
risks and any adverse psychosocial effects. Ultimately, the major consideration in terms of
benefit is the absolute risk of developing colorectal cancer. When absolute risk is low, there
is only a very small chance that the individual concerned will develop cancer over the
screening period, and consequently it is probable that no benefit will accrue from screening.
In contrast, where absolute risk is very high, the likely benefits of screening may be
sufficiently large to justify an intensive screening protocol, despite the financial costs and
possible side effects of screening.
The principal determinant of absolute risk is age, with the incidence of colorectal cancer
increasing markedly later in life. This trend remains consistent for all risk groups, including
those deemed to be at increased genetic risk. Thus, young people with a high relative risk of
developing colorectal cancer may still be less likely to develop colorectal cancer in the next
ten years than older members of the general population. Consequently, the potential target
groups for secondary prevention of colorectal cancer through screening include both
individuals at increased risk and older members of the general population at average risk. It
is necessary, therefore, to consider people at increased risk, whether due to genetic
predisposition or environmental / dietary risk factors, within the context of any wider
screening programme. The key issue is whether or not such people will benefit from more
intensive screening, or intervention at a younger age.
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1.7 Screening for Colorectal Cancer in People at Average Risk
An important consideration regarding screening in average-risk individuals is the large
number of people who are eligible for such screening. In this context issues of cost are
particularly relevant. Similarly, the balance between sensitivity and specificity of screening
must be carefully weighted to maximize the health benefits to the population, whilst
minimizing any adverse health effects. Low specificity of a test applied to a large
population will result in numerous individuals with 'false positive' results, who may be
unnecessarily subjected to further diagnostic procedures.
The exact age at which the population risk of colorectal cancer becomes sufficiently high to
justify screening depends on the technique being employed, and the associated issues of
cost, side-effects, and acceptability to the general public. For pragmatic reasons, 50 years of
age is often considered as the point beyond which screening may be beneficial.
The non-invasive nature and relatively low cost of the faecal occult blood test makes this a
particularly attractive method of screening at the population level. Evidence for the
effectiveness of the FOBT in average-risk individuals comes from several large-scale
randomised controlled trials (100, 142, 151, 190), with a UK study demonstrating a 15%
reduction in cumulative CRC mortality in the screening group (odds ratio = 0.85, 95% CI =
0.74-0.98)(100). A pilot is currently being conducted in the UK, with a view to introducing
FOBT screening nationally. Despite these encouraging results, concerns remain regarding
the sensitivity of FOBT as a means of detecting colorectal cancer; in the randomised
controlled trials considered above the overall sensitivity was in the region of 50%.
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Invasive screening is unlikely to be acceptable to the general public or feasible to conduct
on a population basis, although there is some evidence to suggest that flexible
sigmoidoscopy may be effective in average risk individuals (166, 250).
1.8 Screening for Colorectal Cancer in People at Increased Genetic Risk
The concept of targeting colorectal cancer screening to people at increased genetic risk is
well established. Considerable debate surrounds the appropriate screening protocol in this
context, which centers on the costs and benefits of screening a particular risk group. As
mentioned previously, the absolute risk to the individual being offered screening is the key
factor in determining the extent of screening that is appropriate, and this risk is a synthesis
of age and genetic predisposition. Genetic predisposition is highly complex and is thus
difficult to quantify, meaning that a degree of uncertainty surrounds the calculation of
absolute risk. In addition, the appropriate screening protocol for an individual with a known
absolute risk is still not clear, as it depends not only on the effectiveness of the protocol, but
also on the health risks, financial costs and psychosocial effects of screening.
Despite the uncertainties inherent in determining risk and offering screening to individuals
who may be at increased genetic risks, the overall value of this approach is sufficiently high
to have encouraged its use in research and in clinical practice. The appropriate protocols for
specific rare syndromes such as FAP have been largely established, and due to the relative
insignificance of these syndromes at the population level they are therefore not considered
furthei in the context of this thesis. The evidence to support screening in various other risk
groups is summarized below.
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1.8.1 First Degree Relatives of Colorectal Cancer Patients
First-degree relatives of colorectal cancer patients have been shown to be at an increased
risk of developing the disease themselves (25, 39, 78, 92, 136, 141, 149, 153, 157, 160,
179, 205, 206, 222, 239, 256, 260, 272), with a recent meta-analysis estimating the relative
risk for people with one affected first-degree relative as 2.25 (95% CI = 2.00, 2.53) (134).
In reality, the individuals within this group will have a broad spectrum of risk, ranging from
average population risk for those people who have a relative affected by chance, to
extremely high risk for those people who have a strong genetic predisposition that has,
again by chance, not become manifest as a more extreme family history. This latter
situation may arise in people from very small families. Consequently, targeting first-degree
relatives of colorectal cancer cases is a somewhat crude approach, and does not involve
offering a tailored screening protocol to individuals. Nonetheless, such people constitute a
large sub-group of the population who may merit particular attention with respect to
colorectal cancer screening.
It has been estimated that around 4-7% of people in the general population have an affected
first-degree relative (112, 243, 293). As with people at average risk, the large size of this
sub-group is an important consideration. Consequently, much attention has focused on
faecal occult blood testing, since this approach meets the necessary criteria for screening a
large group of people at a moderately increased risk, being inexpensive and non-invasive.
Several studies have demonstrated that FOBT can be used to identify adenomas and
carcinomas in individuals with a history of colorectal cancer in at least one first-degree
relative (10, 45. 70. 111,115. 239). Nakama et al., found that 8.5% of subjects with an
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affected first-degree relative had a positive FOBT test, compared with 4.8% of subjects
without such a history (204). Furthermore, the positive predictive value of the FOBT test
for colorectal cancer was 6.8% in people with an affected first-degree relative; significantly
greater than the value of 2.4% for people without such a family history (204). Although
FOBT is a feasible and potentially effective means of screening in people with an affected
first degree relative, this sub-group may contain individuals with greater degrees of family
history. Consequently, many authors have queried whether or not the sensitivity and
specificity of the test are sufficient to address the needs of this sub-group.
Identifying people with an affected first degree relative is a convenient means of providing
a group of people at increased genetic risk, but ideally this group should be further stratified
according to their family history. Thus, whilst FOBT may not be adequate as a means of
screening all individuals with a history of colorectal cancer in at least one first-degree
relative, it may have a role in screening people with only one affected first-degree relative,
i.e. those at the lowest end of the increased familial risk spectrum.
Although primary evidence demonstrating the efficacy of colonoscopy as a screening tool
for first-degree relatives of colorectal cancer cases is not available, various studies have
found that the yield from colonoscopic screening, in terms of identifying adenomas, is
greater in people with such a history than in control subjects (96, 111, 269, 316). For
example, a controlled, prospective study calculated a relative risk of 3.49 (P < 0.001) for
harbouring colonic adenomatous polyps among first degree relatives of colorectal cancer
patients compared to controls without such a history (96). This implies that more invasive
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and intensive screening protocols, involving the use of colonoscopy as an initial screening
tool, are likely to be effective in people with one affected first degree relative. Flexible
sigmoidoscopy provides another option for screening in this group, and is intermediate
between FOBT and colonoscopy in terms of the balance between sensitivity and specificity.
However, as with screening older people at average risk, the high cost and the potential for
adverse complications means that invasive screening techniques may not be considered
appropriate in people with a history of colorectal cancer in a first-degree relative.
Screening protocols for people at slightly increased genetic risk are likely to involve large
numbers of people, and may overlap with strategies for people at average risk. Hence, it has
been suggested that screening methods used for average risk individuals are also
appropriate for those with an affected first-degree relative, but that screening should
commence ten years earlier (312).
1.8.2 Strong Family History (More Than One Affected First-Degree Relative, or
One First Degree Relative Affected at <45 Years of Age)
Although there is little primary evidence for a reduction in colorectal cancer incidence from
screening people with a strong family history, proof of the concept that screening can be
effective in this context comes from the observation that the yield from screening such
groups is relatively high in comparison to controls groups and / or the general population
(96. 312). It is reasonable to infer from such data that benefits in terms of reduced incidence
and mortality of colorectal cancer may accrue from screening in this context.
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The risk of colorectal cancer for people with more than one first-degree relative with
colorectal cancer has consistently been shown to be greater than in people with only one
affected first-degree relative (78, 157, 205, 206, 256, 260). In a meta-analysis conducted by
Johns and Houlston, the pooled relative risk for this group compared to the general
population was 4.25 (95% CI = 3.01, 6.02) (134). Similarly, several studies have shown
that relatives of colorectal cancer cases who were diagnosed at less than 45 years of age are
at a comparatively high risk (39, 78, 97, 205, 256), with the pooled estimate for this group
being 3.87 (95% CI = 2.40, 6.22)(134). Both these figures are markedly greater than the
pooled estimate of relative risk for people with one affected first-degree relative, calculated
as 2.25 (95% CI = 2.00, 2.53) in the same meta-analysis (134). In view of the high relative
risks in these sub-groups, screening methods that are appropriate for people with one
affected first-degree relative may be inadequate. Conversely, the intensive screening
programmes offered to people who meet the accepted criteria for HNPCC may be
inappropriate. People with two affected first-degree relatives, or one affected at <45 years
of age thus constitute a convenient sub-group, which merits particular consideration in the
context of screening.
FOBT provides one option for screening in this risk group, and many studies have shown
this approach to be capable of detecting adenomas and colorectal cancer in people with a
family history (10, 38, 45, 70, 111, 115). As mentioned previously, though, FOBT may be
inadequate to meet the needs of people with a strong family history. Houlston et al., found
the negative predictive value of this test to be 78% in a group comprising people with two
affected first-degree relatives or one first-degree relative affected at less than 45 years of
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age, and concluded that the test was unsatisfactory (111). Flexible sigmoidoscopy provides
another option, but the limitations of this technique in terms of sensitivity and extent of
visualisation of the colon may preclude its use in this group. In contrast, colonoscopy is a
relatively sensitive technique, and is known to be capable of detecting neoplasms in people
with a family history of colorectal cancer (38, 54, 64, 83,96, 116, 172, 181, 194, 263,269).
Consequently, this is generally considered the method of choice when screening people
with a strong family history of colorectal cancer, and is extensively used in clinical
practice.
The exact screening protocol that is appropriate for this risk group remains subject to the
interpretation of various researchers and policy-makers, who must evaluate the costs and
benefits. However, a growing consensus is focussed on the selective use of colonoscopic
screening for this group; striking a balance between providing adequate surveillance and
limiting the frequency of colonoscopy. A recent paper by Dunlop outlines a strong case for
performing colonoscopy at around 35-40 years of age, with the procedure not being
repeated until age 55 if findings are normal (56). This recommendation is comparable with
current Scottish guidelines for colorectal cancer screening (249) (see appendix Al).
1.8.3 Hereditary Non-Polvposis Colorectal Cancer
The HNPCC syndrome is currently defined on the basis of the Amsterdam family history
criteria, and this method of diagnosis may lead to misclassification. Nonetheless, the
accepted criteria for HNPCC are a convenient means of identifying people likely to be at a
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substantially increased genetic risk, and individuals meeting these criteria are generally
considered to be eligible for relatively intensive screening.
Numerous studies have produced evidence to support the use of screening in individuals
with a family history of cancer that meets the Amsterdam Criteria for HNPCC (93, 130,
131, 178, 203, 230, 282, 284, 287). Such individuals have a very high risk of developing
colorectal cancer, and a large proportion of tumours develop in the proximal colon.
Consequently, colonoscopy is the most appropriate screening method in this group (55,
130, 203, 284), and this approach has been specifically shown to facilitate early detection
of colorectal cancer (287), and to reduce mortality (130, 230). A screening interval of one
to three years is often recommended, although the observation that interval cancers can
occur within eighteen months of colonoscopy (285) implies that screening should ideally be
at least biennial in order to minimise the chances of such occurrences. Absolute risk of
developing colorectal cancer increases rapidly after around 25-30 years of age in HNPCC
subjects (3, 284), and screening programmes should begin at this time (34, 55, 312). This
consensus is also reflected in the current guidelines for colorectal cancer screening in
Scotland (249) (see also appendix A. I).
Prophylactic colectomy provides another potential option for clinical management of
HNPCC subjects (96, 235). However, considering that effective screening protocols are
available, prophylactic colectomy is not normally justified except for people who do not



























































































































































































































































































































50-54 F SDR 0.90 0.90 0.90 0.90
55-59 F SDR 0.90 0.90 0.90 0.90
60-64 F SDR 0.90 0.90 0.90 0.90
65-69 F SDR 0.90 0.90 0.90 0.90
70-74 F SDR 0.90 0.90 0.90 0.90
75-79 F SDR 0.90 0.90 0.90 0.90
80-84 F SDR 0.90 0.90 0.90 0.90
>85 F SDR 0.90 0.90 0.90 0.90
Abbreviations: FDR = First Degree relative, SDR = Second Degree Relative
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Appendix A9 CSO Grant Application
Grant application CSO reference number: CZH/4/145
form
Project title (not more than 25 words):
The Development of a Computer Model of Cascade Genetic Screening in Complex Disease






Consumables Travel Ex. items Equipment Total
£53,611 £21,444 £10,000 - - - £85,055
Principal investigator:
Name and title Position Institution




Name and title Position Institution
Professor Malcolm Dunlop Professor of Coloproctology University of Edinburgh
Dr. Mary Porteous Consultant & Reader in
Clinical Genetics
University of Edinburgh




Professor Angus MacDonald Professor of Actuarial
Mathematics & Statistics
Heriot-Watt University
Rory J. Mitchell PhD Student University of Edinburgh
Project summary (not more than 150 words):
A current challenge for the scientific and medical community is to utilise recent advances in
our understanding of the genetic basis of complex disease by identifying carriers of
pathogenic mutations and offering the appropriate management. Cascade genetic screening, in
which mutations are detected in high-risk individuals and subsequently traced through
families, is a useful strategy for identifying asymptomatic mutation carriers. The aim of this
project is to address a gap in current knowledge by developing a comprehensive computer
model to facilitate evaluation of this strategy. The model will initially be designed and
validated with respect to mismatch repair gene mutations and colorectal cancer, but it will
have sufficient flexibility to apply to any condition in which high penetrance mutations have
been identified and effective interventions are available. The computer model will thus
provide a valuable tool to inform decisions made by researchers and health policy makers
regarding the use of cascade screening.
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Introduction
Identification of individuals at an increased genetic risk of developing a particular complex
disease can facilitate the targeting of appropriate intervention strategies to this sub-group of the
population. Therefore, in conditions for which pathogenic mutations have been identified, and
effective intervention strategies are available, genetic testing offers a feasible and effective
method for reducing the burden of disease.
For both economic and ethical reasons, it is essential that genetic testing strategies are targeted to
the people most likely to benefit. Population genetic screening is rarely justified, and stratified
screening, in which individuals with a strong family history of disease are targeted, is subject to
various practical and scientific difficulties. In contrast, cascade genetic screening is potentially
both feasible and effective as a means of identifying asymptomatic carriers of pathogenic
mutations. This process involves conducting mutation analysis in individuals, often patients or a
sub-group of patients, who are at a relatively high risk of carrying a mutation. When a mutation
carrier is found, genetic testing can be offered to their relatives, and the specific mutation present
can thus be traced through an expanded pedigree in a 'cascade' fashion.
The concept of tracing a mutation through families is often used in a clinical genetic setting, and
has been applied in the research context to various diseases, including cystic fibrosis (1; 2) and
familial hypercholesterolaemia (3). Additionally, Krawczak et al., have produced equations
designed to estimate the theoretical efficacy and efficiency of cascade screening (4). However,
the outcomes of any cascade screening protocol will depend on numerous factors, including the
genetic epidemiology of the condition in question, the available technology for genetic testing
and the uptake of genetic testing by at-risk individuals. Furthermore, these factors will be
superimposed on the background of population demographics, disease prevalence, other risk
factors and existing screening strategies. A comprehensive evaluation of cascade screening in
complex disease that considers all the above points has not yet been undertaken. The objective of
the proposed project is to address this gap in the collective scientific knowledge. Computer
modelling is the ideal approach to such an evaluation, permitting the complex nature of cascade
genetic screening to be fully explored.
The computer model will be designed with the flexibility necessary for application to any
complex condition, but it will initially be developed and validated with respect to colorectal
cancer, building on ongoing research conducted by the applicants. Around 3400 colorectal cancer
cases are diagnosed in Scotland each year, and a small but significant sub-set of these are caused
by pathogenic mutations in mismatch repair (MMR) genes. The approximate lifetime risk of
colorectal cancer in MMR gene mutation carriers if 80% for males and 40% for females (5; 6; 7).
The prevalence of pathogenic MMR gene mutations in the Scottish population has been estimated
as 1:3139 among the 15-74 years age group (95% CI = 1:1247, 1:7626) (8), implying that 1209
Scots in this age range harbour such mutations (95% CI = 498, 3044). Upon identification,
mutation carriers can be offered colonoscopic screening, an intervention shown to have
significant health benefits in terms of both reduced incidence rates and life-years saved (9). The
UK National Screening Committee have acknowledged the potential of cascade genetic screening
for MMR gene mutations (10), and our systematic literature review relating to MMR genes has
supported this notion (11). It has been estimated that approximately 35% (95% CI = 10%, 38%)
(12) of colorectal cancer cases have a primarily genetic basis, and it is widely accepted that other
undiscovered genes contribute to this condition. Hence, our computer model will have potential
relevance to new colorectal cancer genes as they are discovered, as well as to other multifactorial
conditions.
Results of Pilot Studies
An initial prototype computer model of the cascade screening process as applied to MMR gene
mutations has recently been developed as part of a CSO studentship conducted under the
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supervision of the grant applicants. The methods outlined below were utilised and evaluated
during prototype development, and a summary of the extent of the prototype can be found in
appendix 1. The prototype has been designed to provide a core "engine" around which the rest of
the model can be developed and implemented to form a complete and valid model of cascade
genetic screening. It is restricted in scope to encompass only a few key elements of the process,
and represents only a sub-section of a broader conceptual model. A graphical user interface has
been created, enabling any user to alter various input parameters and view the model outputs in
complete or summary form. The major limitations of the prototype model are that the
identification of new mutation carriers is only considered through testing colorectal cancer cases,
the family structures in the model are very basic, and the process of mutation tracing within a
pedigree is over-simplified. These areas will constitute the focus of the next stage of
development.
Aims:
(i) To create a detailed computer model of cascade genetic screening, as applicable to the
challenge of identifying MMR gene mutation earners in Scotland, using real data
generated by our research group.
(ii) To utilise this model to evaluate the proportion of mutation carriers that could be identified
over time under various cascade genetic screening protocols.
(iii) To evaluate the efficiency of cascade genetic screening.
(iv) To ensure that our model is broadly applicable in the context of identifying carriers of high
penetrance mutations predisposing to complex disease.
Research Questions
(i) What proportion of mismatch repair gene carriers could be identified over time by
applying a comprehensive cascade screening programme to the Scottish population?
(ii) How many non-carriers would undergo testing under such a programme?
(iii) What would be the cost of applying cascade screening to the Scottish population?
(iv) What effect does ascertainment criteria for cascade screening have on the above
outcomes?
(v) What effect does penetrance, population prevalence and other variables have on the
proportion of mutation carriers identified, and the efficiency with which this could be
achieved?
(vi) What proportion of mutations in BRCA1 and BRCA2 could be detected using cascade
screening, and how efficient would this process be?
(vii) What is the potential utility of cascade genetic screening in other complex diseases?
Plan of Investigation
The proposed project is an extension of ongoing pilot work. It is our intention to develop, test,
and improve the model to the extent where it provides a thorough and accurate representation of
the process of cascade screening.
The methods and software identified for development of the proposed model have been chosen
on the basis of the expertise of the Heriot-Watt research team, who have extensive experience of
computer modelling in the medical and biological domains. We have chosen to utilise object-
orientated design, as this is a powerful and widely used technique for creating useful models of
complex systems.
The first step in our overall strategy for developing a computer model using this technique is to
develop a conceptual model. This is perhaps the most important stage as it precisely defines the
requirements of the model, and it is normally completed by a 'domain expert' who has extensive
knowledge of the system to be modelled. In this case, early versions of the conceptual model
have already been produced as part of a CSO studentship, using input from the current applicants
to determine the model's requirements. These inputs come from a variety of relevant
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1.8.4 Mismatch Repair Gene Mutation Carriers
Much of the evidence in favour of screening individuals with HNPCC, and many of the
issues considered above, are also applicable to mismatch repair gene mutation carriers.
Indeed, the two definitions are often interchangeable in the current literature, with
mismatch repair gene mutations being considered as the cause of the HNPCC syndrome. In
reality, only a sub-set of empirically defined HNPCC patients will have MMR gene
mutations, and only a proportion of MMR gene mutation carriers will meet the Amsterdam
criteria for HNPCC. Carriers of mismatch repair genes are at an extremely high lifetime
risk of developing colorectal cancer, estimated at 80% in males and 40% in females, and it
follows that they should be offered intensive surveillance.
Jarvinen et al., have conducted a controlled screening trial on HNPCC families over a
period of fifteen years, and have established the mutation status of the majority of study
subjects (130, 131). This study has provided evidence in favour of screening MMR gene
mutation carriers, finding a 55% (95% CI = 10%, 79%) reduction in risk of colorectal
cancer in mutations carriers who underwent colonoscopic screening at three year intervals,
compared to a control group of mutation carriers, and demonstrating that overall mortality
was also significantly lower in the screening group (130). All participants in this study were
offered screening, and any differences between those who accepted and those who did not
comply in terms of lifestyle or illness behaviour will potentially lead to ascertainment bias.
For obvious ethical reasons, this issue is also likely to affect future studies. Nonetheless,
these findings constitute compelling evidence to support the intuitive view that MMR gene
mutation carriers should be offered intensive screening for colorectal cancer due to their
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perspectives, including clinical cancer genetics, genetic epidemiology and colorectal surgery. The
conceptual model will be revised and overhauled as a first step towards developing a more
comprehensive computer model of cascade genetic screening. This reflects an important aspect of
the model development strategy, namely the testing and revision of the conceptual model in an
iterative fashion. The Unified Modelling Language (UML), which is widely used and has
previously been successfully utilised for modelling biological systems (13), will be employed at
the conceptual stage. The conceptual model provides a framework for a functional model, which
is usually developed by a computer programmer working under the guidance of the domain
expert. In turn, the functional model forms the basis for software implementation using standard
Java programming language. Again, model development will be undertaken in an iterative
fashion.
Whilst the ultimate aim of this project is to create an adaptable model of cascade genetic
screening that can be applied to any complex condition, model development will initially focus
on cascade screening for mismatch repair gene mutations in the Scottish population. As discussed
above, colorectal cancer is one area in which cascade screening is potentially of clinical benefit
and the current applicants are in a unique position to evaluate cascade screening in this context.
A summary of key inputs to our computer model, and the available sources, is presented in
appendix 2. Data on population demographics, and the incidence and mortality of colorectal
cancer in Scotland are available in various publications by the Information and Statistics Division
(ISD) of the Scottish Executive. Current guidelines the management of individuals at increased
genetic risk due to family history will also be used, enabling a complete and accurate
representation of the epidemiology of colorectal cancer in Scotland to be established as the
background to our model. Information regarding the genetic epidemiology of mismatch repair
gene mutations will come from the growing number of publications on this subject. An extensive
literature review covering this issue has been conducted by the applicants (11), and has enabled
the identification of working estimates. It is important to emphasize that the model will be
deliberately constructed with the flexibility to alter such estimates, both to study the influence
that such alterations could have on model outcomes, and to reflect future advances in our
understanding of genetic epidemiology.
In addition to estimates obtained from the available literature, the proposed computer model will
be informed by the existing expertise of the applicants and data from ongoing research into the
genetic epidemiology of colorectal cancer and the application of genetic knowledge at the clinical
level. We have access to valuable information from clinical genetics services, and have also
amassed the largest collection ofMMR gene mutation carriers in the UK, providing a unique data
resource.
The Colorectal Cancer Genetic Susceptibility (COGS) study, a five-year (2003-2008) Cancer
Research UK programme, is a large-scale study into the genetic basis of colorectal cancer. It is
designed to conduct mutation analysis on all Scottish colorectal cancer patients who develop the
disease under the age of 55 and to facilitate subsequent cascade genetic screening. This study will
provide valuable and unique information regarding important aspects of the cascade screening
process, including the acceptance rates of genetic testing among patients and various relative
groups, the time-scale of genetic testing, and the laboratory and administrative costs involved.
The COGS study has also generated detailed pedigree information relating to colorectal cancer
cases and mutations carriers. This real data, and information on family structure relating to the
general population will be utilised to simulate realistic pedigrees as part of the computer model.
This will build on previous pedigree simulation work conducted by Professor MacDonald (14),
and will ensure that the family structures used in the model mirror the real-life situation.
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We intend to integrate the development of the computer model with the COGS study. The model
will initially reflect cascade screening as it is currently being applied as part of this ongoing
research. This will facilitate a high degree of external validation, since the predictions generated
by the model can be compared with actual findings from the COGS study. Subsequently, input
estimates will be manipulated within realistic boundaries to investigate the effects of altering
various model parameters and determine the most favourable conditions for cascade screening in
this context. The combination of domain expertise, 'real' data, and an iterative development
strategy involving continual re-evaluation and revision of the model, will thus facilitate the
expansion of the model to the extent where it constitute a full and realistic representation of
cascade genetic screening for mismatch repair gene mutations.
Ethical approval for the COGS study has already been granted, and data used to inform inputs to
the model will consist of summary statistics only. No subjects will be approached in connection
with the current application.
The next step in model development will be to investigate the adaptability of the model by
applying it to other complex conditions in which pathogenic mutations are known to cause a
proportion of cases. The identification of mutations in the breast cancer genes BRCA1 and
BRCA2 presents an ideal candidate for such an investigation, since the genetic epidemiology of
this condition has been extensively studied. Application of the computer model to investigate the
use of cascade screening in breast cancer will be conducted in a similar fashion to that outlined
above. Inputs relating to breast cancer epidemiology, and the prevalence and penetrance of
BRCA1/BRCA2 mutations etc. will be taken from the available literature. It is also intended to
incorporate aspects of the "genlSYS" project, funded by the CSO and undertaken by the Image
Systems Engineering Laboratory (ISEL) at Heriot-Watt University with the aim of modelling
breast cancer genetic risk analysis. Resulting model outcomes will be evaluated in the context of
current knowledge about these genes.
Subsequently, it will be possible to apply the computer model to various other clinical situations,
the only restriction being the availability of realistic input data. Once again, the model will be re¬
evaluated based on its response to different inputs, and will be adjusted accordingly if
appropriate.
Appendix 3 lists some of the key outputs that will be generated by the model. The proportion of
mutation carriers identified and the efficiency of this process will be crucial to the evaluation of
cascade screening in any context, and this will form the focus of the model. Health benefits and
associated risks resulting from surveillance of identified mutation carriers will vary according to
particular condition in question, and the model will be designed to facilitate the inclusion of such
information as part of future development. Our evaluation of cascade screening in the context of
colorectal cancer will consider the benefits of colonoscopy in mismatch repair gene mutation
carriers, using published estimates (9) supplemented by data from the COGS study. Similarly,
any available information on the risks inherent in surveillance of mismatch repair gene carriers,
including clinical complications and psychological distress will be incorporated into the
evaluation.
The proposed model will include a component relating to administration and laboratory costs
associated with the cascade genetic screening programme undergoing evaluation. A detailed
economic evaluation relating to the costs and benefits of mutation carrier management in a
specific context could be based on information generated by our model, or could be part of future
development using the same methodology. However, a full economic evaluation is out-with the
scope of the current project. The flexibility inherent in the methods we have chosen for model
development also ensures that other features relevant to cascade genetic screening, such as gene-
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gene and gene-environment interactions, could be built into the model if sufficient relevant data
becomes available.
In accordance with recognised principles of good practice in model development, all assumptions
and estimates built into the model will be carefully logged, and presented in as transparent a
fashion as possible (15). Similarly, where the available data may not be accurate, or may not be
sufficiently detailed, this uncertainty will be built into the model. Throughout the modelling
process, particular attention will be paid to parameters that are potentially amenable to
adjustment, such as acceptance rates and genetic test parameters.
The completed model will serve as a valuable tool for evaluating the feasibility and effectiveness
of cascade screening in a variety of complex conditions. The model itself will be user-friendly, in
the sense that no in-depth knowledge of computing will be required for operation. The model
outcomes will, however, be sensitive to the input data provided. The availability and application
of this data will thus be crucial to ensuring that the predictions made by the model are relevant to
the corresponding real-life situation. Where the data parameters are unknown, or subject to wide
confidence intervals, this uncertainty must be incorporated into the input parameters and
considered carefully before drawing any conclusions. The model will thus be aimed at 'domain
experts': individuals or groups with knowledge of the condition of interest and the ability to
apply the model to that condition and interpret results accordingly.
Timetable of Work
Development of the prototype model has formed one aspect of the CSO studentship "Prevention
of Colorectal Cancer in Scotland: Strategies for those at Increased Genetic Risk". The prototype
will have been finalised and thoroughly tested by completion of this studentship on October 1st,
2003. The proposed project is intended to commence immediately, following on from work on
the studentship, but not overlapping. The iterative process of model development will result in
considerable overlap between the phases of the project outlined below.
Pre-Project Grant: Funding from within existing resources in the PhD studentship has been
secured for a four-month period to support the career development of
Rory Mitchell. This time will be utilised to conduct a comprehensive
review of the existing prototype conceptual model, and identify the
requirements of the full version. Through consultation with all the
applicants, and other individuals and groups with appropriate expertise,
the required scope, limitations and outputs of the model will be
carefully defined. During this period further training in computer
modelling and Java programming will be undertaken.
An updated conceptual model will be represented in object-orientated
form.
Using the conceptual model to provide the guidelines and framework, a
functional
computer model of cascade screening for MMR gene mutations will be
developed.
During this latter phase, the computer model will be extensively tested
and validated, with findings providing the feedback necessary to
improve the model to the extent that it constitutes a complete and
accurate representation of the process of cascade screening for
mismatch repair gene mutations. Subsequently, the adaptability of the
model, in terms of its applicability to other complex disease such as
breast cancer, will be investigated. Findings at this stage will facilitate





18-20 Months: In the concluding months of the project the user interface will be
finalised, and findings
will be disseminated in collaboration with the CSO.
Existing Facilities
The University of Edinburgh Colorectal Cancer Research Group is an expanding
multidisciplinary team with considerable research experience in the field of colorectal cancer
genetics. This group provides the ideal environment for the supervision of the proposed project.
They have forged an ongoing functional collaboration with the co-applicants from the School of
Mathematical and Computer Sciences at Heriot-Watt University. The latter researchers have the
capacity to provide expert supervision of the computing aspects of the project, and to provide
training in computer modelling where appropriate. Desk space, computing facilities and
secretarial support are available at the MRC Human Genetics Unit in Edinburgh, where the
research assistant to be employed on this grant is already based.
Justification of Requirements
Whilst all the current applicants will maintain an active interest in the project, it will be essential
to employ a full time research assistant at grade ARIA to carry out the coordination of the project
and to conduct the actual computer modelling work. Rory Mitchell is already established as a
PhD student at the department of Community Health Sciences at the University of Edinburgh,
and is currently completing a PhD thesis on "Prevention of Colorectal Cancer in Scotland:
Strategies for those at Increased Genetic Risk" within the above research environment. He has
been responsible for the pilot work for this project and is thus ideally placed to continue this line
of research. Funding has also been requested for limited secretarial and computing support,
totalling 10% of a full time salary for computing support (grade AD2), and 10% of a full time
salary for secretarial support for the project (grade CN3). Such support will be necessary to
ensure the efficient progress of this project. All staff will be employed on this grant for a period
of 20 months.
Although the applicants themselves will undertake the majority of the modelling work, it will be
necessary to engage the services of a computer modelling expert on an ad-hoc basis, to provide
assistance and advice when required. The School of Mathematical and Computer Sciences at
Heriot-Watt University has considerable experience in arranging such work, and the additional
funding requested for this purpose is budgeted accordingly. Allowance has been made in the
consumables section of the budget to purchase all software required for this project, and funding
for miscellaneous office costs has also been included.
Research Outcomes and Implementation
Identification of people at high genetic risk of disease provides a target group who may benefit
from clinical intervention, and cascade genetic screening provides a feasible option for accurately
identifying such people. Detailed evaluation of the potential of this strategy, in terms of
identifying mutation carriers and in terms of the associated costs and resources, is an essential
prerequisite for introducing cascade genetic screening outside the research context. The proposed
project will generate a detailed computer model of the cascade screening process and will include
a thorough investigation of the process as applied to mismatch repair genes and colorectal cancer.
In this context cascade genetic screening will be assessed in accordance with the National
Screening Committee criteria for appraising the viability, effectiveness and appropriateness of
screening programmes (16). The results of this investigation could directly inform NHS policy in
Scotland. If the appropriate criteria are met cascade screening might be adopted to form an
integral part of clinical genetics services for colorectal cancer, leading to health benefits for a
small but significant proportion of the population.
In the wider context, our computer model will serve as a valuable tool for any researchers or
policy-makers who are interested in the potential of cascade screening in various clinical
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situations. The results and conclusions generated by the model could then be used to inform
decisions regarding future research programmes and clinical treatment and screening policies.
The completed model could be used to provide information on the likely impact of cascade
screening for mutations predisposing to various complex diseases, and could be applied to any
population. It is possible, therefore, that the model could be used for commercial exploitation.
Dissemination
The applicants will undertake to publish findings arising from this project in quality scientific
journals, and to present at relevant conferences. We have recently co-hosted a meeting of the UK
National Screening Committee on strategies for people at increased genetic risk of colorectal
cancer, and we will report findings from this project directly to this committee.
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Appendixl Scope of Prototype
The figure below provides an overview of the scope of the prototype model of cascade genetic
screening, listing some of the inputs required and the outputs generated by the system. The
prototype model is designed to provide a narrow but detailed view of one aspect of cascade
genetic screening as it could be applied to identifying mismatch repair gene carriers. The high-
risk group concerned are colorectal cancer patients, and the model includes the capacity to limit
genetic testing according to age at onset. Information provided by the model regarding the
number of patients found to harbour pathogenic MMR gene mutation feeds back into the model,
as indicated by the arrows, providing the starting point for tracing relatives and offering further
genetic testing in a cascade fashion. The current prototype enables estimates to be generated
regarding the likely outcomes of cascade screening in this context. However, it represents an
oversimplification of the true situation. Initial expansion of the functionality of the model will
include the use of real data will be used to inform estimates of test acceptance and to create a
more realistic model of family structure and the process of tracing relatives. The scope of the
model will also to be broadened in order to consider input from cancer genetics services.
I I
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Appendix 2 Key Inputs to Computer Model
Required Estimate Source(s)
Size and age/sex distribution of Scottish Population Government Statistics (ISD)
Population prevalence of MMR mutations Literature (8), COGS and related analyses
Age/sex dependent penetrance ofMMR gene
mutations
Literature (5-7), COGS
Proportion of colorectal cancer cases meeting




Estimates will vary according to criteria:
(a) Government statistics (ISD), COGS,
published data on MSI status
(b) Literature, COGS
Number of relatives identified and traced per newly
identified carrier*
Family structure simulation informed by
government statistics, COGS
Proportion of cases meeting criteria, that are
actually referred to cascade genetic screening
programme
COGS
Acceptance rate of genetic testing among cancer
cases*
Literature, COGS
Acceptance rate of genetic testing among relatives
of known mutation earners*
Literature (17), COGS
Proportion of individuals presenting to genetic
services who would be offered genetic testing on
the strength of their family history
Genetic Services Data
Acceptance rate of genetic testing among
individuals presenting to genetic services*
Genetic Services Data
Sensitivity of non-specific mutation analyses Literature (18), COGS
Specificity of non-specific mutation analyses Literature (18), COGS
Sensitivity of specific mutation testing Approximately 100%
Specificity of specific mutation testing Approximately 100%
Traceability of relatives COGS, previous research experience,
Register General Office Scotland
Proportion of carriers accepting and complying
with colonoscopic surveillance
COGS
Life-years saved as a result of surveillance
programmes
Literature (9)
Cost of non-specific mutation analysis COGS
Time required for non-specific mutation analysis COGS
Cost of specific mutation test COGS
Time required specific mutation test COGS
Administration costs of genetic screening
programme
COGS
Time required for recruitment COGS
Abbreviations: COGS = Colorectal Cancer Genetic Susceptibility study, MSI =
Microsatellite Instability, ISD = Information and Statistics Division
*Age /sex specific information will be incorporated where possible
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Appendix 3 Key Outputs of Computer Model
STAGE OUTPUTS
Ascertainment Number of cases eligible for referral to cascade genetic screening programme
Number of cases actually referred to cascade genetic screening programme
Number of eligible cases accepting referral to cascade genetic screening
programme
Number of individuals presenting to cancer genetic services
Number of individuals presenting to cancer genetic services who are eligible
for referral to cascade genetic screening programme
Number of individuals presenting to cancer genetic services who are actually
referred to cascade genetic screening programme
Recruitment Number accepting referral to cascade genetic screening programme
Number accepting genetic counselling with genetic nurse
Number accepting genetic testing and providing blood sample
Mutation
Analysis
Non-specific Test results: Number of True Positives
Non-specific Test results: Number of False Positives
Non-specific Test results: Number of True Negatives
Non-specific Test results: Number of False Negatives
Relative
Recruitment
Total number of relatives of mutation carriers
Number of relatives of mutation carriers identified and traced"
Acceptance rate of genetic testing among relatives*
Specific Testing Specific Test results: Number of True Positives
Specific Test results: Number of False Positives
Specific Test results: Number of True Negatives
Specific Test results: Number of False Negatives
Resource
Allocation
Resources required for enrolment in cascade genetic screening programme
Resources required for genetic counselling
Resources required for non-specific genetic testing
Resources required for specific genetic testing
Summary Total number of mutation carriers identified*
Total resources expended*
Follow-up Number of mutation carriers accepting surveillance protocol*
Predicted outcomes of surveillance*
Predicted outcomes of non-surveillance*
^Information specific to age/sex distribution will be presented where appropriate
# Information specific to type of relationship with mutation carrier will be presented where
appropriate
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extremely high absolute risk of developing the disease. Further studies are, however,
required to confirm the findings by Jarvinen et al., and to provide a more accurate
assessment of the benefits of screening in mismatch repair gene earners.
The accepted protocols for screening people who meet the Amsterdam criteria for HNPCC
already constitute highly intensive surveillance, aimed at people with an extremely high
genetic risk. It is unlikely, therefore, that MMR gene mutation carriers would benefit from
yet more intensive screening. This reasoning is reflected in the current guidelines for
colorectal cancer screening in Scotland (249), which endorse the same screening protocol
in both circumstances. Hence, the current recommendation for screening in this group is
biennial colonoscopy, commencing at around age 25 (34, 56, 249, 288, 310). As with
empirically defined HNPCC, prophylactic colonectomy provides an alternative option for
preventing colorectal cancer in MMR gene mutation carriers. Indeed, the more conclusive
risk information provided by the detection of a pathogenic mismatch repair gene mutation
may provide a more convincing rationale for prophylactic surgery in this group (41, 235).
1.8.5 Further Considerations
Acceptance rates and compliance with screening protocols are crucial considerations in the
context of colorectal cancer screening targeted at people at increased genetic risk. Indeed,
non-compliance may be the main limiting factor in terms of achieving successful outcomes
(188). Numerous factors will influence whether or not an individual accepts screening.
These are likely to include such general factors as age, sex and education (74, 188), but
other key influences regarding this decision may be an individual's perception of their own
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risk and the acceptability of the screening techniques being offered (302). Several studies
have found that individuals with a family history of colorectal cancer are more likely to
accept screening than those without such a history (188, 263, 302). This is consistent with
the general observation that screening programmes aimed at people with a family history,
particularly those diagnosed with HNPCC, tend to have a higher uptake than programmes
aimed at the general population. Similarly, it has been noted that people who have declined
screening on the basis that they have empirically defined HNPCC, may undergo screening
after they are positively identified as MMR gene mutation carriers (130). Recommendation
of screening by a health professional is also associated with a greater uptake (74). Many of
the factors that influence acceptance and compliance are amenable to adjustment, primarily
through patient education and raised public awareness.
In addition to offering screening, people at increased genetic risk may benefit from
addressing their risk of developing colorectal cancer through primary prevention. Primary
data to support this hypothesis are scarce, and the extent to which the dietary and
environmental factors known to influence sporadic colorectal cancer also apply in the sub¬
group of the population at increased genetic risk remains poorly understood. Some
evidence exists to suggest that the risk factors that affect the general population also apply
in the subgroup of people with a family history (65), and that familial risk can be modified
by dietary and lifestyle factors (66, 80, 159, 191, 258). Such findings are consistent with the
observation that the spectrum of cancers in HNPCC families has altered during the last
century, with the incidence of colorectal cancer, relative to other malignancies, increasing
both in these families and in the general population. In both instances the observed trends
37
are presumably due to the influence of dietary and lifestyle changes. However, other studies
have found no relationship between colorectal cancer risk and established risk factors
among people with a family history of colorectal cancer (154. 206). Further investigations
are required to determine the most appropriate methods of primary colorectal cancer
prevention in those with a family history of the disease. Similarly, specific evidence
regarding the influence of environmental factors on the risk of colorectal cancer in MMR
gene mutation carriers is scarce. Environmental risk factors that may interact with
mismatch repair genes, and their possible influence on penetrance of mismatch repair gene
mutations, are considered further in chapter 3.
Despite this lack of clarity, though, it seems reasonable to recommend that individuals at
increased genetic risk consider dietary and lifestyle changes, such as reducing fat and
alcohol intake and taking exercise, with the aim of reducing their colorectal cancer risk. It
is also probable that people who are aware that they have a relatively high genetic risk may
be more highly motivated to effect such changes.
Although the specific effectiveness of chemoprevention in people with a family history of
colorectal cancer has yet to be ascertained, preliminary evidence suggests that
chemoprevention does lower risk in this sub-group (42, 240). Consequently,
chemoprevention may prove to be a useful approach to colorectal cancer prevention in
people at increased genetic risk (42, 103, 233). Again, evidence for a specific interaction
between NSAIDs and mismatch repair genes is considered in chapter 3.
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1.8.6 Summary
In summary, screening for colorectal cancer has the potential to offer significant benefits to
individuals at increased genetic risk. Ideally, the extent of family history, and the associated
risk, should be evaluated on an individual basis. For pragmatic reasons, however, it is
necessary to provide broad guidelines for sub-groups meeting particular criteria, and
several papers have attempted to formalise what appears to be a growing consensus
regarding screening of people with a family history of colorectal cancer. The precise
protocols offered will depend primarily on the absolute risk of the individual concerned,
and will be influenced by factors such as compliance, expense and the potential risks
associated with screening. Ideally, a specifically-tailored screening programme should be
available to any individual who is at significant absolute risk of colorectal cancer. At
present, however, considerably more research is required to inform the establishment of
appropriate screening protocols.
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1.9 Strategies For Identifying People At Increased Genetic Risk
Two principal strategies for identifying individuals at increased genetic risk oi colorectal
cancer are currently available, namely family history assessment and genetic testing for
mismatch repair gene mutations.
1.9.1 Family History
The standard means of identifying people at increased genetic risk of colorectal cancer in
Scotland, as elsewhere, has been through referrals from primary care to specialized genetic
services, on the basis of family history. This relies largely on the individuals in question
being aware of that they have a family history, and being sufficiently concerned in this
regard to seek advice from their general practitioner. The general practitioner will (hen
discuss this issue, and, if they deem it appropriate, may refer the patient to genetic services
for further evaluation of their risk and genetic counseling.
Although the above situation does largely address the needs of people who are concerned
about their family history of cancer, it is likely that a large proportion of people with a
family history will not be brought to the attention of genetic services. This has been
illustrated in several studies in which members of the general population, who have not
previously sought or been offered advice about genetic risk, have reported having a family
history in a research context (112, 135, 198, 243, 293). To some extent, this problem can be
addressed by increasing public awareness of the genetic nature of colorectal cancer risk and
the availability of strategies that may help people at increased susceptibility. Likewise,
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people identified as having a family history of colorectal cancer, and people who have
developed the disease themselves, can be advised to inform their close relatives so that they
in turn can seek counselling and genetic risk assessment. Encouraging GP's to enquire
about family history and refer patients where appropriate may also help increase the
proportion of the high-risk sub-group who are offered the appropriate management.
Overall, however, such interventions are likely to have a limited impact, and may produce
the adverse effect of unnecessarily increasing anxiety amongst the public, which in turn
could lead to over-stretching of resources.
The principal alternative for identifying people with a family history of colorectal cancer is
though distribution of questionnaires. This approach has been explored in several studies
(112, 162, 243, 293) and shown to be feasible in the research context. Response rates in
these studies have been highly variable, ranging from 29% (162) to 84.7% (112). This
disparity is likely to be due to differences in the design of questionnaires, the means of
delivery (i.e. whether the questionnaires are mailed directly to potential participants or
distributed through a general practice), and the populations under study. Nevertheless, these
studies have underlined the main limiting factor of questionnaire studies, namely that only a
proportion of the population will participate. A further option for identifying people with a
family history is for a nurse to ask people attending health checks for details of their family
history. Again, this approach has been shown to be feasible (135), but also has limitations,
being labour-intensive and restricted to people attending health checks.
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As a tool for identifying people at increased genetic risk, family history has the
considerable advantages of being relatively easy to assess, and providing a broad
measurement of genetic susceptibility that is not conditional on identification or
understanding of the underlying molecular defects. However, family history is a rather
crude instrument, and lacks sensitivity and specificity in terms of accurately predicting the
absolute risk to an individual. Colorectal cancer is a common disease, and many people
may have an affected relative, or even a strong family history, purely by chance.
Conversely, a high degree of genetic susceptibility may not be reflected in family history,
particularly when family size is small. Hence, offering screening on the basis of family
history alone may lead to some individuals undergoing screening unnecessarily while
others who are at a sufficiently high risk to justify such intervention are not included in
screening programmes. A balance must therefore be struck between the sensitivity and
specificity of family history, and must take into account the available resources and
implications for the individuals concerned.
In addition to the limitations of family history as a means of identifying people at increased
genetic risk, there are various practical issues involved with accurately establishing family
history, which may impact on genetic risk assessment. In the clinical setting, family history
is usually obtained directly from the individual concerned at interview with a geneticist,
and in the research context family history is generally established by interview or
questionnaire. Whilst interview is generally recognized as the preferable approach, it is still
subject to underreporting and inaccuracies on the part of the interviewee (91, 140). This
issue is crucial in the context of genetic risk assessment, and explored further in chapter 3.
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1.9.2 Genetic Testing
Genetic testing has the potential to provide a more precise method of determining genetic
risk, as it permits the analysis of molecular genetic risk factors at the individual level.
Genetic testing may be used for further characterization of genetic susceptibility in people
already known to be at increased familial risk of developing a particular condition, and also
has the potential to identify people at increased genetic risk, irrespective of their family
history. The recent identification of mismatch repair gene mutations as the causal defect in
a small but significant sub-set of colorectal cancer cases therefore provides an opportunity
for improving risk assessment and screening programme for people at increased risk.
From the clinical perspective, the ability to discriminate between people at different risks
within families is a major advantage of genetic testing compared to empirical risk
assessment based on family history. In autosomal dominant syndromes, a parent carrying
the mutation in question will have only a 50% chance of passing the affected allele to each
offspring. Thus, whilst an empirical diagnosis based on family history will classify all
individuals within that family as at increased risk, the kindred will actually comprise a
mixture of mutation carriers, who are at a greatly elevated risk, and non-carriers, with a risk
no different from the general population. Once the causative mutation within a family is
identified, genetic testing can be offered to all family members. Mutation carriers can then
be offered the appropriate surveillance, whereas non-carriers can be reassured about their
risk and removed from any family history-based screening they may have been undergoing.
Genetic testing therefore theoretically facilitates a reduction in the total number of family
members eligible for screening, as illustrated in studies demonstrating a reduction in the
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overall screening effort applied to high-risk families following the introduction of genetic
testing for mismatch repair gene mutations (225, 261). Although further research is
required to inform economic evaluation of genetic testing for colorectal cancer
susceptibility, it is possible that this approach may prove relatively cost-effective (31, 221).
Whilst genetic testing clearly has considerable potential as a tool for identifying people at
increased genetic risk of colorectal cancer, it also has various disadvantages and limitations,
associated with the technical difficulties inherent in both detecting and interpreting gene
variants.
Mismatch repair gene mutations are detected in only a proportion of people who meet the
Amsterdam criteria for HNPCC diagnosis, and are found in even fewer people who have a
lesser degree of family history. Individuals in whom no mismatch repair gene mutation is
detected may harbour pathogenic mutations in other genes, or indeed may have mismatch
repair gene mutations that were 'missed' for technical reasons. Accordingly, apparently
negative mutation status cannot be equated with lack of increased genetic risk, and
individuals who meet empirical criteria for screening should maintain screening despite a
negative genetic test result.
The pathogenicity of different mismatch repair gene variants remains largely unknown, and
may vary considerably. Additionally, other genetic and environmental factors may
influence penetrance, and at present data on these factors are extremely scarce.
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Consequently, information regarding actual absolute risk associated with a particular
mutation may be inaccurate, and may lead to an inappropriate level of anxiety and/or
screening.
The psychosocial implications of genetic testing constitute crucial considerations in the
context of applying genetic knowledge clinically. At the individual level, the identification
of a pathogenic mismatch repair gene mutation may cause anxiety or depression regarding
the risk of developing colorectal cancer, and may create additional concerns regarding
insurance and the reaction of other family members (40, 165, 184, 227). The fact that a
positive genetic test has implications for a whole family as well as the individual
undergoing testing raises a number of complex issues. The perceptions of other family
members, and the impact a positive test may have on them have been cited as a concern by
people undergoing testing (227). Mutation carriers are likely to experience anxiety relating
to the possibility that they may have passed the mutation on to their offspring, and may
have associated feelings of guilt if this is found to be the case (165). Related issues of
consent and confidentiality also arise from the familial nature of genetic testing. Family
members may feel obliged to undergo testing for the benefit of their relatives, and it is
possible that individuals who do not wish to undergo testing may become aware of their
probable mutation status through results in other family members (40).
The uncertainty surrounding the results of genetic testing for mismatch repair gene
mutations is another important issue that can potentially affect attitudes towards screening.
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One concern is that people with a family history of colorectal cancer who have tested
negative may be less inclined to comply with screening programmes. A qualitative study by
Lerman et al., in which first-degree relatives of colorectal cancer patients were interviewed
to ascertain their attitudes towards genetic testing, found that approximately half the
participants anticipated that they would be less inclined to adhere to screening programmes
or primary prevention strategies if they were to test negative (165). Conversely, many
participants in this study felt that a negative test would not remove their anxiety
surrounding their genetic risk (165).
Considerable uncertainty regarding the psychosocial impact of genetic testing for mismatch
repair gene mutations remains, and several studies have indicated that understanding of
genetics, genetic testing, and the concept of genetic risk amongst the general population is
limited (46, 227, 274). Despite this, the potential benefits of genetic testing in this context
are such that this approach is commonly used both clinically and for research purposes.
Hence, there is a clear consensus that advocates the use of genetic counselling before and
after genetic testing, in order to provide education and support to the individuals concerned
(40, 165, 184, 220).
As discussed elsewhere, conducting mutation analysis of mismatch repair genes is also a
lengthy and expensive process. Resulting practical and economic considerations, coupled
with the scientific and psychosocial issues outlined above, have meant that mutation
analysis is predominantly restricted to people deemed to be at high risk of having a
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mismatch repair gene mutation. Hence, a major challenge in this context is that of devising
strategies for efficiently targeting resources towards the identification of kindreds with such
mutations. There are several options for targeting of resources in this manner. Firstly, the
extent of family history may be used to identify people most likely to harbour a mutation.
Similarly, the relatively early age of colorectal cancer onset evident in mismatch repair
gene carriers means that young cases are relatively likely to carry a mutation. Additionally,
the intermediate phenotype of microsatellite instability (MSI), which is considered further
in the next chapter, is associated with mismatch repair gene deficiency, and this can provide
another means of targeting resources. Each of the above approaches has been used in the
context of epidemiological studies to identify mutation carriers, and to some extent have
been applied in the clinical setting. Currently, most mutation carriers are identified by
referral of patients with a family history of colorectal cancer to genetic services. Another
option, under investigation in an ongoing program in Scotland, is to search for mismatch
repair gene mutations among persons with early-onset colorectal cancer.
An overview of findings from one research group (174) provides a consideration of how
best to utilize the above criteria to target mutation analysis to individuals at high risk of
carrying a mutation, concluding that MSI is a useful predictor of mutation status in
individuals meeting the Amsterdam criteria for HNPCC. Estimates of sensitivity and
specificity of various family history criteria, as means of identifying mutation carriers, are
also presented by Syngal et al., (267). At the present time, however, there is no consensus
regarding the most efficient approach to identifying mutation carriers.
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Applying mutation analysis to people deemed to be at high risk of carrying a mismatch
repair gene mutation has so far been useful in two ways. Firstly, mutation analysis in
colorectal cancer patients has enhanced our understanding of the genetic epidemiology of
this disease. In addition, mutation analysis has permitted the characterization of the genetic
defects responsible for the high degree of familial risk seen in a proportion of families with
multiple colorectal cancer cases, and thus enabled screening procedures to be refined.
However, from a public health perspective, the identification of all mutation carriers in a
population at an asymptomatic stage is the ultimate goal of genetic testing.
There are several options for attempting to achieve such a goal, including population
genetic testing, in which mutation analysis is conducted in every member of a population,
and stratified population genetic testing, in which genetic testing is offered only to
individuals meeting specified family history criteria. An alternative strategy to identifying
asymptomatic mismatch repair gene mutation carriers in a population is cascade genetic
testing, which involves performing mutation analysis in colorectal cancer patients or
individuals otherwise deemed to be at high risk of harboring mutations, and subsequently
tracing an identified mutation through a pedigree. The advantages and disadvantages of




Family history is a useful tool for identifying people at increased genetic risk, but lacks
sensitivity and specificity. Although it is frequently employed, various aspects of the
association between family history and increased genetic risk remain to be elucidated. Gaps
in the current knowledge include data relating to the precise absolute risks associated with
various degrees of family history, the prevalence of family history in the general
population, and the accuracy with which family history is reported and recorded. Genetic
testing for mismatch repair gene mutations has recently provided another option for
determining which individuals are at increased genetic risk, and an opportunity to improve
the accuracy of genetic risk assessment. The general consensus is that both these strategies
are relevant, and should be viewed as complementary. However, although understanding of
the genetic epidemiology of colorectal cancer is advancing rapidly, the required data for
informing strategies for people at increased genetic risk is incomplete. Consequently,
considerable debate surrounds the appropriate strategies for people at increased genetic
risk, and further evaluation of the various options is required.
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1.10 Aims
The overarching aim of this thesis is to contribute to available data relevant to prevention of
colorectal cancer in Scotland through targeting people at increased genetic risk. To this end,
there are three core research components addressing gaps in current knowledge, organised
around the central theme of evaluating available strategies for identifying people at
increased genetic risk. Each component has specific research aims as follows:
(i) The role of mismatch repair gene mutations in colorectal cancer
To undertake a systematic literature review of the aetiological role of mutations in DNA
mismatch repair genes in colorectal cancer. This comprises a collation of current
knowledge of the role of the DNA mismatch repair genes, hMLHl and hMSH2, and their
genetic variation and a critical appraisal of published evidence of associations between
mutations in these genes and colorectal cancer.
(ii) Family history as a tool for identifying people at increased genetic risk
To evaluate the use and limitations of family history assessment through analysis of a
unique data set, comprising family history information reported by a colorectal cancer case
or control subject at interview and information obtained through record linkage with the
Scottish Cancer Registry. To estimate prevalence of family history of colorectal cancer in a
population sample, to assess risk associated with a family history, and to investigate the
accuracy with which family history of colorectal cancer is reported at interview.
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(iii) Cascade genetic testing for DNA mismatch repair gene mutations
To develop a computer model of cascade genetic testing to assess the potential utility of
this strategy as a means of identifying asymptomatic DNA mismatch repair gene mutation




Mismatch Repair Genes hMLH1 and hMSH2 and
Colorectal Cancer: A Systematic Literature Review
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A systematic literature review of the mismatch repair genes hMLH 1 and hMSH2 and their
role in colorectal cancer was conducted and presented in accordance with the guidelines
presented by the Human Genome Epidemiology Network (HuGE Net). The completed
review has been published in the American Journal of Epidemiology (199), and is also
available on the HuGE Net Website (114). This chapter has been adapted from the
published review, which is included as an appendix for reference (see appendix A2).
2.1 Abstract
Evidence to support a role for the mismatch repair genes human mutL homolog l (hMLHl)
and human mutS homolog 2 (hMSH2) in the etiology of colorectal cancer has come from
linkage analysis, segregation studies, and molecular biologic analysis. More recently,
carriers of potentially pathogenic mutations in the hMLHl/hMSH2 genes have consistently
been shown to be at a greatly increased risk of developing colorectal cancer compared with
the general population. When considered together, the available evidence shows a strong,
consistent, and biologically plausible association between mismatch repair gene mutations
and colorectal cancer. The penetrance of mutations in hMLHl/hMSH2 is incomplete and is
significantly higher in males (approximately 80%) than in females (approximately 40%).
To date, evidence for gene-gene or gene-environment interactions is limited, although
preliminary studies have revealed a number of avenues that merit exploration. Population
screening for mutation carriers is not currently a feasible option, and mutation analysis
remains restricted to either relatives of mutation carriers or colorectal cancer cases selected
on the basis of phenotype.
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2.2 Introduction
The mismatch repair genes human mutL homolog 1 (hMLHl) and human mutS homolog 2
(hMSH2) are integral components of the DNA mismatch repair pathway. So far, over 200
allelic variants have been identified for each gene, and the majority of these have been
reported to be pathogenic in terms of colorectal cancer. The primary objectives of this
review are to describe what is known about hMLHl and hMSH2 and their variants in
different populations and to examine the evidence implicating these genes as risk factors in
the development of colorectal cancer.
2.3 Methods
2.3.1 Search strategy
The MEDLINE (National Library of Medicine), EMBASE (Excerpta Medica), and
CANCERLIT (National Cancer Institute) databases were searched for papers published
before December 31, 2001, using the keywords hMSH2 and hMLHl. Relevant papers were
identified, critically appraised, and entered into a Reference Manager (ISI ResearchSoft,
Berkeley, California) database. In addition, PubMed was searched via Reference Manager,
by author name, for papers from research groups that had published several times on this
subject. Finally, the database thus created was cross-referenced with papers cited in the
International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer database
of mutations (127).
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For the "Gene Variants" section, a total of 109 papers were considered, which were
identified by the above strategy and fulfilled the following selection criteria: 1) complete
mutation analysis had been performed on more than five patients with colorectal cancer and
2) there was sufficient detail on the molecular nature of the genetic alteration. A database
presenting details of all gene variants described in these published papers is shown in
appendix A3, and posted on the website of the Human Genome Epidemiology Network
(114).
For the "Associations" section, the above strategy led to the identification of eight studies
that had conducted an analysis of the risk of developing colorectal cancer among carriers of
mismatch repair gene mutations. These studies are summarized in table 2.2. A total of 77
papers that included results of complete mutation analysis performed on more than five
colorectal cancer patients selected on the basis of family history, microsatellite instability
(MSI), or age of onset, were also identified. A summary of these studies is presented in
appendix A4, and on the HuGE Net website (114). Many papers included information
relevant to both the gene variants and associations sections.
2.3.2 Classification of Gene Variants
For the purposes of this review, gene variants were classified into one of four categories.
These categories are loosely based on the definitions given below, modified according to
clinical observations.
1. Pathogenic mutation—generally frameshifts, nonsense mutations, and splice variants
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2. Probable pathogenic mutation—generally nonconservative amino acid changes
3. Probable polymorphism—generally conservative changes, often observed in controls
4. Definite polymorphism—synonymous variants
2.4 Genes
2.4.1 hMSH2
The human mutS homolog 2 (hMSH2) gene is located at chromosome 2p21, an area
initially identified as an important candidate region for genes involved in hereditary
nonpolyposis colorectal cancer (HNPCC) syndrome by genetic linkage analysis within
large affected families (161, 218).
2.4.2 hMLH1
The human mutL homolog 1 (hMLHl) gene is located at chromosome 3p21—23, an area
also identified by genetic linkage analysis as an important candidate region within large
HNPCC families that are not connected with the chromosome region 2p21-22 (171, 214).
2.5 Gene Variants
One conclusion generated by early attempts to identify precise genetic alterations in
hMLHl and hMSH2 was that variants in these genes are extremely heterogeneous. All 16
exons of the hMSH2 gene and 19 exons of the hMLHl gene have been found to contain
pathogenic mutations.
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At present, there are no standard criteria for classifying variants as pathogenic mutations or
polymorphisms, and consequently there is considerable variation in interpretation by
different researchers. In general, categorization of alterations is based on the predicted
effect on protein, with segregation of the mutation with colorectal cancer in the kindred in
question and/or analysis of control subjects for that specific mutation also being considered
when possible. However, the functional consequences of many mutations are difficult to
predict accurately. It has been suggested that even alterations that do not affect the amino
acid sequence could lead to aberrant splicing, and that the position of the mutation may be
more significant than the type (211). In vitro functional assays have been developed and
applied to the task of determining the pathogenicity of missense mutations (59, 213, 277)
and may eventually facilitate accurate classification of such changes.
Appendix A3 lists all of the gene variants identified as part of this review, illustrating the
extreme range of mutations identified and the fact that the observed spectrum of mutation is
not entirely uniform. Some features of this table are summarized below. Figures 2.1 and 2.2
illustrate the distributions of unique gene variants that have been fully characterized at the
molecular level in hMLHl and hMSH2, respectively, according to their position on the
gene. Figures 2.3 and 2.4 are designed to show the actual numbers of families in which
pathogenic mutations have been identified.
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Figure 2.1 Distribution of Unique Gene Variants in hMLH1
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Figure 2.1 illustrates the distribution of all unique gene variants that have been identified and fully
characterized in mutation analysis studies of colorectal cancer patients. Variants designated as
categories 1, 1/2, 2, and 2/3 in appendix A3 are considered to be pathogenic for the purpose of this
summary figure, and all other variants are described as polymorphisms. Exon deletions in which the
underlying molecular variant was not known were excluded. Abbreviation: IVS, intervening
sequence.
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Figure 2.2 Distribution of Unique Gene Variants in hMSH2
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Figure 2.2 illustrates the distribution of all unique gene variants that have been identified and fully
characterized in mutation analysis studies of colorectal cancer patients. Variants designated as
categories 1, 1/2, 2, and 2/3 in Appendix A3 are considered to be pathogenic for the purpose of this
summary figure, and all other variants are described as polymorphisms. Exon deletions in which the
underlying molecular variant was not known were excluded. Abbreviation: IVS, intervening
sequence.
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Figure 2.3 Distribution of Pathogenic Mutations in hMLH1 by Number of
Families Identified
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Figure 2.3 illustrates the distribution of pathogenic mutations according to the actual number of
families in which a pathogenic mutation has been identified. These figures include all pathogenic
mutations as defined in figure 2.1, plus exon deletions of unspecified origin. Deletions of more than
one exon were excluded. 'Families are deemed to have a "founder mutation" if they have a
mutation which has been shown to have a founder effect in the same population. Abbreviation: IVS,
intervening sequence.
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Figure 2.4 Distribution of Pathogenic Mutations in hMSH2 by Number of
Families Identified
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Figure 2.4 illustrates the distribution of pathogenic mutations according to the actual number of
families in which a pathogenic mutation has been identified. These figures include all pathogenic
mutations as defined in figure 2.2, plus exon deletions of unspecified origin. Deletions of more than
one exon were excluded. 'Families are deemed to have a "founder mutation" if they have a
mutation which has been shown to have a founder effect in the same population. Abbreviation: IVS,
Intervening Sequence
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In total, 259 different pathogenic mutations, as defined above, have been identified in
hMLHl, along with 45 polymorphisms. In hMSH2, 191 different pathogenic mutations and
55 polymorphisms have been characterized so far. This high degree of heterogeneity is
similar to that found in the breast cancer genes BRCA1 and BRCA2. in each of which over
400 gene variants have been reported. When considering the range and type of gene
variants listed in appendix A3, there are several important sources of bias that merit
consideration. Firstly, a significant publication bias is likely to exist in favor of apparently
pathogenic alterations. Highly penetrant mutations are also likely to be over-represented,
since many studies involved conducting mutation analysis in patients selected on the basis
of a strong family history of colorectal cancer. Secondly, genomic deletions in mismatch
repair genes appear to occur relatively commonly, particularly in hMSH2, and such variants
are not detected by many of the techniques commonly used for mutation analysis (304).
It is evident from the above figures that certain specific mutations have been identified in
more than one kindred. Indeed, some mutations are found with a relatively high frequency.
The most commonly observed mutations are summarized in table 2.1, which displays all
mutations identified in more than four ostensibly independent kindreds.
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Table 2.1 Commonly Observed Pathogenic Mutations






Exon 16 Deletion A-A-G at
nucleotide 1846
IVS 5 g-a at nucleotide 4541
Exon 16 A-A-G-C at nucleotide
1852
Exon 4 C-T at nucleotide 350
Exon 19 G-A at nucleotide 2146
Exon 13 Insertion C at nucleotide
1490
Exon 4 T-G at nucleotide 320
Exon 13 C-T at nucleotide 1459
Exon 17 C-T at nucleotide 1975
Exon 19 G-A at nucleotide 2141
Exon 8 C-T at nucleotide 676
Exon 2 G-A at nucleotide 199
Exon 2 C-T at nucleotide 184
IVS 14 4-base-pair insertion/3-
base-pair deletion at
nucleotide 1667+2
IVS 5 A-T at nucleotide 942+3
Exon 6 G-A at nucleotide 965
Exon 12 Deletion A-A-T at
nucleotide 1786
Exon 7 C-T at nucleotide 1216
HMLH1*
3.5-kilobase deletion 63
In-frame deletion in lysine 21
codon 616
Out-of-frame deletion in 18












Silencing of allele 5
HMSH2*














Abbreviations: hMLH1, human mutL homoiog 1; IVS, intervening sequence; hMSH2, human mutS
homolog 2; STOP, stop codon. Standard notation for nucleotides and amino acids is employed.
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The observed spectrum of gene variants may be largely due to genuine differences in the
mutability of specific nucleotides or sequences within the gene, but in some cases variants
identified in apparently unrelated kindreds can be traced to a common ancestor. Such
"founder effects" have been identified in the Finnish population, where two specific
founder mutations in hMLHl account for the vast majority of families in which mismatch
repair gene mutations have been identified (215, 241). Another hMLHl founder effect is
evident in the Danish population (129). The extent to which founder effects are responsible
for other frequently detected alterations is not entirely clear from the data currently
available, and it is likely that some of the kindreds included in table 2.1 share a common
ancestor. Interestingly, the intervening sequence 5 variant A-T at nucleotide 942+3 has
been shown to occur as a founder mutation in Newfoundland (76), but another study found
no evidence for a common haplotype in 10 carriers of this variant, of various origins, and
concluded that the mutation also arises frequently de novo (51). This example underlines
the notion that observations of mutation frequency are the result of both the probability of a
mutation at a given nucleotide and the demographic history of the population in question.
Overall, little ethnic or population variation is apparent from the available gene variant
data. However, the current biases towards highly penetrant mutations are such that the
effect of the identified mutation is likely to transcend any population differences. Clearly,
there is a need for accurate and extensive population-based data to elucidate any population
differences in the spectrum and frequency of mismatch repair gene variants.
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There is no clear evidence to suggest that any specific mismatch repair gene mutation
produces a specific phenotype of colorectal cancer, although it has been suggested that
some differences exist between the spectrum of extracolonic cancers associated with
hMSH2 mutations in comparison with hMLHi mutations (60, 248).
2.6 Associations
Evidence implying and supporting a causal role for hMLHl/hMSH2 in colorectal cancer
comes from both epidemiologic studies and laboratory-based molecular studies. Initially,
linkage studies revealed that disease expression in a proportion of HNPCC kindreds was
linked to either chromosome 2p21 (161, 212, 218) or chromosome 3p21-23 (77, 171, 212,
214).
The connection between the HNPCC syndrome and mismatch repair arose from the
observation that the majority of tumors from HNPCC families exhibited a replication error
phenotype, a feature resulting from instability of microsatellite repeats during replication
that is found only in a minority of "sporadic" colorectal cancer cases (1,128). Previous
molecular studies in the yeast Saccharomyces cerevisiae had led to the identification of a
group of genes, known as mismatch repair genes, that were involved in maintaining the
fidelity of DNA replication. Defects in yeast mismatch repair genes led to microsatellite
instability (MSI), prompting formulation of the hypothesis that human homologs of these
genes were involved in the HNPCC syndrome (264). Subsequently, several such homologs
were identified, and two of them, hMLHl and hMSH2, were shown to reside on
chromosomes 3p21—23 and 2p21 respectively (29, 69, 161, 216). Further supportive
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evidence came from the observation that pathogenic mutations in hMLHl or hMSH2 could
be identified and shown to segregate with disease in a high proportion of kindreds that had
shown linkage to the corresponding chromosome (69, 161, 216).
The heterogeneity of mutations in mismatch repair genes means that screening for
mutations in these genes is a lengthy and complicated process, and consequently mutation
analysis has largely been restricted to colorectal cancer patients deemed to have a relatively
high probability of carrying such a mutation. Only two studies identified in this review
conducted mutation analysis among control subjects. Farrington et al. (62) found that none
of 26 Scottish blood donors harbored previously identified mutations, although four
variants of unknown significance were found. This was compared with the identification of
potentially pathogenic mutations in 14 of 50 colorectal cancer patients diagnosed at less
than 30 years of age. Similarly, no pathogenic mutations were reported in an analysis of 73
population controls from Utah (242).
Thus, the practical restrictions on mutation analysis, coupled with the low population
prevalence of mismatch repair gene mutations and the fact that such mutations are found
only in a minority of colorectal cancer patients, has meant that traditional cohort and case-
control study designs have not been feasible. However, despite this lack of conventional
epidemiologic evidence, subsequent studies have provided convincing evidence to support
the hypothesis that mismatch repair gene mutations cause a subset of colorectal cancer
cases. This evidence is summarized in figure 2.5.
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Figure 2.5 Pathways of Epidemiologic and Biologic Research Identifying and
Confirming the Causal Role of hMLH1/hMSH2 in Colorectal Cancer
Linkage analysis in ' I Gene function /
families with ^^ I Presence of j expression
extreme phenotypes j rnicrosatellite . analysis in
(HNPCC) i instability I yeast







Abbreviations: HNPCC, hereditary nonpolyposis colorectal cancer; hMLH1, human mutL homolog
1; hMSH2, human mutS homolog 2.
The most compelling supportive evidence comes from studies which demonstrate that
mutation carriers are at greatly increased risk of developing colorectal cancer in comparison
with the general population. Such studies are summarized in table 2.2.
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Table2.2RiskAnalysisStudiofhMLH1/S 2ndC lorectalncer ReferenceAr aofAsc tai m nt studyindexcasesNo.f index casesAscertainmentof mutationcarriers












DunlopetScotlandColorectalcan er al.(57)casesag d<30 yearsidentified througheSc ttis NationalC ncer Registrybetween 1970and93, excludingthosewith afamilyhistor fulfillingthe Amsterdamcriteria.
Relativesweretr ced, testedformutation statuswherepossible, andclassified accordingly.
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AarnioetFinlandFamiliesthatfulfill d al.(3)theAmsterdam criteria.In24of these,mutation analysish d demonstratedthe segregationof hMLH1orh S 2.
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VasenetN th rlaF miliesthatfulfil ed al.(286)ndstheAmsterdam criteria,identified throughhe NetherlandsHNPCC registryandfoundto havemutationin hMLH1orS 2.
19Relativesweretr ced andtestedformu ation carrierstatuswhere possible.
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FroggatteEn landFamiliesthfulfill d al.(75)theAmsterdam criteria,with mutationsinhMLH1 orhMSH2.










362 hMLH1 carriers; 301 hMSH2 carriers
hMLH1:3= 65%;9= 55%;9+8= 60%; hMSH2~.3= 73%;9= 54%;9+(J= 65%(toage 70years)
Netherlands cumulative incidence data publishedby EUCAN(118)
3=2.81%;9
=2.17%(to age70years)
hMLH1:3= 23#;9=5 hMSH2.S= 26#;9=5#
50 (.hMLH1: n=23; hMSH2: n=27)
hMLH1:9+ 3=67%; hMSH2.9+ 3=62%
United Kingdom cumulative incidence data publishedby EUCAN(118)
9+c^ 3.16%
hMLH1:21"; hMSH2-.20*
Millaretal.C nadaWomenwi hb t7 (194)colorectalancerd endometrialcancer beforeag70years, identifiedthroughh OntarioCancer Registryand/orthe tumorregistryat PrincessMargaret Hospital,T ronto andharboringMLH1 orhMSH2mutations.
First-degreerelativ s wereidentified.Carr r statuswanot determined.
N/A
N/A
Ontario provincial cancerr t
First-degree relativesof mutation carriers:8.1 (95%CI:3.5, 15.9); first-degree relativesof mutation- negative probands:2.8 (95%CI:1.7, 4.5)
Linetal.UnitedKindre sw rek own. (167)Statesoh vemutationsin hMLH1(n=2)or hMSH2(n=2).No furtherdetailw s givenonh wthese kindredsw re ascertained.
Mutationc rrierswere identifiedbyt sting(= 78)ordeterminedtbe obligatecarriers(n= 27).
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hMLHt.S= 94%;$= 63%;$+e= 84%; hMSH2.S= 96%;?= 39%;$+S= 71%
N/A
N/A
Abbreviations:HNPCC,hereditarynonp lyposiscol rectalca er;hMLHI,um nmu Lh og1;hMS 2,um nutSh olog2N/Atapplicable; confidenceinterval;EUCAN,Europe nN tworkfCan rRegistries;Sp e anceim lonly$p n trancefe a sly;?+61,penetranceg oupcomprisingb thsexe . WhereEUCANdatah vbeenus dforcomparison,thtimatefts andardizedincid ncr tcrudeod esott ki cc unthgst ucture ofthemutationcarr ergroup.Bec sefthpp oximatenaturft scom rison,wd dnotc nsiderippropriatecalculcon encei t v lsfh estimates.
Aarnio et al. (4) calculated a standardized incidence ratio of 68 (95 percent
confidence interval: 56, 81) for Finnish earners of hMLHl or HMSH2 mutations. In
the other studies considered in table 2.2, researchers did not make a formal
calculation of the standardized incidence ratio, but approximate estimates utilizing
appropriate cancer registry data consistently show that the risk of colorectal cancer
in mutation carriers is greatly in excess of the corresponding risk in the general
population. The relative risk of 8.1 (95 percent confidence interval: 3.5, 15.9) for
first-degree relatives of mutation earners observed by Millar et al. (197) is consistent
with a risk that is an order of magnitude greater in mutation carriers than in non-
carriers.
The clinical presentation of colorectal cancer among mutation carriers appears to
differ from that found among persons with sporadic cases in several respects, an
observation that indirectly supports the hypothesis that mutations in mismatch repair
genes account for a distinct subset of colorectal cancer cases. The most obvious
clinical characteristic associated with colorectal cancer among mismatch repair gene
mutation carriers is familial aggregation. Part a of Appendix A4 provides details on
mutation analysis studies conducted among patients selected on the basis of family
history. The results of these studies are summarized in tables 2.3 and 2.4.
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Table 2.3 Association between the extent of family history of colorectal
cancer and the prevalence of mismatch repair gene mutations
Family history No. of No. of hMLH1 hMSH2 Published References





Fulfillment of the 27 534 145 27.2 87 16.3 (11, 12,33,35,47,49,52,75,
Amsterdam criteria 98, 105, 117, 146, 158, 175,
180, 189,200, 202,209,219,
248, 268, 270, 292, 295, 297,
306)
Strong family history 25 494 46 9.3 43 8.7 (11, 12, 14,35,47,49,52,98,
not fulfilling the 105, 117, 158, 175, 180, 189,
Amsterdam criteria 202,209,219, 248,268,270,
292, 294, 297, 306, 323)
*See table 1.1 for details
Table 2.4 Results of mutation analysis in patients fulfilling the Amsterdam
criteria for colorectal cancer, by geographic origin
Country No. of index hMLH1 mutation hMSH2 mutation Published reference
cases carriers carriers
Asia
Japan 15 1 8 Bai et al. (11)
Japan 11 5 0 Miyaki et al. (200)
Japan 4 0 1 Nomura et al. (209)
Korea 25 8 0 Han et al. (98)
Total 55 14 (25.5%)
Europe
9 (16.4%)
Russia/Moldavia 7 1 3 Maliaka et al. (189)
Sweden 21 5 ' 1 Tannergard et al. (270),
Wahlberg et al. (292)
Sweden 7 1 0 Liu et al. (175)
Switzerland 10 3 3 Buerstedde et al. (33)
Switzerland 15 6 4 Ileinimann et al. (105)
Switzerland 14 10 0 Hutter et al. (117)
Italy 14 4 3 Pensotti et al. (219)
Italy 18 1 2 de Leon et al. (49)
Italy 17 5 2 Viel et al. (290)
72
Italy 17 2 3 Curia et al. (47)
Italy 13 3 3 Calistri et al. (35)
France 10 3 2 Dieutnegard et al. (52)
France 3 2 0 Wang et al., 1997 (294)
France 22 11 3 Wang et al., 1999 (295)
Holland / Norway 92 25 16 Wijnen et al. (306)
Germany 57 11 4 Lamberti et al. (158)
England 17 3 5 Froggatt et al. (75)
Total 344 96 (27.9%)
Australia
54 (15.7%)
Australia 18 4 2 Kohonen-Corish et al.
(146)
Australia 33 11 9 Scott et al. (248)
Total 51 15 (29.4%) 11 (21.6%)
North America
USA 12 4 2 Luce et al. (180)
USA 28 10 1 Syngal et al. (268)
Canada 14 2 5 Bapat et al. (12)
Total 54 16 (29.6%) 8 (14.8%)
The observed prevalence of potentially pathogenic mutations in individuals meeting
the Amsterdam criteria is remarkably consistent across different populations (table
2.4). MSI is evident in 12-15 percent of sporadic colorectal cancer cases, compared
with over 90 percent of cases defined, according to the Amsterdam criteria, as being
from HNPCC kindreds (19). MSI is currently thought to result from defective
mismatch repair, although evidence to support this hypothesis is limited by two
factors. Firstly, the vast majority of studies that examine mutations in MSI-positive
patients concentrate on HNPCC families, introducing considerable bias. Secondly,
few investigators have looked systematically for mutations in patients with MSI-
negative tumors. Interestingly, when this has been done, there have been a few
instances in which tumors from patients with identified mutations in hMLHl or
hMSH2 have not exhibited the MSI phenotype (12, 50, 62). Analysis of all
published results from one research group showed that, among kindreds with
suspected HNPCC, germline mutations could be detected in 16 out of 22 colorectal
cancer patients with MSI-positive tumors, as compared with one out of 37 mutations
in MSI-negative patients (174). The presence of mutations in MSI-negative cases
may reflect mechanisms of tumorigenesis in people with mismatch repair gene
mutations that do not require mutation instability. Mutation analysis studies
involving patients selected on the basis of MSI are summarized in appendix A4, part
b.
The association between early age of colorectal cancer onset and hMLHl/liMSH2
gene mutations is often confounded by the fact that the selection criteria have
included family history, but a few studies have performed mutation analysis on
patients selected solely on the basis of early age of onset. As is illustrated in table
2.5, these studies demonstrate a trend towards a higher pathogenic mutation
detection rate in individuals diagnosed at a relatively young age, an observation that
is consistent with the hypothesis that these genes are involved in colorectal cancer
tumorigenesis. Details on the studies considered in table 2.5 can be found in
appendix A4, part c.
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Table 2.5 Association between age at onset of colorectal cancer and

















No. % No. %
<30 1 50 7 14 7 14 Farrington et al. (62)
<40 1 12 1 8.3 1 8.3 Syngal et al. (268)
<45 1 38 1 2.6 2 5.3 Fornasarig et al. (72)
<50 6 135 6 4.4 6 4.4 Dieumegard et al. (52), Montera et al.
(201), Tomlinson et al. (276), Wang et al.,
1997 (294), Wang et al., 1999 (295),
Weber et al. (299), and Yuan et al. (323)
2.6.1 Penetrance
While it has become widely accepted that mutations in the mismatch repair genes
hMLHl and hMSH2 play a causal role in a subset of colorectal cancer cases, the
precise penetrance of these mutations remains unknown. A number of studies,
summarized in Table 2.2, have addressed this issue. Results are presented differently
for each study, so direct comparison is difficult. One consistent finding is that risk is
higher among male mutation carriers (approximately 80 percent by age 70 years)
than among females (approximately 40 percent by age 70 years), an observation
with important implications for patient management and surveillance. Observed
differences in penetrance between carriers of hMLHl or hMSH2 mutations (170,
286) await confirmation in future studies.
A study by Aarnio et al. (4) classified relatives of clinically defined HNPCC cases as
being at a 25 percent, 50 percent, or 100 percent risk of being mutation carriers and
calculated the cumulative incidence of colorectal cancer amongst carriers up to age
70 years as being 100 percent and 54 percent for males and females, respectively. A
potential source of bias in this particular study is the fact that the majority of the
probands had one of the Finnish founder mutations. A similar study carried out in
Amsterdam Dutch kindreds calculated risk of colorectal cancer among mutation
earners at age 75 years to be 92 percent in males and 83 percent in females (289).
These studies used family history as a selection criterion, an approach that
introduces considerable ascertainment bias. Kindreds identified in this way will
inherently have an unusually large number of colorectal cancer cases, and estimates
of penetrance obtained in this way are likely to be falsely high. Dunlop et al. (57)
used an alternative approach to identify mutation-carrying probands from the
Scottish population, performing mutation analysis on colorectal cancer patients with
a very early age of onset (< 30 years). The cumulative incidence of colorectal cancer
among relatives proven to be mutation carriers was found to be 74 percent in males
and 30 percent in females at age 70 (57).
The identification of families with mismatch repair gene mutations using any
phenotypic selection criteria introduces ascertainment bias, and such kindreds may
not be representative of all mutation-carrying families in the general population.
Thus, there is a considerable need for estimates of penetrance based on
systematically collected familial or population data.
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2.6.2 Survival
Prior to the identification of mismatch repair genes, several studies suggested that
the prognosis for patients with colorectal cancer due to HNPCC was more favorable
than that for patients with sporadic colorectal cancer. Whether improved prognosis
is specifically a feature of colorectal cancer in patients harboring mismatch repair
gene mutations is not yet clear, although preliminary evidence suggests that this may
be the case (105, 245).
A possible explanation for this phenomenon may be that the high frequency of
mutations characteristic of mismatch repair-deficient tumors actually restricts tumor
growth (245). However, kindreds included in survival analysis studies on the basis
of a strong family history of colorectal cancer have, by definition, survived to
produce a large family group for analysis. Therefore, these kindreds may not be
representative of all mutation carriers, and there is a need for survival data from
unselected, population-based cohort studies.
It has also been postulated that mismatch repair deficiency may have an effect on
response to chemotherapy. Results are not entirely consistent, but several studies
suggest an association between hMLHl/hMSH2 deficiency in cell lines and
resistance to chemotherapeutic agents (5, 37, 68, 81).
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2.7 Interactions
While the exact penetrance of specific mutations in hMLHl and hMSH2 is
unknown, it is not complete. Consequently, the age-related risk, pathologic features,
and clinical outcomes associated with such mutations are subject to modification by
other genetic and environmental factors.
The body of epidemiologic data regarding modification of disease resulting from
mismatch repair gene mutations is somewhat limited. The effects of known
environmental risk factors for colorectal cancer in mutation carriers are largely
unstudied, and much of the suggestive evidence for interactions comes indirectly
from studies using MSI-positive or clinically defined HNPCC cases as a surrogate
for mutation carriers. Furthermore, the apparent presence of a statistical interaction
between mismatch repair gene mutations and other genetic or environmental factors
does not necessarily imply the existence of a biologic or causal interaction.
Therefore, the studies considered below do not constitute evidence for true
interactions involving hMLHl and hMSH2, although they may prove useful in terms
of identifying potential interactions that merit further investigation.
2.7.1 Gene-environment interactions
Reports by Ruschoff et al. (240) and Yamamoto et al. (317) have suggested that
treatment of hMLHl- or hMSH2-deficient cell lines with nonsteroidal
antiinflammatory drugs leads to a significant reduction in the proportion of cells
78
exhibiting MSI, indicating that this phenotypic manifestation of mismatch repair
deficiency may be modified by these drugs.
Slattery et al. (254) have presented evidence suggesting that an interaction may exist
between MSI and smoking. Compared with patients with MSI-negative tumors,
patients with MSI-positive tumors were more likely to be heavy smokers: Odds
ratios were 1.6 (95 percent confidence interval: 1.0, 2.5) in men and 2.2 (95 percent
confidence interval: 1.4, 3.5) in women (254). These results are supported by those
of another recent study (315), and the implication that smoking is specifically
associated with a particular subset of colorectal cancer cases is consistent with the
weak associations reported between smoking and sporadic colon cancer. It is
possible that mismatch repair deficiency is involved in the observed association
between smoking and MSI, but further studies involving known mutation carriers
will be required to confirm this hypothesis.
Another recent paper by Slattery et al. (257) showed that the risk of MSI-positive
colon cancer may be reduced by estrogens and increased by estrogen withdrawal.
Dietary heterocyclic aromatic amines are another risk factor that requires further
evaluation. Wu et al. (315) found that patients with MSI-positive tumors had
received a relatively high dietary exposure to heterocyclic aromatic amines, an
observation that remained significant after adjustment for smoking and red meat
intake. This finding is consistent with laboratory studies, which have shown that rats
exposed to particular heterocyclic amines showed the trait of MSI (36).
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2.7.2 Gene-gene interactions
Risk of colorectal cancer among female hMLHl/liMSH2 mutation earners is
approximately half the risk in male mutation carriers (4, 57). In the absence of clear
evidence of hormonal influence, the presence of a genetic modifier, X-linked or
otherwise, remains a possibility.
The possibility of interaction between mismatch repair genes and other genes known
to influence colorectal cancer susceptibility is an area that merits consideration.
Initial studies have suggested that genes involved in carcinogen metabolism might
modify the phenotypic expression of mismatch repair gene mutations. For example,
Moisio et al. (23) demonstrated that a specific polymorphism in the gene encoding
the xenobiotic enzyme /V-acetyltransferase 1 was associated with a lower age of
colorectal cancer onset in Finnish HNPCC kindreds with identified mutations in
hMLHl. Similarly, an alteration in cyclin D1 has been associated with earlier age of
onset in HNPCC cases; patients who harbour the mutant cyclin D1 allele have been
shown to develop cancer an average of 11 years earlier than patients with two wild-
type alleles (148).
Murine studies have demonstrated that MSH2 deficiency accelerates intestinal
tumorigenesis in transgenic mice that are heterozygous for a germlinc mutation in
the adenomatous polyposis coli gene (229). Similarly, Toft et al. (275) have used
mice mutant for both MSH2 and p53 to demonstrate interaction between these
genes. Additionally, in-vitro studies have suggested that interactions may exist
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between mismatch repair genes and transforming growth factor-(3 receptor II (192).
While these molecular studies demonstrate that gene-gene interactions may be worth
further investigation, the above hypotheses have yet to be tested in human
populations for relevance to cancer susceptibility.
2.8 Laboratory Testing
The heterogeneity of mutation types found in hMLHl and hMSH2 has meant that
many different techniques have been employed to test for mutations in these genes.
A number of techniques are described below, along with their benefits and
disadvantages.
2.8.1 In Vitro Synthesized Protein Assay
The in vitro synthesized protein assay technique uses an in vitro system to transcribe
and translate a large polymerase chain reaction product containing several exons.
The translated product is separated on a polyacrylamidc gel electrophoresis system,
and potential mutations are identified as truncated bands. These may represent a
number of mutations that have the effect of altering splicing, therefore producing a
translated fragment with certain exons deleted. Out-of-frame deletions or insertions,
resulting in frameshifts or splice variants, will also be detected using this method.
In vitro synthesized protein assay does not detect missense mutations, in-frame
deletions or insertions, large genomic deletions involving numerous exons, promoter
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mutations, or mutations that silence the gene. The assay also requires the use ot
mRNA for the production of a cDNA polymerase chain reaction product.
2.8.2 Sequencing
cDNA sequencing also relies on mRNA being available. It will identify all mutation
types except large genomic deletions, promoter mutations, and gene silencing
mutations. Genomic sequencing detects even fewer changes than cDNA, but it does
have the advantage of only requiring genomic DNA.
2.8.3 DNA Structure Techniques
A number of techniques rely on changes in DNA structure created by a mutation.
These include denaturing gradient gel electrophoresis (305), including the adaptation
of using two-dimensional gel electrophoresis (246), single-strand conformational
polymorphism analysis (32), heteroduplex analysis, and denaturing high-
performance liquid chromatography.
Table 2.6 summarizes the available information regarding the sensitivity of the
above techniques. The use of various combinations of techniques may enhance
sensitivity, but this is usually impractical. Recently, Yan et al. (319) demonstrated
that the conversion of chromosomes from the diploid state to the haploid state, by
fusion to a recipient rodent cell line, may facilitate improved sensitivity of current
mutation detection techniques.
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Table 2.6 Sensitivity of Mutation Detection Techniques
Technique Sensitivity Published
(%) Reference
In vitro synthesized protein assay 69 Farrington et al. (62)
Genomic sequencing 80 Farrington et al. (62)
In vitro synthesized protein assay/genomic sequencing 93 Farrington et al. (62)
Denaturing gradient gel electrophoresis >67 Fidalgo et al. (67)
Single-strand conformational polymorphism >67 Fidalgo et al. (67)
Protein truncation test 50 Fidalgo et al. (67)
Heteroduplex analysis 19 Fidalgo et al. (67)
Two-dimensional DNA typing * Sasaki et al. (246)
* Comparable to that of denaturing gradient gel electrophoresis.
2.9 Conclusions
The mismatch repair genes hMLHl and hMSH2 are highly heterogeneous, and a
proportion of gene variants constitute pathogenic mutations with a causal role in a
sub-set of colorectal cancer cases. Carriers of pathogenic mismatch repair gene
mutations are at substantially increased genetic risk of developing colorectal cancer,
and thus constitute an important sub-group that merit particular consideration as part







Empirical risk assessment based on family history remains an integral part of current
strategies to identify individuals who are at increased genetic risk of colorectal
cancer. This approach is commonly employed both for clinical purposes, and as part
of studies into the genetic epidemiology of this disease. A thorough understanding of
this subject is essential for optimal utilisation of family history information in the
broader context of preventing colorectal cancer at the population level.
Several gaps in the current knowledge and understanding of family history were
addressed through the analysis of a unique data resource comprising family history
information reported at interview and subsequently validated through record linkage
to death records and the Scottish Cancer Registry. The following studies were
undertaken as part of this analysis:
(i) Accuracy of Reporting of Family History of Colorectal Cancer
(ii) Prevalence of Family History of Colorectal Cancer
(iii) A Retrospective Family History Case-Control Study of the Risk
Associated with Family History of Colorectal Cancer
(iv) A Prospective Study of Risk Associated with Family History of
Colorectal Cancer
This chapter provides an overview of the construction of the data set (section 3.2).
Subsequently, each of the above studies is presented in the general format of a
scientific paper, with the rationale, specific methods, results and discussion
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considered in turn. A discussion of the general methodology is presented in section
3.7, followed by a summary of conclusions from these studies and a consideration of
further work (section 3.8).
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3.2 General Methodology
The data set considered in this chapter was based on two parallel family history
case-control studies, conceived and initiated in the 1990s. The author of this thesis
organised data for record linkage and the conducted the analyses considered in this
chapter, but was not involved in the design of the original study or the ascertainment
of study subjects.
3.2.1 Ascertainment of Study Subjects
(i) Study "A" (Non-Age Selected Study Group)
A total of 199 consecutive colorectal cancer cases were ascertained between 1991
and 1993, from three hospitals in Southeast Scotland (St. Johns Hospital, The Royal
Infirmary of Edinburgh and the Western General Hospital). Cases were referred to
the study by their surgeons. The initial strategy employed to identify suitable control
subjects was to use spouses of cases. However, this approach proved impractical,
and consequently only 25 controls were identified by this means. A further 108
controls, matched by age (to within two years) and sex, were randomly selected
from general practice lists in the Edinburgh area. Subjects were contacted and
invited to attend an interview with a genetics nurse. Where a case or control subject
did not respond, or declined to participate, another subject was selected. The initial
participation rate was over 80%. At interview, subjects were asked to provide
information on the name, date of birth and health status of each of their relatives.
Specific enquires were then made regarding the cancer experience of each relative.
Pedigrees were constructed and the associated health information provided by the
interviewee was recorded.
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(ii) Study "B" (Young Persons Study Group)
Study B utilised the Scottish Cancer Registry in order to specifically identify
colorectal cancer cases from throughout Scotland who were diagnosed between
1971 and 1991, and had an extremely early age at onset (< 30 years). A total of 113
such cases were identified and included in the data set. A total of 100 control
subjects were then identified through Scottish death records, by searching for sex
matched individuals who had died of a traumatic cause and were born in the same
year as the matched case. Subjects in this study were not interviewed.
In both studies, family pedigrees were constructed or extended by searching Scottish
records of births, deaths and marriages for as many first and second-degree relatives
of controls subjects as possible. Where appropriate, death certificates were
examined, and cause of death was recorded.
Information regarding relatives of cases and controls was initially recorded in hard
copy in the form of pedigrees and associated notes. Data relating to each relative
was then entered into an Excel™ spreadsheet.
3.2.2 Record Linkage
The data files created in the above manner were subsequently matched with death
records and the Scottish Cancer Registry, in order to establish whether each relative
(or data subject') was alive or dead, and to determine their personal cancer history.
This was done through computerised record linkage performed by the Information
and Statistics Division (ISD) of the Scottish Executive. Initial matching took place
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in 1993, and the record linkage process was repeated in July 2001. All current
analyses were based on this second linkage.
The Scottish Record Linkage System has been designed to bring together all records
relating to hospital discharge, cancer registration and death for each patient. Using
probability-matching techniques based on patient-specific identifying information,
linkage of such records can be achieved with a rate of false-positive matches
estimated at below 1% (12,13,14). The same methodology can be applied to linking
research data with the health information held by ISD.
The record linkage protocol utilised at ISD is based on the principles of "probability
matching" developed by Howard Newcombe (207), which state that the probability
of a 'true' match increases each time two items of information agree, and decreases
each time they disagree. The information generally used to match records includes
surname, first initial (plus full forename and second initial if possible), sex, date of
birth, and postcode. The databases created through the colorectal cancer case control
family history studies did not contain postcode information, but with this
qualification the linkage process used for these data followed the general procedure
described below.
To begin with, the surnames were coded according to the New York State
Intelligence Information System (NYSIIS) name compression algorithm. This
program removes vowels and unifies commonly confused letter groups such as "ch"
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and "sh". Subsequently the names are coded using the Soundex system (207), which
assigns the same code to non-initial consonants with similar sounds.
The first step in the actual linkage involved 'blocking' of records that did not reach a
minimal level of agreement with the record of interest. This was done in order to
reduce the number of comparisons that need be made. Direct comparisons were then
made between records that agree on all of Soundex/NYSIIS code, first initial and
sex (block A) or all elements of date of birth (block B).
Odds ratios were calculated for each piece of information, providing a measure of
the probability of matching, 'weighted' according to the probability of the result
occurring by chance. For example, agreement of the "sex" item of information
provides an odds ratio of 1.99, calculated by dividing 0.995 (the probability of this
item matching if the records refer to the same person) divided by 0.5 (the probability
of this item matching if the records refer to different people). Separate odds ratios
were then combined, providing an overall estimate of the probability that the two
records genuinely refer to the same person.
The above procedure can only provide relative estimates; the absolute probability of
a true match will also depend on the size of the databases being searched, and the
amount of information available for each entry. Sophisticated mathematical methods
would be required to make a formal assessment of absolute probability, and such an
appioach is time consuming and not necessarily accurate. The alternative approach
used by ISD was manual inspection of a representative selection of records and the
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identification of a probability threshold at which the records are considered more
likely than not to be a true match. Pairs of records with estimates above this
threshold were accepted as matches. In practice, most records would be expected to
clearly match or clearly belong to different people; only a few pairs of matches will
be on the borderline.
Record linkage thus facilitated both the confirmation of cancers reported at
interview, and the identification of previously unknown cancer cases in data
subjects. There are, however, some limitations associated with this approach, which
can be categorised as relating to the quality of the study data used to link records, the
record linkage process itself, and the Scottish Cancer Registry. These limitations and
their possible impact on the results presented in this chapter are considered further in
section 3.7.
3.2.3 Definition of Colorectal Cancer
For the puiposes of this study, the diagnosis of colorectal cancer was considered to
include adenocarcinomas of the colon, rectum, recto-sigmoid junction and anus, as
defined by the International Classification of Disease (ICD) system.
3.2.4 Ethical Approval
Ethical approval for the recruitment and interview of patients and controls was
granted by the appropriate Local Research Ethics Committee (LREC) at the time the
family history case-control studies were initiated.
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Approval for record linkage was sought from the Privacy Advisory Committee at
ISD. This committee was set up by the Chief Medical Officer to advise 1SD and the
Registrar General (for Scotland) on the release of patient-identifiable data and the
linkage of datasets that have not previously been linked. The committee comprises a
chairman and at least four members. The current membership includes a Professor
in Public Health Medicine, a Clinician, a Consultant in Public Health Medicine, and
three lay members. Approval for record linkage to be performed in connection with
the current analyses was granted, with the condition that all linked data remained at
ISD throughout the analyses to ensure the confidentiality of the matched information
regarding relatives' cancer status.
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3.3 Accuracy of Reporting of Family History of Colorectal
Cancer
Elements of the research presented in this section have been published in the journal
Gut (195). This paper is presented for reference in appendix A5.
3.3.1 Rationale
Family history is known to be an important significant risk factor for colorectal
cancer, and is used in the clinical setting to inform decisions regarding the use of
colonoscopic surveillance. The degree of personal risk relates to the extent of family
history and the age of onset of affected relatives (134). Various guidelines based on
degree of family history have been devised to determine when surveillance should
be recommended (55, 56, 109, 249, 310). The accuracy of family history
information is clearly critical whenever family history informs decisions about the
necessity of colonoscopic surveillance. It is also an important consideration in the
context of the epidemiological studies that inform the ongoing debate regarding the
appropriate guidelines for offering surveillance.
In both situations, information on family history is often gathered by interview with
a family member. This approach may be subject to error on the part of the
interviewee, with under-reporting of family history being observed in previous
studies (91, 140). Interview data is also potentially subject to systematic recall bias
arising from the fact that people with raised awareness of colorectal cancer, such as
patients, may be more likely to report a positive family history (71). Furthermore,
the social stigma associated with bowel cancer may mean that this condition is
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discussed less readily within families, and this factor could particularly affect
reporting of family history.
Accuracy of reporting cancer in the family has been addressed in previous studies of
people referred to genetics departments because of a cancer family history (53, 177,
253), people with a personal history of cancer (7, 71, 137, 138, 140, 145,210), or
close relatives of cancer cases (21, 91, 152). However, only a few studies have
related specifically to colorectal cancer cases (7, 91, 137, 138, 140) or to community
based consultands who have not been referred to a genetics clinic (140, 145). An
additional limitation common to many published studies is that validation of the
interviewee's report is only attempted for relatives reported to have had cancer. In
such studies no information can be obtained regarding the sensitivity, specificity or
negative predictive value of reports, and the question of under-reporting of cancer
cannot be addressed.
In this analysis information on family history of colorectal cancer obtained from
colorectal cancer cases and population controls at interview has been compared with
death records and Scottish Cancer Registry, using record linkage. Information was
obtained regarding the cancer experience of a total of 5637 first and second-degree
relatives of 199 colorectal cancer cases and 133 controls. This data set facilitated an
assessment of overall accuracy of reporting of family history of colorectal cancer at
interview, including under-reporting. In addition, the effect of any inaccuracies was
evaluated with respect to clinical genetic risk assessment. The findings have
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considerable relevance to the methods used to validate family history and also have
practical implications for surveillance guidelines based on degree ot family history.
3.3.2 Methods
This study was based on subjects ascertained as part of study A. Summary statistics
(sensitivity, specificity, positive predictive value and negative predictive value)
relating to the accuracy of interviewee reports by various sub-groups of the data
subjects were calculated and compared. Cancers occurring between the interview
date and the record linkage were excluded from all analyses relating to accuracy of
reporting. Confidence intervals were calculated using a normal approximation (308),
which compares favourably with exact methods for this data (6).
3.3.3 Results
The mean age of the 199 cases at the time of interview was 64.0 years. There were
86 females and 113 males. In total, 3290 first and second-degree relatives of these
cases were included in the database. 110 relatives were reported to be resident in
England (n = 46) or overseas (n = 64), and the nurse constructing the pedigrees
classified a further 251 as "untraceable".
The 133 controls had a mean age of 64.2 years at the time of interview, and
consisted of 60 females and 73 males. In total, 2347 blood relatives (i.e. individuals
related genetically, as opposed to by marriage) of controls were included in the
database, of which 107 were reported to be resident in England (n = 61) or overseas
(n — 46) and 91 were deemed to be untraceable. Individuals who have neither died
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nor developed cancer are not matched through record linkage, and it is impossible to
distinguish these individuals from those who cannot be traced. Hence, all lelatives
were included in the subsequent analysis, regardless of apparent 'traceability .
3.3.3.1 Knowledge of Family Members' Health and Occurrence of Cancer
Cases and controls were asked at interview to briefly state their knowledge
regarding the vital status and medical history of their relatives. The proportion of
relatives for whom the interviewees were able to provide any health related
information is shown in table 3.1, which also details the responses given by
interviewees for all relatives found to have cancer by linking with central records.
Table 3.1 Knowledge of Health and Occurrence of Cancer in
Relatives
Interviewee Relative Number Number (%) Number of Number Total Number (%)






























77 202 36 (18%)
(51%) (41%)
linkage to have had cancer.
This column describes the total number of primary cancers in relatives; including multiple
primary cancers.
Abbreviations: FDR, First Degree Relatives; SDR, Second Degree Relatives
In total, 240 cancer cases in first-degree relatives (FDRs) were identified by ISD
record linkage. 106 of these instances had been correctly reported at interview. In
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contrast, 293 cancers were found in second-degree relatives (SDRs), of which only
42 were correctly reported. In the majority of instances where a cancer was not
correctly reported, the interviewee either had no knowledge of the health of the
relative in question, or was unaware that they had developed any type of cancer.
However, in some cases a cancer was reported, but the site was incorrect or
unknown. An indication of the extent to which this situation occurred is provided by
the sixth column in table 3.1, which states the proportion of affected relatives who
were reported as having had some form of cancer.
3.3.3.2 Reporting of Colorectal Cancer Cases
In total, there were 148 cases of colorectal cancer in first or second degree relatives,
of which 62 (41.9%) were reported correctly by the interviewee. The mean age at
onset of cases that were correctly reported was 63.3 years (95% CI = 60.5, 66.1), a
value significantly different from the mean age of 70.2 years (95% CI = 67.8, 72.5)
for cases that were not correctly reported. This observation is not unexpected, as
cancer affecting more elderly relatives is less likely to be discussed within families.
The suggestion that early-onset cases are more likely to be reported accurately at
interview is of clinical interest, as such cases are more significant in terms of
indicating increased genetic risk. A separate trend towards more accurate reporting
in recent years was evident, although this effect was not statistically significant.
Summary statistics associated with the accuracy of reporting of colorectal cancer in
relatives were calculated from contingency tables, and are summarised in Table 3.2.
The contingency tables themselves are presented for reference in appendix A6.
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Table 3.2 Summary Statistics for Reporting of Colorectal Cancer
Group Relative Sensitivity Specificity Positive Negative
Group (95% CI) (95% CI) Predictive Predictive
Value (95% CI) Value (95% CI)
Cases FDR 0.566 0.990 0.698 0.982
(n = 1322) (0.433, 0.690) (0.983, 0.994) (0.549, 0.814) (0.973, 0.988)
Cases SDR 0.271 0.996 0.619 0.982
(n = 1968) (0.166, 0.410) (0.992, 0.998) (0.409, 0.792) (0.975, 0.987)
Controls FDR 0.529 0.995 0.643 0.992
(n = 1037) (0.310, 0.738) (0.989, 0.998) (0.388, 0.837) (0.985, 0.996)
Controls SDR 0.333 0.995 0.667 0.985
(n = 1310) (0.192, 0.512) (0.991, 0.995) (0.417, 0.848) (0.976, 0.990)
Abbreviation: CI, confidence interval
The data shown in Table 3.2 demonstrate substantial under-reporting of colorectal
cancer in relatives. In both cases and controls, sensitivity of reporting in FDRs is
around 50-60%, implying that a large proportion of cancers in FDRs go unreported.
The poor sensitivity of reporting is even more striking in SDRs, with the majority of
cases in SDRs of cases and controls not being reported at interview. The very high
estimates of specificity and negative predictive value shown in Table 3.2 primarily
reflect the fact that in absolute terms colorectal cancer affects only a small
proportion of the population. However, even small effects on these parameters may
have important implications for genetic risk assessment and resource allocation. For
all relative groups, estimates of positive predictive value were in the range of 60-
70%, indicating that approximately one third of reports of individual colorectal
cancer cases are not confirmed using record linkage. There were no differences in
accuracy of family history reporting between cases and controls.
The sensitivity of reporting of colorectal cancer compared to other common cancers
is shown in table 3.3.
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Table 3.3 Sensitivity of Interview as a Means of Identifying Familial
Cancer Cases, by Site
(i) Cases
Site Relative Number Number of Sensitivity of
Group of Cases Interviewee Report
Cases* Correctly (95% Confidence
Reported Interval)
Colorectal FDR 53 30 0.566 (0.433, 0.690)
» SDR 48 13 0.271 (0.166, 0.410)
Breast FDR 23 17 0.739 (0.535, 0.875)
" SDR 22 8 0.364 (0.197, 0.570)
Bronchus & Lung FDR 33 19 0.576 (0.408, 0.728)
n SDR 37 6 0.162 (0.077, 0.311)
Stomach FDR 21 9 0.429 (0.245, 0.635)
n SDR 34 3 0.088 (0.030, 0.230)
(ii) Controls
Site Relative Number Number of Sensitivity of
Group of Cases Interviewee Report
Cases* Correctly (95% Confidence
Reported Interval)
Colorectal FDR 17 9 0.529 (0.310, 0.738)
" SDR 30 10 0.333 (0.192, 0.512)
Breast FDR 5 4 0.800 (0.376, 0.964)
11 SDR 15 3 0.200 (0.070, 0.452)
Bronchus & Lung FDR 33 18 0.545 (0.380, 0.702)
ii SDR 30 4 0.133 (0.053, 0.297)
Stomach FDR 9 3 0.333 (0.121, 0.646)
ii SDR 30 8 0.267(0.142, 0.444)
*Where more than one primary cancer occurred at the same site, it was not possible to
determine whether the interviewee was aware of both these tumours. Therefore, where
metachronous primary cancers occurred, only the first is considered in table 3.3.
Estimates of sensitivity for colorectal cancer were broadly comparable with the other
common cancer types listed in Table 3.3, although numbers are small. However, it
is noteworthy that breast cancer was more frequently reported than the other internal
cancers in FDRs. This may reflect the more enigmatic presentation of visceral
malignancy and possibly social stigma associated with bowel cancer in particular.
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3.3.3.3 Practical Implications of Inaccurate or Incomplete Reporting of
Family History
From a clinical perspective it is important to evaluate the validity ot interviewee
reporting as a means of identifying families that are eligible for genetic counselling,
clinical screening and/or genetic testing. Various guidelines exist to help determine
the extent of family history that warrants such interventions. For illustrative
purposes simple family history criteria (two affected FDRs, or one affected FDR
with age of onset <45 years) were applied to both cases and controls from this study.
These criteria are used by the British Society of Gastroenterology, and the
Association of Coloproctology of Great Britain & Ireland, to indicate a requirement
for surveillance (55, 56). These criteria, which are concerned only with FDRs, were
applied to the original data set. The risk categorisation of these individuals was then
re-evaluated following record linkage.
Cases and controls were considered together since no differences were observed
between these two groups in terms of the accuracy of reporting of colorectal cancer.
In order to gauge the overall impact of inaccurate or incomplete reporting on
surveillance recommendations, cases and controls were considered simply as
consultands, rather than cases meriting post-surgical surveillance following their
own personal history of colorectal cancer.
At interview, 5 of the interviewees reported a family history that met criteria
indicating a need for sui veillance. However, only 2 of these 5 interviewees were
confirmed by record linkage to meet these criteria, giving an overall positive
predictive value of 0.4 (95% CI = 0.12, 0.77). In addition, 4 further interviewees
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who did not report a family history of colorectal cancer fulfilling the applied criteria
actually did have such a family history based on record linkage data. Therefore, only
2 of 6 interviewees who met the applied criteria following record linkage were
identified at interview, suggesting that the sensitivity of interview in terms
identifying appropriate individuals was 0.33 (95% CI = 0.10, 0.70).
3.3.4 Discussion
This study has quantified the accuracy of reported family history of cancer in two
important groups of people, namely those with colorectal cancer and those from the
general population. Because cases reported to have colorectal cancer were
confirmed, and cases that had not been reported by the interviewee were also
identified, it was possible to systematically assess overall accuracy of reported
family history of large bowel malignancy. Using this approach the accuracy of
reporting of colorectal cancer has been determined in a large data set comprising 332
interviewees and 5637 first and second-degree relatives.
3.3.4.1 Knowledge of Relative's Health Status
Evaluation of the extent to which interviewees had any knowledge of their relatives'
health forms a useful background to understanding the accuracy of cancer reporting,
as it provides an indication of the extent to which people are aware of the health of
their relatives.
Table 3.1 shows that interviewees could provide no useful information for
appioximately half of all SDRs, but did have some knowledge of the health status of
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all but around 5% of FDRs. This consistent disparity suggests that many instances in
which cancer in second degree relatives goes unreported are due to lack of contact
with relatives, rather than ignorance of diagnosis in a known family member. The
observation that positive predictive value is similar in FDRs and SDRs lends further
support to this notion. Clearly, one would expect that interviewees would have
greater knowledge about first degree relatives, and would be more likely to receive
and maintain knowledge of a cancer diagnosis from such close family. It is also
possible that the age structure of the relative groups in question will serve to
exaggerate such effects, since FDRs will generally be relatively close in age to the
interviewee. Disparity between FDRs and SDRs is evident throughout this study,
and is consistent with findings from other published studies (53, 145, 177, 253).
The results presented in table 3.1 suggest that controls were actually slightly better
than cases at providing knowledge of health status and reporting cancer events in
relatives. However, this difference is not statistically significant, and is subtle when
compared to the disparity between knowledge of FDRs and knowledge of SDRs.
3.3.4.2 Reporting of Colorectal Cancer in Relatives
In this study, estimates for sensitivity of reporting relating to colorectal cancer are
low, being in the region of 50-60% in FDRs of both cases and controls, and around
30% for SDRs. These estimates were broadly comparable with the other common
cancer types listed in table 3.3. These results imply, therefore, that a large proportion
of cancers in FDRs, and the majority of cancers occurring in SDRs, go unreported.
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A comparable approach to assessing accuracy of reporting of colorectal cancer,
which includes identification of unreported cases as well as checking the accuracy of
cases reported at interview, has been employed in one previous study (140). This
study estimated the sensitivity of reporting a family history of colorectal cancer in
FDRs as 0.65 (95% CI = 0.39, 0.85) for colon cancer cases, and 0.81 (95% CI =
0.54, 0.95) for controls, and the authors concluded that subjects were able to
accurately report family history (140). However, this previous study did not consider
SDRs, and no information is provided regarding the total number of relatives
involved. Furthermore, the focus of this paper was on validation of an
epidemiological study. The observed values for sensitivity of reporting may be less
acceptable for genetic risk assessment where the objective is to determine the need
for clinical intervention, particularly given the wide confidence intervals.
The finding that colorectal cancer cases that are correctly reported have a relatively
young age at onset is of interest, as it suggests that early-onset cases are more likely
to be reported, and such cases are more significant in terms of indicating increased
genetic risk. However, the magnitude of differences observed in this study may have
limited impact in a clinical setting.
Positive piedictive value provides information about the validity of positive reports,
and is thus a highly relevant measurement. The positive predictive values shown in
table 3.3 indicate that a leport of cancer at interview is equally likely to be correct
for a first or second-degree relative. This observation supports the notion that
differences in reporting of cancer in these groups arise largely from a lack of
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knowledge about SDRs, as opposed to inaccurate reports. Estimates for positive
predictive value were in the range of 60-70%, indicating that approximately one
third of reports of individual colorectal cancer cases are not confirmed using cancer
registry data. A proportion of these apparently false positive reports of colorectal
cancer may be true positives not detected by the record linkage. However, such
occurrences are unlikely to account for the number of false positive results observed.
The validity of record linkage as a means of determining the cancer experience of a
data subject is considered in section 3.7.
One of the important questions addressed by the current study is whether or not
individuals who have had colorectal cancer are more likely than controls to provide
false positive reports of the condition in their relatives. In the current study, 21 false
positive reports were found among the 199 cases, compared with 11 false positive
reports by controls among the 133 interviewed controls. There is thus no evidence to
support the hypothesis that cases may over-report their family history.
In this study, family history documentation was optimal since a trained genetics
nurse conducted interviews during a lengthy consultation at the interviewee's home.
Reporting inaccuracies observed in-this study may well be more extreme where
family history is taken in a busy gastroenterology, surgical or general practice clinic.
3.3.4.3 Genetic Risk Assessment
From a clinical perspective, the information provided about the family as a whole is
moie important than the accuracy of individual reports. The results of this analysis
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illustrate that incomplete or inaccurate interviewee reporting could have a
substantial impact on genetic risk assessment. That only 2 of 6 families who actually
met the applied criteria were identified at interview is a particular concern, implying
that reliance on interview data in a clinical context could result in many families
who actually meet criteria for surveillance being overlooked. Conversely, 2 of 5
families were mistakenly classified as meeting the chosen criteria due to false
positive reports made at interview. In practice, such an effect could lead to
surveillance being applied unnecessarily.
The statistical power of these analyses is extremely low, due to the small numbers
concerned. Accordingly, the results should be regarded as indicative of a possible
role for inaccuracy and under-reporting at interview in limiting the validity of
genetic risk assessment, rather than conclusive evidence of such an effect.
3.3.4.4 Conclusion
The appropriate family history criteria for offering genetic counselling, colonoscopic
surveillance or genetic testing is the subject of much current debate, and is likely to
remain so. The findings of this study are highly relevant to this discussion, as they
suggest that family history information obtained by interview may be misleading,
and that verification of both positive and negative interviewee reports should be
conducted whenever possible. In reality, any strategy used to establish family history
of cancer will be a compromise between this ideal situation and what is actually
feasible.
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In principle, the use of central government records to establish family history of
colorectal cancer is potentially useful from a scientific and clinical perspective, but it
raises important issues of consent and privacy, and may not be considered justifiable
at the population level. Under the Data Protection Act (1998) (278), the use of
medical information without the specific consent of the individual to whom the data
refers is severely restricted. This is problematic in the context of obtaining a
complete family history, since it is unlikely to be possible to obtain consent from all
family members of a study subject. In many situations, data is more readily available
for deceased relatives.
Practically, such an approach would be difficult to implement in the UK, as it
necessitates meticulous manual preparation of a data set for record linkage.
Establishing family history through computerised central records is theoretically
more realistic in some Scandinavian countries, in which births, deaths, marriages
and health records are linked through a unique identifying number. Provided
appropriate steps are taken to ensure privacy, a systematic, computerised means of
establishing family history is conceivably a future option for public health policy in
the UK.
Regardless of the techniques applied, the results of this analysis illustrate the
importance of considering the methods used to establish a family history,
particularly when the data is used to make clinical decisions.
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3.4 Prevalence of Family History of Colorectal Cancer in the
General Population
3.4.1 Rationale
Details of family history are regularly collected from colorectal cancer patients, but
at present information regarding the prevalence of family history of colorectal
cancer amongst members of the general population is less readily available.
Obtaining such data is important as it provides an indication of the number of people
in a population who might meet various family history criteria, thus informing
evaluation of the potential of surveillance programmes in terms of costs and
effectiveness at the population level. Addressing this issue is particularly relevant
given the recent increase in public demand for information and advice regarding
genetic risk of cancer. Increasing awareness of the genetic contribution to colorectal
cancer potentially has major resource implications for genetic counselling and
clinical screening.
Current knowledge regarding the prevalence of family history of colorectal cancer
generally comes from interview or questionnaire-based data, often recorded as part
of case-control studies. The extent of family history observed varies considerably,
with most studies suggesting that between 3% and 10% of people in the general
population have a first degree relative that has developed colorectal cancer (22, 78,
112, 135, 153, 205, 243, 256, 260, 293). This variation is likely to reflect differences
in methods of identifying controls and obtaining their reports, as well as genuine
differences in prevalence between the populations under study.
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Interview, as compared to self-administered questionnaires, is generally considered
to be a more valid method of obtaining information about family history. However,
information gathered in this manner may also be both incomplete and unreliable,
particularly with regard to second-degree relatives (91, 140, 198). This is potentially
very relevant in the context of estimating prevalence of a family history of colorectal
cancer in the general population, as it implies that relying on interview data will
result in cases of colorectal cancer in relatives being overlooked. The true
prevalence of family history will consequently be underestimated. Cancer registries
and other databases can provide a more reliable source of family history
information. Such an approach to estimating the prevalence of family history of
colorectal cancer has previously been employed using data from the Utah Population
Database (140, 256), although findings have not been repeated or validated in other
populations.
There is, therefore, a paucity of unbiased information regarding the prevalence of a
family history of colorectal cancer in healthy members of the general population.
The puipose of the current study was to investigate the prevalence of family history
of colorectal cancer in Scotland, using record linkage to death records and the
Scottish Cancer Registry to determine the cancer experience of first and second-
degiee ielatives of population-based control subjects. This approach removes much
of the uncertainty and potential bias inherent in using information reported by the
controls themselves to establish their extent of family history.
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3.4.2 Methods
A descriptive study of the prevalence of family history of colorectal cancer in the
study subjects was conducted. Confidence intervals for proportions were calculated
using a normal approximation (308).
The observable extent of family history may vary according to the age of subjects.
Furthermore, any population-based programme to identify individuals with a family
history of colorectal cancer would probably be aimed at individuals in the 30-70 age
range. For these reasons the primary study group for this prevalence study was
limited to 160 control subjects within this age range from study A or B. The age of
the control subjects is defined as the age at the time the subject was ascertained and
the pedigree established. For Study A, this was the interview date in 1993, and for
the deceased control subjects in Study B this was taken to be the age they would
have been in 1994.
3.4.3 Results
The age distribution of all control subjects is illustrated in figure 4.1.
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The average age of all the participating control subjects was 52.0 years, with a range
of 19 to 85 years. The primary study group, restricted to the 160 control subjects
within the 30-70 year age range, had an average age of 48.8 years.
A total of 61 colorectal cancer cases were identified in first or second-degree
relatives of control subjects in the primary study group. Table 3.4 provides details of
these cases, including the age of onset, age of control subject, and the relationship
between the control subject and the, affected relative.
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Table 3.4 Summary of Colorectal Cancer Family Histories of Control
Subjects
One Case in First
Degree Relative
One Case in Second
Degree Relative





















A (61) Brother (61) A (47) MA (61) A (68) MU (38) PU (75)
A (53) Father (55) A (51) PGF (67) A (67) MGM (62) PA (55)
A (59) Mother (77) A (64) MU (60) A (41) Father (60) PU (73)
A (60) Father (48) A (64) MA (56) A (64) Mother (73) MU (81)
A (53) Mother (77) A (58) PGF (83) A (48) MGM (75) MGF (88)
A (64) Brother (47) A (60) PA (61) A (58) PGF (77) MU (50)
A (58) Father (73) A (68) PGF (69) A (55) MGM (77) Mother (53)
A (60) MA (79) A (55) MGM (73) Father (68) PA (89)
A (63) PU (61) A (68) PGF (76) Brother (64)
A (54) PGF (69) B (53) Father (60) PA (70)
A (52) MA (62) B (33) PGM (32) Father (57)
A (48) MA (76) B (47) PGM (58) PA (55)
A (54) PU (67) B (46) Father (74) PU (79)
B (48) PGF (34) B (40) MGF (53) PA (78)
B (37) PGM (94)
B (32) MA (82)
B (48) PGF (34)
B (51) PU (68)
B (46) MU (54)
B (45) PU (67)
B (48) PGF (36)
B (42) MGM (83)
B (39) PGM (81)
B (38) MA (68)
cm n Tvnc » i _ .l.
B (36) PGM (84)
_ .. _ _ w„„u, oiaooiiicu as nieuiuni hsk, according io curreni uancer
Genetics Guidelines for Scotland (249)
Abbreviations: MA, Maternal Aunt; MU, Maternal Uncle; MGM, Maternal Grandmother;MGF, Maternal Grandfather, PA = Paternal Aunt, PU = Paternal Uncle, PGM = Paternal
Grandmother, PGF = Paternal Grandfather
The mean age of subjects with a positive family history was 52.3 years, a value not
significantly different from the overall mean. Out of the 160 control subjects, 46
(28.8%; 95% CI = 21.7, 35.8) had a family history of colorectal cancer in any first or
second-degree relative. 15 (9.4%; 95% CI = 4.9, 13.9) control subjects had an
affected first degree relative, and 14 (8.8%; 95% CI = 4.4, 13.1) had more than one
affected relative. There were no subjects with more than one affected first degree
relative. Many of the multiple-affected families had affected members on different
sides of the family, implying that the observed clustering is due to chance rather than
a common genetic aetiology.
Applying the current Cancer Genetics Guidelines for Scotland (249) to this data set
revealed that two (1.25%) of the above controls, marked in bold in table 3.4, would
initially be classified as "Medium Risk", since they each have two affected relatives,
of which one is a first-degree relative and one of which was diagnosed at less than
55 years of age. The recommended protocol for management of such individuals is
referral to a genetics counsellor and subsequent colonoscopic surveillance
comprising a single colonoscopy at 30-35 years of age, not repeated until 55 years of
age if initial findings are normal (see appendix Al).
3.4.4 Discussion
This study attempts to provide an insight into the issue of population prevalence of
colorectal cancer in the general population. The proportion of individuals with an
affected first degree relative is often used as a convenient measurement of the
prevalence of family history. In this study 9.4% (95% CI = 4.9, 13.9) of population
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controls have been found to have a history of colorectal cancer in a first degree
relative. This estimate is relatively high when compared to findings from two large
scale questionnaire studies conducted in the UK by Sadhu et al., and House et al., in
which the proportion of controls reporting a history of colorectal cancer in a first
degree relative was 6.8% and 6.0% respectively (112, 243). The current estimate of
the proportion of individuals with an affected first degree relative is also consistent
with, but slightly higher than, the registry-based study by Kerber and Slattery, in
which the corresponding value was 7.8% (140). However, as illustrated by the
confidence intervals attached to the estimate, the observed difference between these
results and those of these previous studies is not statistically significant and may
therefore be due to chance.
A highly relevant study has recently been conducted with the specific aim of
determining the prevalence of a family history of breast, colorectal and ovarian
cancer among people aged 30-65 years in Scotland (293). Out of a total of 7620
participants, 608 (8.0%) reported a history of colorectal cancer in at least one first or
second degree relative. Results were not reported for these relative groups
separately. This estimate contrasts markedly with the current study, in which 28.8%
(95% CI = 21.7, 35.8) of study participants were found to have an affected first or
second degree relative. This difference is statistically significant.
The observed family history of colorectal cancer may be affected by the age
distribution of the study group concerned, and cohort effects may also apply. Hence
it is possible that the difference in the estimates produced by the current analyses
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and the study by Wallace et al., (293) is partially the result of the fact that the study
group considered in this analysis was ascertained earlier and included slightly older
subjects. However, the actual differences between the age groups and the time of
ascertainment are minor, and, furthermore, the hypothesis that older subjects would
be more likely to report a family history of colorectal cancer is not supported by data
from this study, since the mean age for those with a family history does not differ
from the overall mean age.
Another potential cause of the observed differences between the results of these two
studies is the potential for ascertainment bias in each, since the participation was not
complete in this study group (approximately 80%), nor in the questionnaire study
conducted by Wallace et al., (59%). However, both these rates are reasonably high,
and the direction of any bias is unlikely to differ between the studies to an extent
large enough to account for the observed differences.
The most compelling difference between these studies is in the methods used to
ascertain details of family history. In this study, family history has been
systematically established using record linkage to the Scottish Cancer Registry,
whereas the study by Wallace et ak, (293), and the majority of other previous studies
designed to estimate the prevalence of family history, relied on information provided
by population controls themselves. As demonstrated in section 3.3, colorectal cancer
is often under-reported, particularly in second-degree relatives. The degree of under-
teporting observed would account for the magnitude of the disparity observed
between the current findings and those of the study by Wallace et al., (293).
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Out of 160 population controls, 2 (1.25%) had a family history of colorectal cancer
that would meet the required criteria for a classification of "medium risk , according
to the Cancer Genetics Guidelines for Scotland (249). The scale of the current study
is insufficient for this finding to be considered conclusive, but it is consistent with
the findings of the study by Wallace et al., (293) who found that 45 of 7620 (0.6%)
of participants met these same guidelines. Again, the higher prevalence of a
particular family history observed in the present study is consistent with the
hypothesis that family history of colorectal cancer is often under-reported.
Evaluation of family history provides a simple strategy for identifying people at
increased genetic risk of developing colorectal cancer, and hence empirical risk
assessment based on family history is an important aspect of current and future
strategies for preventing colorectal cancer in this sub-group of the population. The
appropriate inclusion criteria, and the methods used to establish family history in
this context are crucial considerations in terms of the planning, funding and
implementation of screening programmes. These issues have generated considerable
debate, and continue to do so in the light of recent advances in our understanding of
the genetics underlying colorectal cancer. Accurate, population specific information
regarding the actual prevalence of a family history of colorectal cancer in the general
population is valuable in terms of informing such debate.
In contrast to most previous studies, that are reliant on interview or questionnaire
data, the current study is based on record linkage with information from a reliable
cancer registry. This study has found that approximately 9.4% of people aged 30-70
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have a family history of colorectal cancer in a first degree relative, and that
approximately 28.8% of people have a first or second degree relative who has
developed colorectal cancer. Furthermore, of 160 control subjects, two were found
to have a family history of colorectal cancer that met current Scottish guidelines for
referral to a genetic counsellor and possible inclusion in a colonoscopic surveillance
programme. These findings should ideally be repeated by more extensive studies,
but they currently provide unique and relatively unbiased information that could
inform decisions made by researchers and policy makers regarding the provision of
genetic services for colorectal cancer.
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3.5 A Retrospective Family History Case-Control Study of the
Risk Associated with Family History of Colorectal Cancer
3.5.1 Rationale
Knowledge of the extent of familial risk associated with various degrees of family
history is crucial to facilitating accurate risk assessment in the clinical setting, and
informing decisions made about screening protocols and genetic testing. Accurate
information regarding the relationship between family history and colorectal cancer
risk also furthers understanding of the genetic epidemiology of colorectal cancer. As
discussed previously, various publications have addressed this issue (see meta¬
analysis by Johns et al., (134)). These have established the consensus that people
with one or more affected relatives are at an increased risk of developing colorectal
cancer, and provided some broad estimates for the magnitude of this risk.
Precise data relating to various family histories, and considering degree, relationship
and age at onset of affected relatives, are comparatively scarce. Hence, there is a
need for further studies in this area. Furthermore, it is possible that the degree of
familial risk evident may vary with the population being considered, either due to
genetic factors, or due to differences in exposure to environmental risk factors.
Presently, data relating specifically to the Scottish population are not available.
Additionally, information regarding risk in people with a relative who has developed
colorectal cancer at a very young age is scarce. Several studies have provided risk
estimates for people with a relative affected at less than 45 years of age (39, 78, 97,
205, 256), and concluded that early onset of colorectal cancer in a relative is
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associated with a higher degree of genetic risk than late or average onset of
colorectal cancer in a relative. Study B offers the potential to provide unique
information on risk for people with a relative affected at the extremely early age of
30 years or less. In Scotland, only 36 colorectal cancer cases in people under 30
years were diagnosed between 1986 and 1995, comprising just 0.24% of all
colorectal cancer registrations in this period (102). Hence, the sub-group who exhibit
such an extremely early onset are considered likely candidates for having an
increased genetic risk.
Many estimates of relative risk associated with having a family history of colorectal
cancer are based on information reported by cases and controls at interview or via
questionnaire. In many studies, reported cases were confirmed using death
certificates, medical records or cancer registry data, but only two previous case-
control studies (256, 272) and two previous cohort studies (39, 92) have attempted to
confirm negative reports of colorectal cancer in relatives. Reliance on reported data
is a potentially important source of bias in risk analysis studies. As illustrated and
discussed in the preceding sections, the use of record linkage provides a relatively
reliable method of establishing family history. Consequently, the current family
history case-control studies were designed to provide relatively unbiased and
population-specific information regarding the risk associated with having a family
history of colorectal cancer in Scotland.
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3.5.2 Methods
The two studies considered in this chapter were analysed using the broad design and
methods of a matched retrospective family history case-control analysis, as
envisioned at the time the original study set was ascertained.
Cases and controls in study B were specifically matched at the time of
ascertainment. Although controls in study A were originally matched to cases,
details of these pairings were not available at the time of the current study. The latter
were thus 're-matched', based on age and sex, and using a random generator to
select pairs when more than one appropriate match existed.
The available family history data was analysed as a matched retrospective family
history case-control study, using methods for calculating a mantel-haenszel
estimator for the odds ratio (ORMn) previously outlined by Liang et al., (167) and
employed in similar study by St. John et al., (260). Importantly, this technique does
not make any assumption of independence of cancer status for each relative, and
thus allows for relatives who are part of the same family to be dependent in their
cancer status. A matched analysis was conducted in order to maximise the power of
the case-control study, since pooling relative data across case and control families is
likely to underestimate the true odds ratio (167).
Each case subject, i, will have nj relatives of which Xj will have developed colorectal
cancer. The matched control subject, i, will have mi relatives of which yj will have
developed colorectal cancer. This statistical notation is summarised in table 3.5:
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Relative of Case Xi (ni - X|) ni
Relative of Control Yi (m, - Yi) ITIj
f (N: - f) Ni
A series of 2 x 2 contingency tables were created for the matched pairs in each of
study A and study B separately. The Mantel Haenszel estimator for the true common
odds ratio is then given by:
ORmn = 2R/XSj
Where: Ri = Xj(rTii - yJ/Nj and Si = yi(nj - Xj)/Ni
An appropriate test statistic for the null hypothesis that ORMn = 1, with an
approximate chi-squared distribution and one degree of freedom, is calculated by:
T = {Z(Xi - nit/Ni)}2/{Z(Xi - nitj/Nj)2}
The approximate test-based standard error, SE, was calculated for log(ORmn),
because the distribution of log(ORMN) is closer to the normal distribution than that
of ORmn- This value was calculated using the following equation:
T = (log[ORMN]/SE)2
Thus the 95% confidence interval for the Mantel Haenszel estimator for the true
common odds ratio is given by:
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95% CI for ORMn= (elog[ORMNl_ 196SE, elo9[ORMNl + 196SE)
Data were recorded in a Microsoft Excel™ spreadsheet, and all calculations were
also carried out using this programme.
3.5.3 Results
In total, 133 case-control pairs were identified as part of study A. Case-control pairs
were matched by sex, and comprised 60 female and 73 male pairs. The subset of
cases included in this study (133 from a total of 199 in the complete data set) had a
mean age of 65.3 years at ascertainment in 1993. Controls were also matched with
cases to within 2-3 years of age, and hence had the similar mean age of 64.9 years.
The data set for study B included 100 matched pairs, comprising 46 female pairs and
54 male pairs. For study B, age was taken as age at ascertainment for surviving cases
and controls, or the age they would have been at this point for deceased individuals.
The case subjects (a subset of 100 from 113 in the complete data set) had a mean age
of 37.0 years, and control subjects had a mean age of 37.1 years.
A summary of the overall number of relatives included in this study, and their
colorectal cancer experience, is shown in table 3.6:
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Table 3.6 Summary of Colorectal Cancer Cases Among Relatives
Study Relative Relatives of Number of Number of Affected
Group Cases/Controls relatives relatives
A FDR Case 850 29
A FDR Control 1037 17
A SDR Case 1339 40
A SDR Control 1310 30
A All Case 2189 69
A All Control 2347 47
A Parents Case 266 15
A Parents Control 268 13
A Siblings Case 355 12
A Siblings Control 451 3
B FDR Case 507 8
B FDR Control 496 3
B SDR Case 885 25
B SDR Control 1004 24
B All Case 1392 33
B All Control 1500 27
B Parents Case 198 8
B Parents Control 200 3
B Siblings Case 240 0
B Siblings Control 222 0
Abbreviations: FDR, first degree relatives; SDR, second degree relatives
Analysis of the data set as a matched retrospective family history case-control study
yielded the following results:
Table 3.7 Results of Matched Retrospective Family History Case-Control
Analysis
Study Relative Group ORmn (95% CI)
A First Degree 2.14 (1,11,4.14)*
A Second Degree 1.45 (0.76,2.75)
A Parents 1.16 (0.53,2.50)
A Siblings 12.02 (2.11, 68.44)*
A All Relatives 1.59 (1.05,2.41)*
B First Degree 2.02 (0.51,8.00)
B Second Degree 1.04 (0.60,1.77)
B Parents 2.67 (0.67, 10.67)
B Siblings N/A (no cases in siblings)
B All Relatives 1.20 (0.69,2.07)
'Significant at the 5% level (p < 0.05)
122
Differences in observed risk of colorectal cancer between relatives of cases,
compared with relatives of controls, were only significant at the 95% level for first-
degree relatives, siblings, and all relatives together for Study A. Significant
differences were not observed for any relative group from study B. This is largely
due to a lack of statistical power, resulting from the small numbers of colorectal
cancer cases developing in each relative group. Combination of the two studies
produced an estimate of the Mantel Haenszel odds ratio (ORmn) for all first-degree
relatives of 2.19 (95% CI = 1.22, 3.93).
For comparison, the data set was also analysed as an unmatched retrospective family
history case-control study, using conventional methods for a case control study. In
both studies cases outnumber controls (study A: 66 additional cases, study B: 13
additional cases). Therefore, whilst matched analysis is a more powerful technique,
unmatched analysis has the advantage of including additional information.
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Table 3.8 Results of Unmatched Retrospective Family History Case-
Control Analysis



















N/A (no cases in cases or controls)
1.80 (1.11, 2.93)*
*Significant at the 5% level (p<0.05)
Results from the unmatched analysis are similar to those from the matched analysis,
although confidence intervals are slightly narrower. As considered further in the
discussion section, the unmatched analysis is not entirely statistically valid, as it
makes the false assumption that all observations are independent. Hence the
matched analysis constitutes the focus of the retrospective family history case
control study considered in this section, with unmatched results included for
comparison only.
3.5.4 Discussion
For study A, the results presented in table 3.7 for first-degree relatives are consistent
with the current literature. In a comparable family history case control study, in
which the cases were not selected on the basis of age, the Mantel Haenszel estimator
of the odds ratio (ORmn) was reported as 2.1 (95% CI = 1.4, 3.1) for parents and
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siblings together (260). The estimate for Odds Ratio for FDRs of cases compared to
controls in study A, is also comparable to the relative risk of having an affected first-
degree relative of 2.25 (95% CI = 2.00, 2.53) reported in a systematic meta-analysis
(134). Hence, this study has provided support for the observation that first-degree
relatives of non age-selected colorectal cancer cases are at an approximately two¬
fold increased risk of developing the disease themselves, and confirmed that this
observation applies to the Scottish population.
Table 3.7 also shows a marked difference between the odds ratios for parents of
colorectal cancer cases and those of siblings. Some previous studies have provided
some evidence to suggest that sibling risks are greater than parent/offspring risks
(39, 92, 149). In contrast, no obvious difference between risks in siblings and
parents of controls was observed by St John ct al., who calculated odds ratios of 2.4
(95% CI = 1.4, 4.2) for parents of cases and 1.9 (95% CI = 1.1, 3.5) for siblings of
cases (134). True differences between sibling risks and parent/offspring risks may
arise due to the influence of environmental effects that are shared more closely
between siblings, or may reflect the mode of inheritance, with recessive inheritance
resulting in a greater risk to siblings being observed. Age cohort effects may also
account for such differences. However, in this study, the total number of colorectal
cancer cases developing in individual relative groups is very low, as reflected in the
wide confidence intervals. This implies that the observed degree of disparity may
well have arisen by chance.
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A slightly increased odds ratio among second-degree relatives of colorectal cancer
cases compared to controls for study A is also evident in table 3.7, although this was
not statistically significant. Second-degree relatives share 25% of their genes,
compared to the 50% of genes shared by first-degree relatives. Accordingly, the
magnitude of increased genetic risk in a group with a second-degree relative with
colorectal cancer would be expected to be approximately half that of a group with an
affected first-degree relative. The results obtained in this study are consistent with
this expectation, although again the number of cancer cases observed in this group
are not high, and the confidence interval for the odds ratio estimate is wide,
precluding any clear conclusions. Data on risk in second-degree relatives of
colorectal cancer cases is generally scarce, and second-degree relatives were not
considered in the study by St John et al., (260).
Study B considers the risk associated with having a relative diagnosed with
colorectal cancer at an extremely early age. In general, a relatively early age at onset
of colorectal cancer is associated with a hereditary origin. Several studies have
estimated relative risk of colorectal cancer in relatives of cases diagnosed at < 45
years of age (39, 78, 97, 205, 260), and a meta-analysis of data from these studies
suggests that the relative risk is 3.87 (95% CI = 2.40, 6.22)( 134). There are currently
no published estimates of relative risk for relatives of colorectal cancer cases
diagnosed at <30 years. The prior hypothesis to this study was that relative risk in
these groups would be considerably greater than risk in relatives of non-age selected
cases (study A). Unfortunately, this hypothesis cannot be accepted or rejected based
on the estimate presented in table 3.7, due to the small number of colorectal cancer
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cases in study subjects, and the resulting lack of statistical power. Indeed, this study
has not shown a statistically significant increase in risk for relatives of cases
compared to relatives of controls. Combination of the two studies in this analysis
does produce an estimate of relative risk in FDRs with a narrower confidence
interval. However, these two studies cannot be considered directly comparable, due
to differences in age and ascertainment methods of cases and controls.
The fact that relatively few colorectal cancer cases were observed in study B,
compared with study A, is likely to reflect the fact that the average age of cases and
controls was younger at the time of ascertainment. Hence relatives are also
comparatively young in age and have contributed fewer years at risk to the study.
The same effect may account for the relative lack of cases in siblings compared with
parents, and in first-degree relatives compared with second-degree relatives.
Overall, the results of this study are severely limited due to the small number of
colorectal cancer events occurring in relatives and consequent lack of statistical
power. In the matched analysis of study A, only 34 case-control pairs were
informative for colorectal cancer in FDRs, and in study B only 10 case-control pairs
were informative for colorectal cancer in FDRs. Neither study has the data required
for meaningful analyses by specific relative group, i.e. siblings or parents.
An unmatched analysis was conducted to determine whether this technique would
provide any more statistical power, and also to establish, through comparison of
results, whether or not the sub-set of cases included in the matched study were
representative of all cases ascertained. The pattern of results from this unmatched
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analysis is very similar to those from the matched study. Confidence intervals are
generally slightly narrower, indicating that the unmatched analysis had slightly more
statistical power. The unmatched results indicate that the elevated risk observed in
FDRs in study B is statistically significant at the 5% level (p < 0.05), although the
confidence intervals are still wide. For siblings in study A, the relative risk was
much lower in the unmatched analysis and closer to the values reported in previous
studies. This suggests that the extremely high relative risk observed in the matched
analysis is an artefact resulting from the small sample size.
The unmatched study does not allow for the dependence of cancer status between
related individuals. This could in theory be addressed using sophisticated statistical
techniques such as Generalized Estimating Equations (164). However, it is unlikely
that such analysis would significantly improve the statistical power of the study.
Another approach that could be employed is Kaplan-Meier survival analysis, as used
by St John et ah, (260). Again, this represents an alternative method of analysis, but
the limitations on power imposed by the small numbers of colorectal cancer events
would remain. Conclusions from the analysis of this data set by different methods
would therefore be unlikely to differ from the analysis presented in this section, and
further analyses were considered inappropriate.
In conclusion, the results of this study are consistent with published literature, and
support the prior hypothesis that people with an affected relative are at an increased
genetic risk of developing colorectal cancer. However, the lack of statistical power
of this study means that only limited conclusions can be drawn from these results.
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3.6 A Prospective Study of Risk Associated with Family History of
Colorectal Cancer
3.6.1 Rationale
Information on relatives of all cases and controls in studies A and B was ascertained
and initially matched at ISD in 1993. The same data underwent record linkage for
the second time at ISD in 2001. Hence there is up to eight years of follow-up on
relatives identified as part of these studies, who were alive at the time of
ascertainment. In theory, this data provides the opportunity to conduct a prospective
cohort study of the various relative groups.
There is a paucity of prospective data on familial risk of colorectal cancer in the
literature. Fuchs et al., (78) have conducted a large-scale prospective study, and
estimated the age-adjusted relative risk of colorectal cancer for people with an
affected FDR, as compared to those without such a history, to be 1.72 (95% CI =
1.34, 2.19). However, this study obtained information on family history from
interview, and reports of colorectal cancer in relatives were not confirmed.
The aim of this study was to provide an estimate for relative risk associated with
family history of colorectal cancer from a prospective study conducted in Scotland.
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3.6.2 Methods
All first-degree relatives of case or control subjects, who were alive and colorectal
cancer free at time of ascertainment, were eligible for the prospective study. From
Study A this group comprised 687 relatives of cases, and 617 relatives of controls.
411 relatives of cases and 366 relatives of controls from Study B were included.
The data set was analysed as a prospective cohort study with 'family history' as the
risk factor of interest. For the puiposes of this study, first-degree relatives of cases
were considered to have a family history, and all first-degree relatives of controls
were considered not to have a family history. Standard notation for a cohort study
was adopted, as shown in table 3.9:
Table 3.9 Statistical Notation for Prospective Risk Analysis
Disease No Disease
Exposed to risk factor
(relative of case)
a b




Relative risk (RR) was calculated by the formula:
RR = a(c+d) / [c(a+b)j
A Chi-squared statistic was calculated by:
X2 = n(|ad-bc|-n/2)2 / (a+b)(c+d)(a+c)(b+d)
Confidence intervals were calculated by standard methods for cohort studies.
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3.6.3 Results
The results of the prospective cohort analysis are presented in table 3.10.






















A FDR 687 (5612) 12 617 (4699) 5 2.16
(0.64, 7.23)
B FDR 411 (3140) 4 366 (2655) 0 N/A
'Abbreviations: FDR, first degree relative; CRC, colorectal cancer
In study A, a total of 12 FDRs of cases and 5 FDRs of controls developed colorectal
cancer during the follow-up period. This number was insufficient to yield a
statistically significant estimate of relative risk. Since no cases occurred in relatives
of control subjects from study B, calculation of a relative risk was not possible.
3.6.4 Discussion
The prospective nature of this study, and the use of record linkage to determine the
true cancer experience of study subjects over time, makes this a unique and highly
valid approach to the challenge of informing risk prediction on the basis of family
history of colorectal cancer. Unfortunately, the scale of the study was insufficient to
allow conclusions to be made from the results shown in table 3.10. The estimated
relative risk of having an affected FDR from study A is similar to the results of a
meta-analysis of other published studies, which quoted a figure of 2.25 (95% CI =
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2.20-2.65) (134). However, the confidence intervals pertaining to this study are very
wide, and the observed results could have occurred by chance.
Clearly, a longer period of follow-up, and / or a larger data set is required to
generate statistically valid results from a prospective study of risk associated with
family history of colorectal cancer. At present, however, prospective analysis of this
data set lacks the statistical power to generate meaningful results.
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3.7 Discussion of General Methodology
3.7.1 Ascertainment of Study Subjects
In study A, both cases and controls were contacted and invited to participate in the
study, and individuals who declined, or did not respond to, this invitation were
excluded, and a replacement was found. This situation may have introduced some
degree of ascertainment bias into the study, since people who opted to take part may
be more likely to have experience of colorectal cancer or have a greater knowledge
about the subject. Similarly, based on experience in other studies, non-responders
may also have been relatively young and more likely to be male. However, the total
proportion excluded on this basis was less than 20%, and this high participation rale
should limit any bias that may exist.
Since all controls were identified from the general population, and ascertainment
was not based on hospital attendance or other health-related criteria, the combined
analysis of the two groups of controls is considered to be valid for the purposes of
the analysis of prevalence of family history of colorectal cancer.
3.7.2 Record Linkage
Within the Scottish Record Linkage System, the false positive rate of records
"matched" via patient-specific identifying information has been estimated as less
than 1% (104, 122, 139), when based on the probability matching algorithm alone.
Data regarding the false negative rate is not available, but false negative "matches"
are likely to occur at a similarly low level. Hence, records that refer to different
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people may be matched in error, and records that genuinely refer to the same person
may not be matched. At a practical level, such errors in record linkage often arise
due to an inability to distinguish people with similar or identical names, who share
similar or identical dates of birth.
The actual frequency of errors in record linkage of study subjects with death records
and the Scottish Cancer Registry is impossible to assess, since such occurrences will
depend on the size of the data set under study and the number of colorectal cancer
registrations in the registry, as well as the accuracy of the record linkage process
itself. The protocol employed by ISD, whereby a threshold for accepting a match is
based on a subjective assessment of the absolute probability that two records match,
is designed to limit the number of false positive matches that are accepted for the
purposes of analysis.
Another limitation of record linkage concerns the inability to trace relatives who
have left Scotland. Information gathered at interview suggests that around 10% of
relatives in this data set may have been untraceable, either due to emigration or
limitations in the quality of available information. The principal effect of an inability
to trace a proportion of relatives will be to underestimate cancer incidence amongst
data subjects. However, it is unlikely that either the fact that some relatives could
not be traced, or the possible occurrence of mismatched records, would introduce
any systematic bias to these studies.
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The record linkage process is wholly reliant on the provision of detailed personal
information for matching with health records. Where information this is provided
solely by interview, information may be more complete for first-degree relatives,
leading to systematic bias in the probability of matching success. In this data set,
such an effect should be limited by the intermediate step of using central records to
extend and verify pedigree information.
Record linkage currently provides the only realistic method of 'confirming' a
negative report of cancer, and alternative methods of confirming reported cancers in
relatives compare unfavourably, being labour intensive and potentially incomplete
(confirmation may not always be found). Overall, record linkage has been found to
be a useful and efficient means of determining the cancer experience of data
subjects, which is not biased by relying on information from the subjects
themselves. It does not, however, constitute a "gold standard" in this context, as
potential for error remains.
3.7.3 Identification of Colorectal Cancer Cases Through Death Records and
the Scottish Cancer Registry
The accuracy and completeness of cancer registry data itself is a crucial
consideration for any study that uses such a resource to validate or confirm cancer
diagnoses, particularly when such data is used to inform clinical policy or
epidemiological studies. Information on data quality of cancer registries is generally
scarce, but several studies have recently been undertaken in Scotland to evaluate the
reliability and validity of the Scottish Cancer Registry.
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The Scottish Cancer Registry was initiated in 1958, and ascertainment is considered
to be sub-optimal prior to 1968. Although ascertainment of any registry is unlikely
to reach 100%, methods of ascertainment have steadily improved since this time,
and the Scottish Cancer Registry is now considered to be reasonably complete in
recent years and to compare favourably with other registries. By comparing cancer
registry data with information re-abstracted from medical records, Brewster et ah,
found that 5.5% (95% CI = 2.5%, 8.6%) of colorectal cancer cases recorded in the
registry did not warrant this diagnosis upon re-evaluation (26). This study related to
incidence in the year 1990. A separate study examined fourteen sources of potential
cancer registrations within the Tayside health board area, and concluded that the
ascertainment rate of colorectal cancer in this area in 1992 was approximately 98.5%
(27). Other estimates of data quality can be obtained by examining the proportion of
cases registered only from death certificates, with a low value being indicative of
good data quality. For the period 1986-1995, 2.8% of colorectal cancer cases were
registered only from death certificates, and a trend towards an increasing proportion
with increasing age was evident (102). A high proportion of microscopically verified
registrations is also considered to imply a high degree of data validity. Over the
same time period, 84.5% of colorectal cancer cases in the Scottish Cancer Registry
were verified in this manner (102).
Hence, although some limitations of the Scottish Cancer Registry are illustrated by
the studies considered above, the data recorded are considered to have a
comparatively high degree of accuracy. This point is supported by the inclusion of
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this registry in the publication "Cancer Incidence in Five Continents", which
maintains high standards for the quality of data included (119).
Cancer diagnoses made prior to the establishment of an effective cancer registry
were only identified for the puiposes of these analyses if they were recorded on a
death certificate. Hence, the ascertainment rate of colorectal cancer cases before
1968 is likely to be relatively low, and data provided in this manner may be less
accurate in terms of site of cancer. With respect to the assessment of the accuracy of
reporting of family history of colorectal cancer, this effect is unlikely to introduce
systematic bias in terms of sensitivity of reporting, but may have resulted in a slight
underestimation of positive predictive value. Also, where confirmation of cancer
was by death certificate as opposed to ISD matching, the age at onset was taken to
be the date of death. This may have resulted in an ovcrestimation of age at onset for
such cases, and conceivably led to an overestimation of family history where age of
onset forms part of the family history criteria. A final consideration is that cancer
cases that occur outwith Scotland are invariably not recorded in the Scottish Cancer
Registry. Again, this factor may have resulted in a slight underestimation of the true
colorectal cancer incidence in the data set.
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3.8 Conclusion and Further Work
The studies described in this chapter represent a comprehensive analysis of a unique
data resource. The key conclusions of the analyses presented and discussed in this
chapter can be summarised as follows:
(i) People in Scotland with a history of colorectal cancer in a first-degree
relative are at a significantly increased risk of developing the disease
(ii) The population prevalence of having a history of colorectal cancer in a
first-degree relative is approximately 9.4% (95% CI = 4.9, 13.9)
(iii) Family history is substantially under-reported at interview by both
colorectal cancer patients and healthy controls, and is often reported
inaccurately
These conclusions are of considerable relevance from a clinical perspective, as well
as in the context of epidemiological studies, since family history is used as part of
clinical genetic services and in research as a means of identifying a sub-group of the
population at increased genetic risk.
The findings presented in this chapter also illustrate the need for further research
into the prevalence of family history of colorectal cancer, the meaning of family
history at the individual and population level, and the methods by which family
history is established. Repetition of the prevalence and the accuracy studies in a
larger data set is ideally required to confirm the findings and to quantify the results
more precisely. Similarly, the analyses of the risk associated with having a family
138
history of colorectal cancer presented here lack statistical power and a larger study,
employing similar methods, is necessary to provide precise and reliable results.
The methods utilised in the prospective study facilitate re-analysis of this data set
after a longer period of follow-up, since record linkage can be repeated, providing
updated information on the colorectal cancer status of study subjects. In theory, it is
also possible to stratify study subjects by extent of family history and estimate
relative risk in each group. Furthermore, the general methodology for constructing
the data set described in this chapter can theoretically be employed to provide data
on absolute risk associated with having a family history of colorectal cancer. This
could be achieved by identifying cohorts of individuals defined by degree of family
history and performing record linkage on this data set before and after a defined
period of follow-up. Age would be a vital consideration in such a study, since
absolute risk is determined by a synthesis of age, environmental risk and familial
(genetic) risk. Information on absolute risk of colorectal cancer associated with
family history could be used directly to inform genetic risk assessment. However,
such analysis is not feasible for the current data set, given the prohibitively small
numbers of colorectal cancer cases occurring in the study subjects.
In conclusion, the current data set has been thoroughly analysed and explored,
yielding results that are highly relevant to the challenge of preventing colorectal
cancer in Scotland through targeting people at increased genetic risk.
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Chapter 4




4.1.1 Rationale for Identifying Mismatch Repair Gene Mutation
Carriers
There is now compelling evidence to support a role for mismatch repair gene
mutations in a small but important subset of colorectal cancer cases. Individuals who
harbour such mutations are at a very high risk of developing colorectal cancer, with
penetrance being approximately 80% in males and 40% in females (4, 57, 170, 286,
289). Furthermore, colorectal cancer cases that are associated with mismatch repair
gene mutations are likely to occur at a relatively early age. Mismatch repair gene
mutation carriers thus constitute an important sub-group of the population who may
be targeted as part of strategies to prevent colorectal cancer.
Information regarding genetic susceptibility to a particular condition is of limited
practical use in the absence of effective intervention strategies. As discussed
previously, clinical screening can potentially reduce the incidence and mortality of
colorectal cancer in people at high genetic risk of this disease. Genetic testing for
mismatch repair gene mutations provides one strategy for identifying such people,
and, in contrast to empirical risk assessment on the basis of family history, has the
important ability to elucidate individual risks within families that harbour a
mutation. These observations provide a compelling rationale for identifying
mismatch repair gene mutation carriers and offering clinical screening.
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In the Scottish Population, the prevalence of pathogenic MMR gene mutations in the
15-74 years age group has been estimated as 1:3139 (95% CI = 1:1247, 1:7626)
(58). Extrapolation of this estimate to the Scottish population (2001 census) implies
that the number of Scots in this age range who have such mutations is 1209 (95% CI
= 498, 3044). Theoretically, identifying these people at an asymptomatic stage, and
providing appropriate surveillance, would have significant benefits for this sub¬
group of the population in terms of colorectal cancer prevention. However, further
evidence of effectiveness, and careful consideration of potential drawbacks, are
required to inform decisions regarding the appropriateness of this approach.
Mismatch repair gene mutation carriers in Scotland are identified either through
clinical cancer genetic services, or as part of research programmes. This situation is
common to most developed countries, and often the approach to the ascertainment of
carriers for research and clinical purposes is integrated. However, mutation analysis
is often targeted to colorectal cancer patients, particularly in the research context,
and, whilst this enhances understanding of the genetic basis of colorectal cancer, it is
of limited clinical benefit to the individual concerned.
At the present time, asymptomatic individuals in Scotland who meet empirical
criteria for "high" genetic risk of colorectal cancer, as defined by guidelines
published by the Scottish Cancer Group (249), are eligible for genetic testing.
However, only a proportion of asymptomatic MMR gene mutation carriers will meet
these criteria, and the identification and testing of those that do is conditional on
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them being aware of their family history and sufficiently concerned to seek medical
advice.
Thus, ongoing research is designed to enhance understanding of the genetic
epidemiology of colorectal cancer, and clinical genetic services offer genetic
counselling and testing, where appropriate, to individuals who seek medical help
regarding a high empirical risk of developing colorectal cancer. However, from a
wider public health perspective, a more co-ordinated and systematic strategy is
required to reduce the burden of colorectal cancer resulting from MMR gene
mutations. The goal of such a strategy must be the identification of all MMR gene
mutation carriers at an asymptomatic stage, and the provision of appropriate
counselling and clinical screening for these people.
Numerous considerations surround the issue of who should be offered genetic
testing. Simply offering a genetic test may lead to increased anxiety in the test
subject, and this may be further compounded by the fact that a significant proportion
of tests are inconclusive. Additionally, conducting complete mutation analysis to
determine the MMR gene mutation status of an individual is both expensive and
time-consuming. Hence, the capacity to minimise the number of people offered
genetic testing in general, and complete mutation analysis in particular, is a critical
feature of an appropriate strategy for identifying mismatch repair gene mutation
earners at the population level.
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4.1.2 Strategies for Identifying MMR Gene Mutation Carriers
There are several theoretical options for attempting to identify asymptomatic MMR
gene mutation carriers from within the Scottish population.
4.1.2.1 Population Genetic Testing
Population genetic testing, in which mutation analysis is conducted in every member
of a population, is in theory the most comprehensive strategy for identifying
asymptomatic mutation carriers at the population level. There are two practical
strategies that could be employed to search for mutations in the context of
population genetic testing; either conducting complete mutation analysis of the
genes in question, or looking for specific mutations that are known or suspected to
occur in the population. The latter option is far less expensive and labour-intensive
and could be of particular benefit in countries where specific "founder" mutations
are prevalent. However, the extreme heterogeneity of mismatch repair gene variants
and the low allele frequency of individual mutations create considerable practical
barriers to testing for specific MMR gene mutations at the population level.
Published information and data from ongoing research in Scotland suggest that
numerous different MMR gene mutations are present in the Scottish population,
many of which will not previously have been identified. Conducting comprehensive
population genetic testing based on identifying specific mutations would therefore
necessitate performing numerous pre-symptomatic tests, and would not be capable
of identifying novel mutations. At present, therefore, non-specific mutation analysis
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represents the most appropriate option for population genetic testing in this context,
despite the fact that mutation analysis is relatively time-consuming and expensive.
Regardless of the strategy used, conducting population-wide genetic screening for a
very rare set of mutations, such as MMR mutations, is difficult to justify on practical
and ethical grounds, since a large number of people would undergo genetic testing
and only a small proportion would actually benefit. Genetic testing may also be
unacceptable to a proportion of the public, resulting in incomplete participation.
These factors, coupled with the practical difficulties outlined above and the current
limitations in knowledge regarding the association between MMR gene mutations
and colorectal cancer, mean that conventional population testing is unlikely to be
recommended in the near future. Indeed, a recent UK National Screening Committee
workshop concluded that there is currently no case to offer population screening in
an attempt to identify MMR gene mutation carriers (237). Authors in the United
States have reached similar conclusions, agreeing that more information regarding
the prevalence and penetrance of mismatch repair gene mutations and more evidence
of effective intervention strategies are essential prerequisites for implementing
population genetic testing (30, 31, 44, 221, 271, 301).
4.1.2.2 Stratified Population Genetic Testing
Stratified population genetic testing, in which genetic testing is offered only to
individuals with a certain extent of family history of colorectal cancer provides
another option for identifying asymptomatic mismatch repair gene mutation carriers.
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However, as discussed previously and highlighted in chapter 3, there are
considerable practical difficulties in obtaining accurate family history information,
and attempting to do so for the entire population may be unfeasible. Recording and
assessment of family history in the primary care setting could potentially circumvent
this problem in the future, but implementing such a policy is problematic in itself
and at present family history information is not routinely gathered.
Additionally, family history has limited sensitivity and specificity as a tool for
identifying MMR gene mutation earners (199), and stratified population genetic
testing may have the additional drawback of raising anxiety amongst people with a
family history of colorectal cancer by targeting them specifically. The targeting of
people with a particularly strong family history as part of a stratified genetic testing
programme may be more acceptable in these respects, since relatively few people
would be offered genetic testing and the probability of those people harbouring a
mismatch repair gene mutation is relatively high. However, there are two major
disadvantages to such an approach. Firstly, application of any family history criteria
will result in a proportion of MMR gene mutation carriers, i.e. those who do not
meet these criteria, remaining unidentified. In addition, if only the minority of
people with a very strong family history of colorectal cancer are to be included in a
stratified genetic testing system, it becomes difficult to justify the implementation of
such a programme at the population level. Considerable overlap would also exist
between highly stratified population genetic testing and clinical genetic services.
Hence, whilst family history may be useful as a means of targeting potential MMR
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gene mutation earners in a clinical context, stratified genetic screening at the
population level is unlikely to prove feasible or desirable at present.
4.1.2.3 Cascade Genetic Testing
Cascade genetic testing initially involves conducting mutation analysis in
individuals who are at a relatively high risk of carrying a mutation. Often, people
with a family history, people who have developed the disease themselves, or a sub¬
group of such patients, are targeted for this purpose. Once a mutation carrier has
been identified, genetic testing can be offered to their relatives, and the specific
mutation present can thus be traced through an expanded pedigree in a "cascade"
fashion. The genetic proximity of the relatives offered testing is an important factor
in determining the effectiveness and efficiency of cascade genetic testing, and is
generally referred to in terms of 'depth'. For example, restricting testing to first-
degree relatives of known carriers is highly efficient, since each individual tested
will have a 50% probability of carrying the same mutation. However, this approach
may miss earners in more distant relatives. The ideal cascade genetic testing system
would test all first-degree relatives of an index case, and subsequently lest first-
degree relatives of those found to have a mutation. In practice, such a system will be
restricted, due to the fact that some first-degree relatives will be deceased, and some
will decline to participate.
The concept of tracing a pathogenic mutation through families is a well-established
aspect of clinical genetic services. Irrespective of how an individual mutation carrier
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is identified, it is possible, and in many instances desirable, to test relatives of that
carrier for the specific mutation they have been found to carry. Hence, one of the
major advantages of cascade genetic testing as a means of identifying asymptomatic
MMR gene mutation carriers is the potential of this approach to complement current
strategies pursued by genetic services. Active cascade genetic testing to identify
MMR gene mutation earners is essentially a systematic and comprehensive
continuation of the way in which current clinical practice has evolved.
Another major advantage of active cascade genetic testing over other strategies for
identifying asymptomatic carriers of pathogenic mutations is its potential efficiency.
By limiting genetic testing to either people deemed on clinical grounds to be at high
risk of carrying a mutation, or close relatives of known carriers, it is theoretically
possible to restrict the number of non-carriers who undergo testing while
maximizing the number of carriers identified. This not only reduces the resources
required to identify mutation carriers, but also reduces the number of asymptomatic
non-earners offered genetic testing.
Cascade genetic testing has a particular advantage in circumstances where
pathogenic mutations in the gene(s) in question are heterogeneous and/or previously
unknown pathogenic mutations may exist, as is the case with MMR genes. In this
situation, identification of a pathogenic mutation usually requires complete mutation
analysis of the entire gene(s), a procedure that is relatively time-consuming and
expensive. At current NHS rates, mutation analysis of hMLHl and hMSH2 costs
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around £750 (Dr. M. Porteous, personal communication). Application of population
or stratified genetic testing involves conducting such mutation analysis in each
participant. In contrast, the design of cascade genetic testing is such that, once
mutation analysis reveals a pathogenic mutation, subsequent genetic testing of
relatives of the identified carrier involves only a simple test for that specific
mutation concerned. Accordingly, such a test is relatively quick to perform, and
compares favourably with mutation analysis in terms of cost, with each test for a
known mutation costing £50 to £100 (Dr. M. Porteous, personal communication).
Throughout this thesis, the term "mutation analysis" or "non-specific test" refers to
conducting complete analysis of the mismatch repair genes hMLHl and hMSH2 in
an attempt to detect any possible mutation in a colorectal cancer case. The term
"pre-symptomatic test" or "specific test" refers to the process of testing a relative of
a known carrier for the specific mutation known to occur in that carrier.
Mutation analysis of MMR genes may be inconclusive or incomplete in the sense
that not all mismatch repair genes are considered, and results are subject to
interpretation as considered in chapter 3. Hence a negative result at this stage cannot
be equated with a lack of increased genetic risk, and, if the appropriate family
history criteria are met, surveillance of the individual concerned must be maintained.
In contrast, the low population prevalence of MMR gene mutations means that a
relative offered a pre-symptomatic test for a pathogenic mutation known to occur in
their family, and found to be negative, can be considered to be at no more than the
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average population risk for colorectal cancer. This is true regardless of their family
history of the condition, provided that the specific mutation in question segregates
with disease in the family. In this manner, cascade genetic testing permits the
identification of asymptomatic carriers of pathogenic mutations without the need for
complete mutation analysis in each individual tested, and provides a conclusive test
result for relatives of a known carrier.
A theoretical application of cascade genetic testing has been considered in a paper
by Krawczak et al., (150). This publication provided a series of equations designed
to estimate the theoretical efficacy and efficiency of cascade genetic testing for
various hypothetical mutations, including autosomal dominant mutations
predisposing to complex disease. MMR genes and colorectal cancer were not
specifically considered. The authors calculated that a cascade genetic testing strategy
involving testing of all children, siblings, grandchildren, nieces, nephews and first
cousins of a mutation carrier would identify 63.4% of mutation carriers in the
population concerned, assuming penetrance of this mutation to be 50% (150). It was
further estimated that such a strategy would necessitate testing 3.5 non-carriers
within a pedigree for each carrier identified (150). The proportion of mutations in
the population that could be identified, and the efficiency of the process, varied with
screening depth and penetrance. The results produced by the equations in this paper
prompted the conclusion that cascade genetic testing may provide a "viable"
approach to identifying asymptomatic carriers of mutations that predispose to
complex disease (150).
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Whilst Krawczak et al., provide a theoretical demonstration of the potential utility of
cascade genetic testing, the equations used are insufficient to permit a
comprehensive assessment of this approach in a specific clinical context such as
MMR gene mutations and their association with colorectal cancer. The outcomes of
any cascade genetic testing programme will depend on numerous factors, including
the genetic epidemiology of the condition in question, the available technology for
genetic testing and the uptake of genetic testing by at-risk individuals. These factors
will be superimposed on the background of population demographics, diverse family
structure, the age/sex distribution of cases and existing strategies for colorectal
cancer prevention in people at increased genetic risk. Only a small proportion of
these factors are considered by Krawczak et al. Furthermore, the equations presented
in this paper make the key assumptions that participation will be complete, and that
penetrance is the same in both males and female carriers.
Another crucial consideration that is not addressed by the equations provided by
Krawczak et al., concerns the timescale of the cascade genetic testing programme. In
reality, it will take time to recruit potential mutation carriers, perform mutation
analysis, trace relatives and so on. As time progresses, the population will age and
new cases of disease will arise. The timescale of a genetic testing programme is also
an essential consideration in terms of planning and resource allocation. Hence, an
evaluation based on the instantaneous completion of a cascade genetic testing
programme is of limited practical use.
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Several authors have taken a more clinically-focused approach to investigating the
potential of cascade genetic testing as a means of identifying carriers of mutations
predisposing to various diseases (110, 265, 266, 280, 307). Super et al., have
outlined the case for cascade genetic testing to identify carriers of mutations that
cause cystic fibrosis (265), and have applied this strategy in a clinical setting (266).
Results of this practical application suggested that cascade genetic testing was both
effective and efficient in this context, and prompted the authors to recommend
widespread application of this approach (266). The utility of cascade genetic testing
in cystic fibrosis has also been formally considered by Holloway and Brock (110),
who concluded that cascade genetic testing was useful in individual families, but
would be less appropriate at the population level in comparison with offering genetic
testing to all couples (a form of population genetic testing).
Cystic fibrosis is a recessive condition that is present from birth, and the combined
allele frequency of pathogenic mutations is in the order of 0.02. These factors
contrast with the extreme rarity and autosomal dominant nature of mismatch repair
gene mutations. Hence, whilst the potential utility of cascade genetic testing as a
means of identifying mutation carriers can be illustrated using cystic fibrosis, it is
not possible to extrapolate conclusions to MMR genes and colorectal cancer. This is
particularly true of information regarding participation rates and the psychosocial
effects of cascade genetic testing, since the issues faced by the individuals being
offered testing are very different in these two situations.
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Cascade genetic testing for Familial hypercholesterolaemia has been explored in the
Netherlands as part of an ongoing project (280). This condition is characterized by
mutations in the low-density lipoprotein receptor gene, which cause elevated blood
cholesterol and thus predispose to atherosclerosis and vascular disease. Cascade
genetic testing beginning with 237 mutation carriers identified 2039 additional
earners from a total of 5442 relatives (280). The protocol employed involved testing
first-degree relatives of known carriers, with second-degree relatives being tested
where testing of first degree relatives was not possible. The overall participation rate
in this study was 90% (280).
In many respects, the low-density lipoprotein receptor gene and its role in familial
hypercholesterolaemia is comparable with MMR gene mutations and their
association with colorectal cancer. The condition is inherited in an autosomal
dominant manner, and over 300 different mutations in the same gene have been
found to be pathogenic. A small number of these mutations occur with a relatively
high frequency, whereas the majority have only been identified in one family (73).
Furthermore, the condition is rare, affecting 1:500 people in the population of the
Netherlands, and it influences the probability of developing particular complex
diseases in adult life. However, there are also important differences between these
two situations. Familial hypercholesterolaemia can be effectively treated by a
combination of lifestyle modification and the administration of drugs to lower
cholesterol, whereas intervention for MMR gene mutation carriers involves regular
invasive surveillance. This difference may affect participation rates, since the
necessary interventions entailed by a diagnosis of familial hypercholesterolaemia
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may be comparatively acceptable to potential participants. There are also practical
differences associated with identifying earners of mutations in MMR genes and the
low-density lipoprotein receptor gene. While mutations in the latter gene are
heterogeneous, it has been shown that in the Netherlands nine specific mutations
account for 66.5% of familial hypercholesterolaemia, and that some mutations occur
in specific geographical areas (73). The fact that specific mutations can be identified
in the majority of low density lipoprotein receptor gene mutation carriers largely
precludes the need for comprehensive mutation analysis.
Cascade genetic testing for mismatch repair gene mutations has not been conducted
and formally evaluated on a population-wide scale, but an ongoing large-scale study
into the genetic basis of colorectal cancer in Scotland, entitled the Colorectal Cancer
Genetic Susceptibility (COGS) programme, can potentially provide some data
relevant to such an evaluation. The COGS programme was initiated in 2000, and has
been funded by two Cancer Research UK programme grants through to 2008. The
Chief Scientist Office (CSO) has provided essential co-funding support to the COGS
programme through project grants. The main aim of COGS is to conduct genetic
testing for mismatch repair gene mutations in all Scottish colorectal cancer patients
diagnosed under the age of 55 years and to characterise the impact of these
mutations in terms of penetrance, survival and interactions. Another objective is the
detection of novel genetic variants that cause colorectal cancer. Thus far, 26 definite
mismatch repair gene mutation carriers have been identified.
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The COGS programme is not specifically designed to conduct or evaluate cascade
genetic testing. However, funding and ethical approval is in place for the recruitment
and genetic testing of relatives of identified carriers, in order to better characterise
the pathogenicity of mismatch repair gene mutations. Consequently, a considerable
body of data that are relevant to the evaluation of cascade genetic testing are
currently becoming available through the COGS programme.
Overall, there is some information from ongoing research programmes, published
literature and expert recommendations to suggest that cascade genetic testing may be
a feasible means of identifying asymptomatic carriers of mutations in MMR genes.
However, a formal evaluation of cascade genetic testing in this context has not been
undertaken, and there is no direct evidence of the effectiveness of this approach.
Information regarding the outcomes of cascade genetic testing for mismatch repair
gene mutations, particularly with respect to the number of mutation carriers that will
be identified and the relative efficiency of this process, is not currently available.
Such information is required to inform the planning of cascade genetic testing
programmes, either for research purposes or as part of public health policy.
4.1.3 Aims and Objectives
The overall aim of the research presented in this chapter is to conduct an evaluation
of cascade genetic testing for mismatch repair gene mutations through the
development of a computer model of this process that runs on a chronological basis,
starting at a particular point in time rather than with an initiating event. The
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population demographics and genetic epidemiology of colorectal cancer at this point
will be defined. A hypothetical cascade genetic testing programme, with adjustable
parameters and scope defined by the user of the model, will then be applied and the
outcomes of this system will be studied.
The vast majority of pathogenic mismatch repair gene mutations have been reported
in hMLHl and hMSH2, and data relating to other genes is comparatively scarce.
Accordingly, the computer model considered in this chapter focuses on these two
genes, and in the context of this model the term "mismatch repair genes" refers to
hMLHl and hMSH2.
The specific objectives of the computer model were to:
(i) Conduct a comprehensive "task analysis", outlining the required nature
and scope of a computer model capable of evaluating a hypothetical
cascade genetic testing programme for MMR gene mutations
(ii) Develop a computer model of cascade genetic testing as it applies to
MMR gene mutations
(iii) Determine suitable quantitative 'default' estimates as inputs for this
model, identified through the available literature and the use of 'real
data' from the COGS study
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(iv) Utilise this model to estimate the number of MMR gene carriers that
would be identified over time under an active cascade genetic testing
program in Scotland
(v) Estimate the efficiency, according to the computer model, with which
MMR gene carriers could be identified by cascade genetic testing, in
terms of the number of genetic tests required to achieve this
(vi) Investigate the sensitivity of key model outcomes to variations of input
parameters on a realistic scale
(vii) Critically interpret the outcomes from the computer model and consider
the wider implications of findings in the context of evaluating cascade
genetic testing as a strategy for identifying asymptomatic MMR gene
earners in the Scottish population.
Defining the aims and scope of a proposed computer model in detail is an integral
part of to model development. This process is referred to as the "task analysis". This
is, essentially, a document designed to answer two crucial questions:
(i) What exactly is going to be modelled?
(ii) What are the requirements of the completed model?
A simplified version of the task analysis document is presented in the results section.
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4.2 METHODS
4.2.1 Strategy for Model Development
Computer modelling provides a valuable means to represent complex systems.
Increasingly, this approach has been used in the field of biomedical research and
health service provision. In some circumstances, biomedical researchers will have
developed sufficient expertise to enable a computer model to be developed entirely
by one individual, or within one research group. More commonly, computer
modelling is used as one of many research tools by researchers whose area of
expertise resides in the field to which the model relates, not in the actual process of
computer modelling. Conversely, an expert in computer modelling is unlikely to
have sufficient knowledge and understanding of the scientific research in question to
enable them to create a meaningful model. In such circumstances, model
development will be the result of collaboration between at least two people. A
"domain expert", will provide the knowledge and expertise to understand and define
the system to be modelled, and a computer programmer will undertake the technical
task of writing the computer programme that will form a working model.
Throughout the development of this computer model, the author of this thesis
assumed the role of "domain expert", and a computer programmer was employed on
an ad-hoc basis to implement the model. Reconciling these different perspectives
and facilitating productive communication between domain experts and computer
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programmers is one of the major challenges in the task of modelling biological and
medical systems.
The strategy chosen to overcome this challenge was to use a five-stage process of






In this approach, the design of the computer model comes from the domain expert.
The computer programmer then implements the model according to pre-defined
specifications and requirements, working in close collaboration with the domain
expert. Finally, the domain expert evaluates the functions of the model and uses the
model to generate relevant data for analysis and interpretation. Thus, the domain
expert retains ultimate control of the process of model development.
The inception phase involved the production of a task analysis document. This was
conducted in a systematic manner, with the aim of defining and recording the
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precise requirements and scope of the model, and identifying sources of data to
inform model parameters. In many ways, this is the most important aspect of model
development, since it determines the capacity of the final computer model. The next
stage in model development was the creation of a "conceptual model", which is a
representation of the model from the perspective of the domain expert. To facilitate
the creation of a conceptual model it was necessary for the domain expert to attain a
thorough understanding of the system to be modelled, the factors that influence it,
and the issues that may be encountered. This was the most creative stage, in which
the broad concept of 'creating a model of cascade genetic testing' was given detail
and definition. At this stage the quantitative estimates that provide inputs to the
model were identified. The completed conceptual model facilitated communication
of the model system to a computer programmer, who used the conceptual framework
thus provided as the basis for creating a functional model. In turn, the functional
model formed the basis for 'coding' the software that constitutes a working version
of the model. Subsequently, the model was 'run' at various settings to generate the
data that forms the basis of an evaluation of cascade genetic testing.
A crucial feature of this approach is the iterative and incremental fashion in which
the computer model was developed. Both the conceptual and functional models were
constantly revisited during development to enable unforeseen hurdles to be
overcome, and to incorporate new ideas.
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Details of the methods used at each stage of model development are considered
below.
4.2.2 Inception (Task Analysis)
The task analysis was informed by published literature on the subject of the
epidemiology of colorectal cancer, the genetic epidemiology of mismatch repair
gene mutations, and the concept and practice of cascade genetic testing. Additional
input at both the task analysis and conceptual model stage was sought from experts
with a variety of relevant perspectives, including clinical cancer genetics, genetic
epidemiology and colorectal surgery.
4.2.3 Development of Conceptual Model
The most effective and systematic manner in which to represent a conceptual model
is to use a 'visual modelling' system that provides a structured way of representing
systems organized around concepts that exist in the real world and can therefore be
understood with comparative ease. The conceptual model of cascade genetic testing
was developed and represented using an object-orientated visual modelling design.
Object-orientated design is a powerful technique for creating useful models of
complex systems (224). Specifically, the conceptual model was created using
Rational Rose software (Rational™), which employs the Unified Modelling
Language (UML) to create detailed visual models. The Unified Modelling Language
is widely used, and has previously been successfully utilised for modelling
biological systems (182).
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A major advantage of the above approach is that the UML can be used both to create
a conceptual model, and to represent a functional model. This dual use ensures
optimal communication between domain expert and computer programmer, and
facilitates a smooth transition from conceptual model to functional model.
Development of a conceptual computer model took a bottom-up approach, starting
with the various parts of the cascade genetic testing system, and trying to understand
and represent how the properties of the system arise from the interaction of its
components. In object-orientated design, objects are used to represent entities,
including their state and behaviour, in a real-world system. Objects that share
common properties, behaviour, semantics and relationships can be grouped together
into classes. This reflects an important concept of object-orientated modelling,
whereby such characteristics are detailed only once in the model, and are shared by
each object that uses them. In the context of modelling cascade genetic testing, an
example of an object may be a member of the population, referred to in the
conceptual model as a "Scot". Each Scot will have similar properties, or "attributes",
and similar interactions with other objects in the cascade genetic testing system.
Hence a "class" that includes the shared characteristics of Scots can be created.
The methods employed in this project were ideally suited to the production of a
conceptual model by a domain expert, since they employ the language of the
domain, rather than the terminology of computer programming. They provided a
rigid structure to the conceptual model, which enabled it to be expressed and
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understood in the systematic way required by a computer programmer, and indeed
by a computer programme, in the implementation phase.
Using the UML, the conceptual model can be represented in various different ways,
using diagrams that view the model from distinct but related perspectives. The types
of diagrams used, and their basic UML notation, are outlined below:
(i) Use Case Diagrams
Use case diagrams are used to document the behaviour of the system, in terms of its
intended functions (use cases), people who interact with the system (actors) and the
relationships between these. These diagrams form the starting point of the
conceptual model, and communicate the functional objectives of the model.




An example of a use case diagram is given by figure 4.3.3 (page 182).
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(ii) Class Diagrams
Class diagrams illustrate a sub-set of classes that are included in the conceptual
model. They often relate to use cases, and include each class involved in a particular
use case. Classes and class diagrams contain much of the information that provides
the framework for creating a functional model.
Figure 4.2.2 Class Diagram Notation
An example of a class diagram is given by figure 4.3.7 (page 187).
(iii) Sequence Diagrams
A sequence diagram displays the chronology of interactions between objects during
a particular scenario. These diagrams invariably correspond to a particular use case,
and document the sequence of interactions and communications between objects that
are required to complete the use case in question.
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An example of a sequence diagram is given by figure 4.3.4 (page 183).
(iv) Collaboration Diagrams
Collaboration diagrams essentially provide an alternative view of a scenario
described by a sequence diagram. Both sequence and collaboration diagrams may be
referred to as scenario diagrams. The key difference is that a collaboration diagram
illustrates object interactions arranged around the objects in question, and their links
to one another. Hence they are able to represent the scenario in broader terms.
Figure 4.2.4 Collaboration Diagram Notation
An example of a collaboration diagram is given by figure 4.3.5 (page 184).




The conceptual model was represented using a combination of the diagrams outlined
above, with associated documentation. Further details of the model were
communicated verbally during discussions between the domain expert and the
computer programmer.
4.2.4 Input Estimates
The validity of any computer model is crucially dependent on the accuracy and
quality of the data used to provide inputs and set parameters for the model system.
Resources identified at the task analysis stage; principally published literature, data
from the COGS study, and expert opinion, were used to define the estimates
required as inputs to the model. In accordance with recognised principles of good
practice in model development (300), all assumptions and estimates built into the
model were logged, and presented in as transparent a fashion as possible. The
estimates identified and used in this computer model are presented in the results
section. The number of expected colorectal cancer cases in the population, and the
distribution of these cases by age, sex and mutation status was calculated using
formulae entered into a Microsoft Excel™ spreadsheet.
4.2.5 Development of Functional Model
The methods employed were designed to ensure a logical transition from conceptual
model, which represents the domain expert's view of the cascade genetic testing
system, to functional model, which represents the same system from the perspective
of the functions of the model. In essence, the conceptual model was designed to
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describe the real-life cascade genetic testing system, whereas the functional model
provided a blueprint for writing the computer programme ("coding") that constitutes
the working model software.
At this stage, communication between domain expert and computer programmer was
essential. This was primarily achieved through the conceptual model itself and the
associated documentation that describes in detail what the objects, classes and
diagrams represent. The use of the UML for both the conceptual and functional
models ensured rapid and efficient development, since many of the objects and
classes already identified as part of the conceptual model were directly utilized or
adapted for use in the functional model.
4,2.6 Coding of Functional Model
The completed functional model provided the framework for a working version of
the model system. It is, however, still represented as a visual model, which needs to
be translated into a functional computer language that is capable of conducting
calculations, reading spreadsheets, and presenting outputs. This process is referred to
as "coding". Java programming language was used in this phase of model
implementation. The software used was Sun ONE Studio 4 Update 1 (Sun™) (133).
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4.2.7 Evaluation of Model Function
The software with which the model was developed has in-built debugging facilities
to ensure that the consistency of the code is maintained. Thus, technical and typing
errors in the code are brought to the attention of the computer programmer and
subsequently resolved. Scope for human error in model development was minimized
by review of the model throughout development, and the completed model was
tested to ensure that outputs were realistic and responded logically to alterations in
model parameters and in the code itself.
4.2.8 Analysis of Model
Default settings for model inputs were defined by analysing and interpreting
available information (see results section), and the influence of various input
parameters was studied by incrementally altering the value of interest and examining
the results. In order to make the model as realistic as possible, a random element was
incorporated into the calculation of probabilities. This is discussed in more detail in
the results section, but the general process was as follows. A probability is defined,
and the model generates a random value between 0 and 1. If this random value is
less than the defined probability, the event (e.g. test acceptance) will take place; if it
is greater than the defined probability it will not (e.g. test refusal). This procedure
was employed at numerous points in the model, ensuring that a range of possible
outcomes exist for each specified set of input values.
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The operator of the working model must initiate each 'run' of the working computer
model, and manually process the output data to facilitate analysis. Hence, an
acceptable balance between the time-consuming process of repeatedly running the
model and the statistical power required of the observed results was required.
Accordingly, the model was run ten times for each set of input values considered in
this project in order to standardize the recording and interpretation of results. This
strategy for generating model outcomes is considered further in the discussion
section.
Data from each run of the model was saved in an excel spreadsheet (Microsoft
Excel™). Mean values, and the associated standard deviation and confidence
intervals, were calculated by manually constructing mathematical functions within
this software, using standard statistical methods. Where the estimate of interest was
calculated from other estimates (e.g. ratio between two values), this was done
separately for each run, and an overall mean was calculated.
Cascade genetic testing is a long-term strategy for identifying asymptomatic
mutation carriers, and therefore results over a long period of time are of interest.
However, it is not feasible to assume that conditions defined by the model will
remain constant over very long periods of time. To reflect a balance between these
two considerations, results were generated and analysed over a hypothetical time
scale of twenty years. This issue is considered further in the discussion section.
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The computer model generates a wide range of outcomes values. Two key output
values were used to facilitate a broad comparison between results under different
input conditions. These were "yield", measured as the total number of asymptomatic
mismatch repair gene mutation earners identified over time, and "relative
efficiency", measured in a simplified manner by dividing the number of
asymptomatic mismatch repair gene mutation earners identified by the number of
mutation analyses conducted. Mutation analyses are the most expensive and time
consuming aspects of the cascade genetic testing system, and the ratio of mutation
analyses performed to carriers identified thus provides a useful indicator of overall
efficiency.
4.2.9 Interpretation of Model Results
Model results were interpreted in the context of the identification of asymptomatic
mismatch repair gene mutation carriers at the population level, as considered in the
discussion section.
4.2.10 Summary
The stepwise process of computer model development is summarized in figure 4.2.5.
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Figure 4.2.5 Strategy For Computer Model Development
□ Phase conducted by author ("domain expert")
Q Phase conducted by computer programmer in collaboration with author




The task analysis was used to set the terms of reference for model development,
outlining the requirements and defining the scope of the model. The requirements
and scope were subject to alteration during model development to reflect new ideas,
revised estimates, or difficulties encountered in the later stages.
4.3.1.1 Scope and Requirements of Model
Figure 4.3.1 provides an overview of the task analysis constructed. This schematic
diagram illustrates the key stages of cascade genetic testing to be included in the
model, and indicates the main factors that must considered at each stage. These
stages are considered in more detail in the subsequent text.
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Figure 4.3.1 Task Analysis: Overview
NB: Exit points from the system are not shown
NB: Arrows indicate links, as opposed to a progression
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Stage 1: Description of Population
The size of the Scottish population, and its age and sex distribution, will be
presented in the form of a spreadsheet, or "look-up table", so that the computer
model can access this data. The sub-group within the Scottish population who carry
a pathogenic MMR gene mutation will also be defined in these terms (i.e. total
number, and age/sex distribution).
Stage 2: Probability of Entering the Cascade Genetic Testing
Programme
In cascade genetic testing, mutation carriers are identified by targeting individuals
deemed to be at high-risk of having a mutation. In the context ofMMR gene
mutations, the principal options are to target individuals with a family history of
colorectal cancer, or to target colorectal cancer cases. For practical reasons
(considered further in the discussion section) this computer model will consider only
the latter situation, an approach that is comparable to the ongoing COGS study.
Conducting mutation analysis is therefore limited to colorectal cancer cases. For the
purposes of the computer model, cases in which mutation analysis reveals a
mismatch repair gene mutation are referred to as "index cases", since these people
provide a route into a mutation-carrying family.
Since a relatively high proportion of colorectal cancer cases occurring at a young
age are of hereditary origin, potential index cases can be targeted more efficiently by
considering age at onset of colorectal cancer as the criteria for inclusion in the model
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cascade genetic testing system. Variable age limits will thus provide one of the
crucial inputs to the model.
The probability of developing colorectal cancer for individuals without pathogenic
MMR gene mutations (non-carriers) can be assumed to be equal to the population
incidence of colorectal cancer. People with pathogenic MMR gene mutations
(carriers) will have an increased likelihood of developing colorectal cancer,
determined by the penetrance of the mutations in question. The number and age/sex
distribution of carriers and non-carriers that are predicted to occur over a period of
time will be calculated and recorded in a spreadsheet for use by the model.
Stage 3: Ascertainment & Recruitment
Figure 4.3.1 illustrates the two potential routes into the cascade genetic testing
programme; either as a potential index case, or as a relative of a known carrier. If the
appropriate criteria are met, the individual concerned should be referred for genetic
testing, but ascertainment will depend on several factors. Firstly, the potential
participants must be willing and able to allow contact with the system. A small
proportion of patients may reject such contact, and patients who are very ill, or who
die before referral for genetic testing may not be included in the cascade genetic
testing programme. Secondly, potential participants must attend an interview and
genetic counselling session with a genetic nurse, and must consent to genetic testing
and provide a blood sample for this purpose. Each of these stages constitutes a
possible exit point from the programme, and the probability of completing each
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stage will be defined by acceptance rates set for each individual. Acceptance rates
may vary by age, sex, whether mutation analysis or a pre-symptomatic test is being
offered and, in the latter situation, by distance of relationship to a known earner.
Accordingly, a spreadsheet that records acceptance rates and has the capacity to vary
rates by these factors will be created.
Stage 4: Genetic Testing
The results of genetic testing will clearly depend on the mutation status of the
individual in question, but will also be influenced by the parameters of the test being
applied. False negative and false positive results may occur if sensitivity and
specificity of the genetic testing are less than 100%. Consequently the capacity to
adjust test parameters will be incorporated into the model.
Stage 5: Identification and Tracing of Relatives
The 'depth' of any cascade genetic testing program is an important consideration.
For the purposes of this model, cascade genetic testing will be restricted to first and
second-degree relatives of a known carrier. This option represents a pragmatic
approach to cascade genetic testing. Testing first-degree relatives only is likely to
limit the effectiveness of cascade genetic testing, due to the fact that some first-
degree relatives will be unavailable or will decline testing. Similarly, extending
testing beyond second-degree relatives is problematic since more distant relatives
will be harder to trace and contact, and may be less willing to participate. Testing
first and second-degree relatives is also the approach used as part of the COGS
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programme, and hence modelling this strategy will ultimately facilitate comparison
between the model and this programme.
Current ethical guidelines regarding consent to genetic testing mean that relatives of
known carriers cannot usually be contacted and offered testing without the
permission of the index case or known carrier in question (see discussion). Thus, the
model will include a facility for blocking the cascade genetic testing process within
a family if such consent is not forthcoming. The probability that consent to contact
relatives will be given will depend on age, sex, and possibly the route of testing (i.e.
whether the known carrier themselves underwent mutation analysis or a pre-
symptomatic test). These estimates will be recorded in spreadsheet form. The
traceabilty of relatives is another issue that must be acknowledged in the model.
Relatives who are eligible for testing may be untraceable, or may not respond to
contact from the cascade genetic testing program. These factors will be dealt with at
the ascertainment stage, by providing an estimate of probability of contact with the
cascade genetic testing programme that is specific to relatives.
Stage 6: Resources
The computer model of cascade genetic testing is designed to facilitate the
evaluation of this strategy in terms of the number of carriers that will be identified
and the relative efficiency with which this is achieved. Decisions on whether or not
such a program should be implemented in real life will depend on a wider
assessment of the health benefits and economic issues involved. These issues are
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considered in the discussion section of this chapter, but a detailed economic
evaluation is beyond the scope of the proposed modelling project. However, a
component relating to the resources required for direct implementation of cascade
genetic testing will be included in the model. This will be designed to facilitate
investigation of the effect of resource limitations on the outcomes of cascade genetic
testing, and to provide an indication, in relative terms, of the appropriate allocation
of available resources.
4.3.1.2 Required Estimates and Sources of Data
The data sources available to inform the inputs and parameters of the model were
also considered at the task analysis stage, and are presented in table 4.3.1. In many
instances, data are scarce or the available estimates have wide confidence intervals.
The need to build the resulting uncertainty and flexibility into the model was
acknowledged and emphasized at the task analysis stage.
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1 Size and age/sex distribution of Scottish
Population
Government Statistics (ISD)
1 Population prevalence of MMR
mutations
Literature (58), COGS and related
analyses
2 Age/sex dependent penetrance of MMR
gene mutations
Literature (3, 4, 57, 289), COGS
2 Proportion of colorectal cancer cases
meeting criteria for inclusion in cascade
genetic testing programme for:
(a) Non-carriers
(b) Carriers
Estimates will vary according to
criteria:
(a) Government statistics (ISD),
COGS
(b) Literature, COGS
3 Delay before presenting to system COGS
3 Proportion of cases meeting criteria that
are actually referred to cascade genetic
testing programme
COGS
3 Acceptance rate of genetic testing
amongst colorectal cancer cases*
COGS
3 Acceptance rate of genetic testing
among relatives of known mutation
carriers*
Literature (164), COGS
3 Time required for recruitment COGS
4 Test parameters for mutation analyses Literature (62), COGS
4 Time required for mutation analysis COGS
4 Test Parameters for pre-symptomatic
test
Literature, COGS
4 Time required for pre-symptomatic test COGS
5 Number of relatives identified and
traced per newly identified carrier*
Family structure simulation
5 Acceptance rate for allowing contact
with relatives*
COGS
5 Traceability of relatives COGS, previous research
experience, Register General
Office Scotland
*Age /sex specific information will be incorporated where possible




The iterative nature of model development dictates that the conceptual model
evolves through numerous versions. Various aspects of the model that were initially
included were discarded in subsequent iterations, and conversely other aspects were
incorporated in the later stages. The final conceptual model, presented in this thesis,
was designed to provide an efficient model that includes all the information required
to inform development of the functional model, with minimal surplus material.
A visual model is best communicated and understood through direct exploration of
the model using the appropriate software. It is not feasible to represent the entire
conceptual model in the main text of this thesis, and for this reason details of the
conceptual model are confined to appendix A7. The objective of this section is to
give an overview of the conceptual model, illustrating the scope of the model, and
focusing on some key areas as examples of how the model is constructed.
4.3.2.1 The Use Case View
The use case view represents the conceptual model form the domain perspective,
and describes the actors and use cases involved and their relationships. To organise
the conceptual model, and facilitate its logical presentation, the aforementioned
actors and use cases are grouped into various packages. The packages created in the
use case view are illustrated in the screenshot below, both in the browser view and
in diagrammatic form.
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Figure 4.3.2 Overview of Packages Created in Use Case View
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NB: The "Scot" actor represents any member of the Scottish population that interacts with
the cascade genetic testing system, and is represented in the overview because it is
common to several packages.
Figure 4.3.2 illustrates the inter-dependency of the five main packages. The
"Epidemiology Team" package contains details of all 'actors' involved in
implementing cascade genetic testing, including health professionals such as a
genetics nurse. It should be emphasised that actors are created to carry out the
functionality required in the model system, and do not directly correspond to actual
people who may implement a real-life cascade genetic testing programme.
To illustrate how each package is represented in the use case view, the actors and
use cases created in the recruitment package, which describes the process of
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recruiting an eligible Scot to the cascade genetic testing programme, are displayed in
the following use-case diagram.
Figure 4.3.3 Use Case Diagram for Recruitment Package




Update non specific waiting list Update specific waiting list
The general message of the above diagram is that the genetic nurse will receive
information from the genetic nurse waiting list regarding a Scot who is eligible for
genetic testing and has agreed to an interview. The genetic nurse will arrange and
conduct this interview, and will ask the Scot if they consent to genetic testing. If
consent is forthcoming, the genetic nurse will initiate genetic testing by taking a
blood sample and updating the appropriate waiting list.
The detail of the recruitment process is contained within each specific use case, and
is represented as the documentation, sequence diagram, collaboration diagram and
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flow of events pro-forma for each use case. The vital "Recruit Consent" use case is
represented in these terms below, by way of an example.
Documentation for "Recruit Consent" Use Case
The "Consent" use case is a vital one, and can be adapted to several similar
situations in the model. At various stages in the model system, the "Scot" in question
will be asked to give their consent to proceed to the next stage. Consent at the
recruitment stage is concerned with obtaining consent to undergo genetic testing.
The probability that this consent will be forthcoming is defined in an "Acceptance"
look-up table.
Sequence Diagram for "Recruit Consent" Use Case
Scenarios relating to the Recruit Consent use case were illustrated using sequence
diagrams, as shown in figure 4.3.4.

















Collaboration Diagram for "Recruit Consent" Use Case
An alternative means of representing a scenario of the "Recruit Consent" use case is
provided by a collaboration diagram, as illustrated in figure 4.3.5.




Flow of Events for "Recruit Consent" Use Case
A textual description of the various possible paths through a use case is provided by
the "Flow ofEvents", which has a strict presentation format. The flow of events for
the Recruit Consent use case is as follows:
1.1 Preconditions
The "Recruit Invitation" use case must have been completed successfully.
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1.2 Main Flow
This use case is begun by a "Scot" who has developed colorectal cancer, upon being
invited to undergo genetic testing by a genetic nurse. The Scot in question will study
the information pack (i.e. obtain and process the relevant information from the
genetic nurse) and then consider whether to take part. They will then complete a
consent form specifying their decision. If they agree to take part the S-l: Accept
sub-flow will be applied, if they do not the S-2: Decline sub-flow will be used.
1.3 Sub-flows
S-l: Accept: The Scot is prepared to participate in the next stage of the cascade
genetic testing programme (i.e. undergo testing), and completes a consent form to
that effect.
S-2: Decline: The Scot does not wish to participate in the next stage of the cascade
genetic testing programme, and completes a consent form to that effect.
1.4 Alternative flows
E-l: The Scot does not complete a consent form. This can occur whether the
invitation is made by post or in person, as there is no guarantee that a decision will
be reached at interview. In this scenario the individual in question is assumed to
have declined the invitation and accordingly takes no further part in the system.
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4.3.2.2 The Logical (Class) View
This view is primarily designed as an intermediate step between the domain
perspective and the computer programming perspective. Essentially, constructing a
"logical view" of the model involves representing the largely abstract functionality
described in the use case view in a systematic object-orientated manner. As
considered previously, objects can be organised into classes, based on their
attributes, behaviour and semantics. Thus classes, their functions and their
relationships, constitute the key feature of object-orientated model development. The
structure of a class is defined by its 'attributes', and the functionality of the class
(the role of the class in the model) is defined by its 'operations'. Generally,
operations are mapped to messages in the scenario diagrams of the use case view.
Classes can also be grouped into packages to facilitate clear presentation of the
logical view. The packages created for the model are presented in figure 4.3.6.












The classes contained within the 'Participation' package, and their interactions, are
presented in the following class diagram for illustrative purposes.
Figure 4.3.7 Class Diagram for Participation Package
Further detail of the "Interview" class was communicated through the attributes,
operations and documentation of this class, as illustrated below.
Attributes and Operations for "Interview" Class










Documentation for "Interview" Class
This class represents any interview that takes place during ascertainment or
recruitment, between a 'Scot' and a member of the 'Epidemiology Team'.
4.3.2.3 Further Considerations
The above examples provide an overview ofhow the conceptual model was
developed. Further details of the conceptual model were provided verbally at
discussions between the author and the computer programmer. In addition, the
capacity provided by the UML to document specific attributes and operations, and to
specify associated data types and other detail, was used in some circumstances.
4.3.3 Estimates and Default Settings
The estimates and default settings used for the computer model are presented in this
section. The validity, accuracy and limitations of these estimates are considered
further in the discussion section.
4.3.3.1 Population Demographics & Genetic Epidemiology of
Colorectal Cancer
Data on the size and age/sex distribution of the Scottish population came from the
2001 census (228), and information regarding the incidence and age/sex distribution
of colorectal cancer in Scotland was obtained from statistics provided by 1SD (123).
For the purposes of the model, these figures were assumed to remain constant over
time, and the implications of this are considered in the discussion.
Dunlop et al., (2001) (58) have provided the only available estimate of the
population prevalence ofMMR gene mutations. Hence this figure of 1:3139 (95%CI
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= 1:1247, 1:7626) was directly used as a model input. Estimates of penetrance were
obtained from the consensus ofpublished studies (3, 4, 57, 289) which suggest that
penetrance is approximately 80% in males and 40% in females. The cumulative
incidence of colorectal cancer in MMR gene mutation earners was presented in
another paper by Dunlop et al., (57). The shape of the chart of cumulative incidence
from this paper was used to estimate the lifetime cumulative incidence in various
age groups (considered equal to cumulative incidence at age 70 for the purposes of
the model).
Using the above estimates it was possible to estimate the number ofmutation
carriers and the number of non-carriers in a particular age group that would be
expected to develop colorectal cancer per year. These estimates were set out in an
excel (Microsoft™) spreadsheet, and functions were set up to allow the estimates
pertaining to mutation carriers to be re-calculated according to defined changes in
prevalence and penetrance. Estimates were calculated separately for males and
females. This spreadsheet constitutes a vital input to the computer model, as it
essentially defines the demographics of the population in question and the genetic
epidemiology of colorectal cancer with respect to MMR gene mutations. Results
from this spreadsheet, calculated for default settings of penetrance and prevalence,
are presented in table 4.3.2.
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Table 4.3.2 Expected Colorectal Cancer Cases in Scotland
(i) Males
Age group Males, 2001 Annual No. of Male Cumulative Average Annual
Census Expected Carriers in Incidence in annual Expected
Cases in Male Population Mutation incidence in Cases in
Non-Carriers Carriers - mutation Male
Male carriers - Carriers
males
All ages 2,432,494 1,622
0-4 142,360 0 0.000 0.000
5-9 157,030 0 0.000 0.000
10-14 165,583 0 0.011 0.002
15 - 19 160,935 1 51 0.022 0.002 0.111
20-24 157,116 1 50 0.032 0.002 0.108
25-29 154,112 2 49 0.065 0.006 0.318
30-34 184,674 5 59 0.141 0.015 0.890
35-39 194,618 13 62 0.249 0.022 1.341
40-44 184,176 23 59 0.422 0.035 2.030
45-49 166,925 45 53 0.616 0.039 2.070
50 - 54 174,118 77 55 0.703 0.017 0.959
55-59 140,835 137 45 0.757 0.011 0.485
60-64 124,651 197 40 0.789 0.006 0.258
65-69 110,009 274 35 0.800 0.002 0.076
70-74 90,053 298 29
75-79 66,057 261
80-84 36,355 182
85 & over 22,887 107
15 - 74 1,842,222 1,072 587 8.65
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(ii) Females
Age group Females, Annual No. of Cumulative Average Annual
2001 Expected Female Incidence in annual Expected
Census Cases in Carriers in Mutation incidence in Cases in
Female Non- Population Carriers - mutation Female
Carriers Female carriers - Carriers
Females
All ages 2,629,517 1,606
0-4 134,514 0 0.000 0.000
5-9 150,108 0 0.000 0.000
10-14 157,287 0 0.000 0.000
15 - 19 156,338 1 50 0.000 0.000 0.000
20-24 157,271 1 50 0.007 0.001 0.067
25-29 163,191 3 52 0.020 0.003 0.139
30-34 197,420 4 63 0.060 0.008 0.503
35-39 208,336 12 66 0.120 0.012 0.796
40-44 193,734 22 62 0.187 0.013 0.823
45-49 170,544 37 54 0.280 0.019 1.014
50 - 54 176,989 61 56 0.347 0.013 0.752
55-59 147,164 100 47 0.373 0.005 0.250
60 - 64 137,082 153 44 0.393 0.004 0.175
65 - 69 129,107 207 41 0.400 0.001 0.055
70 - 74 116,864 254 37
75-79 99,466 260
80-84 68,634 253
85 & over 65,468 240
15-74 1,954,040 853 623 4.57
NB: The sources and references for the data contained in table 4.3.2 are stated in the
preceding text, and the limitations of these estimates are considered in the discussion
section. Blank cells indicate that the relevant data was unavailable.
4.3.3.2 Age Limits
The age criteria for inclusion of colorectal cancer cases in a cascade genetic testing
programme are arbitrary, in the sense that they are chosen rather than dictated by
available data. At default settings, the age limit for eligibility to the hypothetical
cascade genetic testing programme was set to 55 years, to reflect the pragmatic age
limit chosen for the COGS study. The age limit for recruiting relatives ofmutation
carriers was set to 70 years, reflecting the fact that it may be considered
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inappropriate to contact elderly relatives and/or offer clinical screening in this group.
The minimum age of recruitment for both colorectal cancer cases and relatives of
known mutation carriers was set to 18 years at default.
4.3.3.3 Acceptance Rates
Information regarding the uptake of cascade genetic testing for mismatch repair gene
mutations is very limited. For the purposes of the computer model, the probability of
acceptance at each of four stages was specified. These stages were:
(i) Probability ofhaving contact with cascade genetic testing programme
(ii) Probability of attending interview with genetic nurse
(iii) Probability of accepting genetic test
(iv) Probability of allowing contact with other family members
Several factors have the potential to influence acceptance rates at each of these
stages, including age, sex, whether the individual in question is a colorectal cancer
patient or relative of a known carrier, and, in the latter situation, the degree of
relationship between the known carrier and the relative being offered the test.
Reliable information about acceptance rates in this context is not available, and
estimates for this model were largely based on limited data from the ongoing COGS
study. These data suggest that around 74% of colorectal cancer patients diagnosed
under the age of 55 will undergo genetic testing. Accordingly, simplified and
conservative default values that were consistent with this estimate of overall
acceptance rate were applied to the model. The default probability of acceptance at
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each stage was thus set to 0.9, regardless of the age, sex and circumstance of the
individual in question. This gives an overall probability of accepting genetic testing
of (0.9) = 0.73. Acceptance rates were recorded in table form in an excel file, which
was converted to a text file to be 'read' by the computer model. This file, which
illustrates both the default settings and the capacity to include detailed acceptance
information at a later stage, is presented in Appendix A8.
4.3.3.4 Waiting Times (Delays)
In practice, any cascade genetic testing programme is likely to feature delays at
various stages, notably during the time consuming process of conducting mutation
analysis. Consequently, delays, often manifest as time on a particular waiting list,
were incorporated into the model. This feature contributes to the realism of the
model, and manipulating the delays and studying the effect on model outcomes
should provide data on the effect that delays will have on the overall utility of
cascade genetic testing. Default values for delays were again based on experience
with the ongoing COGS study, although in practice delays will depend on various
financial and administrative factors, and may vary considerably. These default
values are presented in table 4.3.3.
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Table 4.3.3 Default Values for Delays
Stage Explanation Delay
(weeks)
EC Registration Referral of potential index case or relative of 4
known carrier to cascade genetic testing
system, and subsequent registration by the
epidemiology coordinator (EC)
Genetics Nurse Administrative processing of individual eligible 4
for genetic testing, and arrangement of
recruitment interview with genetics nurse
Mutation analysis Time taken to perform mutation analysis 52
Pre-symptomatic test Time taken to perform pre-symptomatic test 4
EC Lab Results Time for interpretation and processing of lab 2
results
Relative Presentation Delay between identification of an index case 4, 8 or 12
and presentation of relatives of that mutation
carrier to the cascade genetic testing system
The estimate of one year for performing mutation analysis on a sample from a
potential index case is a conservative one, reflecting the maximum waiting time at
this stage in the ongoing COGS programme. The other delays are also conservative.
In theory the administrative tasks and pre-symptomatic test could all be performed
within a week, but in reality some delays are likely to occur, and this is reflected in
the default estimates. Each delay outlined in table 4.3.3 can be manipulated by
changing the default settings in the graphical user interface of the completed
computer model.
One further source of delay occurs with the presentation of relatives of known
carriers to the system. This process is staggered, with relatives presenting at either 4,
8 or 12 weeks after a mutation was found in their relative. This reflects the likely
pattern ofpresentation that would occur in practice, since newly identified mutation
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carriers may not inform their relatives of their potential risk immediately after
diagnosis, and relatives in turn may take time to consider whether or not to become
involved in the cascade genetic testing programme. An additional advantage of this
staggered presentation is that relatives will enter the model system over a period of
weeks, and will not overload the available resources by presenting at one time.
4.3.3.5 Resources
The component of the computer model relating to 'resources' is designed to
facilitate an assessment of the impact that limitations in available resources may
have on the outcomes of the model system. Resource limitations have the potential
to severely affect model outcomes. At default settings, however, the model was
intended to run as if resources were effectively unlimited. This was achieved by
setting all resources to 1000 resource units per week, where one resource unit is
sufficient to carry out a specific task (for example, genetic nurse interview) once in
the given week. Resource inputs and default settings are presented in table 4.3.4.
Table 4.3.4 Resource Inputs and Default Settings
Resource Detail Default
Setting
Referrals The number of colorectal cancer cases that can 1000
be ascertained and processed per week
Lab Results The number of lab results that can be received 1000
and processed per week
Genetic Nurse Interview The number of genetic nurse (recruitment) 1000
interviews that can be conducted per week
Mutation analysis The number of mutation analyses that can be 1000
carried out per week
Pre-symptomatic test The number of pre-symptomatic tests that can 1000
be carried out per week
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In a real cascade genetic testing programme, the mutation analysis resource is likely
to be crucial, since this is likely to be the most time consuming and expensive aspect
of such an undertaking. Resources and the impact of their limitations are considered
further in the discussion section.
4.3.3.6 Test Parameters
Pre-symptomatic testing for a specific mutation is a straightforward laboratory
process, and for the purposes of the model the sensitivity and specificity of this test
is assumed to be 100%. The model retains the capacity to set different values for
these test parameters.
Mutation analysis is more complex. The test parameters will depend on the
laboratory protocol and techniques employed, and the results may be open to
different interpretations. However, there is no "gold standard" method for
determining whether or not an individual has a pathogenic MMR gene mutation, and
hence no systematic means of determining the test parameters. For the purposes of
the model, therefore, it was decided to set the default values for sensitivity and
specificity ofmutation analysis to 100%. This is not considered to be an accurate, or
even realistic, estimate, but rather is designed to standardize this aspect of the model
and thus facilitate study of the effect of other factors. The implications of this
approach are considered further in the discussion section.
4.3.3.7 Summary
A summary of default model settings is presented in table 4.3.5.
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Population age/sex distribution See table 4.3.2
Genetic Epidemiology




Probability of Allowing Contact 0.9
Probability of Attending Genetics Nurse Interview 0.9
Probability of Accepting Genetic Testing 0.9
Probability of Allowing Relative Contact 0.9
Waiting Times (delays)
EC Registration delay 4 weeks
Genetics Nurse 4 weeks
Mutation analysis 52 weeks
Pre-symptomatic test 4 weeks
EC Lab Results 2 weeks
Age Criteria (eligibility for recruitment)
Minimum age of colorectal cancer cases 18
Maximum age of colorectal cancer cases 55
Minimum age of relatives 18







*Acceptance rates can vary according to the age and sex of the individual in question, and
also according to whether this individual is a potential index case, a first-degree relative of a
known carrier, or a second-degree of a known carrier. However, at default settings





As detailed in the methods section, the functional computer model was developed
and implemented by a computer programmer, working in conjunction with the
author of this thesis. Throughout this process, the functionality of the model was
controlled and specified by the author, whereas the technical aspects of model
development were the responsibility of the computer programmer. Reflecting this
division of labour, this section consists of a description of the model's functionality
from the domain perspective, focussing on what the model does rather than how the
computer programme works.
The model itself is designed using the Java programming language, utilising Sun
ONE Studio 4 Update 1 software. The model can be accessed through this software,
facilitating the examination and alteration of the functional model and programming
code using the "Editing" tab for the appropriate project. A separate "Edit Graphical
User Interface (GUI)" tab allows access to the code of this aspect of the working
model. These commands can be used to alter the appearance or functionality of the
model at the "coding" level, and are mainly included to facilitate future model
development by the author, the computer programmer, or other researchers. For the
purposes of this thesis, no such alterations were made and the coding remains the
original work of the computer programmer. Consequently these aspects of the model
are not considered in this section, which is primarily concerned with the operation or
"running" of the model from the domain perspective.
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In a functional model, the requirements of the model user are represented as use
cases. These high-level use cases are shown in figure 4.3.9.
Figure 4.3.9* User-Orientated Use Cases in Functional Model
*This figure has been modified from a design by Jeff Lloyd, who acted as the computer
programmer for the development of the functional model
The functional model is centred on an "engine" class that actually drives the model.
The following classes were created to implement the functional model.
• Graphical User Interface (GUI)
• Engine (responsible for running the model)
• Epidemiology Co-ordinator (responsible for holding the coordinator waiting
lists and performing the tasks of the co-ordinator)
• Genetic Nurse (responsible for holding the genetic nurse waiting lists and
performing the tasks of the genetic nurse)
• Lab (responsible for holding the laboratory waiting lists and performing the
tasks of the lab worker)
• Waiting List (a simulation of a "first-in-first-out" waiting list)
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• Waiting List Item
• Person (responsible for holding the methods and operations of a "Scot").
• DataHolder (accesses data files and holds input values)
• Resources (allocates resources to waiting lists on a weekly basis)
• Result (responsible for recording and presenting model outcomes)
A class diagram illustrating these classes, and the relationships between them is
presented in figure 4.3.10.
Figure 4.3.10* Class Diagram: Overview of Functional Model
This figure has been reproduced from a design by Jeff Lloyd, who acted as the computer
programmer for the development of a functional model
Abbreviation: GUI, Graphical User Interface.
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4.3.4.2 Graphical User Interface (GUI)
The model is 'run' using the "execute project" command, which opens up the
Graphical User Interface (GUI). This window is shown in figure 4.3.11, below.
Figure 4.3.11 Graphical User Interface (Annotated)
Toolbar 1 Result Display Options
b%>Cascade Screening vl.l
File Model About Toolbar 2
Run Save Reset Exit Weeks: I 52
- IDI x|
Column 4: Resources remaining
Toolbar 1 forms the address bar at the top of the GUI, and states the model and
version that is running. Cascade Screening vl.l is the name of the final version of
the model used for the subsequent analyses. Toolbar 2 contains the "About" button,
which states the technical information about the model; the "File" button, which
gives the standard options of "Save", Save As" or "Exit", and finally the Model
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button, which opens a new window entitled "Settings and Resources". This latter
window is considered in more detail later. The third tool bar provides the user with
the option to "Run", "Save", "Reset", or "Exit" the model, and also contains a
window in which the user can specify the number ofweeks the model is to be run.
This is set to 52 weeks as a default. Clicking on the "Run" button will run the model
for the specified length of time. If it is clicked more than once the model will run
through additional time periods, with each run following on from where the previous
one ended, and recording output each time. Hence, to run the model for a
hypothetical ten-year period, and record results annually, the run time can be set to
52 weeks and the "Run" button clicked ten times.
4.3.4.3 Settings & Resources




Settings that are designed to remain unchanged are specified in the model code, and
can only be altered by changing this code and effectively creating a new version of
the model. An example such a setting is the probability of a first-degree relative of a
known MMR gene mutation carrier being a carrier themselves: this is always
maintained at 0.5.
Complex inputs that the user may wish to vary include population demographics,
estimates related to the genetic epidemiology ofMMR gene mutations (prevalence,
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penetrance), and acceptances rates according to age, sex and circumstance. Such
inputs are defined in text files or "look-up tables", and can be changed by either
altering the look-up tables themselves, or using the "Settings and Resources" and
"Files" commands to specify a different look-up table for the model to access. For
instance, in the analysis stage, a number of look-up files were created, each
representing the "expected colorectal cancer cases" file (see table 4.3.2) with
different assumptions of the prevalence ofmismatch repair gene mutations in the
Scottish population.
Finally, settings that the user may wish to change regularly, such as delays,
resources and age limits can be adjusted directly using the "Settings and Resources"
option of the GUI. Settings may be specified using simple entry boxes, as used for
delays, or a sliding scale, as used for age limits. Windows for these two parameters
are illustrated in figure 4.3.12.
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Figure 4.3.12 Settings Adjustment Windows
(i) Delays
ill I
Delays Age Limits Resources Lab Tests File Locations I ►
EC Ftegistrations Delay |4
EC Lab Results Delay [2
Genetic Nurse Delay [4
Lab Non-specific Test Delay |52
Lab Specific Test Delay [4
Close
(ii) Age Limits
Delays ~]\ Age Limits ! Resources Lab Tests File Locations
Referrals Age Limits
Lower Age Limit 18
Upper Age Limit 55
Relatives Age Limits
Lower Age Limit 18
Upper Age Limit 70
xj
0 10 20 30 40 50 60 70 00 90100
0 10 20 30 40 50 60 70 80 90100
0 10 20 30 40 50 60 70 80 90100
0 10 20 30 40 50 60 70 80 90100
Close
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4.3.4.4 Running the Model
The starting point for the model system is defined chronologically. However, to
understand and communicate what the model actually does it is useful to consider
one particular instance ofmodel functionality, relating to one hypothetical
individual, and follow this scenario through from the generation of this person to
genetic testing and subsequent tracing of a mutation through their extended
pedigree.
4.3.4.4.1 Generation of Colorectal Cancer Patients
People are generated in the model system either as colorectal cancer patients (also
known as "referrals" to the model system) or relatives of known mutation carriers.
Clearly, the latter event requires an index case to have been generated, and so the
initiating event in terms of the function of the model is the development of
colorectal cancer in a member of the Scottish population.
Colorectal cancer cases are generated on a weekly basis. In the model, male and
female patients are generated separately, but the methodology used is exactly the
same. The total number of expected colorectal cancer registrations for males or
females per annum is specified in the "expected cases" look-up table discussed
above (see table 4.3.2). This figure is simply divided by 52 in order to determine the
expected number in one week. This number represents a prediction, based on
colorectal cancer incidence in carriers and non-carriers, and the actual number of
registrations in a particular week will vary randomly around this prediction. This
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random element is incorporated into the model through the use of an algorithm
'loop', which is presented below, written in "pseudocode".
Step 1: Calculate X = 1/(expected number + 1)
Step 2: Generate Y = Random number between zero and one.
Step 3: IfX < Y a new case will be created and the algorithm is repeated
If X > Y no further cases will be created and the algorithm will terminate.
Hence the number of cases generated varies randomly from week to week, but, on
average, the model will produce the expected number of registrations specified in
the look-up table.
For each referral, age is specified on the basis of the population data presented in the
expected cases look-up table. Age is allocated by firstly determining the cumulative
proportion of expected cases in each age group. For example, a negligible number of
registrations would be expected to be under 20 years old, but 0.00-0.01 referrals may
be in the 20-24 age bracket, 0.01-0.03 may be 25-29, 0.03-0.06 may be in the 30-34
age group and so on. A random number between zero and one is then generated, and
the age group that includes this number becomes the age group of the referral. In this
manner, age group is assigned on a random basis, but following the age distribution
of colorectal cancer occurrence specified in the look-up table. Hence, the majority of
referrals will be elderly, and the average age will be 60-64, reflecting the average
age at onset of colorectal cancer in Scotland. Once the age group has been
established, the age of the referral is assigned randomly within the group parameters
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(i.e. a referral in the 50-54 age group will have a 20% chance of being assigned an
age of 50, 51, 52, 53 and 54 years).
Age criteria, as specified by the model user, are applied to new referrals. If the
referral is older than the maximum age limit, they take no further part in the cascade
genetic testing process, although their existence is recorded. Referrals with an age
below the minimum criteria are withheld from the cascade genetic testing system
until they reach the minimum age. In practice, referrals below the minimum age
limits are extremely rare.
The probability that a given referral will be a mutation carrier varies according to the
age at onset (i.e. the age group of the referral). This probability can be determined
by simply dividing the number of expected colorectal cancer cases in mutation
earners by the total number of expected cases for the specified age/sex group. A
random number between zero and one can then be generated, and if this number is
less than the calculated probability ofbeing a mutation carrier the referral in
question is assigned mutation carrier status. Once again, this algorithm ensures that
the attributes of the referral (in this case mutation status) are assigned randomly but
follow the demographic and epidemiological data specified in the expected cases
look-up table.
4.3.4.4.2 Progression of Referrals Through Cascade Genetic Testing
Programme
Essentially, the progression of a newly created referral through the model system
can be described in terms ofwaiting lists and acceptance probabilities. The
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acceptance algorithm for allowing contact with the cascade genetic testing system is
applied to each new referral of an age within the specified inclusion criteria. If the
individual in question is deemed to 'accept' at this stage, they are placed on the
'Epidemiology Co-ordinator Waiting List'. At such time as the referral has been on
the waiting list for the minimum period (delay) and there are sufficient resources
available, they will be removed from this waiting list and the acceptance algorithm
for "probability of accepting genetic nurse interview" will be applied. If the
individual in question is deemed to be willing to attend a genetic nurse interview
they will be placed on the 'Genetic Nurse Waiting List". Once again, they will
remain on this waiting list until the minimum waiting period has elapsed and there
are adequate resources to allow the genetic nurse to perform the interview. Whether
or not the individual in question, having attended the genetic nurse interview, will
accept genetic testing is determined by the acceptance algorithm for genetic testing.
If this process determines that they will undergo genetic testing, they will progress
to the 'Lab Waiting List', and will finally undergo testing as and when the minimum
period has elapsed and there are sufficient laboratory resources. At each stage
involving an acceptance algorithm, a result of'non-acceptance' will result in
removal from the waiting list, and the individual concerned will take no further part
in the system.
Acceptance algorithms are applied as follows. Once the age, sex and mutation status
of a new referral has been established, the "Acceptance" look-up table will be used
to determine the probability that the particular referral will participate in various
stages of the cascade genetic testing system. At each stage the relevant probability is
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applied by generating a random number. A decision of acceptance will be assigned
if the random number is less than the specified probability, and a decision of non-
acceptance will be assigned if it is greater.
All waiting lists in the model operate on a first-in-first-out basis. Each week the
model is running, a check is made to establish if there are any entries on each
waiting list. If there are, the length of time that the person at the top of the list has
been waiting is obtained. If this time is less than the minimum waiting time specified
by the 'delay' settings of the model the list is left as it is. If the individual at the top
of the list has been waiting for longer than the minimum delay period they are
removed from the list and progress to the next stage of the cascade genetic testing
process, provided that there are sufficient resources available for this to be done. If
resources are inadequate they will be left on the list and considered again the
following week. The above process is repeated until either there are no further
people on the list who have waited the minimum period, or until there are no
resources left.
The progression of a new referral through the cascade genetic testing system can be
presented as a decision tree, as illustrated in figure 4.3.13.
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Remove from system if
criteria are not met
Remove from system if
non-acceptance is assigned
Remove from System if
non-acceptance is assigned
Remove from System if
non-acceptance is assigned
NB: Progression from one waiting list to another is subject to the minimum delay period and
to the availability of adequate resources.
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The user defines the length of time required to perform mutation analysis. After this
delay, a test result is produced, based on the mutation status of the individual
concerned, and the test parameters (for the purposes of the analyses considered in
this thesis the sensitivity and specificity of all tests are considered to be 100%). If
the test result is negative, this fact is recorded, and the individual concerned takes no
further part in the system. However, if the results reveal that the referral is a MMR
gene mutation carrier they become an 'index case', eligible for the next stage of the
cascade genetic testing system, namely tracing of relatives. At this stage the
algorithm "probability of allowing contact with relatives" is applied to the new
index case. If they are deemed not to accept such contact, the index case will take no
further part in the model system. However, if the index case does 'accept' contact
with relatives a family tree is created as described below.
4.3.4.4.3 Generation ofPedigrees
A highly simplified representation of family structure was applied by the model,
which makes the key assumptions that each sibship consists of two siblings (i.e. the
population is stable) and the generation gap is 25 +/- 5 years. The pedigree initially
created for a new index case consists of all first and second-degree relatives, as
shown in figure 4.3.14. Standard pedigree notation, whereby square symbols are
used for males and circular symbols for females are used in all pedigree diagrams.
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Figure 4.3.14 Pedigree for Index Case
Key
= Mutation Carrier
1 = First-Degree Relative (50% Risk of Carrying Mutation)
= Second-Degree Relative (25% Risk of Carrying Mutation)
= Not Blood Relation
= Index Case
For each new index case, the model generates five first-degree relatives (two
parents, one sibling and two children), and 12 second degree relatives (four
grandparents, two uncles/aunts, two nieces/nephews and four grandchildren).
Relatives are assigned an age based on the age of the index case and the generation
difference, with a random variation of +/- 5 years. Relatives are created even if they
are unfeasibly old, or of a negative age (not yet born). They will, however, only
interact with the model system if and when they meet the specified age criteria.
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The sex of relatives is random, but is conditional on the sex of their spouse where
applicable. For example, the first parent created will have a 50% chance of being
designated as female. If they are deemed to be female, the other parent will
automatically become male.
Mutation status is assigned to relatives as followed:
• Siblings and children of known earners have a 50% probability of being a
mutation carrier. A random number between 0 and 1 is thrown, and if this
number is < 0.5 they are deemed to be a mutation carrier.
• The first parent has a 50% probability of being a mutation carrier, decided as
above. The mutation status of the second parent will be the opposite of the
first, ensuring that each carrier has one, and only one, carrier parent.
• Once carrier status in first-degree relatives has been assigned as above, all
second degree relatives will have a first-degree relative with a carrier status
defined by the model system, and their own mutation status becomes
conditional on this factor. For example, the mutation status of uncles/aunts is
conditional on the status of their sibling (parent of index case). If their
sibling is a carrier, the probability of being a carrier themselves is 50%, again
randomly assigned. If their sibling is not a carrier, they are not either.
• The principle that one and only one parent of each known carrier is also a
carrier is applied to all couples, including grandparents.
• Non-blood relatives (i.e. spouses/partners) are ignored by the model system.
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• The computer model assigns carrier status to relatives prior to any
consideration of genetic testing. Therefore, although obligate carriers only
interact with the model system if they undergo testing themselves, they are
indirectly identified at this stage.
Hence, a set of relatives, with known age, sex and mutation status, is created for
each index case identified. The probability that each relative will 'accept' any
contact with the cascade genetic testing system is specified by the user in the
acceptance look-up table, and may vary according to age, sex, and/or degree of
relationship to known carrier. This probability is applied in the manner described
previously. Similarly, the age limits set by the user for inclusion of relatives in the
system are applied. As with referrals, relatives of known mutation carriers who meet
these criteria are placed on the Epidemiology Co-ordinator waiting list, and will
progress through the cascade genetic testing system in the same way, subject to
delays and resources. In order to stagger the presentation of relatives to the system,
and to make the process more realistic, a randomly assigned delay of 4, 8 or 12
weeks will be applied between the identification of the index case and the
presentation of each relative.
When a relative undergoes genetic testing and is found to be a mutation carrier, they
become the focal point for the creation of new first and second-degree relatives. At
this stage, the "allow contact with relatives" algorithm will be applied to the relative
in question, and cascade genetic testing will only proceed if acceptance is
forthcoming. By definition, many of the relatives of this new mutation carrier will
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have already been offered testing due to their relationship with the index case.
However, the identification of a new mutation carrier will facilitate the expansion of
the pedigree to include new family members who are at 25% or 50% risk of having a
mutation. This tracing ofmutation carriers through an extended family constitutes
the core principle of cascade genetic testing.
The following figures illustrate the new at-risk family members who are generated
by the model after various relatives of index cases are demonstrated to have a
mutation themselves. For the purposes of the model, no relatives who are more than
two generations distant from the index case are included, since such relatives are
almost certain to be too old or too young to participate in cascade genetic testing
within a meaningful timeframe.
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Figure 4.3.15 Expansion of Pedigree After a Mutation is Identified in
Sibling of Index Case











■ = Mutation Carrier
2 = New First-Degree Relative (50% Risk of Carrying Mutation)
= New Second-Degree Relative (25% Risk of Carrying Mutation)
3 = Previously Eligible for Testing
^l= Index CaseU= Not Blood Relation
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Figure 4.3.16 Expansion of Pedigree After a Mutation is Identified in
Parent of Index Case
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Key
n= Mutation Carrier= New First-Degree Relative (50% Risk of Carrying Mutation)
= New Second-Degree Relative (25% Risk of Carrying Mutation)
2 = Previously Eligible for Testing
Index Case
□ = Not Blood Relation
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Figure 4.3.17 Expansion of Pedigree After a Mutation is Identified in










n= Mutation Carrier= New First-Degree Relative (50% Risk of Carrying Mutation)
= New Second-Degree Relative (25% Risk of Carrying Mutation)
= Previously Eligible for Testing
= Index Case
□ = Not Blood Relation
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Figure 4.3.18 Expansion of Pedigree After a Mutation is Identified in
Aunt/Uncle of Index Case
Key
n= Mutation Carrier= New First-Degree Relative (50% Risk of Carrying Mutation)
= New Second-Degree Relative (25% Risk of Carrying Mutation)
= Previously Eligible for Testing
Index Case
IZ]= Not Blood Relation
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Figure 4.3.19 Expansion of Pedigree After a Mutation is Identified in












™= New First-Degree Relative (50% Risk of Carrying Mutation)
= New Second-Degree Relative (25% Risk of Carrying Mutation)
= Previously Eligible for Testing
2^ = Index Case1—1= Not Blood Relation
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Figure 4.3.20 Expansion of Pedigree After a Mutation is Identified in
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Key
= Mutation Carrier
= New First-Degree Relative (50% Risk of Carrying Mutation)
= New Second-Degree Relative (25% Risk of Carrying Mutation)
= Previously Eligible for Testing
= Index Case
q= Not Blood Relation
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The process of identifying index cases and tracing their specific mutation through an
extended pedigree where appropriate continues throughout the running period of the
computer model, restricted only by delays, acceptance rates and age criteria.
4.3.4.5 Presentation of Model Outcomes
Model outputs are recorded weekly, and summary data is recorded after each run
period. For clarity, the results display is broken up into various stages of the model
system, as specified using the "Results Display Options" on the right of the GUI (see
figure 4.3.11). The key to the results displayed is shown at the foot of the screen.
The possible displays are as follows:
(i) EC Registrations
(ii) EC Lab Results
(iii) Genetic Nurse
(iv) Lab: Non-Specific Tests [Mutation analyses]
(v) Lab: Specific Tests [Pre-symptomatic tests]
For each set of results, the GUI will display the week number, the number of people
on that particular waiting list, the longest waiting period and the resources that
remain at the end of that week.
The "Summary Screen" displays all results in a user-friendly manner, providing
details of all the relevant model outcomes as they stand at the end of each run
period. Usually the run period is set to 52 weeks, and so this feature acts as an
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annual report of the status and progress of the cascade genetic testing system. A
typical "Summary Screen" display, after running the model at default settings for
one 52-week period, is shown in figure 4.3.21.
Figure 4.3.21 Summary Screen Display
Week 52
*******************************************
Number of people generated, 2517 (number of individuals entering the system)
Total males generated, 1390
Referrals, 1390 (colorectal cancer patients)
Relatives, 0 (relatives of known carriers)









Below minimum age limits:
Male Referrals , 1
Female Referrals, 0












Numbers accepting invitation to see Epidemiology Co-ordinator, 368
Referrals, 368
Relatives, 0




Numbers accepting invitation to see Genetic Nurse, 306
Referrals, 306
Relatives, 0
Numbers not accepting invitation to see Genetic Nurse, 41
Referrals, 41
Relatives, 0
Numbers still waiting to be invited to see Genetic Nurse, 21
Referrals, 21
Relatives, 0
Number of referrals accepting non-specific blood test, 245
Number of referrals not accepting non-specific blood test, 33
Number of referrals still waiting to be seen by Genetic Nurse, 28
Number of relatives accepting specific blood test, 0
Number of relatives not accepting specific blood test, 0
Number of relatives still waiting to be seen by Genetic Nurse, 0
Mutation Analysis True Positives, 0
Mutation Analysis False Positives, 0
Mutation Analysis True Negatives, 0
Mutation Analysis False Negatives, 0
Number of people still waiting for mutation analysis, 245
Pre-symptomatic test True Positives, 0
Pre-symptomatic test False Positives, 0
Pre-symptomatic test True Negatives, 0
Pre-symptomatic test False Negatives, 0
Number of people still waiting for pre-symptomatic test, 0
////////////////////////////////////////////
The summary display can be saved as a text file or an excel file, or can be copied
and pasted into an existing excel spreadsheet.
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4.3.5 Analysis of Model
The broad strategy for analysis of the model was to firstly examine the model
outcomes at default settings in detail, and then systematically alter various inputs in
turn and observe the effects of such alterations on the main model outcomes. Results
are presented below. On all graphs, Y-error bars represent 95% confidence intervals.
4.3.5.1 Default Settings
Figure 4.3.22 illustrates the total number of genetic tests that the computer model
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As expected under the assumption that the incidence of colorectal cancer in Scotland
remained constant over the period of the hypothetical cascade genetic testing
programme, the number ofmutation analyses performed increases over time in a
linear fashion. Since a delay of 52 weeks for mutation analysis is specified in the
default settings of the model, no such tests are recorded in year 1. Subsequently, the
number ofmutation analyses performed was predicted to increase at the rate of
approximately 380 per year, reaching 1443 (95% CI = 1394, 1490) after 5 years,
3387 (95% CI = 3339, 3436) after ten years, and 7142 (95% CI = 7037, 7250) by 20
years.
The predicted number ofpre-symptomatic tests performed averaged 126 (95% CI =
109, 143), 334 (95% CI = 312, 356) and 849 (95% CI = 812, 886) after 5 years, 10
years and 20 years respectively. There was a slight trend towards an exponential
increase in the number ofpre-symptomatic tests performed over time.
The predicted number ofMMR gene mutation carriers identified through cascade
genetic testing at default settings is presented in figure 4.3.23.
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The computer model indicated that an average of 79.9 (95% CI = 74.8, 85.0) index
cases (i.e. colorectal cancer patients who harbour a pathogenic mismatch repair gene
mutation) would be identified after 10 years of cascade genetic testing, with this
number increasing to 171.5 (95% CI = 163.6, 179.4) after twenty years. The number
of relatives identified as carriers was predicted to average 124.9 (95% CI = 115.8,
134.0) after ten years and 321.2.(95% CI = 305.3, 337.1) after twenty years. This is
the most crucial outcome, as the identification of asymptomatic mutation carriers is
the primary goal of cascade genetic testing. In total, the model indicates that the
number of carriers identified would average 204.8 (95% CI = 192.4, 217.2) after ten
years and 492.7 (95% CI = 468.9, 516.5) carriers would be identified after 20 years.
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The divergent nature of the two measurements presented in figure 4.3.23 is an
important observation, as it indicates that the number of relatives (i.e. asymptomatic
members of the Scottish population) identified as earners increases more steeply
over time than the number of index cases identified. The net effect of this
observation is that the ratio of asymptomatic carriers identified to index cases
identified is predicted to increase over time, as illustrated in figure 4.3.24.
Figure 4.3.24 Predicted Ratio of Asymptomatic Carriers Identified to
Index Cases Identified at Default Settings
The model estimated that an average of 1.88 (95% CI = 1.80, 1.95) asymptomatic
mutation carriers would be identified per index case after 20 years.
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One of the primary objectives of the computer model is to evaluate the efficiency of
cascade genetic testing. A calculation of absolute efficiency would necessitate a
detailed assessment of the economic aspects of the process that is beyond the scope
of the current model. However, an indication of relative efficiency is readily
obtained from the model outcomes. A simple and useful index of efficiency is given
by comparing the number of asymptomatic MMR gene mutation carriers identified
to the number ofmutation analyses performed to achieve this. This approach
disregards the ascertainment and testing of relatives of index cases, which in reality
will form a substantial part of the work undertaken as part of the cascade genetic
testing programme. However, the majority of resource is likely to be expended on
mutation analysis. Furthermore, the number ofmutation analyses performed is
directly proportional to the number of pre-symptomatic tests performed. Hence, the
number ofmutation analyses performed provides an indication of total resources
expended. The predicted cumulative ratio ofMMR gene mutation carriers identified
per mutation analyses performed is illustrated in figure 4.3.25.
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Figure 4.3.25 Predicted Number of Gene Mutation Carriers Identified
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The number of index cases identified per mutation analysis provides an indication of
the capacity of the chosen ascertainment criteria, in this model based on the age at
colorectal cancer diagnosis, to target carriers ofMMR gene mutations. As shown in
figure 4.3.25, results provided by the model at default settings imply that the number
of index cases identified per mutation analysis after 20 years would be 0.0240 (95%
CI = 0.0230, 0.0250). This equates to approximately one positive result for every 44
mutation analyses performed. Over the entire twenty-year period the model
predicted that 171.5 (95% CI = 163.6, 179.4) index cases would identified, and 7144
(95% CI = 7037, 7250) mutation analyses would be performed. As illustrated in
figure 4.3.25, the cumulative ratio of asymptomatic MMR gene mutation carriers
identified per mutation analyses performed was predicted to be 0.0339 (95% CI =
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0.0282, 0.0395), 0.0369 (95% CI = 0.0343, 0.0394) and 0.0449 (95% CI = 0.0429,
0.0469) after 5, 10 and 20 years respectively.
The plots ofboth measurements considered in figure 4.3.25 take a similar shape,
which is reflected in the overall number of test positives identified per mutation
analysis. However, there is a slight difference in the rate of increase, with the
number of relatives identified as carriers per mutation analysis continuing to
increase to 20 years, whereas the number of index cases identified per mutation
analysis levels out after 5 years.
On an annual basis, as opposed to a cumulative total, the predicted number of
asymptomatic MMR gene mutation carriers identified each year per number of
mutation analyses performed in that year was as illustrated in figure 4.3.26.
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Figure 4 .3.26 Predicted Annual Number of Asymptomatic MMR Gene
Mutation Carriers Identified Per Mutation Analysis







































One of the potential advantages of cascade genetic testing is the capacity to limit the
number of asymptomatic non-carriers who undergo genetic testing, whilst
maximising the number of asymptomatic carriers identified. Accordingly, the
proportion of people undergoing a pre-symptomatic test who actually have a MMR
gene mutation is of considerable relevance. This proportion, according to the
predictions of the computer model, is illustrated below.
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After 20 years, the overall proportion of pre-symptomatic tests with a positive result
was 0.38 (95% CI = 0.37, 0.39).
The average number of interviews conducted by a genetic nurse as part of a cascade
genetic testing programme at default settings was predicted to be 2197 (95% CI =
2141, 2253) after five years, 4608 (95%CI = 4514, 4702) after ten years and 9349
(95% CI = 9174, 9523) after twenty years. Hence the average number of genetic
nurse interviews conducted each year would be around 468.
Default settings for resources are deliberately set at very high levels (1000 events
per week) so that there are effectively no restrictions on the model system due to
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settings will simply be a reflection of the number of people who are eligible for a
particular stage of the model, and the delay that is built into the model at that stage.
Waiting list data at default settings is included in the 'resources' section for
comparison with outcomes under restricted resources.
4.3.5.2 Prevalence
Prevalence settings utilised for model evaluation were taken directly from the
estimate of prevalence provided by Dunlop et al., (58) and the associated confidence
intervals, and were defined as follows: default prevalence = 1:3139, low prevalence
= 1:7626, high prevalence = 1:1247. The results generated by the computer model
at these low, default and high prevalence settings are presented below, and form the
basis of an evaluation of the effect of prevalence on model outcomes.
Even when the prevalence ofMMR gene mutations is estimated to be relatively
high, the vast majority of colorectal cancer cases that are likely to occur in the
Scottish population will be sporadic in origin. Hence, prevalence would be expected
to have only a minimal impact on the total number ofmutation analyses performed
during the modelled cascade genetic testing process. The model, as illustrated in
figure 4.3.28, upholds this expectation.
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Figure 4.3.28 Predicted Number of Mutation Analyses Performed at
Low, Default and High Prevalence
8000
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Conversely, the proportion ofMMR gene mutation carriers amongst the colorectal
cancer cases that present to the cascade genetic testing system will increase with the
prevalence of such mutations in the population. Figure 4.3.29 illustrates the effect,
according to the model, of various prevalence estimates on the number of index
cases identified. Y-error bars displaying 95% confidence intervals are shown for all
estimates in this figure.
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Figure 4.3.29 Predicted Number of Index Cases Recruited at Low,
Default and High Prevalence
Years
The number of relatives identified as MMR gene mutation carriers is directly related
to the number ofpre-symptomatic tests performed, which in turn is related to the
number of index cases identified. Therefore, the pattern observed in figure above is
reflected in figure 4.3.30, which shows the actual number of relatives identified as
carriers.
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Figure 4.3.30 Predicted Number of Asymptomatic Mutation Carriers




The model predicts that the total number of asymptomatic mutation carriers
identified through cascade genetic testing will vary considerably according to the
prevalence of such mutations. After twenty years, the number of asymptomatic
mutation carriers identified at low, default and high prevalence respectively were
predicted to be 132.5 (95%CI = 120.7, 144.3), 321.2 (95% CI = 305.3, 337.1) and
803.4 (95% CI = 731.8, 875.0).
As considered previously, an insight into the relative efficiency of cascade genetic
testing can be obtained by considering the ratio of asymptomatic MMR gene
mutation carriers identified to mutation analyses performed. This data, relating to














































Predicted Number of Asymptomatic Mutation Carriers
Identified Per Mutation Analysis Performed at Low,
Default and High Prevalence
V
T T T T I I I 1
i I i * *- ■i I 1 i I » »
1 2 3 4 5 6 7 9 10 11 12 13 14 15 16 17 18 19 20
Years
A similar pattern is evident at all prevalence levels considered in figure 4.3.31, with
the number ofpositive pre-symptomatic tests per mutation analysis performed
increasing rapidly from zero over the first two or three years, and then increasing at
a diminishing rate (i.e. levelling off) over the remainder of the modelled cascade
genetic testing programme. The predicted number of asymptomatic mutation carriers
identified per mutation analysis performed after 20 years was 0.019 (95% CI =
0.017, 0.020) at low prevalence, 0.045 (95% CI = 0.043, 0.047) at default settings,
and 0.112 (95% CI = 0.104, 0.120) at high prevalence.
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4.3.5.3 Penetrance
To investigate the effect ofpenetrance on the model system, the model was run ten
times at each of the various penetrance settings, listed in table 4.3.6. There are no
reliable data regarding confidence intervals for penetrance estimates. Hence these
settings represent a spectrum ofpossible penetrance values that may apply in the
real-world situation. For ease of comparison, the ratio ofpenetrance in males and
females has been kept constant at 2:1 respectively, with the obvious exception of the
'complete' penetrance estimate.
Table 4.3.6 Penetrance Settings for Model Evaluation
Setting Penetrance (Males) Penetrance (Females)
M=0.40 / F=0.20 0i40 020
M=0.50 / F=0.25 0.50 0.25
M=0.60 / F=0.30 0.60 0.30
M=0.70 / F=0.35 0.70 0.35
Default 0.80 0.40
M=0.90 / F=0.45 0.90 0.45
Complete TO TO
The penetrance ofMMR gene mutations directly influences the number of carriers
expected to develop colorectal cancer each year. However, the fact that prevalence
of such mutations is estimated to be low (58) means that, even at high penetrance,
mutation carriers will constitute a small proportion of all colorectal cancer cases.
Consequently, different penetrance settings had no significant effect on model
predictions of the total number ofmutation analyses performed (data not shown).
The proportion of colorectal cancer cases which have a MMR gene mutation would
be expected to increase in line with increasing penetrance, as shown in figure 4.3.32.
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For clarity, in this figure, and subsequent figures in which numerous results are
presented, confidence intervals are shown only for default settings.
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As before, since the average number of relatives identified as carriers per index case
remains constant (although individual measurements can vary at random), the effect
of varying penetrance on the number of relatives identified as mutation carriers will
follow a similar pattern to that for index cases, as shown below.
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Figure 4.3.33 Predicted Number of Asymptomatic Mutation Carriers
Identified at Various Penetrance
600
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The model predicts that the total number of asymptomatic carriers identified if the
default estimate of penetrance applied would be 321.2 (95% CI 305.3, 337.1). If
penetrance was complete, 521.1 (95% CI = 502.7, 539.5) asymptomatic carriers
were predicted to be identified in this time. At the opposite end of the spectrum, with
penetrance being only 0.4 in males and 0.2 in females, this figure is predicted to be
161.6 (95% CI = 138.6, 184.7).
Figure 4.3.34 provides an illustration of the predicted effect of penetrance on the
relative efficiency of cascade genetic testing. For clarity, 95% confidence intervals
are only displayed for default settings in this figure.
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Figure 4.3.34 Predicted Number of Asymptomatic Mutation Carriers
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As illustrated in figure 4.3.34, the computer model supports the hypothesis that the
relative efficiency of cascade genetic testing is directly proportional to penetrance.
4.3.5.4 Age Limits
Sporadic colorectal cancer incidence increases rapidly with advancing age, whereas
cases that are primarily hereditary in origin tend to manifest at a relatively young
age. Hence, the proportion of all colorectal cancer cases that are caused by MMR
gene mutations would be expected to be greater in relatively young cases, providing
a useful and established means of targeting potential carriers. To illustrate this point,
and to investigate the potential effect of various age limit criteria on the outcomes of
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cascade genetic testing, the model was run ten times each with the maximum age
limit set to 30, 35, 40, 45, 50, 55 (default), 60, 70 and 100 years. Throughout this
chapter, these settings are referred to as "under 'x' years" or "Ux".
Figure 4.3.35 demonstrates the predicted number ofmutation analyses that would be
performed if each of the above settings were applied in a cascade genetic testing
programme. The U100 setting is included this figure to illustrate the predicted
number ofmutation analyses that would be required if no age limits were applied.
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At the U100 setting the model predicted that an average of 42574 (95% CI = 42007,
43140) mutation analyses would be performed over the twenty-year period. In
contrast, when the maximum age limit was set to 30 years, only 199 (95% CI = 190,
208) mutation analyses were predicted to be performed over the same time period.
The underlying hypothesis that lowering the age limit will improve the efficiency
with which index cases are identified, at the expense of reducing the overall yield of
the programme is explored below.
In practical terms, cases developing after age 70 are unlikely to be included in a
genetic testing programme, due to the fact that only a very small proportion of such
cases are likely to harbour MMR gene mutations, and that elderly patients may be
less able and willing to participate. Due to limitations in the available data, as
indicated in table 4.3.2 and considered further in the discussion section, the model
itself does not generate an estimate of'expected cases' amongst mutation carriers
over 70 years of age. Accordingly, U70 is the maximum age limit considered in the
subsequent figures, which are concerned with the identification ofmutation carriers.
Figure 4.3.36 shows the average total number of index cases that the model
predicted would be identified at each age limit setting. In order to preserve the
clarity of this figure, 95% confidence intervals are shown for default settings only in
this figure and point markers are not displayed.
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Figure 4.3.36 Predicted Number of Index Cases Identified at Various
Age Limits
200
The most striking feature of the above figure is the clustering of estimated index
cases identified for all age limits above 55 years. Indeed, values for the U60, U65
and U70 settings generally fall within the 95% confidence intervals for the results at
default (U55) settings. Predictions of the number of asymptomatic MMR gene
mutation carriers identified at various age limits follow a similar pattern, as
illustrated in figure 4.3.37. Again, 95% confidence intervals are shown for default
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Figure 4.3.37 Predicted Number of Asymptomatic Mutation Carriers
Identified at Different Age Limits
The above figure shows that cascade genetic testing with age limits ofU60, U65 and
U70 are predicted to yield a total number of positive pre-symptomatic tests that is
not significantly different from the yield at default (U55) settings. Although a
statistically significant difference may become evident based on a larger number of
simulations (runs), this finding implies that applying maximum age limits for
recruitment of index cases of greater than 55 years would have only a minor effect in
terms of increasing yield. For almost all of the twenty year 'run' period of the
model, the predicted number ofpositive pre-symptomatic tests at the U50 setting arc
also within the confidence intervals for default settings, suggesting that reducing the
default age limits by five years may have limited impact on yield. In contrast, setting
the model age limits to just 30 or 35 results in a substantial reduction in predicted
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yield, with less than a third of the number of asymptomatic mutation carriers being
identified compared to default settings. A large increase in overall yield is evident
between age limit U35, at which the predicted number of positive pre-symptomatic
tests was 98 (95% CI = 84, 112) and age limit U40 at which an average of 213 (95%
CI = 194, 232) relatives were identified as MMR gene mutation carriers.
Again, an indication of the relative efficiency of cascade genetic testing using
various age limit criteria was obtained by plotting the number of relatives identified
as MMR gene mutation carriers per mutation analysis performed. This analysis is
presented in figure 4.3.38. 95% Confidence intervals are again shown for default
settings, and also for U35 settings to illustrate the fact that where fewer total tests
have been performed confidence intervals are relatively wide. For clarity, point
markers and other confidence intervals are not displayed.
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Figure 4.3.38 Predicted Number of Asymptomatic Mutation Carriers
Identified Per Mutation Analysis Performed, at Various
Age Limits
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At the U30 setting, the average number of asymptomatic carriers identified per
mutation analysis performed reached 0.2940 (95% CI = 0.2433, 0.3447) after twenty
years, implying that only around four mutation analyses would be required to
identify one asymptomatic mutation carrier if such criteria were implemented. This
high relative efficiency is inevitably offset by a low overall yield, as illustrated in
figure 4.3.37. At the other extreme, the model suggests that if no maximum age limit
were applied to colorectal cancer cases in a cascade genetic testing program, as
represented by the U100 setting, the average number of asymptomatic carriers




The extent to which eligible individuals participate is a crucial issue consideration in
terms of the utility of any cascade genetic testing programme. In the model system,
there are four points at which participation, or "acceptance", may or may not occur.
Firstly, it may not be possible to contact the individual in question, due to non-
cooperation or other practical reasons. A contacted individual may or may not attend
a genetic nurse interview, and if they do attend they may or may not consent to
genetic testing. Finally, index cases, once identified, will decide whether or not to
allow their family members to be contacted in connection with the cascade genetic
testing programme. The first two of these points essentially lead to the same result;
either the individual in question will be offered a genetic test or will not. A
conservative estimate of 0.9 is applied to the probability of acceptance at each of
these points at default settings. With the exception of the "acceptance 100" setting,
at which 100% participation is assumed at all stages, these two settings have been
kept constant throughout the following analysis to facilitate an investigation of the
effect on model outcomes ofparticipation at the 'genetic testing' and 'allowing
contact with relatives' stages. The acceptance settings used as model input in this
investigation are shown in table 4.3.7.
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Table 4.3.7 Acceptance Settings for Model Evaluation







Acceptance 100 1.00 1.00 1.00 1.00
Default 0.90 0.90 0.90 0.90
Acceptance 1 0.90 0.90 0.80 0.90
Acceptance 2 0.90 0.90 0.70 0.90
Acceptance 3 0.90 0.90 0.60 0.90
Acceptance 4 0.90 0.90 0.50 0.90
Acceptance 5 0.90 0.90 0.40 0.90
Acceptance 6 0.90 0.90 0.30 0.90
Acceptance 7 0.90 0.90 0.90 0.80
Acceptance 8 0.90 0.90 0.90 0.70
Acceptance 9 0.90 0.90 0.90 0.60
Acceptance 10 0.90 0.90 0.90 0.50
Acceptance 11 0.90 0.90 0.50
0.9 Patient, 0.5
0.50
Acceptance 12 0.90 0.90 FDR/SDR
0.9 Patient/FDR, 0.5
0.90
Acceptance 13 0.90 0.90 SDR
0.5 Patient, 0.9
0.90
Acceptance 14 0.90 0.90 FDR/SDR 1.90
Abbreviations: FDR, first degree relative; SDR, second degree relative
Model outcomes relating to the predicted number ofmutation analyses that would be
performed at various acceptance settings for genetic testing, with other acceptance
probabilities remaining constant at 0.9, are presented in figure 4.3.39.
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Figure 4.3.39 Predicted Number of Mutation Analyses Performed at
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The predicted number ofmutation analyses performed decreases in direct proportion
to the probability that eligible patients will accept the genetic test. The predicted
impact of this effect on yield from cascade genetic testing is illustrated in figure
4.3.40.
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Figure 4.3.40 Predicted Number of Asymptomatic Mutation Carriers
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In general, the pattern observed for number of pre-symptomatic test positives is
similar to that for number ofmutation analyses performed. However, a linear
increase in probability of test acceptance results in a subtle exponential increase in
positive pre-symptomatic tests, due to the fact that this probability applies to both
potential index cases and relatives of known MMR gene mutation carriers. A
consequence of this feature is that cascade genetic testing is predicted to be more
efficient, in relative terms, when the probability of test acceptance is high, as
illustrated in figure 4.3.41.
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Figure 4.3.41 Predicted Number of Asymptomatic Mutation Carriers
Identified Per Mutation Analysis Performed, at Various


































Model settings 12, 13 and 14 were designed to further explore the issue of genetic
test acceptance by specifying different probabilities for undergoing the test
depending on whether the individual being offered testing is a colorectal cancer
patient (potential index case), a first degree relative of a known carrier, or a second
degree relative of a known carrier. The predicted numbers of asymptomatic mutation
carriers identified at these settings are presented in figure 4.3.42.
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Figure 4.3.42 Predicted Number of Asymptomatic Mutation Carriers
Identified at Additional Acceptance Rates for Genetic
Testing
Year
As shown by the close proximity of the plots of acceptance 12 and acceptance 14,
the model predicts that the effect of the probability of test acceptance being limited
to 0.5 for potential index cases would be very similar to the effect of the probability
of test acceptance by relatives of known carriers being limited to this level. The plot
of acceptance 13 indicates that if this probability was 0.9 (default) for potential
index cases and first-degree relatives of known carriers, but only 0.5 for second-
degree relatives, the yield would still be significantly less than at default settings.
Figure 4.3.43 illustrates the relative efficiency of cascade genetic testing at these
settings.
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Figure 4.3.43 Predicted Number of Asymptomatic Mutation Carriers
Identified Per Mutation Analysis Performed at Additional
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At the acceptance 13 setting, the reduced yield associated with fewer second-degree
relatives accepting a genetic test is reflected as a proportional reduction in relative
efficiency compared with default settings. No significant difference in relative
efficiency is apparent between default settings and acceptance 14. This result would
be expected, since the probability of test acceptance for relatives is the same at each
of these settings. Hence, these results clearly demonstrate the intuitive point that the
yield of cascade genetic testing will vary with the probability of test acceptance by
potential index cases, but that efficiency in terms of laboratory resources will not be
affected. There are, of course, likely to be some administration time and resources
expended on colorectal cancer patients who do not accept genetic testing, so in this
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respect the cascade genetic testing may be slightly more efficient when acceptance
at this stage is higher. In contrast, to these findings, the acceptance 12 setting
illustrates the fact that a decrease in probability of accepting genetic testing among
relatives of known carriers will restrict the actual 'cascade' process, whereby a
mutation is traced through a pedigree. Consequently the model predicts that the
estimates specified in acceptance 12 would result in a relatively inefficient cascade
genetic testing system.
The model was run at acceptance settings 7, 8, 9 and 10 to study the effect on key
model outcomes of reduced probability of index cases allowing contact with other
family members. At these settings, the number of index cases identified would not
be expected to differ, other than at random, and this assumption was borne out by
the model results (data not shown). The average number of asymptomatic mutation
carriers predicted to be identified at these settings is shown in figure 4.3.44.
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Figure 4.3.44 Predicted Number of Asymptomatic Mutation Carriers
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The computer model predicts that the number of asymptomatic mutation carriers
identified will decrease with the probability that index cases will allow contact with
their relatives. For example, at the acceptance 10 setting, when this probability is
just 0.5, the yield was approximately half that at default settings. The predicted
impact of probability of index cases allowing contact with their relatives on relative
efficiency is shown in figure 4.3.45.
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Figure 4.3.45 Predicted Number of Asymptomatic Mutation Carriers
Identified Per Mutation Analysis Performed, at Various
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The above results indicate that cascade genetic testing becomes markedly less
efficient in relative terms as the probability ofmutation carriers allowing contact
with their relatives decreases.
4.3.5.6 Delays
At default settings, the model has several inbuilt delays, designed to reflect the
approximate time that various tasks will take in a real-life situation. The most
significant delay is associated with conducting mutation analysis, and the default
time for this process is 52 weeks. Intuitively, it would be expected that delays in the
model system would influence the time taken to reach certain targets, but would not
otherwise affect the model outcomes, and would hence have no impact on the
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overall utility of cascade genetic testing. To test this hypothesis, the model was run
ten times at each of the following mutation analysis delay settings: 4 weeks
(considered the minimum realistic time for conducting mutation analysis), 13 weeks,
26 weeks, and 39 weeks. The predicted number of asymptomatic mutation carriers
identified through cascade genetic testing at these settings is shown below.
Figure 4.3.46 Predicted Number of Asymptomatic Mutation Carriers
Identified at Various Mutation Analysis Delays
Year
This chart shows a slight tendency towards increased yield when mutation analysis
delay settings are relatively short. However, the differences observed are minor, and
are only significant at some of the annual time points at which results are recorded.
The influence of such differences on the relative efficiency of the model system are
presented in figure 4.3.47.
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Figure 4 3.47 Predicted Number of Asymptomatic Mutation Carriers
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Again, differences between outcomes under different mutation analysis settings
were minor, and non-significant at most measurement points. Other delays built into
the model are short in comparison to the mutation analysis delay, and hence it was
anticipated that decreasing these delays would exert even less influence on model
outcomes. To demonstrate this, the model was run ten times with all delays except
mutation analysis delay set to just one week. Finally, to determine the maximum
effect of reducing delays in the model system, it was run ten times at "minimum
delay" settings, with a mutation analysis delay of 4 weeks and all other delays being
1 week. Results, in terms of yield and relative efficiency, are presented in the
following two figures.
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Figure 4.3.48 Predicted Number of Asymptomatic Mutation Carriers
Identified at Various Delays
Year
Figure 4.3.49 Predicted Number of Asymptomatic Mutation Carriers
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As illustrated in figure 4.3.48, the computer model predicts that minimising the
delays within the cascade genetic testing system exerts a small but significant
influence on the number of asyptomatic MMR gene mutation earners identified over
time and the relative efficiency with which this is accomplished. However, the
observed increase in yield does, as expected, appear to be a shift in the time taken to
reach certain yield, rather than the total number of earners that will be identified.
Figure 4.3.49 suggests that cascade genetic testing is more efficient, in terms of the
number of asymptomatic mutation carriers identified per mutation analysis,
whenever delays within the system are minimised. The differences illustrated are
small, and there appears to be a convergence of relative efficiency in later years,
implying that the impact in the long run would not be large.
4.3.5.7 Resources
The resources required to implement a cascade genetic testing programme are a
major consideration with respect to the feasibility of such an enterprise. The model
system allows the user to specify the resources available at various key stages, in
terms of the number of events (interviews, tests etc.) that can be performed each
week. An inherent disadvantage ofhaving a fixed level of resource is that
"bottlenecks" can then occur at any stage in the cascade genetic testing process at
which resources are inadequate. This effect will be evident from the model
outcomes, both directly, in its impact on waiting lists at the relevant stage, and also
indirectly, since the overall yield of the system may be affected.
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At default settings, resources are set at an extremely high level, to ensure that the
performance of the system is not restricted by limitations in the resources allocated.
It was anticipated that, for each point at which resources are utilised, there will be a
threshold beyond which the resources will be unable to cope with the demand,
resulting in increasing waiting lists and potentially reduced yield. In a real life
situation, the bulk of the available resources, both in terms of time and money, are
likely to be expended on conducting mutation analysis. Hence, the model was run
ten times each at various resources settings for this stage, in order to determine the
aforementioned threshold and investigate the effect that restricted resources would
have on the overall number of asymptomatic MMR gene mutation carriers identified
through the cascade genetic testing system. The effect on the number of people on
the waiting list for mutation analysis of having tests resources limited to 2, 3, 4, 5,
10 and 1000 (default) tests per week is illustrated in figure 4.3.50.
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Figure 4.3.50 Predicted Impact of Limited Mutation Analysis
Resources on the Waiting List Length of the Mutation
Analysis Waiting List
6000
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The above figure illustrates the principle that limiting resources will have no effect
on the functionality of a cascade genetic testing system, provided they remain above
the demand threshold. The number of people on the mutation analysis waiting list
when resources are limited to 10 mutation analyses per week does not differ from
default settings, when up to 1000 mutation analyses can be performed. In contrast, if
the resource level is further reduced to 5 mutation analyses per week, demand
exceeds the capacity for supply, and the number of people on the waiting list
increases rapidly. Predictably, when resources are reduced further the rate of
increase in the size of the waiting list becomes proportionally greater. The predicted
effect of the increased waiting list size on the potential yield from cascade genetic
testing is shown in figure 4.3.51.
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Figure 4.3.51 Predicted Impact of Limited Mutation Analysis
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Again, there is no consistently significant difference between yield at default
settings and yield when mutation analysis resources are limited to ten per week.
Reducing resources to five per week, and below, results in a substantially reduced
number of asymptomatic mutation carriers being identified. Hence, the model
predicts that a cascade genetic testing programme would require the capacity to
perfonn up to ten mutation analyses per week, in order to operate to its full potential.
Since a genetic nurse interview is a pre-requisite for mutation analysis, and only
10% of individuals attending a genetic nurse interview decline genetic testing, it can
be anticipated that the hypothetical cascade genetic testing programme also requires
the capacity to conduct approximately ten genetic nurse interviews a week.
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Conversely, reduction of genetic nurse interview resources to five per week would
be expected to introduce a 'bottleneck' effect. These inferences were borne out by
running the model ten times each with resources at this stage set to 5 and 10 weeks,
as shown in figure 4.3.52.
Figure 4.3.52 Predicted Impact of Limited Genetic Nurse Resources
on the Number of Asymptomatic Mutation Carriers
Identified
Year
An indication of the minimum resources required for maintaining model
performance can be obtained using the general principle of analysing the resource
expended at default settings. For example, at default settings, an average of 850 pre-
symptomatic tests were performed over the twenty-year period: a rate of 0.82 per
week. Hence, it can be assumed that a resource capacity ofjust one pre-symptomatic
test per week would be adequate to maintain yield attained at default settings.
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4.4 DISCUSSION
Cascade genetic testing provides a potential strategy for identifying asymptomatic
carriers ofMMR gene mutations in the Scottish population. A thorough evaluation
of the potential utility of cascade genetic testing in this context has not yet been
undertaken, and the development and analysis of the computer model described as
part of this thesis was designed to address this issue.
4.4.1 Approaches to the Evaluation of Cascade Genetic Testing
In general terms, there are three possible approaches to the evaluation of cascade
genetic testing. These are considered in turn.
4.4.1.1 Implementation and Analysis of a Real Cascade Genetic
Testing Programme
As discussed previously, the principle of tracing a pathogenic mutation through a
family is widely employed in clinical cancer genetics practice, and introducing a
systematic population-wide programme of cascade genetic testing may be a logical
next step.
In many ways, simply implementing and analysing a real cascade genetic testing
programme provides an ideal means of evaluating this strategy. Certainly, this real-
life approach has numerous advantages over computer modelling, as no computer
model can be considered a substitute for practical experience. However, there arc
two major drawbacks to such a strategy. Firstly, whilst implementing cascade
genetic testing will provide a wealth of information about the application of a
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specific programme in a particular context, it will not be capable, other than by
inference, of providing information on cascade genetic testing under alternative
conditions. The other major drawback to evaluating cascade genetic testing through
direct implementation arises from the time-scale. At the population level, where the
goal is the identification of asymptomatic mutation carriers, the medium and long-
term outcomes of cascade genetic testing are of primary importance, and these may
be measured over many years. Hence, it would be necessary to wait for many years
for data from a current cascade genetic testing programme to mature sufficiently to
inform predictions of medium and long-term outcomes for another programme.
Thus, the implementation of cascade genetic testing will provide valuable
information on the application of a particular programme in a specific context, and
this information may help inform the planning of future programmes. However,
inference and assumptions will remain a necessary part of planning a future
programme, since the population, genetic epidemiology, human behaviour and
inclusion criteria involved may all be different. Furthermore, there is currently a
paucity of data on the long-term results of cascade genetic testing, and this will
inherently take many years to resolve, even if systematic cascade genetic testing is
introduced immediately or is presently ongoing. A thorough and useful evaluation of
the potential utility of cascade genetic testing must include the capacity to project
results forward to provide an indication of the long-term outcomes, and the ability to




A mathematical evaluation, based on a series of equations to calculate theoretical
outcomes, offers an alternative approach to the evaluation of cascade genetic testing.
This approach has previously been utilised by Krawczak et ah, (150).
Straightforward mathematical evaluation, as opposed to computer modelling, has the
advantage of presenting a relatively simple and transparent evaluation of cascade
genetic testing. The main disadvantage of this approach is that even complex
equations are inherently limited in the extent to which they can represent a real-life
cascade genetic testing programme. Cascade genetic testing is inherently a highly
complex system, as it incorporates such elements as family structure, population
demographics, genetic epidemiology and participant behaviour. Consequently, a
series of equations that do not consider all such factors, and do not incorporate data
specific to a particular clinical context, represent a gross oversimplification of
cascade genetic testing as it may be applied to the challenge of identifying
asymptomatic mismatch repair gene mutation carriers in the Scottish population.
Furthermore, the time-scale of a cascade genetic testing programme is an essential
consideration from a practical perspective, as the yield from any cascade genetic
testing programme will be conditional on the length of time the programme is in
operation. This factor is not addressed by a theoretical mathematical approach. A
meaningful evaluation must address not just the potential achievements of a cascade
genetic testing programme, but also the length of time required to reach such
achievements. Hence, a mathematical evaluation is of limited practical use in terms
of predicting outcomes and informing practical planning for cascade genetic testing.
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4.4.1.3 Computer Modelling
Computer modelling provides a very powerful tool for representing, understanding
and studying complex biological and medical systems. This ability to cope with
complexity enables numerous factors and their interactions to be considered, and
provides the capacity to conduct an evaluation that is highly specific to a particular
situation; in this case the evaluation of cascade genetic testing for mismatch repair
gene mutations in Scotland. The capacity to incorporate practical experience and
real data into a computer model can be used to ensure that the model is
representative of the real system under consideration. Another major advantage of
developing a computer model as a tool for evaluating a complex system is
flexibility. A computer model can readily be updated to incorporate new ideas and
information, and the model inputs can be manipulated to facilitate the evaluation of
various cascade genetic testing programmes under different conditions.
There are, however, drawbacks and limitations to computer modelling. Firstly, a
computer model is, in essence, a simplification of a real-life system, and as such
model outcomes may not be entirely realistic. Computer modelling is also a
somewhat subjective process, as the model created will represent the system as it is
understood by the modeller. A further crucial limitation of computer modelling is
that the accuracy and validity of the information provided by the model is dependent
on the quality of the data used as inputs to the model system. Each of these
limitations is considered in subsequent sections of this discussion.
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Overall, the development of a computer model of cascade genetic testing for
mismatch repair gene mutations in the Scottish population currently represents the
most appropriate approach to the evaluation of this strategy. The computer model
described in this thesis represents an attempt to integrate this approach with real data
relevant to cascade genetic testing, by developing a computer model that is partly
based on and informed by the ongoing COGS programme.
4.4.2 Justification of Methods
The development of a computer model of cascade genetic testing was based on an
object-orientated approach to visual modelling. The object-orientated approach in
general provides a useful and proven technique for modelling complex systems. The
principal merit of object orientated modelling in the current context is that it is based
around "real-world" entities, with the model system being described by these entities
and their interactions. This approach to modelling is designed to reflect the way in
which the human brain itself understands systems: through objects and their
interactions. Consequently, object-orientated modelling enabled a researcher with a
background in the 'domain' to develop a computer model and communicate this
both to other researchers and computer programmers.
The strategy outlined in the section 4.2 facilitated collaboration between the domain
expert and the computer programmer, whilst the stepwise process of model
development enabled the domain expert to retain overall control of the model's
design and functionality. The unified modelling language (UML) is a widely used
and user-friendly language for object orientated modelling (196, 224, 296). Hence,
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the utilisation ofUML to develop an object-orientated visual model of cascade
genetic testing constituted the most appropriate strategy for model development.
Based on the experience of developing this computer model, the decision to use
object-orientated modelling and the UML has been fully justified. It is intended to
utilise these tools for further work on the model (see 'further work' section),
reflecting the success of the overall approach.
4.4.3 Limitations and Sources of Error
In essence there are three potential sources of error that may be present in the
completed computer model of cascade genetic testing:
(i) Model Conception - Does the model accurately represent reality?
(ii) Model Application - Does the working model function properly and does
it accurately reflect the conceptual model?
(iii) Model Inputs - Is the data that informs the model complete and accurate?
The limitations of the model with respect to these aspects are considered below.
4.4.3.1 Conception
A computer model is essentially a representation of a complex system as it is
understood by the modeller. Consequently limitations, omissions and inaccuracies in
this understanding will become manifest as such in the computer model. It is
imperative, therefore, that the modeller first attains a thorough and accurate
understanding of the system to be modelled. The methods employed, specifically the
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task analysis and the development of the conceptual model, are designed to ensure
that this level of understanding is attained. Discussion with various collaborators
with expertise in clinical cancer genetics, genetic epidemiology and conducting
genetic testing also helped to achieve the goal of a conceptual model that provides a
comprehensive, detailed and accurate representation of the system in question.
However, it must be acknowledged that the model created does constitute one
interpretation of cascade genetic testing, and is thus subject to human error with
respect to the accuracy with which the model reflects reality.
Once a thorough and accurate understanding of the system to be modelled has been
attained, the next requirement is that this understanding is properly represented
using the chosen modelling tools. Again, this aspect of model development is
difficult to monitor in an objective manner. Effectively, the success, or otherwise, of
the visual representation of the abstract model is determined subjectively by the
computer modeller. Therefore, work on the conceptual model continued in an
iterative fashion until the modeller was satisfied that the visual model was indeed an
accurate representation of the system.
As before, a degree of external validity was provided by ensuring, through
discussion with collaborators, that the conceptual model conveyed the desired
information. The research environment in which the computer model was developed
was ideal in this respect, since the research group and collaborators involved
included experts from a variety of disciplines, including coloproctology, genetic
epidemiology, clinical genetics and computer modelling. Hence, through discussion
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and collaboration with other researchers it was possible to develop a model that was
valid from a variety of relevant perspectives. The existence of alternative conceptual
models of cascade genetic testing is inevitable, but the conceptual model considered
herein is considered to be both valid and complete for the purpose of evaluating
cascade genetic testing within the terms of reference set out in the 'aims' section.
4.4.3.1.1 Scope of Conceptual Model
For the purpose of creating a computer model, cascade genetic testing can be
considered at a number of levels. At its simplest, this would include only the tracing
of a known mutation through a pedigree. However, to provide a meaningful
evaluation of cascade genetic testing in a particular context the population
concerned, the genetic epidemiology of the genes involved, and the means by which
index cases are identified must also be considered. Other aspects relating to cascade
genetic testing in a wider context, such as clinical disease, alternative strategies for
identifying mutation carriers, interventions in known mutation carriers and
concurrent strategies for disease prevention, may also be relevant. However, it is not
feasible to represent the complexity of cascade genetic testing in a particular context
in its entirety, and pragmatic decisions regarding the aspects of cascade genetic
testing that warrant inclusion in.the model must be made. Therefore, whilst the
conceptual computer model is considered to be a reasonably accurate representation
of cascade genetic testing from the domain perspective, the scope of the conceptual
model is inherently limited, and these limitations form a crucial consideration in the
model's evaluation.
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Early iterations of the conceptual model included a consideration of the process of
colorectal cancer diagnosis. However, the end point of this section, or "package", of
the conceptual model was cancer registration. Since cancer registry data can be
accessed directly, both in real life and in the context of a model, the putative model
of the diagnostic process was considered redundant. This provides an example of
how a conceptual model can be refined and restricted without detriment to its overall
utility.
In contrast, the effective absence of cancer genetic services from the model presents
a major limitation in terms of how closely the model system represents reality.
Individuals who are concerned about their family history of colorectal cancer and
consult a general practitioner in this regard, or individuals who are otherwise found
to have such a history at a primary care consultation, may be referred to cancer
genetic services. Subsequently, individuals deemed to meet particular criteria may
be offered genetic testing. Essentially, therefore, cancer genetic services provide an
alternative strategy for identifying mismatch repair gene mutation carriers that is
based on family history. A cascade genetic testing programme can potentially
ascertain mutation carriers in this way as well as, or instead of, testing a sub-group
of colorectal cancer cases.
Initially, the task analysis and early iterations of the conceptual model included the
capacity to identify mutation carriers by targeting both colorectal cancer cases and
individuals with a family history of the disease. For practical reasons, it was later
decided to disregard family history in order to focus on the evaluation of cascade
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genetic testing based on identifying index cases through testing colorectal cancer
cases. This was done for several reasons. Firstly, the computer model was largely
informed by the ongoing COGS study, which is concerned only with genetic testing
in colorectal cancer cases and their families. Also, the inclusion of cancer genetic
services would add another layer of complexity to the model, making it relatively
difficult to evaluate specific hypothetical cascade genetic testing programmes
against this background. Similarly, clinical information on the identification of
MMR gene mutation carriers through genetic services is limited and its inclusion
would add yet more uncertainty to the model. The decision to limit the scope of the
computer model to exclude cancer genetic services was also a practical one, made
on the basis that there was insufficient time available to model this aspect of cascade
genetic testing in the appropriate level of detail. In this respect the completed model
represents a balance between comprehensiveness and coherence.
The inability of the current model to consider cancer genetic services as a means of
identifying mutation carriers constitutes a significant limitation. This will be
addressed in future model development. Accordingly, results currently generated by
the model must be interpreted on the understanding that they represent one particular
approach to the identification ofmutation earners in cascade genetic testing.
Another aspect of cascade genetic testing that is not considered as part of the
computer model is the follow-up surveillance of mutation carriers. As discussed
elsewhere, the appropriate intervention strategy for MMR gene mutation carriers
remains the subject of debate, but it is likely to involve regular colonoscopic
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surveillance. The surveillance implications of cascade genetic testing are of
enormous importance in the wider context of using this strategy to reduce the burden
of colorectal cancer in the population, and health risks as well as benefits may
accrue from colonoscopic surveillance. Modelling of clinical services is a major
undertaking, and accordingly the relevant aspects of colonoscopic surveillance could
not feasibly be included in the current model. The predicted outcomes from the
model do, however, form a potential starting point for assessing the surveillance
implications of cascade genetic testing at the population level.
Realistically, the decision to implement cascade genetic testing at a national level
would be based on the costs involved, as well as the predicted health benefits.
Again, early versions of the task analysis and conceptual model contained packages
relating to the economics of cascade genetic testing. However, a thorough economic
evaluation of cascade genetic testing would have to consider not just the direct
laboratory, staff and administrative costs involved in implementing the programme
itself, but also the costs of clinical interventions for mutation carriers and conversely
the economic implications of preventing symptomatic colorectal cancer in this
group. This would involve developing a model that includes the financial aspects of
cancer genetic services and health care provision for colorectal cancer in Scotland.
Such a model would constitute a major project on its own, and thus an economic
evaluation of the cascade genetic testing was considered well outwith the scope of
the current model.
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Whilst the current model does not provide detailed economic information, it is
designed so that the outcomes can be used to inform economic considerations. The
yield of a particular cascade genetic testing programme states the number of
mutation carriers identified over time, and the model also predicts when and how
each carrier will be identified. Although it is not a direct outcome of the current
version, the computer model also retains the capacity to predict the age and sex of
newly identified mutation earners. This information, coupled with surveillance
guidelines for mutation carriers, could feasibly be used to determine the number of
surveillance colonoscopies that would be performed over time as a direct result of
cascade genetic testing. In turn, such estimates could be used to calculate the
associated costs and staff time required.
Direct costs associated with implementing a particular cascade genetic testing
programme can be estimated in a similar way. The model will provide data
regarding the number of events (interviews, tests etc.) that are required, and this
information, coupled with estimates of the cost per event can give an overall
indication of the costs involved.
The inclusion of a 'resources' output was designed to facilitate economic
considerations by providing a concise weekly report of the resource requirements of
the programme in question. Thus, as well as providing estimates that can be used to
inform the economic assessment of cascade genetic testing, the model can also
provide information, in relative terms, regarding the resources required for various
cascade genetic testing programmes under different conditions.
278
The estimated number of mutation analyses performed provides a useful indicator of
the total resources expended as part of a cascade genetic testing programme. This is
partly because conducting mutation analysis is likely to be the most expensive and
time-consuming single event in the programme, and also because the number of
mutation analyses performed is directly related to the number of other events
(interviews, pre-symptomatic tests etc.). The relationship between the number of
mutation analyses performed and the number of asymptomatic mutation carriers
identified can thus be used as an indicator of relative efficiency, as illustrated
throughout the analysis of model outcomes in this thesis.
Ultimately, the computer model is not capable of providing a detailed evaluation of
the financial requirements and economic implications of a cascade genetic testing
programme. This can be considered a significant limitation from the point of view of
planning such a programme. However, whilst the economic aspects of cascade
genetic testing do not form part of the computer model per se, it is possible to use
the model outcomes provide to data to inform such considerations. Furthermore, the
methods used to develop the computer model are designed to facilitate the expansion
of the scope of the model, and consequently an economic component could be added
as part of future work.
Cascade genetic testing may be associated with various psychosocial issues (40, 165,
184, 227). The risk of anxiety inherent in genetic testing, and the psychological
impact of being identified as a mutation carrier and undergoing surveillance
colonoscopy, are relevant considerations in the planning of any cascade genetic
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testing programme. Additional considerations with respect to cascade genetic testing
arise from the decision to involve family members in the programme. Much of the
available information regarding the psychosocial aspects of genetic testing comes
from qualitative studies, and thus appropriate data for inclusion in a computer model
is scarce. Furthermore, specific information on cascade genetic testing for mismatch
repair gene mutations is not currently available. Accordingly, the model does not
include a component relating to psychosocial issues, although as with economic
considerations model outputs can potentially be used to provide a quantitative
assessment of the psychosocial impact of cascade genetic testing at the population
level.
Additional aspects related to cascade genetic testing that could not feasibly be
included in the current model include the possible presence of concurrent colorectal
cancer prevention strategies, such as FOBT screening, and the inclusion of
extracolonic cancers that are associated with MMR gene mutations in ascertainment
criteria for genetic testing. Once again, these considerations could not be included in
the computer model for pragmatic reasons, but could feasibly be incorporated at a
later stage.
4.4.3.1.2 Simplification of Conceptual Model
Oversimplification of aspects of cascade genetic testing that are included constitutes
a further source of potential limitation of the computer model. This is particularly
evident with respect to construction of pedigrees. A key assumption that is built into
the computer model relates to family size and structure. The process of tracing a
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mutation through a pedigree is central to cascade genetic testing as it effectively
determines the number of asymptomatic mutation carriers that will be identified for
a particular index case. For practical reasons, the model generates a simple, stylised
pedigree for each mutation earner identified. This pedigree assumes that the
population remains constant, and that the generation gap is 25 +/- 5 years. These
assumptions are not unreasonable in themselves, since the Scottish population is
relatively stable and the majority of children are bom to parents between the ages of
20 and 30 years (84). However, the model does not reflect the true diversity of the
Scottish population in terms of family size and structure.
A real-life cascade genetic testing programme would feature considerable variation
in the number of relatives identified for each index case, reflecting differences in
pedigree size, structure and the age of family members. Large numbers of
asymptomatic carriers may be identified from one index case, whereas other index
cases may yield no further carriers. In contrast, although a random element is
introduced with respect to the generation of age and acceptance rates of relatives, the
model applies the same uniform pedigree structure to all mutation carriers, and
hence each index case has the same potential for the subsequent identification of
earners amongst relatives. The impact of this limitation on the outcomes form the
computer model is difficult to predict, but it is apparent that, in terms of pedigree
structure, the current model represents an oversimplification of real life. A more
accurate and detailed means of generating pedigrees for mutation carriers, which is
informed by real pedigrees from the COGS programme, will form a crucial aspect of
future model development.
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The interrelatedness of individuals within the population provides a further concern.
Currently, the model generates entirely separate pedigrees for each index case.
These pedigrees are extended outwards through cascade genetic testing and do not
overlap, regardless of how large they become. In reality, there is a distinct
possibility that different index cases may share a common ancestor, and may thus
have inherited their MMR gene mutation from the same source. In such
circumstances, the index cases will be related to some extent, although this may not
be apparent at the time they are identified. Such an occurrence has already been
observed in the Scottish population, with mutation earners identified through genetic
services subsequently being found to be distantly related (Dr. M Porteous, personal
communication).
The extent to which index cases identified as part of a cascade genetic testing
programme are likely to be related depends on the genetic variation of the Scottish
population in general and the genetic epidemiology of colorectal cancer in
particular. Considerable heterogeneity of mismatch repair gene mutations has been
observed in previous mutation analysis studies involving Scottish subjects (57, 62,
173), and no founder effect has been established in the Scottish population. This
suggests that a large proportion ofMMR gene mutations in the Scottish population
have arisen de novo, resulting in discrete 'mutation families'. However, in many
cases these mutation events will have taken place many generations ago, and the
possibility that mutation carriers in Scotland may be distantly related persists.
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The probability that interrelatedness will become apparent through cascade genetic
testing will be determined by the 'depth' to which cascade genetic testing is capable
of tracing mutations through families. Outcomes from the computer model suggest
that an average of 1.88 (95% CI = 1.80, 1.95) carrier relatives are identified for each
index case, implying that pedigrees in the model do not generally become extensive
and that overlapping of pedigrees is unlikely.
From a more practical perspective, it is clear that the high risk of colorectal cancer
conferred by a pathogenic mismatch repair gene mutation means that there is a high
probability of more than one family member developing colorectal cancer within the
time-frame of a cascade genetic testing programme, and thus potentially presenting
as separate index cases.
In disregarding the potential relatedness of index cases, the computer model may
overestimate the yield of cascade genetic testing, since the assumption that each
referral or relative identified through cascade genetic testing is 'new' to the system
may be violated. Again, the impact of this effect on the validity of the model's
outputs is difficult to assess, although it is not likely to exert a major influence in
comparison with other potential.limitations. Ideally, the computer model should
have the capacity to generate information on the interrelatedness of the entire
Scottish population, but this is unlikely to be feasible. Future model development
will take a more realistic approach, utilising findings from the COGS programme to
predict the convergence of pedigrees.
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4.4.3.1.3 Summary of Limitations at Conception Stage
In conclusion, since the conceptual model was developed in an iterative fashion
using the powerful object-orientated approach, and expert consultation as well as
extensive research was used to define and understand cascade genetic testing prior to
model development, it is considered to be as accurate a reflection of the real-life
process of cascade genetic testing as can be reasonably achieved. The model is,
however, inherently limited in scope and thus does not constitute a comprehensive
representation of all the aspects of cascade genetic testing that may be of interest.
Inevitably, these limitations are reflected in the model outcomes and the conclusions
that can be directly drawn from these results. Nonetheless, the key model outcomes
are often highly relevant to aspects of cascade genetic testing that are not included in
the model, and to some extent may be used to inform estimates and calculations
outwith the model's frame of reference. In addition, the model's design retains the
capacity for additional functionality to be incorporated at a later stage, and some of
the aspects of cascade genetic testing discussed above will form part of future model
development.
4.4.3.2 Application
There are two major issues in terms of assessing the potential for error in application
of the conceptual model. Firstly, the extent to which the functional model reflects
the conceptual design must be considered. In addition, the potential for undetected
programming errors to occur must also be evaluated.
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Although the conceptual model was designed to be comprehensive and thoroughly
documented, a degree of scope for interpretation remains. Similarly, for each piece
of functionality specified by the conceptual model (e.g. construction of pedigrees),
there may be more than one possible approach to programming of that functionality.
Consequently, the question of whether or not the functional model accurately
reflects the conceptual model is a somewhat subjective one. Frequent meetings
between the domain expert and the computer programmer ensured that the
functional model is a complete and accurate representation of the conceptual model
from each of these perspectives. Each package and diagram created at the conceptual
design stage is included in the functional model, and the objectives of the project
outlined in the conceptual model are met by the working version. To some extent, an
external assessment of the transition from concept to function can be made through
comparison of the functional model outlined in the results section and the conceptual
model presented in appendix A7.
The functional model was directly translated into Java code by the computer
programmer to create the working version of the computer model. The Sun ONE
Studio 4 Update 1 (Sun™) (133) integrated development environment contains a
robust "debugging" function that identifies coding errors. This was used throughout
the development and implementation of the functional model, ensuring that at a
technical level the model does function correctly. Inevitably, there is some potential
for human error at the coding stage, but this technical task was performed by an
experienced programmer and the potential for error was further minimised by the
use of frequent review and extensive documentation of the code. Hence, no
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functional alterations to the model are anticipated to have occurred at this stage.
Additional checks on the functionality of the computer programme were made at the
evaluation stage, through consistency checking and adjusting the model parameters
and/or code to ensure the model reacts in a logical manner.
A final consideration with respect to the application of the computer model concerns
the manner in which results for analysis were obtained. A random element is
incorporated into the model, such that the actual results from any 'run' of the model
at the same settings will vary. This feature makes the model system more realistic,
but also means that a particular set of results may not be representative of all model
outcomes at those settings. To account for this random element, the model was 'run'
ten times at each setting, and the mean values and associated confidence intervals
were used for analyses. The confidence intervals associated with the key estimates
provided by the model were reasonably narrow, and therefore ten runs at each
setting were generally adequate to observe statistically significant differences
between the outcomes of interest at different settings. Hence, whilst further
repetition of the cascade model would undoubtedly result in more accurate estimates
and narrower confidence intervals, this was considered unnecessary for the purpose
of this analysis. The capacity to automatically run numerous simulations will be
incorporated as part of further development of the computer model.
4.4.3.3 Inputs
As stated previously, outcomes from a computer model are only as valid as the
information used to inform it. Consequently, a critical evaluation of the inputs used
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in the development of the computer model forms a crucial aspect of the overall
interpretation of the model results. In this context 'inputs' refer to all assumptions
and all numerical estimates used to determine the model's behaviour and output,
including estimates that are modified by the model user.
A general consideration concerning the quality of data relating to the genetic
epidemiology of mismatch repair genes stems from the potential for bias in the
published studies that provide the source for much of this data. Inherently, all the
data relating to MMR genes and their epidemiology that are used to inform the
computer model come from mutations that have been identified and are generally
considered to be pathogenic. There is an inherent ascertainment bias in many such
studies, since potential mutation carriers were often targeted on the basis of family
history or microsatellite instability. Further bias may be associated with the specific
laboratory techniques employed. This constitutes a limitation of the entire model,
and emphasizes the need for unbiased information relating to mismatch repair gene
mutations and their role in colorectal cancer.
The quality of data available to provide input estimates is highly variable, and in
some cases such data has a high degree of uncertainty attached, or is simply not
available. In general terms, the computer model can accommodate such limitations
in data quality by including a range of possible values designed to cover all realistic
inputs. Each run of the model thus provides information on the behaviour and
outcomes of cascade genetic testing under a particular set of assumptions. The
assumptions identified as default values, and the alterations made to default values
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during analysis of the effects of various inputs are presented in the results section,
and considered in the subsequent discussion and interpretation. This transparency is
an essential aspect of the evaluation of cascade genetic testing using a computer
model, and ensures that model analysis adheres to recognised principles of good
practice in computer modelling (300).
4.4.3.3.1 Population Demographics
Data relating to the demographics of the Scottish population are considered to be
robust, since they were obtained directly from the 2001 census (228). The only
caveat to the reliability of this data is that in the model assumes that the 2001 figures
remain constant throughout the 'run' period, i.e. a static, rather than a dynamic,
population is modelled. The Scottish population is following the general pattern of
an ageing population in a developed country, and is predicted to decrease by around
3.3% over the next twenty-year period (84). Although changing population
demographics may influence outcomes from cascade genetic testing this effect is
likely to be minor.
4.4.3.3.2 Colorectal Cancer Incidence
Cancer incidence data comes directly from the Scottish Cancer Registry, which is
considered to be approximately 96.5% complete (27), and therefore constitutes a
reliable and detailed source of information. Through the 'expected cases' look-up
table, the computer model utilises average figures from 1989-1998 to predict the
annual incidence and age/sex distribution of colorectal cancer in the Scottish
population. These figures were the most up-to-date available at the time the model
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was developed, but are obviously slightly dated. Again, the model does not attempt
to project forward cancer incidence data, but rather assumes that the incidence of
colorectal cancer remains constant throughout the run period of the model. It is
possible that incidence will change over the next twenty years, with the current
pattern of increasing incidence and decreasing mortality possibly continuing. Future
interventions, such as national screening using the faecal occult blood test, may also
have an impact on the epidemiology of colorectal cancer. Hence, the assumption that
colorectal cancer incidence will remain constant throughout the period of cascade
genetic testing is not entirely valid.
4.4.3.3.3 Penetrance
The number ofMMR gene mutation carriers expected to develop colorectal cancer
each year is calculated from available data on the prevalence and penetrance of
MMR gene mutations, and is thus subject to the limitations and uncertainty of these
data. Several studies have indicated that penetrance in terms of colorectal cancer is
greater in males than in females (4, 57, 170, 286, 289) and a conservative estimate of
penetrance based on the consensus of these studies is 80% in males and 40% in
females (199). This estimate also reflects the results of the only one of the above
studies that is not biased by family history status, in which penetrance to age 70 was
estimated to be 74% in males and 30% in females (57). Consequently the estimates
of 80% penetrance in males and 40% penetrance in females were used as default
settings for the model, and, with the exception of the complete penetrance setting,
the assumption that penetrance in males was double that in females was made for all
input settings.
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However, the applied estimates of penetrance reflect a consensus based on results
from only a few studies conducted in different populations, and a range of estimates
have been reported (see table 2.2 for details). Statistical evaluations of the accuracy
of these estimates are not reported, but each study is relatively small in terms of the
actual number of mutation earners considered, and the number of these carriers who
have developed colorectal cancer. The low number of index cases included in these
studies also means that the carriers involved may not be representative of all
mutation carriers. Similarly, there is potential for geographical variation in mismatch
repair gene mutations, and therefore the extent to which the specific mutations
considered in previous studies are representative of the Scottish population is
unclear. Furthermore, the ascertainment of these cases, which, with one exception
(57) usually involved family history criteria, creates a further source of bias.
Consequently, the estimates of penetrance used as model inputs cannot be
considered accurate, and model outcomes must be interpreted accordingly.
A related issue is that of competing mortality. The model makes the assumption that
all individuals predicted to develop colorectal cancer on the basis of carrier status
and penetrance estimates will do so, but this is not necessarily the case since they
may die of unrelated causes beforehand. Hence there is a possibility that the
estimates of penetrance used to inform the model may slightly overestimate the true
number of carriers developing colorectal cancer. Another consideration in terms of
'expected cases' arises from the potential for clinical interventions to alter the
number ofMMR gene mutation carriers who actually develop cancer. If a significant
proportion of mutation carriers were undergoing surveillance due to having a strong
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family history of colorectal cancer, the effective penetrance ofMMR gene mutation
in this group may be reduced. However, the inconsistent relationship between family
history and carrier status, and the fact that not all those with a strong family history
are aware of it and actively engaged in clinical surveillance, means that this effect
may not exert a major influence on the number of cases occurring amongst earners.
Inaccuracy of penetrance estimates used to inform the model may result in
systematic bias in model results in comparison to the outcomes of a real-life cascade
genetic testing programme. If the true penetrance ofMMR gene carriers is greater or
less than expected, the number of carriers developing colorectal cancer each year
will differ systematically from the observed model inputs. To some extent, this
possibility is dealt with by the range of penetrance estimates used in the analysis of
the model. Similarly, the assumption that penetrance in males is approximately
double that in females may be incorrect, in which case the number of expected cases
occurring each year will be correspondingly inaccurate compared to real life. Again,
whilst this assumption is made for almost all input settings used in the analysis of
the model presented herein, the model at least retains the capacity to alter penetrance
estimates to determine outcomes over a realistic range, and also to incorporate new
and improved estimates of penetrance obtained from future research.
A further and more complex consideration is that penetrance is likely to vary
according to the mutation in question. There is some evidence to suggest that
penetrance of hMLHl mutations differs from that of hMSH2 mutations (75, 170,
286), and it is possible that penetrance of different mutations within the same gene
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will vary according to their precise site and molecular nature. Hence, the computer
model's assumption that penetrance is constant in all mutation earners may not be
valid.
The impact that variation in penetrance according to the specific mutation involved
may have on model outcomes is difficult to predict. If penetrance varies according to
the mutation involved, then the estimate of penetrance used as a model input can be
considered as the mean of all individual penetrance estimates. However, the clinical
interpretation of model results would be significantly affected if penetrance varied
by mutation. Although the overall number of MMR gene mutation earners
developing colorectal cancer each year may remain constant, the majority of these
cases would be in people with mutations of relatively high penetrance. Conversely,
carriers of low-penetrance mutations are less likely to develop cancer and present to
a cascade genetic testing programme. This may lead to a clinical benefit, since the
people most likely to develop colorectal cancer would be identified early, but it
would result in a decrease in the number of expected cases in MMR gene mutation
carriers, due to the fact that the remaining carriers in the population have a low
penetrance. Such an effect would compound the lack of feedback in the computer
model, which is considered later.
4.4.3.3.4 Prevalence
Data regarding the prevalence ofMMR gene mutations were only available from
one paper by Dunlop et al., 2000 (58). This was calculated using the following
equation, derived from Bayes' theorem, for population carrier frequency:
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Population Carrier Frequency = [(carrier frequency in colorectal cancer patients) x
(population prevalence of colorectal cancer)] / (prevalence of colorectal cancer in carriers)
The values used for carrier frequency in colorectal cancer patients were obtained
from two studies by Aaltonen et al., 1998 (2) and Liu et al., 1995 (173) that
conducted mutation analysis on systematically collected cohorts from Finland and
the USA respectively. These studies in themselves are subject to bias. The observed
carrier frequency in colorectal cancer patients is specific to the population concerned
and thus may not be representative of the Scottish population. In particular, the
Finnish population is noted for a high prevalence of founder mutations. Also,
microsatellite instability was used as a prerequisite to genetic testing in both studies,
potentially resulting in a proportion of earners being overlooked. The population
prevalence of colorectal cancer used in the above expression was obtained from the
Scottish Cancer Registry, and can therefore be considered robust. However, the
prevalence of colorectal cancer in earners was estimated from data on only 48
Scottish MMR gene mutation carriers, seven of whom had developed the condition,
and this estimate is therefore subject to considerable uncertainty.
A further limitation of the available data on the population carrier frequency stems
from the fact that the estimate provided by Dunlop et al., (58) refers to the 15-74 age
group. Intuitively, it seems possible that the prevalence of MMR gene mutations in
the population may decrease with age, due to the relatively high mortality associated
with carrying such a mutation. However, there are no data available concerning the
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age distribution ofMMR gene mutation carriers in the population that might confirm
or disprove this hypothesis, and consequently the assumption that carrier prevalence
remains constant in the 15-74 age group was made for the puipose of the model.
For the reasons outlined above, the population carrier frequency calculated by
Dunlop et al., (58), and subsequently utilised as the default input for the computer
model of cascade genetic testing, can be considered an indication, but not a reliable
estimate, of the population prevalence ofMMR gene mutations . To a large extent,
this is reflected in the wide confidence intervals around the estimate. Accordingly,
this level of uncertainty is incorporated into the model, with the upper and lower
confidence intervals corresponding to the high and low prevalence inputs. However,
due to the limitations and potential sources of bias associated with the prevalence
estimate, it is conceivable that the true prevalence may be outside these inputs.
Again, the estimate of prevalence used in the model settings must be considered as
an assumption, rather than a conclusive input, and the results must be interpreted
with this in mind.
4.4.3.3.5 Cumulative Incidence
As well as the penetrance and prevalence settings themselves, the expected number
of colorectal cancer cases in MMR gene mutation carriers is subject to the
distribution of cumulative incidence obtained from the charts of cumulative
incidence constructed by Dunlop et al., (1997) (57). These charts are calculated from
67 gene carriers from six families and thus may not be representative of the
cumulative incidence in all MMR gene mutation carriers. However, the shape of the
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charts is consistent with the cumulative incidence of a disease with a genetic origin,
and hence the age distribution of expected colorectal cancer cases used as a model
input is considered to be a reasonable, if approximate, estimate of the true
distribution.
4.4.3.3.6 Calculation of 'Expected Cases'
Limitations at this stage are the product of inaccuracies and uncertainty in the above
data, since these data are used to calculate the expected number of cases, as outlined
in the methods section. An additional restriction stems from the lack of detail in
some of the available estimates, specifically from the fact that data relating to
population demographics and colorectal cancer incidence are entered in five-year
age groups. Cumulative incidence of colorectal cancer cases in mutation carriers was
also estimated for each age group, and the average annual incidence over a five-year
period was calculated, as opposed to the actual expected incidence each year.
Consequently, the model lacks precision with respect to the number of colorectal
cancer cases expected, since this estimate depends on the five-year age group of the
individual concerned rather than their exact age. However, this effect is unlikely to
have a significant influence on the model outcomes, particularly in comparison to
the potential influence of other limitations relating to input data quality.
No cumulative incidence data are available for MMR gene carriers over 70 years of
age, and information on prevalence ofMMR gene mutations is unavailable after age
74. Consequently, the model does not consider the possible occurrence of colorectal
cancer in mutation carriers over 70 years of age. This is unlikely to have a major
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effect on the validity of the model outcomes, since the number of MMR gene
carriers developing cancer after the age of 70 is likely to be very small, both in
absolute terms and in relation to the number of sporadic colorectal cancer cases
occurring in this age group. Most age criteria for inclusion in a cascade genetic
testing programme, including default settings for the model, are unlikely to include
patients over the age of seventy due to the large number of sporadic colorectal
cancer cases in elderly people and competing morbidity in this age group. Hence the
lack of data in elderly mutation carriers does not constitute a major limitation of the
computer model in most circumstances.
A lack of feedback in the computer model in relation to the estimation of expected
colorectal cancer cases in mismatch repair gene carriers constitutes a further
important limitation of the calculation of expected cases. In reality, as asymptomatic
mutation carriers are identified in the course of a cascade genetic testing programme,
the number of carriers.remaining in the population will decrease accordingly. For
practical reasons, such feedback is not included in the computer model, although it
constitutes an important aspect of future work. Removing carriers from the
population will exert a self-limiting influence on the yield from cascade genetic
testing, since as the number of unidentified carriers decreases, the expected number
of colorectal cancer cases in this group will also decrease. The magnitude of this
effect depends on the ratio of identified carriers to unidentified carriers.
Extrapolation of data from Dunlop et al., (58), suggests that there are an estimated
1209 (95% CI = 498, 3044) mutation carriers aged 15-74 in the Scottish population.
At default settings, the computer model predicts that 204.8 (95% CI = 192.4, 217.2)
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mutation carriers would be identified through cascade genetic testing after ten years,
and 492.7 (95% CI = 468.9, 516.5) would be identified after twenty years. This
represents a substantial proportion of all mutation carriers in the population. In a real
cascade genetic testing programme, the identification of this number of carriers may
have a significant impact on the number of colorectal cancer cases expected to occur
in the 'unidentified' carrier population. In this respect, the computer model tends to
overestimate the number of index cases that would be identified by cascade genetic
testing, particularly in later years. A feedback 'loop' to account for the removal of
mutation earners from the population as they are identified by the model system will
constitute a vital part of future model development.
4.4.3.3.7 Acceptance Rates
The level of participation on the part of the target population is a crucial factor in
determining outcomes of a cascade genetic testing programme. The computer model
applies a 'probability of participation' algorithm at each of four stages, namely the
probability of initial contact with the system, the probability of attendance at an
interview with a genetic nurse, the probability of accepting genetic testing and the
probability of allowing contact with relatives. This straightforward pattern is broadly
representative of a real-life cascade genetic testing programme. However, the actual
figures utilised by the model for determining the probability of participation at each
stage are subject to error. As discussed previously, although some general
information regarding the acceptance rates of genetic testing is available, data that
relate specifically to MMR gene mutations were available only from the COGS
study. The strategy devised to accommodate the uncertainty surrounding acceptance
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rates in the computer model was to apply deliberately conservative estimates that are
consistent with the COGS data at default settings, and then systematically
investigate the effect of various acceptance rates on model outcomes. At default
settings, the overall acceptance rate of genetic testing in the computer model is 72%,
a rate close to the preliminary estimate of 74% from the COGS study. Data on the
probability that an index case will allow contact with relatives are even more scarce,
although initial experience with the COGS study suggests that refusal at this stage is
very rare. Hence, the acceptance rate of 0.9 applied at default settings is a realistic
yet conservative estimate.
Conservative and simple estimates as inputs in the absence of other reliable data
were adopted in several situations to simplify the model and facilitate
straightforward comparison between various cascade genetic testing programmes
and various input settings. The rationale for this approach is that clarity with respect
to inputs is an important consideration in the evaluation of the model, and that the
use of simple, conservative inputs is preferable to the inclusion of complex estimates
that are not necessarily accurate. Hence, the model is considered to comprise a
realistic representation of the complex process of recruitment in cascade genetic
testing, but the acceptance rates applied may not accurately represent acceptance
rates in a real programme. The model has, however, been designed with the capacity
to incorporate detailed information on acceptance rates, and such data can be utilised
as they become available in the future.
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4.4.3.3.8 Test Parameters
A pre-symptomatic genetic test for a specific mutation is technically very
straightforward to perform using PCR-based methods, and, although there is some
potential for laboratory error, the model's assumption that the sensitivity and
specificity of such a test is 100% is justified. Mutation analysis is far more
complicated, and worthy of further consideration. Essentially, for the purposes of the
computer model, a MMR gene mutation is either present or absent, and will either
be detected by mutation analysis or will not. This, again, is an oversimplification of
reality. Numerous genes are involved in the mismatch repair system, not all of which
have been identified, and various laboratory techniques, each with their own test
parameters, may be applied as part of an overall mutation analysis protocol.
Complete analysis of all known mismatch repair genes may not be possible and the
results may be inconclusive. The potential also exists for misclassification of gene
variants, such that an essentially harmless variant is assigned pathogenic status or
vice versa. Furthermore, as considered previously, a spectrum of pathogenicity may
exist with some gene variants having relatively modest effects on risk of colorectal
cancer.
In many ways it is not appropriate to consider mutation analysis in terms of
sensitivity and specificity, since the actual situation is far more complicated than this
implies. However, once again due to time constraints it was not possible to
incorporate such additional complexity into the model. Accordingly, these test
parameters were assumed to be to 100% throughout the analysis of the computer
model, in order to simplify this part of the model and thus facilitate evaluation of
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other aspects of cascade genetic testing. This assumption is not considered to be
entirely valid, and the possibility that false positive or false negative results could
occur in a real cascade genetic testing programme provides a potential source of
inaccuracy in outcomes from the model system. The capacity to model the process
of mutation analysis in detail, and consider the implications of inaccuracy at this
stage, will form part of future model development.
4.4.3.3.9 Delays
The inclusion of delays at various stages of the model system is essential as these
delays partly determine the chronological nature of the computer model. Where
possible, delays were based on experience with the COGS programme. However,
these delays are a simplified representation of cascade genetic testing in real life,
and as such the timescale of cascade genetic testing as predicted by the model may
not be accurate. The model retains the capacity to adjust these delays to reflect
improved estimates or explore the effects of different delays on model outcomes.
4.4.3.3.10 Summary
In view of the limitations considered above, the current version of the computer
model as considered in this thesis may thus be regarded as a "prototype", and future
work is required to develop a model that provides detailed and accurate predictions
of outcomes from a real-life cascade genetic testing programme. Nonetheless, whilst
the results of the current model must be interpreted with caution, it does constitute a
unique evaluation of the potential application of cascade genetic testing, and has the
capability to provide a considerable body of relevant data for analysis.
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4.4.4 Evaluation of Model Outcomes
4.4.4.1 Default Settings
At default settings, the computer model is designed to provide estimates for the
outcomes of a cascade genetic testing programme in which index cases are identified
through offering mutation analysis to all colorectal cancer cases diagnosed under the
age of 55.
The number of mutation analyses performed over time is directly determined by
colorectal cancer incidence, inclusion criteria and the specified participation rates.
The model predicts that approximately 380 such tests would be completed per year
(not including the first year in which no tests would be completed due to the delay
involved), and that the total number of mutation analyses performed over a 20-year
cascade genetic testing programme would be 7142 (95% CI = 7037, 7250). Using
current laboratory protocols, this represents a substantial amount of work and
involves exposing a large number of colorectal cancer patients to genetic testing.
An average of 171.5 (95% CI = 163.6, 179.4) patients undergoing mutation analysis
were predicted to be MMR gene mutation earners, implying that approximately
2.4% (95% CI = 2.3%, 2.5%) of mutation analyses performed in colorectal cancer
cases diagnosed at less than 55 years of age yielded a positive result. This estimate is
considerably less than that found in the initial stages of the COGS programme, in
which 11% of colorectal cancer cases undergoing mutation analyses were found to
harbour a mutation in hMLHl or hMSH2. There are several possible explanations
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for this difference. Firstly, the COGS data is only preliminary and includes missense
mutations of unclear pathogenicity. The resulting figure of 11% is thus not
necessarily representative of long-term outcomes, and may overestimate the number
of truly pathogenic mutations identified. Conversely, the estimate generated by the
model may be inaccurate, reflecting the limitations of the computer model itself and
the quality of data used to determine inputs.
Published data regarding the proportion of colorectal cancer cases that have a MMR
gene mutation is scarce and so it is difficult to evaluate the external validity of the
computer model in this respect. There are, however, several published studies that
provide such data for colorectal cancer cases occurring under the age of 50 (52, 201,
276, 294, 295, 299, 323), and pooling of these data suggests that 8.9% of these
harbour a mutation in hMLHl or hMSH2 (199). The mean corresponding estimate
produced by the computer model for this age group is approximately 3.9%. This
reinforces the previous observation, based on comparison between the model at
default settings and the COGS study, and implies that the computer model may
underestimate the proportion of colorectal cancer cases that carry a mutation. Whilst
the precise reason for this disparity is not clear, both the estimates provided by the
computer model and those obtained from real-life studies are potentially subject to
bias and errors of an order of magnitude that could account for the observed
differences. Irrespective of the observed disparity, it is apparent that the vast
majority of colorectal cancer patients diagnosed at less than 55 years of age do not
harbour a mismatch repair gene mutation.
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From a clinical perspective, conducting mutation analysis on colorectal cancer
patients is of limited use in the absence of cascade genetic testing, since, although
identification of a mutation may prompt intensive screening and help prevent
metachronous malignancies, it is inherently too late to prevent colorectal cancer. In
the context of cascade genetic testing, where the primary aim is the identification of
asymptomatic mutation earners, mutation analysis can be considered as a sacrifice
in terms of time and resources, which is necessary to identify index cases.
In comparison to the number of mutation analyses performed over time, the number
of pre-symptomatic tests predicted to be performed during a twenty-year cascade
genetic testing programme is small, averaging 849 (95% CI = 812, 886). Hence, at
the population level, the impact of cascade genetic testing on asymptomatic
members of the population is minimal, since only a tiny proportion of the population
will be offered genetic testing. This observation illustrates one of the major
advantages of cascade genetic, testing over the alternative options for identifying
asymptomatic carriers in a population. Population-wide genetic testing would
inherently involve offering genetic testing to the entire population, with the number
undergoing testing limited only by participation rates. Similarly, population genetic
testing stratified on the basis of family history would necessitate testing a large
proportion of the population. Extrapolation of the estimate of 9.4% for people with a
history of colorectal cancer in a first degree relative, presented in chapter 4, to the
Scottish population implies that nearly 250,000 people aged 30-70 would be offered
testing if this criterion was used to determine eligibility for stratified genetic testing.
Hence, both these approaches would involve conducting genetic testing in a much
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larger proportion of the ostensibly healthy population, as compared to cascade
genetic testing. The number of people offered genetic testing, and thus having to
decide whether or not to participate, would also be much larger.
Theoretically, an exponential effect with respect to the cumulative number of pre-
symptomatic tests performed may be anticipated, since cascade genetic testing
involves offering genetic testing to an increasing number of family members as the
mutation is traced through various relatives causing an expansion of pedigrees. Such
an effect is evident in figure 4.3.22, but is very subtle. The probable reason for this
is that the small size of sibships and the incomplete acceptance of genetic testing
assumed by the computer model combine to limit the expansion of pedigrees
through cascade genetic testing. The consequence of this would be that cascade
genetic testing in a particular pedigree will be halted after one or two rounds of
genetic testing, and hence all the relatives that will be tested for a particular index
case will be tested within a short space of time.
Figure 4.3.22 shows that the average number of asymptomatic carriers predicted by
the model to be identified during a 20-year cascade genetic testing programme at
default settings was 321.2 (95% CI = 305.3, 337.1). Figure 4.4.1 illustrates the
overall impact of a 20-year cascade genetic testing programme on the carrier
population, as predicted by the computer model at default settings.
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Figure 4.4.1 Involvement of Mutation Carrier Population In Cascade
Genetic Testing at Default Settings
NB: All percentages refer to the percentage of all asymptomatic mutation carriers (i.e. 100*n
/ 1209). The number of carriers diagnosed with colorectal cancer and the number
undergoing genetic testing are taken directly from summary model outputs; other values
were subsequently calculated only for the purpose of figure 4.4.1, using the assumption of
90% acceptance amongst people offered genetic testing. Hence it was not possible to
calculate confidence intervals for the majority of values displayed in this figure and these are
provided for numbers accepting genetic testing only. Abbreviation: CI, confidence interval.
The above figure indicates that 45.4% of all mutation carriers will be offered genetic
testing over the course of a 20-year cascade genetic testing programme, and implies
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that 26.6% of all carriers will be offered testing whilst asymptomatic. However, as
discussed previously, the model makes the assumption that index cases are
unrelated, and accordingly that relatives identified as carriers through cascade
genetic testing have not developed colorectal cancer themselves. In reality, some
relatives of index cases will have a personal history of colorectal cancer, and
consequently the estimated yield of cascade genetic testing provided by the
computer model, in terms of the number of genuinely asymptomatic carriers
identified, may be an overestimate.
Nonetheless, although limitations in terms of accuracy apply to estimates from the
model, it is apparent that a significant proportion of mutation carriers in the Scottish
population may be identified through cascade genetic testing at an asymptomatic
stage. Offering and applying clinical surveillance to this group may significantly
reduce their risk of colorectal cancer, and thus contribute towards the prevention of
colorectal cancer at the population level. The actual health benefits that would result
from the identification of a sub-group ofMMR gene mutation carriers, in terms of
colorectal cancer prevention and overall mortality, are difficult to assess accurately.
A recent controlled trial found that the incidence of colorectal cancer over a 15-year
period in MMR gene carriers undergoing colonoscopic screening was 18%,
significantly less than the 41% incidence observed in carriers that did not undergo
screening (130). This provides support for the hypothesis that the identification and
screening ofMMR gene mutation earners provides a means of preventing colorectal
cancer in this sub-group of the population, yet also illustrates another issue that may
limit this approach; namely, that health benefits are conditional on compliance with
306
screening. Thus, at the population level, any reduction in morbidity and/or mortality
that is associated with identification ofMMR gene earners will depend not only on
the number of carriers concerned, but also on their age/sex distribution, the
effectiveness of screening and the extent of compliance. The computer model does
not, at present, have the capacity to consider these additional issues.
Ultimately, whether or not a cascade genetic testing programme is justifiable or
desirable will depend on the costs involved in the identification of mutation carriers
and their follow-up, as well as the health benefits that are expected to accrue. As
mentioned previously, an economic evaluation of cascade genetic testing is outwith
the scope of the computer model. The model is, however, designed to inform the
planning of cascade genetic testing through the estimation of the yield of a particular
cascade genetic testing programme and the resources required to achieve this. The
relationship between these two key outcomes constitutes a crucial consideration in
the context of planning the implementation of cascade genetic testing at the
population level.
Throughout the results section, the number of asymptomatic mutation carriers
identified per mutation analysis performed is used as an estimate of the relative
efficiency of the cascade genetic testing programme in question. This is an inexact
measurement of efficiency, but does provide a useful indication of the resources
expended in the implementation of a cascade genetic testing programme in
comparison to the yield. This estimate rises steeply over the first two years of
cascade genetic testing, reflecting the year-long delay applied to conducting
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mutation analysis. After this point, the ratio of number of asymptomatic earners
identified to mutation analyses performed continues to increase at a slower rate,
peaking at 0.0449 (95% CI = 0.0429, 0.0469) after twenty years. This observation
suggests that cascade genetic testing becomes relatively more efficient the longer the
programme lasts for, lending support to the notion that cascade genetic testing
should be viewed as a long-term strategy for identifying MMR gene mutation
carriers. It is evident, however, that cascade genetic testing at default settings is not
very efficient in terms of the ratio of yield to mutation analyses performed, with over
20 such tests being required to identify one asymptomatic mutation earner even in a
mature cascade genetic testing programme.
In the model system, pre-symptomatic tests are offered to first and second-degree
relatives of known carriers. Hence, people undergoing pre-symptomatic testing will
be at a 50% or 25% risk of harbouring a mutation themselves. The observation that
the proportion of pre-symptomatic tests with a positive result was 0.38 (95% CI =
0.37, 0.39) thus implies that the ratio of first to second-degree relatives undergoing
genetic testing is approximately 1:1. This high proportion of positive tests is one of
the main advantages of cascade genetic testing, which is that relatives of known
carriers form a sub-group of the population at an extremely high risk of harbouring a
MMR gene mutation and thus present an ideal target for genetic testing.
4.4.4.2 Prevalence
Results provided by the computer model and presented in figures 4.3.29, 4.3.30 and
4.3.31 illustrate the major impact that the true prevalence of MMR gene mutations in
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the Scottish population is likely to have on the outcomes of cascade genetic testing.
Outcomes from the model at high and low prevalence settings differ considerably
from outcomes at default settings with respect to the number of index cases
identified. This in turn leads to significant differences in the number of pre-
symptomatic tests performed and the overall yield of cascade genetic testing. The
model predicts that the increase in yield associated with higher prevalence would be
achieved with only a minor effect on the total number of mutation analyses required,
as shown in figure 4.3.28, and that consequently the relative efficiency of cascade
genetic testing is positively correlated with prevalence. This latter point is illustrated
in figure 4.3.31. The true prevalence ofMMR gene mutations in the population is
thus a vital consideration in any assessment of the utility of cascade genetic testing.
It is noteworthy that differences in prevalence do not, in theory, affect the proportion
ofMMR gene mutation carriers that are detected through cascade genetic testing.
There is clearly a need for precise information on the population prevalence of
MMR gene mutations. For the purposes of planning cascade genetic testing, this
should be specific to the population in question and should ideally be obtained
directly from mutation analysis in randomly selected control subjects. At present
such information is unavailable, largely due to the cost involved in mutation
analysis. Improvements in laboratory technology, and the resources provided by
large-scale programmes designed to obtain and analyse DNA from numerous
healthy population controls (e.g. UK Biobank), may facilitate the gathering of such
data in the future. An updated prevalence estimate based on COGS data will also be
calculated as part of future work and incorporated into the computer model.
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4.4.4.3 Penetrance
Alterations in penetrance ofMMR gene mutations can be predicted to have a similar
effect to prevalence on the yield and relative efficiency of cascade genetic testing,
since higher penetrance will also result in a greater number of earners developing
colorectal cancer each year with a relatively minor increase in the overall number of
mutation analyses required. Figure 4.3.33 illustrates the predicted magnitude of this
effect on yield. In comparison with default settings, complete penetrance is predicted
to result in an additional 200 asymptomatic mutation earners being identified over a
twenty-year period. The model also predicts that if true penetrance was only half the
default estimates (i.e. 0.4 in males and 0.2 in females), 160 fewer asymptomatic
carriers would be identified, a reduction of approximately half. However, whilst
uncertainty remains over the true penetrance ofMMR gene mutations, the vast
majority of studies in this area have concluded that penetrance is incomplete (3, 4,
57, 289), and hence the high yield predicted by the model under the assumption of
complete penetrance is unrealistic. Similarly, the penetrance is unlikely to be as low
as 0.8 in males and 0.4 in females. A further consideration is that penetrance is a
major factor in determining the appropriateness and extent of surveillance.
Therefore, the identification of carriers of low penetrance mutations may not be
considered appropriate.
Overall, the model predicts that penetrance will have a significant impact on the
yield and efficiency of cascade genetic testing. When considered within probable
boundaries, disparity between current estimates and true penetrance is likely to
result in a difference in predicted yield of up to approximately 100 in either
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direction. The magnitude of such differences are not as great as those caused by
realistic variations in the prevalence estimate, but are highly relevant in terms of
planning and implementing a real cascade genetic testing programme.
4.4.4.4 Age Limits
The age criteria for inclusion in any cascade genetic testing programme directly
determine the number of mutation analyses that are required. Because early onset is
a feature of colorectal cancer of hereditary origin, the proportion ofMMR gene
mutation carriers in a sub-group of colorectal cancer cases selected on the basis of
age will increase as the age cut-off for inclusion is decreased. The resultant increase
in the efficiency with which index cases are identified as part of a cascade genetic
testing programme is counterbalanced by a decrease in the overall yield.
The necessity for applying some degree of age criteria to the ascertainment of
colorectal cancer cases is amply illustrated by figure 4.3.35, which shows that
approximately 42,500 mutation analyses would be required over twenty years if no
such criteria were applied, at a rate of over 2100 per year. The resources and lime
required to conduct this number of tests are likely to be prohibitive. No difference is
evident between the mean number of index cases predicted to be identified at default
setting and with no age cut-off. Although repeated simulations may reveal a
statistically significant difference in this regard, the model clearly shows that
undertaking mutation analyses in colorectal cancer cases over the age of 55 is not
likely to substantially increase the number of index cases identified as part of a
cascade genetic testing programme. The model also predicts that limiting the age
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cut-off value to less than 55 would result in considerably fewer mutation analyses
being required. However, even a five-year decrease in age cut-off would result in a
small but significant reduction in the number of index cases identified. The inherent
trade-off between yield and efficiency that occurs when age limits are applied in this
context is clearly evident in figure 4.3.38, which shows that the relative efficiency of
cascade genetic testing is inversely proportional to the age limits applied.
Ultimately, deciding on which age criteria to apply to a cascade genetic testing
programme is a pragmatic decision that must be made according to the resources
available, and must also consider the appropriateness of offering testing to older
colorectal cancer cases who are comparatively unlikely to harbour a MMR gene
mutation. The default setting for age cut-offs of 55 years initially came from the
COGS study, and the computer model supports the use of this value in the sense that
it appears to facilitate the ascertainment of the vast majority of colorectal cancer
cases with MMR gene mutations whilst keeping the number of mutation analyses
performed to manageable levels.
4.4.4.5 Acceptance Rates
The level of participation on behalf of the target population is crucial to any genetic
testing strategy, yet it is one of the most difficult aspects of cascade genetic testing
to predict. The probability of an individual undergoing genetic testing may depend
on numerous factors. Some of these, like age, sex and the context in which testing is
offered, can be accommodated by the current model. Other factors that may
influence acceptance include family history, ethnicity, social class, awareness of
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genetic testing programmes and knowledge of colorectal cancer. The latter two
factors in this list are of particular interest as they can potentially be manipulated
through education and publicity generated in connection with a cascade genetic
testing programme. Whilst the probability of participation at various stages of
cascade genetic testing should ideally consider the above factors and be calculated
specifically for each individual, inclusion of this level of detail is restricted by the
paucity of relevant data and is currently outwith the scope of the model.
With all other variables, including other acceptance rates, being constant, the
predicted number of mutation analyses performed is directly related to the
acceptance rate of genetic testing by eligible colorectal cancer cases, and the
predicted number of index cases identified will vary accordingly. However, as
illustrated by figures 4.3.39 and 4.3.40, the family-based nature of cascade genetic
testing will serve to exaggerate the effect of genetic test acceptance at this stage, if
acceptance rates also apply to relatives of index cases. In a real-life setting,
acceptance rates for index cases and relatives will probably differ, since the risk of
having a mutation, the manner of approach and the situation (asymptomatic
individual or cancer patient) will be entirely different. However, it is possible that
external factors such as knowledge of colorectal cancer and awareness of the
cascade genetic testing programme may influence acceptance rates of both potential
index cases and relatives of mutation carriers.
In the cascade genetic testing system represented by the computer model, the major
resource investment is required for the identification of index cases, whereas the
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yield is crucially dependent on the actual process of tracing a mutation through
asymptomatic individuals in the pedigree of a known carrier. Therefore, whilst yield
is affected by the acceptance rate of genetic testing amongst both potential index
cases and relatives of known carriers, the predominant effect on efficiency will stem
from the acceptance rates amongst relatives. This point is illustrated in figures 4.3.42
and 4.3.43. In practical terms, this observation suggests that ensuring high
participation amongst relatives should be of the highest priority.
A problem specific to cascade genetic testing arises from the possibility that a
known mutation carrier will not consent to their relatives being contacted. The
computer model predicts that this effect will lead to a reduction in both the yield and
the efficiency of cascade genetic testing, with the magnitude of the effect being
determined by the probability of allowing contact (see figures 4.3.44 & 4.3.45).
Accordingly, the procedure for obtaining consent to contact relatives, and the rate at
which such consent is forthcoming, may have implications for the utility of cascade
genetic testing.
4.4.4.6 Delays
As demonstrated in the results section, delays in the model system affect the time
taken to achieve certain model outcomes. However, such delays will have limited
influence on the overall utility of the model system, and are mostly significant from
a clinical perspective, rather than being a major consideration in terms of the
outcomes of a cascade genetic testing programme. Additional resources may be
employed to reduce delays in comparison with the default estimates obtained from
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the COGS study. Additionally, future advancements in the technology used to
conduct genetic testing may reduce the time required for this process. However, the
incidence rate of colorectal cancer in the population will remain the primary limiting
factor in terms of the timescale of any cascade genetic testing programme based on
identifying index cases by targeting a sub-set of colorectal cancer patients.
4.4.4.7 Resources
The 'resources' component of the computer model provides the capacity to
determine the requirements of a particular cascade genetic testing programme. The
computer model demonstrates that inadequate resources at any stage can potentially
cause a 'bottleneck' effect, whereby the entire programme is delayed. Estimates
from the computer model are thus theoretically useful as a guide to the actual
resources required by a particular cascade genetic testing programme. For example,
it is apparent from figure 4.3.50 that a programme at default settings must have the
capacity to conduct up to ten mutation analyses per week. Of course, as with other
model outcomes, such estimates are subject to the limitations of the computer model
outlined above, and must be interpreted with caution. In reality, it is unlikely that
resource allocations would be entirely static. It is conceivable, for example, that a
base resource designed to conduct five mutation analyses but with the capacity to
stretch to ten when necessary would be adequate in the above circumstance. Overall,
the model confirms the intuitive notion that the provision of a minimum resource
level is crucial to the effective application of cascade genetic testing, but that
increasing resources beyond the demand threshold will have no effect on outcomes.
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4.4.5 Conclusions
The methods used for developing a computer model of cascade genetic testing are
appropriate and the overall approach has been found to be highly effective.
Limitations with respect to the input estimates and scope of the model mean that the
model outcomes are subject to considerable uncertainty and potential bias,
precluding the direct interpretation of these outcomes as accurate and reliable
predictions of cascade genetic testing in a real-life situation. However, whilst the
quantitative estimates provided by the computer model must be interpreted with
caution, the computer model provides a detailed and realistic representation of
cascade genetic testing, and the broad conclusions and observations obtained from
the model are thus of relevance to understanding and planning the implementation of
this strategy.
The computer model broadly supports the prior hypothesis that cascade genetic
testing is potentially both feasible and effective as a means of identifying
asymptomatic MMR gene mutation carriers in the Scottish population. At default
settings, the model outcomes suggest that approximately 27% of all mutation
carriers in the population will be identified in the course of a 20-year cascade
genetic testing programme. The actual number of asymptomatic mutation earners
identified is predicted to total approximately 321.2 (95% CI = 305.3, 337.1).
Applying colonoscopic surveillance to a group of mutation carriers of this size may
confer significant health benefits at the individual and group level, and would
potentially make a minor contribution towards the prevention of colorectal cancer in
the population. To achieve this yield, the model predicts that around 7142 mutation
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analyses would be required, which constitutes a major investment in terms of the
time and resources involved.
The application of age limits to the ascertainment of colorectal cancer cases is a
logical approach, since a relatively low proportion of older patients are likely to
harbour MMR gene mutations. In this context, adjustment of the age limits
facilitates the manipulation of the relationship between the yield from a cascade
genetic testing programme and the number of mutation analyses required as part of
that programme. Lowering the age limits decreases the yield but improves the
efficiency, and vice versa. Outcomes from the model suggest that an age limit of 50
or 55 may represent an appropriate balance between yield and efficiency. Decisions
regarding the age limits applied in a real cascade genetic testing programme could
be informed by the model, but would be made on a pragmatic and subjective basis.
The computer model demonstrates that various other factors, including prevalence,
penetrance and the acceptability of cascade genetic testing to the population
concerned, will have a significant impact on yield and relative efficiency of cascade
genetic testing. This emphasises the need for accurate data regarding these factors.
The current unavailability of such data presents a considerable challenge to the
evaluation of any strategy for identifying asymptomatic MMR gene mutation
carriers, as well as limiting the utility of the computer model. In the absence of
accurate and reliable input estimates, a broad spectrum of possible outcomes are
predicted by the computer model, depending on the conditions under consideration.
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The computer model is designed to provide quantitative estimates to inform
decisions regarding the potential implementation of cascade genetic testing, and is
not intended to make such a decision itself. Ultimately, the utility of cascade genetic
testing must be judged in terms of the acceptability, effectiveness and cost of the
interventions available for mutation earners, as well as on the feasibility and cost of
the cascade genetic testing process itself. There is some direct evidence to suggest
that interventions in mutation earners can lead to prevention of colorectal cancer in
this group (130). It can thus be inferred that cascade genetic testing may be
justifiable in the above terms, but the limitations of the current model preclude a
conclusion in this regard.
Cascade genetic testing approaches the identification ofMMR gene mutation
carriers from the family perspective, as well as at the individual level. In this respect,
identification of a mutation-carrying family may have beneficial effects beyond the
timescale of the active cascade genetic testing programme, since specific genetic
testing could theoretically be offered to family members in the future. Genetic
testing of relatives of known earners can potentially benefit both mutation carriers,
who can be offered the appropriate level of clinical screening, and non-carriers, who
can be reassured regarding their genetic risk of colorectal cancer, and removed from
existing screening protocols.
The computer model only considers the identification of index cases through genetic
testing of colorectal cancer patients. In reality, however, a cascade genetic testing
programme applied to the Scottish population would be run against the background
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of cancer genetic services. Mutation carriers identified through presentation to
cancer genetic services with a strong family history of colorectal cancer could
potentially be incorporated into a cascade genetic testing programme. The
integration of these two strategies for identifying mutation carriers may constitute an
ideal approach to cascade genetic testing.
4.4.6 Future Work
Outcomes from the current computer model provide a degree of insight into the
potential outcomes of cascade genetic testing, with a chronological component
permitting the assessment of the likely time-scale for this strategy. However, various
limitations exist, both in the structure of the model and in the input estimates used to
inform it. Hence the current model provides relevant data for analysis as part of this
thesis, but in the wider context must be viewed as a prototype of an accurate
computer model with practical applications.
Improved input estimates, a realistic method of generating pedigrees and defining
the interrelatedness of mutation carriers, and a consideration of mutation analyses
performed as part of clinical genetic services are required to provide truly accurate
estimates relating to the outcomes of cascade genetic testing. Further work is thus
necessary to address these limitations, as indicated in preceding sections of the text.
Additionally, the flexibility inherent in the methods used for model development
provide the capacity to adapt the current model to evaluate cascade genetic testing in
any complex disease in which a sub-set of cases have a known genetic aetiology and
for which effective interventions are available. On this premise, a two-year project
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grant has been sought and obtained from the Chief Scientist Office (CSO) to pursue
the further development of the current computer model of cascade genetic testing.
The proposal for this grant is presented for reference in appendix A9.
Although the COGS programme is not designed to evaluate cascade genetic testing
directly, it does involve the recruitment and genetic testing of families of known
mutation carriers. This process is funded by an additional grant, and ethics approval
was obtained in August 2003. Over the next few years, the COGS programme will
provide valuable and unique information regarding important aspects of cascade
genetic testing, including the acceptance rates of genetic testing among patients and
various relative groups, the time-scale of genetic testing, and the laboratory and
administrative costs involved. In addition, data from the COGS programme will
provide the opportunity to calculate estimates of the prevalence and penetrance of
mismatch repair gene mutation that are robust and specific to the Scottish
population.
The COGS programme has also generated detailed pedigree information relating to
colorectal cancer cases and mutations carriers. This real data will be utilised to
simulate realistic pedigrees as part of the computer model. This will build on
previous pedigree simulation work conducted by co-investigators on the CSO
project grant (187), and will ensure that the family structures used in the model
mirror the real-life situation.
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Thus, the future development of the computer model will be integrated with the
COGS programme. The model will initially reflect cascade genetic testing as it is
currently being applied as part of this ongoing research. This will facilitate a high
degree of external validation, since the predictions generated by the model can be
compared with actual findings from the COGS programme. Subsequently, input
estimates will be manipulated within realistic boundaries to investigate the effects of
altering various model parameters. The combination of domain expertise, 'real' data,
and an iterative development strategy involving continual re-evaluation and revision
of the model, will thus facilitate the expansion of the model to the extent where it
constitutes a full and realistic representation of cascade genetic testing for mismatch
repair gene mutations. Conversely, the computer model will have the capacity to
generate long-term estimates of the likely outcomes of the COGS programme, and
will thus inform future planning of this and related programmes.
The next step in model development will be to investigate the adaptability of the
model by applying it to other complex conditions in which pathogenic mutations arc
known to cause a proportion of cases. The identification of mutations in the breast
cancer genes BRCA1 and BRCA2 presents an ideal candidate for such an
investigation, since the genetic epidemiology of this condition has been extensively
studied. Application of the computer model to investigate the use of cascade genetic
testing in breast cancer will be conducted in a similar fashion to that outlined above.
Inputs relating to breast cancer epidemiology, and the prevalence and penetrance of
BRCA1/BRCA2 mutations etc. will be taken from the available literature. It is also
intended to incorporate aspects of the "genlSYS" project, funded by the CSO and
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undertaken by the Image Systems Engineering Laboratory at Heriot-Watt
University, with the aim of modelling breast cancer genetic risk analysis. Resulting
model outcomes will be evaluated in the context of current knowledge about these
genes.
Subsequently, it will be possible to apply the computer model to various other
clinical situations, the only restriction being the availability of realistic input data.
Once again, the model will be re-evaluated based on its response to different inputs,
and will be adjusted accordingly if appropriate.
Ultimately, the completed computer model is intended to serve as a valuable tool for







The central tenet of this thesis is that the identification of people at increased genetic
risk of colorectal cancer, and the subsequent provision of appropriate clinical
screening, provides an opportunity to reduce the incidence of colorectal cancer in
this sub-group of the population, and consequently to contribute to the overall
prevention of colorectal cancer in Scotland. At present, family history assessment
and genetic testing for mismatch repair gene mutations constitute the two principal
strategies for identifying individuals at increased genetic risk of colorectal cancer.
Both approaches have been applied in the research context and in the clinical setting.
However, current understanding of the associations between family history,
mismatch repair gene mutations and risk of colorectal cancer is limited, and thus
optimisation of strategies for people at increased genetic risk remains an ongoing
challenge. The research presented within this thesis endeavours to contribute to
current knowledge and understanding of the strategies available for identifying
people at increased genetic risk of colorectal cancer in the Scottish population.
5.2 Family History Assessment
Family history has traditionally been the mainstay of genetic risk assessment, and it
remains an integral part of current practice in clinical cancer genetics. The research
presented in chapter 3 demonstrates the potential utility of family history as a means
of identifying people at increased genetic risk, yet also illustrates some of the
associated limitations and practical difficulties of this approach. This research
confirms that family history is a significant risk factor for colorectal cancer in the
Scottish population. The prevalence of a family history of colorectal cancer in the
324
general population of Scotland is shown to be high, with 9.4% of population controls
aged 30-70 years having an affected first degree relative. These findings imply that
people with a family history of colorectal cancer constitute a large sub-group of the
Scottish population who are at significantly increased genetic risk, yet also
emphasise the scale of the task of identifying and screening this group. The inherent
limitations of genetic risk assessment based on family history are further
compounded by the considerable degree of under-reporting and inaccuracy in family
history information observed in data obtained at interview.
5.3 Genetic Testing for Mismatch Repair Gene Mutations
Genetic testing for predisposition to colorectal cancer, excluding very rare cancer
syndromes such as Familial Adenomatous Polyposis, has become available
relatively recently, following the implication of mismatch repair gene mutations in
the aetiology of a sub-set of colorectal cancer cases. As illustrated by the literature
review described within this thesis, such genetic testing also has considerable
advantages and disadvantages as a strategy for identifying people at increased
genetic risk of colorectal cancer. Mismatch repair gene mutation carriers are at a
very high risk of developing the disease compared to the rest of the population, and
thus constitute an important subgroup. However, genetic testing for mismatch repair
gene mutations is expensive and time-consuming at present, necessitating the
targeting of such analyses to individuals at high risk of carrying a mutation. This
drawback stems from the extreme heterogeneity of mismatch repair genes. The fact
that interpretation of gene variants remains somewhat subjective is a further
concern. Such specific issues relating to mismatch repair genes apply in addition to
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more general considerations regarding the practical and ethical application of
genetic testing at the population level.
5.4 The Evaluation of Cascade Genetic Testing
In light of the above limitations of family history, and the high risk associated with
mismatch repair gene mutations, it is apparent that identifying carriers of such
mutations and providing appropriate clinical screening in this sub-group of the
population constitutes a key aspect of the prevention of colorectal cancer through
targeting individuals at increased genetic risk. Presently, the cost and time-
consuming nature of conducting mutation analysis, coupled with the remaining
uncertainty surrounding the interpretation of gene variants, precludes conventional
population genetic testing for mismatch repair gene mutations. Population genetic
testing stratified by family history provides another approach, but substantial
resources would still be required, and the limitations of family history information
outlined above and considered throughout this thesis are also applicable in this
context. As an alternative to these options, cascade genetic testing currently
represents the most realistic approach to identifying mismatch repair gene mutation
carriers in the Scottish population. The main advantage of this approach is that
genetic testing is restricted to people with a high probability of carrying a mismatch
repair gene mutation and relatives of known carriers.
The major barrier to the systematic implementation of cascade genetic testing is the
lack of data to inform the planning of an appropriate programme. The computer
model developed and analysed as part of this thesis provides some relevant data to
326
help address the gaps in current knowledge of cascade genetic testing. The methods
employed, based on visual object-orientated modelling, were appropriate and
effective, facilitating a smooth transition from conceptual model to functional
model, and finally to a working version. Data obtained as part of the systematic
literature review described in chapter 2 was crucial to the conceptual construction of
a computer model, and provided quantitative estimates to inform the model inputs.
The use of real data from the ongoing COGS study to provide other key input
estimates helped ensure the realistic nature of the computer model.
At default settings, the computer model constitutes a realistic representation of a
cascade genetic testing system for identifying mismatch repair gene mutation
carriers in the Scottish population. Model outcomes predict that approximately 27%
of carriers in the population will be identified at an asymptomatic stage during a
twenty-year cascade genetic testing programme. The model also demonstrates the
major effect that penetrance and population prevalence of mismatch repair genes are
likely to have on outcomes of cascade genetic testing, further emphasising the need
for further studies into the genetic epidemiology of mismatch repair gene mutations.
Additionally, the model predicts that outcomes from cascade genetic testing will be
heavily influenced by acceptance rates and the age criteria for recruiting colorectal
cancer cases. These are vital considerations in the planning of any cascade genetic
testing programme.
Outcomes generated by the computer model generally support the hypothesis that
cascade genetic testing is a potentially useful and effective strategy for identifying
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asymptomatic mismatch repair gene mutation earners in the Scottish population.
However, the model is subject to various limitations in scope and detail, as well as
inaccuracies arising from the poor quality of data available to inform input
estimates. Consequently, further work is required to address these limitations and
ensure that the outcomes from the computer model are sufficiently accurate to
inform future planning and implementation of cascade genetic testing.
Cascade genetic testing provides an ideal framework for integration of the dual
approaches of family history and genetic testing as tools for identifying people at
increased genetic risk of colorectal cancer. Individuals with a family history,
whether ascertained through clinical cancer genetics services or as part of a
population-based intervention, can potentially be incorporated into a cascade genetic
testing programme as possible mutation carriers. Asymptomatic individuals
presenting to clinical cancer genetics services who meet certain family history
criteria are currently eligible for genetic testing. This provides a clear alternative
route into a hypothetical cascade genetic testing programme, and incorporating this
process into the computer model is a priority for future work.
Conversely, cascade genetic testing has the potential to contribute towards the
optimisation of strategies aimed at people with a family history of colorectal cancer.
This conclusion is based on the principle that identifying a pathogenic mutation in
an individual and subsequently testing family members for that mutation will allow
elucidation of risk on an individual basis within a family. Hence, mutation carriers
can be offered the intensive clinical screening warranted by this status, and non-
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carriers could be reassured as to their personal risk and removed from screening.
Effectively, this type of approach is already in use in the clinical setting, and this
process may be enhanced through the systematic application of cascade genetic
testing.
The computer model is currently designed to evaluate cascade genetic testing in
relative isolation, whereas in reality this strategy must be considered in the context
of ongoing clinical cancer genetics services and possibly the presence of alternative
strategies for colorectal cancer prevention such as population-wide faecal occult
blood testing. Economic considerations relating to the cascade genetic testing
programme and the impact of such a programme on clinical services such as
colonoscopy are likely to dictate whether or not cascade genetic testing is feasible,
and determine the precise programme applied. At present, the computer model does
not have the capacity to consider these factors directly, although data obtained from
the model can be used to inform such considerations. Crucially, however, the
methods used to develop the computer model are highly flexible, ensuring that
additional considerations can be included in the model at a later stage.
The flexible and adaptable nature of the computer model also ensures that future
advances in understanding of the genetic epidemiology of colorectal cancer can be
incorporated into future versions. The model could be adapted to consider other
genes implicated in the aetiology of colorectal cancer, and improved knowledge of
the influence of genetic and environmental modifiers of risk mediated by mismatch
repair gene mutations could also be accommodated. Additional quality data
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regarding the prevalence and penetrance of mismatch repair gene mutations, and
other factors such as acceptance rates, can be directly added to the model via the
user interface.
Although the model is designed to represent cascade genetic testing for mismatch
repair gene mutations, it is also sufficiently adaptable to potentially represent other
genes and other clinical situations. This raises the possibility of applying the
computer model to any complex disease in which causative genetic mutations have
been identified. The broader application of the computer model of cascade genetic
testing is a secondary consideration in the context of this thesis, but constitutes a
vital feature of future model development.
5.5 The Population Impact of Strategies for Colorectal Cancer
Prevention in People at Increased Genetic Risk
The identification of mismatch repair gene mutation earners and the provision of
appropriate screening forms a key element of an overall approach for preventing
colorectal cancer through targeting those at increased genetic risk. Devising and
implementing an appropriate strategy for achieving this may confer significant
health benefits to this subgroup of the population. At the population level, however,
the identification and screening of mismatch repair gene mutation carriers would
have only a very minor impact on the overall incidence of colorectal cancer in the
Scottish population. Moreover, the majority of people at increased genetic risk will
not have a mismatch repair gene mutation. Therefore, strategies based on accurately
establishing family history of colorectal cancer, and providing clinical screening
accordingly, are essential to meet the needs of such people.
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Although the magnitude of risk associated with a family history of colorectal cancer
is less than that associated with mismatch repair gene mutations, this increased risk
applies to a relatively large sub-group of the population. Hence the population
impact of interventions aimed at people with a family history may be comparatively
large. However, the numerous limitations of family history information, including
the practical difficulties and potential inaccuracies inherent in obtaining such data,
are such that population-based strategies to identify people at increased genetic risk
of colorectal cancer through assessment of family history may not be appropriate at
present. Additionally, clinical cancer genetic services already address the needs of
people who are concerned about their family history, and the benefits of identifying
and screening additional people, who may not be aware of or concerned about their
family history, are unclear.
Strategies for people at increased genetic risk form just one approach to the
prevention of colorectal cancer. Absolute risk is the crucial consideration in the
context of secondary prevention through the provision of appropriate clinical
screening, and hence strategies aimed at older members of the general population arc
highly relevant. From a public health perspective, primary prevention of colorectal
cancer achieved through the adoption of a healthy lifestyle and diet is an ideal means
of reducing the burden of colorectal cancer in Scotland. Nonetheless, people at
increased genetic risk constitute a large and important sub-group of the Scottish
population, and the targeting of such people represents an important aspect of an
overall strategy for colorectal cancer prevention.
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5.6 Summary
The conclusion of this thesis is that cascade genetic testing for mismatch repair gene
mutations merits further evaluation as a potential strategy for addressing the needs
of people at increased genetic risk of colorectal cancer. Integration of this approach
with ongoing clinical cancer genetics services based on family history currently
represents an appropriate framework for developing and improving strategies for
prevention of colorectal cancer in people at increased genetic risk. The research
presented herein contributes to the information available to facilitate this goal, but
further research relating to the molecular genetic epidemiology of colorectal cancer
and the utility of family history is required to determine the optimal approach to
identifying such people. Ultimately, targeting people at increased genetic risk of
colorectal cancer has the potential to provide substantial health benefits to a small
sub-group of the population, and thus to make a minor contribution to the overall
prevention of colorectal cancer in Scotland.
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Appendix A1 Cancer Genetics Guidelines for Scotland: Risk
Stratification for Colorectal Cancer
Low Medium High
Risk Stratification
• anyone not fulfilling medium or high
risk criteria
Risk Stratification
• One 1st degree relative affected
by colorectal cancer when aged
<45yrs
• Two (one affect at less than
55yrs), one a 1st degree relative of
subject
• Three affected with colorectal
or endometrial cancer who are 1st
degree relatives of each other and
one a first degree relative of
subject
• Two affected Is1 degree relatives
(one affected at lees than 55yrs)
Risk Stratification
• Gene carriers of HNPCC mutation
• Untested lsl degree relatives of
gene carriers
• People with a family history
compatible with HNPCC
Counselling
Individuals deemed at low risk will be
informed either by:
• Telephone consultation with a
genetic nurse associate, followed by
a letter with a copy to GP, or
• Face to face consultation with the
genetic nurse associate and then by
letter to the patient and the GP
Counselling
Individuals deemed to be at
medium risk will be counselled
by the genetic counsellor
Counselling
Individuals deemed to be at
medium risk will be counselled by
the clinical genetic physician
Management
• Reassurance
• Healthy lifestyle advice
• Advise to report any changes
• Return to GP care
Management
Screening:
• Colonoscopy at 30-35 yrs, if
findings are normal this need not
be repeated until 55 yrs of age
• Incomplete colonoscopy should
be followed by a barium enema,




• Colonoscopy every 2 yrs from age
30, of 5 yrs younger than the
youngest affected, up until the age
of 70
• Dicussion of prophylactic surgery,
if recurrent polyps arc identified
• Consideration needs to be given
to screening for other cancers that




• Should ideally be available to all
high-risk families
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Evidence to support a role for the mismatch repair genes human mutL homolog 1 (hMLHI) and human mutS
homolog 2 (hMSH2) in the etiology of colorectal cancer has come from linkage analysis, segregation studies, and
molecular biologic analysis. More recently, carriers of potentially pathogenic mutations in the hMLH1/hMSH2
genes have consistently been shown to be at a greatly increased risk of developing colorectal cancer compared
with the general population. When considered together, the available evidence shows a strong, consistent, and
biologically plausible association between mismatch repair gene mutations and colorectal cancer. The
penetrance of mutations in hMLH1/hMSH2\s incomplete and is significantly higher in males (approximately 80%)
than in females (approximately 40%). To date, evidence for gene-gene or gene-environment interactions is
limited, although preliminary studies have revealed a number of avenues that merit exploration. Population
screening for mutation carriers is not currently a feasible option, and mutation analysis remains restricted to either
relatives of mutation carriers or colorectal cancer cases selected on the basis of phenotype.
colorectal neoplasms; epidemiology; genetic screening; germ-line mutation; hMLH1\ hMSH2, penetrance;
survival
Abbreviations: hMLHI, human mutL homolog 1; hMSH2, human mutS homolog 2; HNPCC, hereditary nonpolyposis colorectal
cancer; MSI, microsatellite instability.
INTRODUCTION
The mismatch repair genes human mutL homolog 1
(hMLHI) and human mutS homolog 2 (hMSH2) are integral
components of the DNA mismatch repair pathway. So far,
over 200 allelic variants have been identified for each gene,
and the majority of these have been reported to be patho¬
genic in terms of colorectal cancer. The primary objectives
of this review are to describe what is known about liMLIII
and hMSH2 and their variants in different populations and to
examine the evidence implicating these genes as risk factors
in the development of colorectal cancer. Relevant Internet
sites are listed in appendix 1.
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United Kingdom (e-mail: Harry.Campbell@ed.ac.uk).
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TABLE 1. Commonly observed pathogenic mutations in persons with colorectal cancer









Exon 16 3.5-kilobase deletion 63 Finland 62
Exon 16 Deletion of AAG at nucleotide
1846
In-frame deletion in lysine
codon 616
21
IVS* 5 g-a at nucleotide 4541 Out-of-frame deletion in
exon 6 codon 152182
18 Finland 15
Exon 16 AA-GC at nucleotide 1852 Lys618Ala 15
Exon 4 C-T at nucleotide 350 Thr117Met 12
Exon 19 G-A at nucleotide 2146 Val716Met 12
Exon 13 Insertion of C at nucleotide 1490 Frameshift from codon 497 10
Exon 4 T-G at nucleotide 320 lle107Arg 7 Finland 7
Exon 13 C-T at nucleotide 1459 Arg487STOP 7
Exon 17 C-T at nucleotide 1975 Arg659STOP 7
Exon 19 G-A at nucleotide 2141 Trp714STOP 6
Exon 8 C-T at nucleotide 676 Arg226STOP 6
Exon 2 G-A at nucleotide 199 Gly67Arg 5
Exon 2 C-T at nucleotide 184 Gln62STOP 5
IVS 14 4-base-pair insertion/3-base-pair




IVS 5 a-t at nucleotide 942+3 In-frame deletion in exon 5 46 Newfoundland 10
Exon 6 G-A at nucleotide 965 Gly322Asp 32





Exon 7 C-T at nucleotide 1216 Arg406STOP 6
* hMLHl, human mutL homolog 1; IVS, intervening sequence; hMSH2, human mutS homolog 2.
GENERAL METHODOLOGY
Search strategy
The MEDLINE (National Library of Medicine),
EMBASE (Excerpta Medica), and CANCERLIT (National
Cancer Institute) databases were searched for papers
published before December 31, 2001, using the keywords
hMSH2 and hMLHl. Relevant papers were identified, criti¬
cally appraised, and entered into a Reference Manager (ISI
ResearchSoft, Berkeley, California) database. In addition,
PubMed was searched via Reference Manager, by author
name, for papers from research groups that had published
several times on this subject. Finally, the database thus
created was cross-referenced with papers cited in the Inter¬
national Collaborative Group on Hereditary Nonpolyposis
Colorectal Cancer database of mutations (1).
For the "Gene variants" section, we considered a total of
109 papers, which were identified by the above strategy and
fulfilled the following selection criteria: 1) complete mutation
analysis had been performed on more than five patients with
colorectal cancer and 2) there was sufficient detail on the
molecular nature of the genetic alteration. Details on all gene
variants described in these published papers are given in the
first supplementary table, which is posted on the website of
the Human Genome Epidemiology Network (http://
www.cdc.gov/genomics/hugenct/default.htm), as well as on
the Journal's website (http://aje.oupjournals.org/).
For the "Associations" section, the above strategy led to
the identification of eight studies that had conducted an anal¬
ysis of the risk of developing colorectal cancer among
carriers of mismatch repair gene mutations and 77 papers
that included results of complete mutation analysis
performed on more than five colorectal cancer patients
selected on the basis of family history, microsatellite insta¬
bility (MSI), or age of onset. These studies arc summarized
in table 2 and the second supplementary table, respectively.
Many papers included information relevant to both gene
variants and associations.
Classification of gene variants
For the purposes of this review, we classified gene variants
into one of four categories. These categories are loosely
based on the definitions given below, modified according to
clinical observations.
1. Pathogenic mutation—generally framcshifts, nonsense
mutations, and splice variants
2. Probable pathogenic mutation—generally nonconscrva-
tive amino acid changes
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3. Probable polymorphism—generally conservative changes,
often observed in controls
4. Definite polymorphism—synonymous variants
GENE
hMSH2
The hMSH2 gene is located at chromosome 2p21, an area
initially identified as an important candidate region for genes
involved in hereditary nonpolyposis colorectal cancer
(HNPCC) syndrome by genetic linkage analysis within large
affected families (2, 3).
The hMSH2 protein product is a component of the DNA
mismatch repair pathway, the role of which is well estab¬
lished in bacteria and yeast. liMSH2 can form a heterodimer
with one of two other mismatch repair proteins, hMSH6 or
hMSH3. This protein complex recognizes and binds any
errors that may have occurred during DNA replication, and a
larger protein complex is then recruited to excise the incor¬
rect daughter sequence and replace it with the correct
sequence, using the parental strand as a template. In Escher¬
ichia coli, mutS has been implicated in both short- and long-
patch repair systems (4).
hMLH1
The hMLHl gene is located at chromosome 3p21—23, an
area also identified by genetic linkage analysis as an impor¬
tant candidate region within large HNPCC families that are
not connected with the chromosome region 2p2l-22 (5, 6).
The hMLHl protein product is another component of the
DNA mismatch repair pathway, and it has been shown to
form a heterodimer with hMLH3, hPMS2, or hPMSl. The
hMLHl protein has no known enzymatic activity and prob¬
ably acts as a "molecular matchmaker," in that it recruits
other DNA repair proteins to the mismatch repair complex.
Again, the bacterial homolog of hMLHl has been implicated
in both short- and long-patch repair (4).
GENE VARIANTS
One conclusion generated by early attempts to identify
precise genetic alterations in hMLHl and hMSH2 was that
variants in these genes are extremely heterogeneous. All 16
exons of the hMSH2 gene and 19 exons of the hMLHl gene
have been found to contain pathogenic mutations.
At present, there are no standard criteria for classifying
variants as pathogenic mutations or polymorphisms, and
consequently there is considerable variation in interpretation
by different researchers. In general, categorization of alter¬
ations is based on the predicted effect on protein, with segre¬
gation of the mutation with colorectal cancer in the kindred
in question and/or analysis of control subjects for that
specific mutation also being considered when possible.
However, the functional consequences of many mutations
are difficult to predict accurately. It has been suggested that
even alterations that do not affect the amino acid sequence
could lead to aberrant splicing, and that the position of the
mutation may be more significant than the type (7). In vitro
functional assays have been developed and applied to the
task of determining the pathogenicity of missense mutations
(8-10) and may eventually facilitate accurate classification
of such changes.
The first supplementary table lists all of the gene variants
identified as part of this review, illustrating the extreme
range of mutations identified and the fact that the observed
spectrum of mutation is not entirely uniform. Figures l^t
summarize some features of this table. Figures 1 and 2 illus¬
trate the distributions of unique gene variants that have been
fully characterized at the molecular level in hMLHl and
hMSH2, respectively, according to their position on the
gene. Figures 3 and 4 are designed to show the actual
numbers of families in which pathogenic mutations have
been identified.
In total, 259 different pathogenic mutations, as defined
above, have been identified in liMLHl, along with 45 poly¬
morphisms. In hMSH2, 191 different pathogenic mutations
and 55 polymorphisms have been characterized so far. This
high degree of heterogeneity is similar to that found in the
breast cancer genes BRCA1 and BRCA2, in each of which
over 400 gene variants have been reported. When consid¬
ering the range and type of gene variants listed in the first
supplementary table, there arc several important sources of
bias that merit consideration. Firstly, a significant publica¬
tion bias is likely to exist in favor of apparently pathogenic
alterations. Highly penetrant mutations arc also likely to be
overrcprcscntcd, since many studies involved conducting
mutation analysis in patients selected on the basis of a strong
family history of colorectal cancer. Secondly, genomic dele¬
tions in mismatch repair genes appear to occur relatively
commonly, particularly in hMSH2, and such variants are not
detected by many of the techniques commonly used for
mutation analysis (11).
It is evident from the above figures that certain specific
mutations have been identified in more than one kindred.
Indeed, some mutations arc found with a relatively high
frequency. The most commonly observed mutations are
summarized in table 1, which displays all mutations identi¬
fied in more than four ostensibly independent kindreds.
The observed spectrum of gene variants may be largely
due to genuine differences in the mutability of specific
nucleotides or sequences within the gene, but in some cases
variants identified in apparently unrelated kindreds can be
traced to a common ancestor. Such "founder effects" have
been identified in the Finnish population, where two
specific founder mutations in hMLHl account for the vast
majority of families in which mismatch repair gene muta¬
tions have been identified (12, 13). Another hMLlll
founder effect is evident in the Danish population (14). The
extent to which founder effects arc responsible for other
frequently detected alterations is not entirely clear from the
data currently available, and it is likely that some of the
kindreds included in the first supplementary table share a
common ancestor. Interestingly, the intervening sequence 5
variant A-T at nucleotide 942+3 has been shown to occur
as a founder mutation in Newfoundland (15), but another
study found no evidence for a common haplolypc in 10
carriers of this variant, of various origins, and concluded
that the mutation also arises frequently dc novo (16). This
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FIGURE 1. Distribution of unique gene variants in the mismatch repair gene hMLH1. The figure illustrates the distribution of all unique gene vari¬
ants that have been identified and fully characterized in mutation analysis studies of colorectal cancer patients. Variants designated as categories
1, 1/2, 2, and 2/3 in the first supplementary table are considered to be pathogenic for the purpose of this summary figure, and all other variants are
described as polymorphisms. Exon deletions in which the underlying molecular variant was not known were excluded. IVS, intervening sequence.
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FIGURE 2. Distribution of unique gene variants in the mismatch repair gene hMSH2. The figure illustrates the distribution of all unique gene
variants that have been identified and fully characterized in mutation analysis studies of colorectal cancer patients. Variants designated as cate¬
gories 1, 1/2, 2, and 2/3 in the first supplementary table are considered to be pathogenic for the purpose of this summary figure, and all other
variants are described as polymorphisms. Exon deletions in which the underlying molecular variant was not known were excluded. IVS, interven¬
ing sequence.
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FIGURE 3. Distribution of gene variants in the mismatch repair gene hMLH1 by the number of families affected. The figure illustrates the dis¬
tribution of pathogenic mutations according to the actual number of families in which a pathogenic mutation has been identified. These figures
include all pathogenic mutations as defined in figure 1, plus exon deletions of unspecified origin. Deletions of more than one exon were excluded.
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FIGURE 4. Distribution of gene variants in the mismatch repair gene hMSH2 by the number of families affected. The figure illustrates the
distribution of pathogenic mutations according to the actual number of families in which a pathogenic mutation has been identified. These
figures include all pathogenic mutations as defined in figure 2, plus exon deletions of unspecified origin. Deletions of more than one exon were
excluded. Families are deemed to have a "founder mutation" if they have a mutation which has been shown to have a founder effect in the
same population.
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example underlines the notion that observations of muta¬
tion frequency are the result of both the probability of a
mutation at a given nucleotide and the demographic history
of the population in question.
Overall, little ethnic or population variation is apparent
from the available gene variant data. However, the current
biases towards highly penetrant mutations are such that the
effect of the identified mutation is likely to transcend any
population differences. Clearly, there is a need for accurate
and extensive population-based data before any population
differences in the spectrum and frequency of mismatch
repair gene variants become apparent.
There is no clear evidence to suggest that any specific
mismatch repair gene mutation produces a specific pheno-
type of colorectal cancer, although it has been suggested that
some differences exist between the spectrum of extracolonic
cancers associated with HMSH2 mutations in comparison
with hMLHl mutations (17, 18).
DISEASE
Colorectal cancer is a major public health problem world¬
wide, with a current annual incidence approaching 950,000
cases (19). Colorectal cancer is more common in males than
in females, and in both sexes the incidence rate increases
with advancing age. Incidence rates vary globally and are
about four times higher in developed countries than in devel¬
oping countries (20). While incidence rates do vary
according to ethnicity (21), there is compelling evidence that
the observed variation between countries is primarily due to
the role of environmental factors. This hypothesis is
supported by the rising incidence of colorectal cancer in
populations undergoing rapid economic development, with
associated "westernization" of diet and lifestyle. Further
evidence for a strong environmental influence comes from
migrant data; despite the relatively low incidence of
colorectal cancer in Japan, incidence rates in Hawaiian Japa¬
nese are among the highest in the world (22).
Considerable effort and resources have been expended
with the aim of elucidating the precise dietary and other vari¬
ables responsible for the observed environmental influences
on colorectal cancer incidence. A report commissioned by
the World Cancer Research Fund and the American Institute
for Cancer Research concluded that evidence was sufficient
to suggest that colorectal cancer risk could be substantially
reduced by adhering to a diet high in vegetables and low in
meat, together with regular physical activity and avoidance
of alcohol (23). Other reviews have reached similar conclu¬
sions (24), but some studies have failed to provide evidence
to uphold the hypothesis that dietary modification can
prevent colorectal cancer. Clinical intervention studies (25,
26) and observational cohort studies (27), as well as studies
utilizing animal models (28, 29), have shown no evidence of
polyp prevention related to diet. Nonetheless, polyp preven¬
tion may not be the best endpoint, so results of further clin¬
ical studies with cancer prevention as the endpoint are
awaited.
Both epidemiologic evidence and experiments utilizing
murine models have suggested that nonsteroidal antiinflam¬
matory drugs have antitumor properties that may prevent
colorectal cancer. Sulindac has been shown to inhibit tumor
growth in experimental systems and to reduce adenoma
counts in humans with familial adenomatous polyposis (30),
as has a recent study of the specific cyclooxygenase-2 inhib¬
itor celecoxib (31).
A number of case-control and cohort studies have reported
an association between hormone replacement therapy and
colorectal cancer, with the majority of these providing
evidence in favor of a protective effect (24). Accumulating
evidence also implicates obesity as a risk factor for
colorectal cancer (32), and a positive association may exist
between colorectal cancer and diabetes (33, 34). The weight
of evidence also suggests that smoking may be a significant
risk factor (35).
Colorectal cancer is a multifactorial condition, and while
environmental factors are clearly important in the etiology of
the disease, there is a significant input from genetic factors.
A recent study of twins provided evidence suggesting that
about 35 percent of all colorectal cancer cases have a genetic
component (36), and first-degree relatives of colorectal
cancer patients are well-recognized to have a 2- to 4-fold
increased risk of developing the disease themselves. The
genetic factors involved are poorly understood and may
include recessive genes, pathogenic mutations of low pene¬
trance, and complex gene-gene and gene-environment inter¬
actions.
In addition to the less obvious genetic factors, two autoso-
mally inherited cancer syndromes account for a significant
minority of colorectal cancer cases. Familial adenomatous
polyposis is a rare syndrome caused by mutations in the
adenomatous polyposis coli gene and is characterized by the
presence of multiple adenomas. In the HNPCC syndrome,
affected kindreds have an unusually high occurrence of
colorectal and certain extracolonic cancers, with a relatively
early age of onset. HNPCC has traditionally been diagnosed
on the basis of family history, and the various criteria used
for defining HNPCC are summarized in appendix 2. For
research purposes, the Amsterdam criteria are the most
widely used, and by this definition of HNPCC, the syndrome
may account for 2-5 percent of all colorectal cancer cases.
It has been established that a large proportion of families
diagnosed with HNPCC harbor potentially pathogenic muta¬
tions in mismatch repair genes. Of the mutations identified
so far, over 90 percent occur in hMLHl and hMSH2.
HNPCC families in which mutations in hMLHl and hMSH2
are not identified may harbor pathogenic mutations in other
mismatch repair genes, such as I1MSH6 and HPMS2, or in
genes as yet unidentified. Pathogenic mutations in hMLHl
or hMSH2 have also been identified in kindreds that do not
meet the traditional criteria for diagnosis of HNPCC. This
observation may be due to the inherent misclassification bias
involved in diagnosing a condition on the basis of family
history alone, particularly in small families.
ASSOCIATIONS
Evidence implying and supporting a causal role for
hMLHHhMSH2 in colorectal cancer comes from both epide¬
miologic studies and laboratory-based molecular studies, as
summarized in figure 5. Initially, linkage studies revealed
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FIGURE 5. Pathways of epidemiologic and biologic research identifying and confirming the causal role of the mismatch repair genes hMLH1
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that disease expression in a proportion of HNPCC kindreds
was linked to either chromosome 2p21 (2, 3, 37) or chromo¬
some 3p21-23 (5, 6, 37, 38).
The connection between the HNPCC syndrome and
mismatch repair arose from the observation that the majority
of tumors from HNPCC families exhibited a replication error
phenotype, a feature resulting from instability of microsatel¬
lite repeats during replication that is found only in a minority
of "sporadic" colorectal cancer cases (39, 40). Previous
molecular studies in the yeast Saccharomyces cerevisiae had
led to the identification of a group of genes, known as
mismatch repair genes, that were involved in maintaining the
fidelity of DNA replication. Defects in yeast mismatch
repair genes led to MSI, prompting formulation of the
hypothesis that human homologs of these genes were
involved in the HNPCC syndrome (41). Subsequently,
several such homologs were identified, and two of them,
hMLHl and UMSH2, were shown to reside on chromosomes
3p21-23 and 2p21, respectively (2, 42-44). Further
supportive evidence came from the observation that patho¬
genic mutations in hMLHl or hMSH2 could be identified
and shown to segregate with disease in a high proportion of
kindreds that had shown linkage to the corresponding chro¬
mosome (2, 43, 44).
The heterogeneity of mutations in mismatch repair genes
means that screening for mutations in these genes is a
lengthy and complicated process. Consequently, for purely
economic, practical, and ethical reasons, mutation analysis
has been carried out almost exclusively among colorectal
cancer patients, particularly those identified as being at high
risk of harboring mutations. Only two studies identified in
this review conducted mutation analysis among control
subjects. Farrington et al. (45) found that none of 26 Scottish
blood donors harbored previously identified mutations,
although four variants of unknown significance were found.
This was compared with the identification of potentially
pathogenic mutations in 14 of 50 colorectal cancer patients
diagnosed at less than 30 years of age. Similarly, no patho¬
genic mutations were reported in an analysis of 73 popula¬
tion controls from Utah (46).
Thus, the practical restrictions on mutation analysis,
coupled with the low population prevalence of mismatch
repair gene mutations and the fact that such mutations are
found only in a minority of colorectal cancer patients, has
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meant that traditional cohort and case-control study designs
have not been feasible. However, despite this lack of
conventional epidemiologic evidence, subsequent studies
have provided convincing evidence to support the hypoth¬
esis that mismatch repair gene mutations cause a subset of
colorectal cancer cases.
The most compelling supportive evidence comes from
studies which demonstrate that mutation carriers are at
greatly increased risk of developing colorectal cancer in
comparison with the general population. Such studies are
summarized in table 2. Aarnio et al. (47) calculated a stan¬
dardized incidence ratio of 68 (95 percent confidence
interval: 56, 81) for Finnish carriers of hMLHl or hMSH2
mutations. In the other studies identified in table 2,
researchers did not make a formal calculation of the stan¬
dardized incidence ratio, but approximate estimates utilizing
appropriate cancer registry data consistently show that the
risk of colorectal cancer in mutation carriers is greatly in
excess of the corresponding risk in the general population
(see table 2). The relative risk of 8.1 (95 percent confidence
interval: 3.5, 15.9) for first-degree relatives of mutation
carriers observed by Millar ct al. (48) is consistent with a risk
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* Males: penetrance in males only; Females: penetrance in females only; Females + Males: penetrance in group comprising both sexes,
t HNPCC, hereditary nonpolyposis colorectal cancer; hMLH1, human mutL homolog 1; hMSH2, human mutS homolog 2; N/A, not applicable;
CI, confidence interval; EUCAN, European Network of Cancer Registries.
X Where EUCAN data have been used for comparison, the estimate of the standardized incidence ratio is a crude one and does not take into
account the age structure of the mutation carrier group. Because of the approximate nature of this comparison, we did not consider it
appropriate to calculate confidence intervals for these estimates.
that is an order ofmagnitude greater in mutation carriers than
in noncarriers.
The clinical presentation of colorectal cancer among muta¬
tion carriers appears to differ from that found among persons
with sporadic cases in several respects, an observation that
indirectly supports the hypothesis that mutations in
mismatch repair genes account for a distinct subset of
colorectal cancer cases. The most obvious clinical character¬
istic associated with colorectal cancer among mismatch
repair gene mutation carriers is familial aggregation. Part a
of the second supplementary table, which is available on the
website of the Human Genome Epidemiology Network
(http://www.cdc.gov/genomics/hugenet/default.htm) and the
Journal's website (http://aje.oupjournals.org/), provides
details on mutation analysis studies conducted among
patients selected on the basis of family history. The results of
these studies are summarized in tables 3 and 4. The observed
prevalence of potentially pathogenic mutations in individ¬
uals meeting the Amsterdam criteria is remarkably consis¬
tent across different populations (table 4).
MSI is evident in 12-15 percent of sporadic colorectal
cancer cases, compared with over 90 percent of cases
defined, according to the Amsterdam criteria, as being from
HNPCC kindreds (49). MSI is currently thought to result
from defective mismatch repair, although evidence to
support this hypothesis is limited by two factors. Firstly, the
vast majority of studies that examine mutations in MSI-posi-
tive patients concentrate on HNPCC families, introducing
considerable bias. Secondly, few investigators look system¬
atically for mutations in patients with MSI-ncgativc tumors.
Interestingly, when this has been done, there have been a few
instances in which tumors from patients with identified
mutations in hMLHl or HMSH2 have not exhibited (he MSI
phenotype (45, 50, 51). Analysis of all published results
from one research group showed that, among kindreds with
suspected HNPCC, germlinc mutations could be detected in
TABLE 3. Association between the extent of family history of colorectal cancer and the prevalence of














(ref. no. from current review)
No. % No. %
Fulfillment of the
Amsterdam criteria
27 534 145 27.2 87 16.3 (18, 50, 57, 93-116)
Strong family history not
fulfilling the Amsterdam
criteria
25 494 46 9.3 43 8.7 (18, 50, 57, 94, 96-101, 103-106,
108-118)
* See appendix 2.
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16 out of 22 colorectal cancer patients with MSI-positive
tumors, as compared with one out of 37 mutations in MSI-
negative patients (52). The presence of mutations in MSI-
negative cases may reflect mechanisms of tumorigenesis in
people with mismatch repair gene mutations that do not
require mutation instability. Mutation analysis studies
involving patients selected on the basis of MSI are summa¬
rized in the second supplementary table, part b.
The association between early age of colorectal cancer
onset and hMLHlthMSH2 gene mutations is often
confounded by the fact that the selection criteria have
included family history, but a few studies have performed
mutation analysis on patients selected solely on the basis of
early age of onset. As is illustrated in table 5, these studies
demonstrate a trend towards a higher pathogenic mutation
detection rate in individuals diagnosed at a relatively young
age, an observation that is consistent with the hypothesis that
these genes are involved in colorectal cancer tumorigenesis.
Details on the studies considered in table 5 can be found in
the second supplementary table, part c.
Penetrance
While it has become widely accepted that mutations in the
mismatch repair genes liMLHl and hMSH2 play a causal
role in a subset of colorectal cancer cases, the precise penc-
TABLE 4. Results of mutation analysis in patients fulfilling the Amsterdam criteria* for colorectal










Japan 15 1 8 Bai et al. (94)
Japan 11 5 0 Miyaki et al. (107)
Japan 4 0 1 Nomura et al. (109)
Korea 25 8 0 Han et al. (100)
Total 55 14 (25.5%)
Europe
9 (16.4%)
Russia/Moldavia 7 1 3 Maliaka et al. (106)
Sweden 21 5 1 Tannergard et al. (112) and Wahlberg et al. (113)
Sweden 7 1 0 Liu et al. (104)
Switzerland 10 3 3 Buerstedde et al. (95)
Switzerland
. 15 .6 4 Heinimann et al. (57)
Switzerland 14 10 0 Hutter et al. (101)
Italy 14 4 3 Pensotti et al. (110)
Italy 18 1 2 de Leon et al. (98)
Italy 17 5 2 Viel et al. (119)
Italy 17 2 3 Curia et al. (97)
Italy 13 3 3 Calistri et al. (96)
France 10 3 2 Dieumegard et al. (99)
France 3 2 0 Wang et al., 1997 (114)
France 22 11 3 Wang et al., 1999 (120)
Holland and Norway 92 25 16 Wijnen et al. (116)
Germany 57 11 4 Lamberti et al. (103)
England 17 3 5 Froggatt et al. (93)
Total 344 96 (27.9%)
Australia
54 (15.7%)
Australia 18 4 2 Kohonen-Corish et al. (102)
Australia 33 11 9 Scott et al. (18)
Total 51 15 (29.4%)
North America
11 (21.6%)
USA 12 4 2 Luce et al. (105)
USA 28 10 1 Syngal et al. (111)
Canada 14 2 5 Bapat et al. (50)
Total 54 16 (29.6%) 8 (14.8%)
* See appendix 2.
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TABLE 5. Association between age at onset of colorectal cancer and mismatch repair gene mutations
Qf hMLH1 mutation hMSH2 mutation
A™ index carriers carriers Published reference(s)
<30 1 50 7 14 7 14 Farrington et al. (45)
<40 1 12 1 8.3 1 8.3 Syngaletal. (111)
<45 1 38 1 2.6 2 5.3 Fornasarig et al. (121)
<50 6 135 6 4.4 6 4.4 Dieumegard et al. (99), Montera et al. (122),
Tomlinson et al. (123), Wang et al., 1997 (114),
Wang et al., 1999 (120), Weber et al. (124), and
Yuan et al. (118)
trance of these mutations remains unknown. A number of
studies, summarized in table 2, have addressed this issue.
Results are presented differently for each study, so direct
comparison is difficult. One consistent finding is that risk is
higher among male mutation carriers (approximately 80
percent by age 70 years) than among females (approximately
40 percent by age 70 years), an observation with important
implications for patient management and surveillance.
Observed differences in penetrance between carriers of
hMLHlov hMSH2 mutations (53, 54) await confirmation in
future studies.
A study by Aarnio et al. (47) classified relatives of clini¬
cally defined HNPCC cases as being al a 25 percent, 50
percent, or 100 percent risk of being mutation carriers and
calculated the cumulative incidence of colorectal cancer up
to age 70 years as being 100 percent and 54 percent for males
and females, respectively. A potential source of bias in this
particular study is the fact that the majority of the probands
had one of the Finnish founder mutations. A similar study
carried out in Amsterdam Dutch kindreds calculated risk of
colorectal cancer among mutation carriers at age 75 years to
be 92 percent in males and 83 percent in females (55).
These studies used family history as a selection criterion,
an approach that introduces considerable ascertainment bias.
Kindreds identified in this way will inherently have an
unusually large number of colorectal cancer cases, and esti¬
mates of penetrance obtained in this way are likely to be
falsely high. Dunlop et al. (56) used an alternative approach
to identify mutation-carrying probands from the Scottish
population, performing mutation analysis on colorectal
cancer patients with a very early age of onset (<30 years).
The cumulative incidence of colorectal cancer among rela¬
tives proven to be mutation carriers was found to be 74
percent in males and 30 percent in females at age 70 (56).
Note that the identification of families with mismatch
repair gene mutations using any phenotypic selection criteria
introduces ascertainment bias, and such kindreds may not be
representative of all mutation-carrying families in the
general population. Thus, there is a considerable need for
estimates of penetrance based on systematically collected
familial or population data.
Survival
Prior to the identification of mismatch repair genes,
several studies suggested that the prognosis for patients with
colorectal cancer due to HNPCC was more favorable than
that for patients with sporadic colorectal cancer. Whether
improved prognosis is specifically a feature of colorectal
cancer in patients harboring mismatch repair gene mutations
is not yet clear, although preliminary evidence suggests that
this may be the case (57, 58).
A possible explanation for this phenomenon may be that
the high frequency of mutations characteristic of mismatch
repair-deficient tumors actually restricts tumor growth (58).
However, kindreds included in survival analysis studies on
the basis of a strong family history of colorectal cancer have,
by definition, survived to produce a large family group for
analysis. Therefore, these kindreds may not be representa¬
tive of all mutation carriers, and there is a need for survival
data from unselected, population-based cohort studies.
It has also been postulated that mismatch repair deficiency
may have an effect on response to chemotherapy. Results are
not entirely consistent, but several studies suggest an associ¬
ation between hMLHI/hMSH2 deficiency in cell lines and
resistance to chemolherapcutic agents (59-62).
INTERACTIONS
While the exact penetrance of specific mutations in
liMLHI and hMSH2 is unknown, it is not complete. Conse¬
quently, the age-related risk, pathologic features, and
outcomes associated with such mutations arc subject to
modification by other genetic and environmental factors.
The body of epidemiologic data regarding modification of
disease resulting from mismatch repair gene mutations is
somewhat limited. The effects of known environmental risk
factors for colorectal cancer in mutation carriers are largely
unstudied, and much of the suggestive evidence for interac¬
tions comes indirectly from studies using MSI-posilivc or
clinically defined HNPCC cases as a surrogate for mutation
carriers. Furthermore, the apparent presence of a statistical
interaction between mismatch repair gene mutations and
other genetic or environmental factors does not necessarily
imply the existence of a biologic or causal interaction.
Therefore, the studies considered below do not constitute
evidence for true interactions involving hMLH1 and liMSII2,
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although they may prove useful in terms of identifying
potential interactions that merit further investigation.
Gene-environment interactions
Reports by Ruschoff et al. (63) and Yamamoto et al. (64)
have suggested that treatment of hMLHl- or hMSH2-defi¬
cient cell lines with nonsteroidal antiinflammatory drugs
leads to a significant reduction in the proportion of cells
exhibiting MSI, indicating that this phenotypic manifesta¬
tion of mismatch repair deficiency may be modified by these
drugs.
Slattery et al. (65) have presented evidence suggesting that
an interaction may exist between MSI and smoking.
Compared with patients with MSI-negative tumors, patients
with MSI-positive tumors were more likely to be heavy
smokers: Odds ratios were 1.6 (95 percent confidence
interval: 1.0, 2.5) in men and 2.2 (95 percent confidence
interval: 1.4, 3.5) in women (65). These results are supported
by those of another recent study (66), and the implication
that smoking is specifically associated with a particular
subset of colorectal cancer cases is consistent with the weak
associations reported between smoking and sporadic colon
cancer. It is possible that mismatch repair deficiency is
involved in the observed association between smoking and
MSI, but further studies involving known mutation carriers
will be required to confirm this hypothesis.
Another recent paper by Slattery et al. (67) showed that the
risk of MSI-positive colon cancer may be reduced by estro¬
gens and increased by estrogen withdrawal.
Dietary heterocyclic aromatic amines are another risk
factor that requires further evaluation. Wu et al. (66) found
that patients with MSI-positive tumors had received a rela¬
tively high dietary exposure to heterocyclic aromatic amines,
an observation that remained significant after adjustment for
smoking and red meat intake. This finding is consistent with
laboratory studies, which have shown that rats exposed to
particular heterocyclic amines showed the trait of MSI (68).
Gene-gene interactions
Risk of colorectal cancer among female hMLHl/hMSH2
mutation carriers is approximately half the risk in male
mutation carriers (47, 56). In the absence of clear evidence of
hormonal influence, the presence of a genetic modifier, X-
linked or otherwise, remains a possibility.
The possibility of interaction between mismatch repair
genes and other genes known to influence colorectal cancer
susceptibility is an area that merits consideration. Initial
studies have suggested that genes involved in carcinogen
metabolism might modify the phenotypic expression of
mismatch repair gene mutations. For example, Moisio et al.
(69) demonstrated that a specific polymorphism in the gene
encoding the xenobiotic enzyme iV-acetyltransferase 1 was
associated with a lower age of colorectal cancer onset in
Finnish HNPCC kindreds with identified mutations in
hMLHl. Similarly, an alteration in cyclin D1 has been asso¬
ciated with earlier age of onset in HNPCC cases; patients
who harbor the mutant cyclin D1 allele develop cancer an
average of 11 years earlier than patients with two wild-type
alleles (70).
Murine studies have demonstrated that MSH2 deficiency
accelerates intestinal tumorigenesis in transgenic mice that
are heterozygous for a germline mutation in the adenoma¬
tous polyposis coli gene (71). Similarly, Toft et al. (72) have
used mice mutant for both MSH2 and p53 to demonstrate
interaction between these genes. Additionally, in-vitro
studies have suggested that interactions may exist between
mismatch repair genes and transforming growth factor-p
receptor II (73). While these molecular studies demonstrate
that gene-gene interactions may be worth further investiga¬
tion, the above hypotheses have yet to be tested in human
populations for relevance to cancer susceptibility.
LABORATORY TESTING
The heterogeneity of mutation types found in hMLHl and
hMSH2 has meant that many different techniques have been
employed to test for mutations in these genes. A number of
techniques are described below, along with their benefits and
disadvantages.
In vitro synthesized protein assay
The in vitro synthesized protein assay technique uses an in
vitro system to transcribe and translate a large polymerase
chain reaction product containing several exons. The trans¬
lated product is separated on a polyacrylantidc gel electro¬
phoresis system, and potential mutations arc identified as
truncated bands. These may represent a number of mutations
that have the effect of altering splicing, therefore producing
a translated fragment with certain exons deleted. Out-of-
frame deletions or insertions, resulting in framcshifts or
splice variants, will also be detected using this method.
In vitro synthesized protein assay does not delect missensc
mutations, in-frame deletions or insertions, large genomic
deletions involving numerous exons, promoter mutations, or
mutations that silence the gene. The assay also requires the
use of mRNA for the production of a cDNA polymerase
chain reaction product.
Genomic sequencing
cDNA sequencing also relies on mRNA being available. It
will identify all mutation types except large genomic dele¬
tions, promoter mutations, and gene silencing mutations.
Genomic sequencing detects even fewer changes than cDNA,
but it does have the advantage of only requiring genomic
DNA. Table 6 shows a comparison of the sensitivity of the
two techniques, in vitro synthesized protein assay and
genomic sequencing, as described by Farringlon et al. (45).
DNA structure techniques
A number of techniques rely on changes in DNA structure
created by a mutation. These include denaturing gradient gel
electrophoresis (74), including the adaptation of using two-
dimensional gel electrophoresis (75), single-strand confor-
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TABLE 6. Sensitivity of mutation detection techniques
Sensitivity (%) Published reference
In vitro synthesized protein assay 69 Farrington et al. (45)
Genomic sequencing 80 Farrington et al. (45)
In vitro synthesized protein assay/genomic sequencing 93 Farrington et al. (45)
Denaturing gradient gel electrophoresis >67 Fidalgo et al. (125)
Single-strand conformational polymorphism >67 Fidalgo et al. (125)
Protein truncation test 50 Fidalgo et al. (125)
Heteroduplex analysis 19 Fidalgo et al. (125)
Two-dimensional DNA typing * Sasaki et al. (75)
* Comparable to that of denaturing gradient gel electrophoresis.
mational polymorphism analysis (76), heteroduplex analysis,
and denaturing high-performance liquid chromatography.
Table 6 summarizes the available information regarding
the sensitivity of the above techniques. The use of various
combinations of techniques may enhance sensitivity, but this
is usually impractical. Recently, Yan et al. (77) demon¬
strated that the conversion of chromosomes from the diploid
state to the haploid state, by fusion to a recipient rodent cell
line, may facilitate improved sensitivity of current mutation
detection techniques.
POPULATION TESTING
The population prevalence of hMLHIIhMSH2 mutation
carriers in the Scottish population aged 15-74 years has
been estimated at 1 in 3,139 (78). A recent UK National
Screening Committee workshop concluded that there is
currently no case to offer population screening in an
attempt to identify mutation carriers (Rose 'et al., UK
National Screening Committee, unpublished data). Authors
in the United States have reached similar conclusions,
agreeing that more information regarding the prevalence
and penetrance of mismatch repair gene mutations and
more evidence of effective intervention strategies are
essential prerequisites for implementing screening outside
of the research context (79-84).
There are essentially two strategies that could be
employed to search for mutations in the context of popula¬
tion screening: searching the entire gene(s) for mutations
using the techniques considered above or looking for
specific mutations. The latter option is far less expensive and
labor-intensive and could be of particular benefit in countries
where specific "founder" mutations are prevalent. It may
also be possible to apply DNA pooling strategies in this
context to enhance efficiency (85). However, this approach
is not currently feasible because of the extreme heteroge¬
neity of mismatch repair gene variants and the low allele
frequency of individual mutations. The ethical issues
inherent in genetic screening, coupled with the poor effi¬
ciency and high cost of detecting mutations using current
technology, mean that population testing in any form is
unlikely to be recommended in the near future.
Another approach to identifying mutation carriers is
performing mutation analysis in colorectal cancer patients
deemed to be at high risk of harboring mutations, and subse¬
quently performing "cascade screening" of their relatives. The
major issue in the context of a cascade screening program is
that of how resources can be efficiently targeted towards the
identification of kindreds with hMLHlthMSH2 mutations. This
issue is considered in detail in an overview of findings from
one research group (52), and the sensitivity and specificity of
various clinical criteria are considered by Syngal ct al. (86).
Currently, most mutation carriers arc identified by referral
of patients with a family history of colorectal cancer to cancer
genetics services. Another option, under investigation in an
ongoing program in Scotland, is to search for mismatch repair
gene mutations among persons with early-onset colorectal
cancer and subsequently perform cascade screening in the
relatives of mutation carriers. The phenotypic features of age
at onset, family history, and MSI are commonly used selection
criteria in mutation analysis studies, as summarized for refer¬
ence in the second supplementary table.
At the present time, there is no consensus regarding the
most efficient approach to identifying mutation carriers. It is
clear, however, that further understanding of the role of
mismatch repair genes in colorectal cancer has important
scientific and clinical implications.
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APPENDIX 1
Internet Sites
The following Internet sites may be useful to investigators wishing to pursue further study of the above issues.
Database ofGene Variants and Summary ofMutation Analysis Studies (supplementary tables)
Human Genome Epidemiology Network http://www.cdc.gov/genomics/hugenet/default.htm
Colorectal Cancer Statistics
International Agency for Research on Cancer http://www-dep.iarc.fr/eucan/eucan.htm
Surveillance, Epidemiology, and End Results Program http://seer.cancer.gov/
Genetic Information and Databases
National Centre for Biotechnology Information http://www.ncbi.nlm.nih.gov/
Online Mendelian Inheritance in Man http://www.ncbi.nlm.nih.gov/omim
ICG-HNPCC* database http://www.nfdht.nl/
Cambridge Public Health Genetics Unit http://www.medinfo.cam.ac.uk/phgu/
Patient Education and Support
World Cancer Research Fund http://www.wcrf.org/
Genetic Health http://www.genetichealth.com/
Medicine Online http://www.meds.com/colon/colon.html
American Cancer Society http://www.cancer.org/
Cancer Research Campaign http://www.crc.org.uk/
International Union Against Cancer http://www.uicc.org/
UK National Screening Committee http://www.nsc.nhs.uk/
* ICG-HNPCC, International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer.
(Appendix 2 follows)
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APPENDIX 2
Clinical Criteria for Diagnosis of Hereditary Nonpolyposis Colorectal Cancer





Three relatives with colorectal cancer, one of which is a first-degree relative of the Vasen et al. (87)
other two; colorectal cancer affecting more than one generation; at least one
colorectal cancer case diagnosed before age 50 years
Two colorectal cancer cases in first-degree relatives in very small families that
cannot be expended further; colorectal cancer affecting more than one
generation; at least one colorectal cancer case diagnosed before age 55 years
Two first-degree relatives affected by colorectal cancer, plus a third relative with an
unusually early-onset neoplasm or endometrial cancer
Three or more colorectal cancer cases among first-degree relatives
Two or more colorectal cancers among first-degree relatives and any of the
following: diagnosis before age 50 years; right colon involvement; synchronous
or metachronous multiple colorectal cancers; association with extracolonic
malignancy
Individuals from families that fulfill the Amsterdam criteria
Individuals with two HNPCCJ-related cancers, including synchronous and
metachronous colorectal cancers or associated extracolonic cancers
Individuals with colorectal cancer, plus colorectal cancer and/or HNPCC-related
extracolonic cancer and/or colorectal adenoma in a first-degree relative; at least
one of the cancers diagnosed before age 45 years and the adenoma diagnosed
before age 40 years
Individuals with colorectal or endometrial cancer diagnosed before age 45 years
Individuals with right-sided colorectal cancer with an undifferentiated
histopathologic pattern (solid/cribiform) diagnosed before age 45 years
Individuals with signet-ring cell type colorectal cancer diagnosed before age 45
years
Individuals with colorectal adenomas diagnosed before age 40 years
Bellacosa et al. (88)
Fujita et al. (89)
Rodriguez-Bigas et al. (90)
* Fulfillment of all criteria listed in any paragraph in this section is sufficient.
t Cases can be classified as fulfilling either the first set of criteria or the second set and can be diagnosed with hereditary nonpolyposis
colorectal cancer if they fulfill either set of criteria.
$ HNPCC, hereditary nonpolyposis colorectal cancer.
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Appendix A3 Database of Gene Variants in hMLH1 and hMSH2
All the gene variants listed below have been published in the ICG-HNPCC database {1596},
or in other relevant papers. It should be noted, however, that the various sources differ
considerably in the way alterations are presented, and the amount of detail provided. The
authors of this review have interpreted the available information for presentation in the format
shown, and in some cases have inferred details not specifically given in the original
publication. In several instances, variants have been published which are inconsistent with
the consensus sequence of hMLH1/hMSH2, and could not easily be re-interpreted. In such
cases, variants have been entered as given in the publication, with possible alternative
interpretations given afterwards in Italics.
Spaces within the table indicate that relevant information was not available.
The 'cancer' column lists the types of cancer found in the affected kindred(s). The extent to
which such information is provided varies considerably, and in many cases very little clinical
information is provided. Information in this column should thus be interpreted with particular
care.
In the ID column, identification codes separated by commas refer to different families with
identical alterations, whereas identification codes separated by a forward slash refer to the
same kindred, which has been included in more than one publication under different IDs.
Classification of mutations, as given in the mutation/polymorphism (M/P) column, has been
performed by the authors of the review for the purpose of summarising the information
contained in this table, and is based on the predicted consequences of each variant,
incorporating the results of functional assays where available. These classifications do not





























































































































































































































































































































































































































































































































































































































Case10 12 Case11 28,51,67,477 614,661,811 355 0434* LG 5 SB-2575
IVS3g-a,06+1 IVS3g-ant06+1 IVS3c-gnt06+15 IVS3c-ant07 29 IVS3c-ant07-29 IVS3c-ant07-29 Ex4T-Gnt320 Ex4T-Gnt320 Ex4C-Tnt332 Ex4C-Gnt341(350) Ex4C-Gnt350 Ex4C-Tnt350 Ex4C-Tnt350 Ex4C-Tnt350
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NL-30 1805 Patient519 4 MD1435 NL-37 TF2 Control SNU-H19 FF2 A-AV2 SIF1 NL-24 Case3 GDLG-31#111 1 1515* 3273 DAC CFS70.CFS136 A-AV18 GDLG-26#ll-4 1515* 96 2 21 RIE-SG125 SNUH-H4 A-PD1* VS003 Patient339 22 15
Ex10C-Gnt806 Ex10delTCCTTnt811- 815 Ex10C-Tnt842 Ex10delAnt856 Ex10A-C Ex10delAnt861 Ex10A-Gnt883 Ex10A-Gnt883 IVS10t-ant885-24 Ex11insTt888 Ex11G-Tnt889 Ex11C-Tnt901 Ex11A-Tnt912 Ex11insGCt923 Ex11insAt938 Ex11delCnt954 Ex11delCnt954 Ex11T-Cnt977 Ex11T-Cnt977 Ex11T-Cnt977 Ex11T-Cnt977 Ex11T-Cnt977 Ex11T-Cnt977 Ex11T-Cnt977 Ex11A-Cnt986 Ex11A-Cnt986 Ex11A-Cnt986 Ex11A-Cnt986 Ex11delAnt994 Ex11delGnt005 Ex11delCnt0 0 Ex11insCt0 2 Ex11insGt027 IVS11c-tnt1038+51 IVS11c-tnt1038+51 IVS11(TA)n-(T)nlength polymorphism IVS11insant 039-7
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Ex16 Ex16 Ex16 Ex16 Ex16 Ex16 Ex16
A-Gnt1733 A-Gnt1733 C-Gnt1744 T-Cnt1745 delTTnt1747 insCt1756 insCt1758
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DF260* NLB-526 Case14, control 4 6 18 F103 US-6/4A 35 Case5* 73 EC MTS-K14
NL-3,L-4.NL- 204 NL-14 14kindreds 20kindreds 9Kindreds 5Kindreds 7Kindreds 7,14,27,58,98, 131,142 VS009 K-25/HNP85 Case2 DF397
Ex16AA-GCnt852 Ex16AA-GCnt852 Ex16AA-GCnt852 Ex16AA-GCnt852 Ex16AA-GCnt852 Ex16A-Gnt852 Ex16A-Gnt853 Ex16A-Cnt853 Ex16A-Ccodon618 Ex16A-Cnt853 Ex16A-Cnt853 Ex16AA-GCnt 1855/1856(1852?) Ex16delTnt877 Ex16delTCTCTTTnt 1877 Ex16TTC.TCT-TCC.ACT Ex16delGGAAAnt884 Ex16G-Ant896 Ex16delGnt896 Ex16genomicd lof 5.5kb Ex163.5kbdeletion Ex163.5kbdeletion Ex163.5kbdeletion Ex163.5kbdeletion Ex163.5kbdeletion Ex163.5kbdeletion Ex163.5kbdeletion Ex16deleted IVS16g-tinsplicedonor site IVS16g-ant1896+1


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































control 114-1-OL*Ex6T-Cnt997 IMS5Ex6G-Ant998 59Ex6A-Tnt1000 Ex6C-Tnt1006 Family23Ex6C-Tnt1009 Ex6G-Ant1012 NL-21Ex6delAAnt1016 GDLG-49#IV-2Ex6Ant1024 h86Ex6delGnt1059 RHEx6173bpinst076-
1092
Ex6G-A,polyAregion
NL-33/NLB-Ex613kbgenomic 50490deletion OZ-5Ex2-6deleted FF15IVS6g-ant1076+1 14IVS6g-ant076-35(+35) IVS6t-cnt1077-10 1kindredIVS6t-cnt1077-10 15IVS6t-cnt1076(7077)-
10
cases&IVS6t-cnt1076-8 controls 30Ex7insAnt1 97 H23Ex7insAnt1097 2Ex7insTAnt1127 NL-7Ex7delTnt1137 He1587Ex7C-Tnt1147 6Ex7C-Tnt1147 177ExC-Tnt1147 Ex7C-Tnt1147 Ex7C-Tnt1165 HNPCC-2Ex7C-Tnt1165 DP7Ex7C-Tnt1165 201Ex7C-Tnt1165 449Ex7C-Tnt1168
Cys333Arg Cys333Tyr Lys334STOP Pro336Ser Gln337STOP Gly338Arg
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89.SasakietlMutationalnalysisofthehMLH1genei gautomat dtw -dimensionalDNAtypi gsystem.HumM t io1997;9:164-71. 90.ScottRJealHereditarynonp lyposisc lorec alnceri 5fami ies:differeasim laritiesbetw nmutation-positivdmutation- egat ekindr ds. Am.J.Hum.Genet.2001;68:118-27. 91.SwensenJ,LewisCM,Cannon-Albr ghtIdentificatiofone-baseg rm ined l tio( do888l)dintr nspli eaccept ritepolym rphismihM H2. HumanM tatio1997;10:80-1. 92.SyngaletalInterpretationofgene ict sr sul sf rhe di ryn npolyposc lorect lca cer:implicationfoclini lr dis o itiontesting.[comm nt].JAMA 1999;282:247-53. 93.TannergardPtalMutationscree ingithhMLH1genSwedisher d t rynonpolyposisc lona c rfamili s.Ca c rRese rch1995;55:6092-6. 94.TomlinsonIPMetalGermlineHNPCCge ev r antsh vlitt einflu cthriskf rspo adicc l r ctalancer.Journ lfMedGen tics1997;34:39-42. 95.VielAetalChar cterizationofMSH2ndL 1mu ationsinIt lfa lieswithher d t rynonpolyposic lor ctalc c r.G ,Chrom some&a c r1997;18:8-18. 96.WahlbergSetVariousmutationscreenintechn queiDNAism chr p rg neshMSH2a dLH1.G neticT t ng1999;3:259-64. 97.WahlbergSSetLowfrequencyfhMSH2mutationsinSw dishHNPCCfa ili s[letter]Int r tionalJournalfC cer1997;74:134-7. 98.WangQetalGermlinehMSH2ndL 1genmut tio sinncomp eHNPCCfamilies.Inter atio alJou nalfCanc r1997;73:831-6. 99.WangQetalPrevalenceofgerm imut tio shMLH1,S 2PMS ,handMSH6g sin75Frenchkindr dwi hnonpolyposic l r ctala cer.Human Genetics1999;105:79-85. 100.WeberTKtalNov lhMLH1ndS 2g rm inemutatio sinAfricameric nsw thcolo ectalan er.Journ lftAmeMed lssocia ion1999;281:2316-2 . 101.WeberTKtalGenomicDNA- asedhMSH2ndL 1mut tionscre ningi32Ea ternUniStaher dita ynonpolypos sc lorec alc rpedigr .Ca Research1997;57:3798-803. 102.WehnerMtalH reditarynonpolyposisc lorectalanc( NPCC):Eighn v lg m inemutatio sih SH2oL 1gen s.Hu nMutati1997;10:241-4. 103.WijnenJ,FoddeRKhaPMDGGEpolymorphismintr n0fMSH2,tHNPCCge .um.M l.Genet1994;3:2268. 104.WijnenJetalM jorityofhMLH1mutatio sr sponsiblef rered tarnonpolyp sisc lorec aclustthx nicr gi n15-16.Am icaJou fHumaGen ti s 1996;58:300-7. 105.WijnenJetalHereditarynonpolyposisc lor c ala cerfamilic mply ngwiththAmsterdamcrit riash wextremelylofrequ ncfmi match-r ai -geneutati ns. AmericanJou n lfHumaGenetics1997;61:329-35. 106.WijnenJetalMSH2ge omicdel ti nsrfr que tcauseofHNPCC[l tter]NaG netics1998;20:326-8. 107.WijnenJetalSevenewmutatio sihMSH2,nHNPCCg ed n ifiedbyde aturinggradient-gelelectrophoresis.Am icanJour lHu aGen tic1995;56:1060-6. 108.WijnenJTetalCl nicalfindingsw thmplicatio sorge ictes i gam lic us eringfcolorec alc r.N wEng andJour alfMed i1998;339:511-8. 109.WuYetalMSH2ndL 1mutationsispora icreplic tionerror-positivecol rec alc rcin maa sessedbytwo-di e i nalDNAelectro ho s s.G n , Chromosomes&ancer1997;18:269-78. 110.YuanetalGermli emut tionsofhMLH1ndS 2genesipa ientw hs sp ctedher d aryn npolyposisc lorectalncera dsporad carly-onscol re tal cancer.Dis.ColonRectum1998;41:434-40.
Appendix A4 Summary of Studies Conducting Analysis of hMLH1 /
hMSH2 in Colorectal Cancer Cases
The aim of this table is to summarise the findings of studies that conducted
mutation analysis of hMLH1 / hMSH2 in colorectal cancer cases. Therefore,
for the purpose of this table, "mutations" have been defined as those variants
considered significant by the authors of the original papers.
Definitions of commonly used family history criteria can be found in table 1.1
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0 (Plustwo missense mutations) 1(9.1%)
1 (25%) 4(36.4%) (Plusthree missense mutations)
RNA => LongRT-PCR => Sequencing
(44)
Korea
Kindredsregisteredwi hth KoreanHe ditaryC lorectal CancerRegistryh ving HNPCCorsuspected HNPCC.
42
Group1:Fulfilmentof AmsterdamCri ria Group2:Str ngfamilyhist ry, butAmsterdamcriteriano fulfilled
25 17





Kindredsregisteredwithth31 KoreanHe ditaryColorectal CancerRegistry.NB-This studywasanextensionof Hanetl.,(1996),and includesth17famili previouslyanalysed Kindredsregisteredwi hth88 KoreanHe ditaryC lorectal CancerRegistry.
Strongfamilyhist ry,but Amsterdamcriterianotfulfill d FulfilmentofthAmsterdam Criteria(n=33),oahistory suggestiveofHNPCC(n=55)
31 88
5 (16.1%) 18 (20.5%)


















Group1:Fulfilmentof AmsterdamCri ria Group2:Clusteringofcol r ctal andendometrialca ceri consecutivegenerations Group1:Fulfilmentof AmsterdamCri ria Group2:Anaverageof4 affectedmemb rsofea h family,butnotee ingth AmsterdamCri ria
35 20
1 (14.3%) 1 (25%) 29 (82.9%) 5 (25%)




=> 2-DDNA electrophoresis => Sequencing
(45)
Sweden Sweden Sweden Switzerland
Kindredsreferredtoh39 clinicforam lialancert theKarolinskaHospit l, Stockholm.Threefamilies wereofFinnishrigin,hil therestwereSw dish Kindredsreferredtoh39 clinicforfamilialancert theKarolinskaHospit l, Stockholm.Threefamilies wereofFinnishrigin,hil therestwereSwedish FamiliesrecruitedfromN.34 Swedenandthtockholm regionthroughcancerfamily clinicsattheKaroli ska HospitalandUme UniversityHospital Kindreds10
Group1:Fulfilmentof AmsterdamCri ria
21
Group2:FamilyhistorofCRC18 Group1:Fulfilmentof AmsterdamCri ria
21
Group2:FamilyhistorofCRC18 Group1:Fulfilmentof AmsterdamCri ria Group2:Morethanon7 memberaffectedwithCRCor associatedtum urs,plusfou familieswithatleastonca e withonset<35years FulfilmentofAmsterdamCri ria10
5 (23.8%) 3 (16.7%) N/A N/A 1 (14.2%) 1 (3.7%) 3 (30%)
N/A N/A
1 (4.8%) 1 (5.6%) 0 3 (11.1%) 3 (30%)
DGGE
=> Sequencing DGGE => Sequencing DGGE => Sequencing
(62) (67) (34)
Direct(6) Sequencing
SwitzerlandKindredsreferreto UniversityHospital,Basel fromallpartsfSwitze land, duetofamilialaggreg tionf CRCcases
26





SwitzerlandIndexcasesw rer f r dto afamilialcancerl nicwith suspectedHNPCC
23
Group1:Fulfilmentof AmsterdamCri ria Group2:"HNPCC-like"but Amsterdamcriterianotfulfill d
14




Familiesidentifi dthrough16 probandshospitalisedatthe NationalTumourInstituteof Milan Italiancolorectalancer36 patientsiden ifiedthrough thespecialisedModenaCRC Registry.
Group1:Fulfilmentof4 AmsterdamCri ria Group2:Str ngfamilyhist ry, butAmsterdamcriterianot fulfilled Group1:Fulfilmentof8 AmsterdamCri ria Group2:"suspectedHNPCC",18 Amsterdamcriterianotfulfill d.
4 (28.6%) 0 1 (5.6%)
3 (21.4%) 1 (50%) 2 (11.1%)














CRCpatientsiden ified30 througheInstitutef Pathologyandthe DepartmentofClinical Physiopathologyfthe UniversityofFl rence,and fromtheRegisterf ReginaElenCancer InstituteinRome. CRCpatients.Somefthes45 patientsh dreviouslybe reportedbyPensottial.,
Group1:Fulfilmentof7 AmsterdamCri ria Group2:"HNPCCfamilies",but13 Amsterdamcriterianotfulfill d Group1:Fulfilmentof3 AmsterdamCri ria Group2:IncompleteHNPCC11 families,ofpatientw ths rong familyhistory,plusoneatient withmultipleprimarytu ours
2 (11.8%) 2 (15.4%) 3 (23.1%) 1 (9.1%)




Italy,CRCpatientsiden fied threeinstitutions-Aviano, April1994-ModenaandR me March1996witputativeHNPCC,b t fromamiliesnote ingth standardAmster mcriteria
32




Group1:Fulfilmentof AmsterdamCri ria Group2:Str ngfamilyhistory, butaleastoneAmsterdam criterionnotfulf lled
FranceFamili swithsuspected17Aleastonf milymemberw o HNPCC,afterexclusionofdevelopedCR t<50years FAPIndexpatienth dtle sone firstdegreeelativewi hCRCor atumourinheHNPCC spectrum Atleast2successive generationsaff cted France+Turk yFrenchfamilies(n=10)were recruitedthro ghgenetic consultationsatheCen re LeonB rardanHopital EdouardHerriot. TwoAmsterdam+vefamili s wereidentifiedTurkey.12Group1:Fulfilmentof AmsterdamCri ria Group2:"incompleteHNPCC syndrome",iwhichonefth Amsterdamcriteriaitemswa missing
32SSCP( 2) (9.4%)=>
Sequencing
NB-including twomissense mutationsof uncertain significance




20IVSP(68) (66.6%)+ HA + 31Sequencing (33.3%)(11.1 )
France Holland
Kindredsweresel ct dafter75 geneticconsulta ionsath CentreL onB rard,Hopital EdouardHerriot,C ntre HospitalierLyon-Sud,Ce tr HospitalierJeanMinjozand CentreRenGauducheau. NB-17kindredsw re previouslydescribed(Wang etal.,1997) DutchKindreds( =30)were34 recruitedfromva iousclinical centres,largelyth ough NetherlandsFound tionf r theDetectionofHereditary Tumours.heremainderf thekindr dsstudiedw re Italian(n=3)andD nish (n=1)iorigin.
Group1:Fulfilmentof22 AmsterdamCri ria Group2:"incompleteHNPCC33 syndrome",iwhichonefthe Amsterdamcriteriaitemswa missing Group3:Kindredswithonecas ofCRCandtleasteca f8 anextra-colonictumour belonging,totheHNPCC spectrum FulfilmentofAmsterdamCri ria34
11 (50%) 6 (18.2%) 2 (25%) 12 (35.3%)
3 (13.6%) 2 (6.1%) 2 (25%) 2 (20.6%)
RNA+D based screening strategy, utilisingHA, RT-PCRand sequencing
(69)
DGGE => Sequencing
(65) NB-These sameresults arelso included subsequent papers: Wijnen.J.et al.,1995nd Wijnenetal., 1996
HollandThe34kindre sfrom125
+previousaper(V s nt Norwayetc.al ,1996)regaininclud d inthisanaly is.Iotal,97 Dutchkindredsw re included,larg lyrecruited througheNetherlands Foundationf rtheDetect ofHereditaryTumours. Otherkindr dsincluded wereNorw gian(n=23), Italian(n=3),Danish(n=1) andCzech(n=1)
Group1:Fulfilmentof AmsterdamCri ria
86
Group2:FamilyhistorofCRC, butaleastonefth Amsterdamcriteriaitemswa missing
39






+beenstudiedpr viously. Norwayetc.Ov rall,67kindredswere recruitedthroughe NetherlandsFoundationf theDetectionofHer ditary Tumours.Furtherkindreds fromtheNetherlands(n=56) andfromNorway(n=56) wererecruitedbyclini ians orclinicalgeneticscentres. Otherkindredsinclud wereNor egian(n=23), Italian(n=3),Danish( 1 andCzech(n=1)
184Group:Fulfilmentof AmsterdamCrit i Group2:Familyhist rofCRC, butale sonefthe Amsterdamcriteriaitemswas missing
Holland
+
Norwayetc. Holland + Norwayetc.
Thispaperre-examinall137 samplesinwhichoMMR mutationsweredetec edin previousstudie ,usinga differenttechniqueosea ch forgenomicdeletions. Thefamili sstudiedwer Dutch(n=86)andNorwegian (n=51) Familiesregister dw hth251 NetherlandsH PCCr gistry betweenJanuaryduly 2000(n=193,orwhich116 metAmsterdamcriteriaIo II);plussuspectedHNPCC familiesfromtheClinical GeneticC treRadium Hospital,O lo,N rway (n=58)
Group1:Fulfilmentof AmsterdamCrit i Group2:Familyhist rofCRC, butatleasonefthe Amsterdamcriteriaitemswas missing SuspectedHNPCC,including familieseetingthAmsterdam criteria




Group1:Fulfilmentof57 AmsterdamCri ria Group2:Fulfilmentofalo s r12 criteria,extendedtoin lu extra-colonictumours
11 (19.3%) 0
4 (7.0%) 2 (16.7%)
SSCA










SSCA + HA => Sequencing
(72)
France
Families,inwhicho alterationofMMRg neshad beenpr viouslydetectedy classicalmethods
19











Kindredswithsuspected HNPCC,presentingto SouthamptonGeneral Hospital,UK HNPCCfamilies
17











Familiesascertainedthrough18 threecentres;ThRoyal MelbourneHospital,The PrincessMargaretHospital forChild en,andtJ hn CurtinSchoolofMedical Research Familieswithhistoryof95 colorectalancer
FulfilmentofAmsterdamCr ria18 FulfilmentofAmsterdamCr ria33 FulfilmentofBethesdaCr t ri
62
4 (22.2%) 11 (33.3%) 6 (9.7%)
2 (11.1%) 9 (27.3%) 6 (9.7%)
Acombination
ofRNA-based andDNA based methods DGGE=> Sequencing
(28) (58)












KindredsfromthUSA29 (n=26),Finland=2)an NewZealand(n=1) Patientswithf milyhis or19 ofcolorectaland/or endometrialcancerwere identifiedfromaconsecutive seriesofCRCpati nts referredtoh GastrointestinalCa cer PreventionCli icoftheD pt. ofInternalMedicineatthe UniversityofMichigan Patientswithf milyhis or39 ofCRCwereidentified throughheDept.fM dical GeneticsattheMayoclinic, Minnesota,USAorthrough theDept.ofSurgeryt UniversityofDusseldorf. Kindredswithsuspected28 HNPCC.Originisnotclear, butaleast7ofthekindr ds wereFinnish
FulfilmentofAmsterdamCr ria29 Group1:Fulfilmentof AmsterdamCri ria
12
Group2:Amsterdamcriterianot7 entirelyfulfilled Group1:Fulfilmentf20 AmsterdamCriteria Group2:Indexpatientlust19 leastoneth rfamilymember withCRC Group1:Fulfilmentof0 AmsterdamCriteria,andlinkage previouslyshownt3pmarker Group2:Fulfilmentof AmsterdamCriteria(kindreds18 toosmallf rlinkageanalysis)
N/A
4 33.3%) 4 (20%) 3 (15.8%) 9 (90%) 1 (5.6%)
10 (34.5%) 2 (16.7%) 5 (25%) N/A N/A








USAFamiliesself-referred,o58 referredbyhealthc providerstacanc r geneticsprogramonth basisofmult pleCRCcases, earlyonsetfamilial associationofCRCw h otherHNPCC-associated tumours USAHNPCCpedigreesr gist red32 withtheRoswellPark FamilialC ncerReg stryand theVermontCancerentre FamilialC ncerProgram CanadaPatientsw reidentifi d3 througheFamilialGl CancerregistrytMoun SinaiHospital,T ronto.All butonefamili sweref Europeandesce t,thther beingChinese.
Group1:Fulfilmentof AmsterdamCri ria Group2:Familiesfulfillinga modifiedAmsterdamCriteria Group3:HNPCCvariant- familieswithhistory suggestiveofHNPCC,bnot fulfillingtheabovecr t ria Allbutonefthekindr dsm t theAmsterdamCri ria.Int kindredthatdido ,allffected individualswereconfin dthe samegeneration. Group1:Fulfilmentof AmsterdamCri ria Group2:Familiesfulf lling modifiedAmsterdamcriteria, referredtoasheMountSinai HospitalCriteri .
11N/ASequencing(60) (9.1%) 2810Sequencing(61) (35.7%).6 1102 (18.2%) 1903 (15.8%) 325SSCP^(71) (15.6%)(9.4Sequencing 1425RT-PCR( )
+ PTT =>
194Sequencing









Datawascollectedfr m surveyformsmailedto membersofthICG- HNPCC.Dataweregather d fromeightinstitutionsn sevencountries. Amsterdam+vefamilies wereexclud dfromth analysis,ndthefamili ies includedwereclassifi d accordingtohecrit iaf familiesw thsusp cted HNPCC,asdefinedbyth ICG-HNPCCatthe8,h annualmeetingiBuffalo, USA







(b)MutationAnalysisiPatientw thSI+veTumours (i)Asia Areaof Study; Recruitment periodStudyPopulationan ascertainmentcri eria
AgeTotalNumber RangeNumb rMSI+v
CriteriafoMSINumberHMLH1h 2 +vestatuselectedformuta ionu ation mutationcarriers analysis
Method
Reference



















































Indexpati ntsident fiedfromth<3527 ScottishNationalC nceryears Registry.Patientsref rredold specificallybecausetheyfulfill d HNPCCcriteriawereexcluded. Lateons tsporadicCRCca s,>4043 withnofamilyhist rofHNPCCyears associatedcancers,dwithoutol synchronousormetachronou cancers.
13 (48.1%) 4 (9.3%)
RERphenotype









GroupA:s merelatives affectedbytumoursofhe HNPCCspectrum,wi hout meetingthAmsterdamCri ria GroupB:Apparentlys radic colorectalancer
<50 years old
45 46
29 (MSI-H) 26 (57.8%) 16 (34.8%)
RERphenotype
inatleast>40% ofupt12loci RERphenotype inatleast>40% ofupt10l ci
29 17 10
3 (10.3%) 4 (23.5%) 2 (20%)
1 (3.4%) (5.9%) 1 (10%)
PCR+single
/double conformational analysis Sequencing SSCA +HA +PTT(where possible) => Sequencing
(54) (29)














FinlandTumourDNAwasfrompri ary colorectalcarcinomasp eviously foundtohaveRER+ve phenotype
36-89 years mean age= 70
N/A
33




inatleast2/7 loci,r1f7 plusatleast1 froman additionalpane DNAwas studiedforMSI usingtheBAT26 andTGF-PRII poly-Amarkers DNAwas studiedforMSI usingtheBAT26 andTGF-PRII poly-Amarkers
63 66
9* (14.3%) 'Mostly founder mutations 17*(26%) 'Mostly founder mutations 5 (83.3%)
(1.6%) (1.5%)
Founder mutation analysis => Sequencing Founder mutation analysis => DGGE => Sequencing Founder mutation analysis => Sequencing
(1) (55) (35)
RERphenotype
inat1ormo e ofandditional sixmarkers
11'mild' RERtumour specimens




































NB:eight were randomly chosen,four werechosen onthebasis ofclinical features
(8.3%)
SSCP => Sequencing NB:Some sequenced directly
(50)











+registrationsbetwee1970andd: Scotland1993,thatmepracticaliteri<30(38of foranalysis(n=17)ye rthe227
oldsamples
USA:(i)PatientswithstageIIorrenot
IIICRCundergoingc rativeUSA:of surgicalresectionsathJohns(i)ad quate Hopkinsspitalbetween1986unknowquality) and1990(n=145) (ii)Randomlyselectedpatientsi<50 inwhomsurgeryasperfo medye r between1978and85(n=65)ol Allpatientswereexclud dif theym tAmsterdamcriteria forHNPCC,hadevidencef FAPorIBD
37 (19.6%)
USA




+AmsterdamcriteriafoHNPCC NewZealandwereincludedthst y.T +originfthekindredsw reUSA Europe(n=50),NewZealand12)nd Europe(n=12)
74
68 (91.9%)
NB:19ofthe31mutation+ve patientsh dbeeidentified throughpreviousstudies
USA






=> IVSP => Sequencing
N/A1001(1 %)RT-PCR(31)










Colorectalcan erp tientsw r38-8361 recruitedth oughey ars WashingtonUniversitySc oolofmean Medicine,St.Lou s,issouriage=
65.6
Unselectedprospectiveriesf29-9157 patientsresentingtohM yoy ar , clinic,Minnesota,betw enm a December1995andApril7,g= andco sentingtparticipate69
13 (21.3%) 51 (19.8%)
RERphenotype






SSCP => Sequencing Sequencing
(26) (12)
USA















FranceCaucasianRCpatientsiclin - basedpopulation,sel ctedol lyn thebasisofgetns tCRC. FranceP tientsrecrui edthro ghg n tic consultationsatheCen reL oB r rd andHopitalEdouarderriot. FranceP tientsselectedaft rg tic consultationsatheCentreL oB r rd, HopitalEdouarderriot,C n e HospitalierLyon-Sud,Ce treHospitali r JeanMinjozandC ntreRen Gauducheau. ItalyPatientsw rerecruit d"fromvarious surgicalandcli lits".Familyhis or wasnotusedanen rycrit rion. ItalyP tientswithoutf milyhist ry suggestiveofhereditaryCRC,treated theCentradiRiferimentoOncologico, Aviano,It ly(-1995-1999) KoreaDatonearly-onsetCRCwithouf mily historywerecollect dthroughhDept. ofSurgery,eoulNati nalUn versity Hospital.











RNA+Dbased screeningt ategy, utilisingHA,RT-PCR andsequencing SSCP + PTT






























Abbreviations:CRC=olorectalan er,DGGEa uringG deelElectropho esis,FAP=amilialAden matousPolyp is,HAteroduplexA aly is,N CC= HereditaryNon-PolyposisColorect lan er,IBD=I flammatoryB w lDise e,ICGHNPCC=InternationalC l abor iveGr upoHNP C,IVTT=Vi Transcription-Translation,IVSP=V t oSyn hesi edPr teinass y,MSI=icro telliteI stabi ity,CRP lymeraseChaR ction,TT=ProteinTru i tRER=eplicationError,RT-PCR=everseTranscriptionPolymeraseChaReaction,SS P=inglStr ndedConf m tio alPolymorphism References 1.AaltonenLAetl.Incidencefh r ditaryno polyposiscolorectalcan ea dhf sib ityfm l ularscr ningfti ease[ omme ts].N wE gl dJ urnalfMedicine1998;338:1481-7. 2.AbeY,MasudaH.Geneticalterationsofporadiccolore talancerwithmic osatelliteinstab ty,sp iallychar ris icsfp im rmultiplec lorectac er .J rn lfSurgicalOncology2000;74:249-56. 3.BaiYQetal.Predominantgerm-li emutat onfthehMSH2geiJapaneseh reditaryno -p lyposiscolor ctalcki dr d .Int r a i nalJ u n lfC er1999;82:512-5. 4.BapatVetl.F milyhistorcharacteristics,tu ormicr satellitenstab lityndgermlinMSH2L 1mu at onser ditaryolorect ln er.Hu anG tics1999;104:167-76. 5.BeckNEtal.G ne ict stingiimporta tfamil eswithhi oryugg stivefhe editarynon-polyposiscol rectalcerv nthAmsterd mcri eriatf lf ll d[ comments].BritishJour alfS gery1997;84:233-7. 6.BuersteddeJMtal.D tectionofn wmuta ionsi xoutf10SwisHNPCCf m liebygenomics quen ingfhhMSH2dL 1g es.Journalfedic lG tics1995;32:909-12. 7.CalistriDel.Microsatelliteinst bilityncolorectal-cancerpa ie tsw huspect dg n ticpr disposi ion.I ernationalJour afCa er2000;89:87-91.8.ChanTLetal.Fr quentmicrosatelliteinstab litydmi matchrep irg nmutat onsiyoungChi sep tie swcolor c alc n er.J u lfhN alC erI s tute1999;91:1221-6. 9.CharbonnierFetl.D tect onfxod leti sa dduplicationsfhmismatchrep irgenesih r itarynpolyposisc l rectala efa ilu ingultiplexpolym rase chainreact onofshortflu rescentfragme ts.Can erRes arch2000;60:2760-3. 10.ColemanMGtal.Minisatellitein tabilityfoundcolorectaltumoursw hismatchr p irdefici ncy.BritisJ ur alfC cer2001;85:1486-91.11.CravoMetl.BAT-26identifiessporadiccolor ctalcancerswithmutatorpheno ype:c relatives udywi hclinic -pathologicalfe r sndm ationssmatchre ir genes.JournalfPathology1999;188:252-7.
12.CunninghamJMetalThefrequ ncyofh redit rdef ctivemismatchr pairipr s ect vs riesfunselectedcol r lca cinom s.Am.J.H .G ne .2001;69:780-90. 13.CuriaMCetalUnbalancedgerm-lineexpress onofh LH1ndS 2allelesiher dit rynpolypocolor ctalc c r.Ca c rRese ch1999;59:3570-5. 14.deLeonMPtalHereditarycolorec lancerinthgen ralpopulatio :fromc c rregistrtm l culardiag sis.Gut1999;45:32-8 15.DebniakTtalV lueofpedigree/clinicald t ,immunohis o h mistryandmicrosatel iinstab ityan lys sr uc gthc tofdetermi ihMLH1a dS 2g mutationsinpa ientw hcolor ctalncer.Eur peanJour lfCa c r2000;36:49-54. 16.DieumegardBtalExtensivemol cularscr eningforher dit rynon-polyposiscolore t lcer.Bri ishJournalfCa r2000;82:871-80. 17.DunlopMGetalC ncerriskssociatedwithgermlinNAmi matchr p rg tat onsHum.Mol.Genet.1997;6:105-10. 18.FarringtonSMelystematicanalys sofhMSH2dL 1iyoungcolonncerpatientsdcon r ls.AmericanJou lfHumaGenet cs1998;63:749-59. 19.FidalgoPetalDetectionofmutati sinismatchr p irg nesPortuguesefam li swithhe di arynon-polypo isc l rec ala c r(HNPCC)bmulti- thodpp ach. EuropeanJourn lfHumanGenetics2000;8:49-53. 20.FornasarigMetalicrosatelliteinst b litydLH1S 2g rmlinedefectar lattcl nicopathologicalfeatu esispor d ccol ec lca cer.On l yR p s 2000;7:39-43. 21.FroggattNJetalMutationscree ingfSH2ndL 1mRNAihered tarynon-polyp sisc l ncancersyndr m .Jour alfMedicGen i s1996;33:726-30. 22.GenuardiMtalLH1ndS 2constitutionalmutatio sic lorectalncerfa il sne tingthsta darcrit iafoher d ynonpolyposiscolorecta cer. InternationalJournalfCa cer1998;75:835-9. 23.Han-JetlGenomicstructureofhumanmism tchr p rge ,MLH1anditmutation lysispa ntw thHNPCC.uMol cu arGen tic1995;4:237-42. 24.Han-JetalGermli emutat onsofhMLH1ndS 2ge einKo eaereditaryn npolyposisc lorectalancer.Jou n lftNatiC c rIns t t1996;88:1317-9. 25.HeinimannKtalInfluenceofsel ctiocriteriamu ati nd t ctioip tie tsw hher d arynonpolyposic lor lca r.Canc1999;85:2512-8. 26.HerfarthKalMutationsinLH1remo efreque tthS 2sporadiccol ectalnc rswi hmicrosat liteinstab lity.G s,Chro os m s&ancer1997;18:42-9. 27.HutterPetalExcessofhMLH1germ inemutationsinSwisfa liithher ditarynon-polypo isc lo c alancer.Inter ti nalJour fC r1998;78:680-4. 28.Kohonen-CorishMtalRNA-basedmut tionscreeningiher di arynonpolyp sic lo ctalncerAmeri nJour lfHu anGenetic1996;59:818-24. 29.LambertiCetlMicrosat lli einstability-au efuldi gnos cto lsel cp ti ntshi hri kf re d aryn n-polyposiscol rectalanc r:s udyidiffe ngr psof patientsw thcolorectalncer.Gu1999;44:839-43 30.LiuBetalGeneticinstab lityoccursthm jorifyo ngpati ntw thcol rectalnce[sc mm n s].NaturMedi n1995;1:348-52. 31.LiuBetalMismatchrepairgenedef c sinpor diccol rectalancerwithmicr sat ll teinst bili y.Nat.G n1995;9:48-55 32.LiuBetalAnalysisofmisma chrep rgeneiher di arynon-polyposic lorect lncp ti ts.[comm nt].Na urMedici1996;2:169-74. 33.LiuBetalhMSH2mutationsinereditaryonpolyposisc lorec alancerkindre s.Canc rR search1994;54:4590-4 34.LiuTetalDGGEscreeningofmutatio sinismatchrep irgen(hMSH2ndh L 1)Sw dishfam li swithc lorectalc rClini lGe ti s1998;53:131-5. 35.LoukolaAetalMicrosatelliteinst bilityden massmarkerf rher dit rn npolyposisolorectalc rAm.J.P tho1999;155:1849-53. 36.LuceMCetalInvitrotranscription/translations yfohcre ningfhMLH1dS 2muta ionsifa li lcoloc n rG stroent ology1995;109:1368-74. 37.MaliakaYKetlCpGdinuc eotidesithehMSH2nL 1g nesrotspof rHNPCCmutati ns.umGenet c1996;97:251-5. 38.MauillonJLetIdentificationofovelgermlinehMLH1mutatio sincludi g22kbAl -di dde iopatien sw thfam l lc lor ctalncer.CancR s. 1996;56:5728-33. 39.MiyakietalG rmlinemut tionsofhMSH2ndL 1ge eiJapa sefa ili swi hHNPCC:Usef lD An ysisf scr eningddi g osfHNPCC patients.JournalfM lecul redi i e1995;73:515-20. 40.MonteraetalutationalgermlinealysisfhMSH2ndL 1enesi ys tcolor c la c rp tient[let r].Jo r alfM dicG n(O l e)2000;37:E7. 41.MosleinGetalicro atelliteinst b lityndmutationalysisfhMSH2L 1patien sw hspora ic,fa ili la dher d aryc l rec alc rHuMolec Genetics1996;5:1245-52. 42.NakaharaMetlIdentificationofcon urrentgerm-l nemutatio sihMSH2and/ rL 1Japa esHNPCCkindredC cEpidemio oqy,Biom rke s&Prev ion 1997;6:1057-64. 43.NilbertMetalicrosatelli einst b lityrenectacarcinomasdignifieshe d t rc c r.Eur p anJouCa1999;35:942-5 44.NomuraSetalEnhanceddetectionfd leteriousdth rg rmlinemutatihMSH2h L 1iJapaneser d rynonpolyp sisc lo e talncerk nd s. Biochemical&i physicalRes ar hCommunications2000;271:120-9. 45.Nystrom-LahtiMetalDNAmisma chep irgeneutationsin5kindredswiv if edrput vHNPCC.uol cu rGe tics1996;5:763-9.
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Accuracy of reporting of family history of colorectal cancer
R J Mitchell, D Brewster, H Campbell, MEM Porteous, A H Wyllie, C C Bird, M G Dunlop
Gut 2004;53:291-295. doi: 10.1136/gut. 2003.027896
Background and aims: Family history is used extensively to estimate the risk of colorectal cancer but there
is considerable potential for recall bias and inaccuracy. Hence we systematically assessed the accuracy of
family history reported at interview compared with actual cancer experience in relatives.
Methods: Using face to face interviews, we recorded family history from 199 colorectal cancer cases and
133 community controls, totalling 5637 first and second degree relatives (FDRs/SDRs). We linked
computerised cancer registry data to interview information to determine the accuracy of family history
reporting.
Results: Cases substantially underreported colorectal cancer arising both in FDRs (sensitivity 0.566 (95%
confidence inteival (CI) 0.433, 0.690); specificity 0.990 (95% CI 0.983, 0.994)) and SDRs (sensitivity
0.271 (95% CI 0.166, 0.410); specificity 0.996 (95% CI 0.992, 0.998)). There was no observable
difference in accuracy of reporting family history between case and control interviewees. Control subjects
similarly underreported colorectal cancer in FDRs (sensitivity 0.529 (95% CI 0.310, 0.738); specificity
0.995 (95% CI 0.989, 0.998)) and SDRs (sensitivity 0.333 (95% CI 0.192, 0.512); specificity 0.995 (95%
CI 0.991, 0.995)). To determine practical implications of inaccurate family history, we applied family
history criteria before and after record linkage. Only two of five families reported at interview to meet
surveillance criteria did so after validation, whereas only two of six families that actually merited
surveillance were identified by interview.
Conclusions: This study has quantified the inaccuracy of interview in identifying people at risk of colorectal
cancer due to a family history. Colorectal cancer was substantially underreported and so family history
information should be interpreted with caution. These findings have considerable relevance to identifying
patients who merit surveillance colonoscopy and to epidemiological studies.
See end of article for
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People who have relatives affected by colorectal cancerhave an increased personal risk of the disease comparedwith the general population. The degree of personal risk
relates to the extent of family history and age of onset of
affected relatives.1 Thus family history is used in the clinical
setting to inform decisions regarding the use of colonoscopic
surveillance. Because of the increasing awareness of the
genetic contribution to colorectal cancer, in the UK, else¬
where in Europe, and in the USA there has been a rapid
increase in colonoscopy workload where family history is the
primary concern. Guidelines based on degree of family
history have been devised to determine when surveillance
should be recommended.2 ' This empiric approach inherently
places considerable importance on the accuracy of family
history information. Accuracy is also an important considera¬
tion in the context of the epidemiological studies that inform
the guidelines for offering surveillance. In both situations,
information on family history is usually gathered by inter¬
view with a family member. This approach is potentially
subject to inaccuracy on the part of the interviewee.
Underreporting of family history has being observed in
previous studies'"s and there is evidence that systematic recall
bias may arise from the fact that people with raised
awareness of a particular cancer may be more likely to report
a positive family history.' Furthermore, the social stigma
associated with bowel cancer may mean that this condition is
discussed less readily within families, and this factor could
particularly affect reporting of family history.
Accuracy of reporting cancer in the family has been
addressed in previous studies of people referred to genetics
departments because of a cancer family history,7"' people
with a personal history of cancer,'6 10~" or close relatives of
cancer cases." 15 " However, only a few studies have related
specifically to colorectal cancer cases"5 " 12 '" or to commu¬
nity based consultands who have not been referred to a
genetics clinic.'Another limitation of the published
literature is that validation of the interviewee's report is
often only attempted for relatives reported to have had
cancer. In such studies no information can be obtained
regarding the sensitivity, specificity, or negative predictive
value of reports, and the question of underreporting cannot
be addressed.
In this study, information obtained at interview from
colorectal cancer cases and community controls was linked
systematically to Scottish Cancer Registry data in order to
investigate the true accuracy of reporting of a family history
of colorectal cancer. We determined the cancer experience of
5637 relatives, irrespective of the reporting of cancer by the
interviewee, and so we were able to determine overall
accuracy, including underreporting of cancer in relatives.
We also evaluated the effect of any inaccuracies on clinical
interpretation of family history with respect to recommend¬
ing surveillance colonoscopy. The findings have considerable
relevance to the methods used to validate family history and
also have practical implications for surveillance guidelines.
METHODS
A genetics nurse conducted face to face interviews with cases
and controls to obtain their reported family history. A total of
199 consecutive colorectal cancer cases were ascertained from
Edinburgh Royal Infirmary, Western General Hospital,
Edinburgh, and St Johns Hospital, Livingston. For commu¬
nity controls, our initial strategy was to recruit spouses of
Abbreviations: FDR, first degree relatives; SDR, second degree
relatives; ISD, Information and Statistics Division
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No (%) for whom
interviewee could supply
health information
No of relatives with
confirmed cancer*





No (%) of cancers
accurately
reported
Cases FDR 1322 1250 (95%) 215 152 (71%) 240 106 (44%)
Cases SDR 1968 713(36%) 274 84 (31%) 293 42(14%)
Controls FDR 1037 991 (96%) 113 76 (67%) 124 51 (41%)
Controls SDR 1310 671 (51%) 189 77(41%) 202 36(18%)
*This column refers to the total number of relatives in a particular group found by ISD linkage to have had cancer.
tThis column describes the total number of primary cancers occurring in relatives, including multiple primary cancers.
FDR, first degree relatives; SDR, second degree relatives.
cases. However, this approach proved impractical, and only
25 controls were identified by this means. A further 108 age
and sex matched controls were ascertained from general
practice lists in North West Edinburgh. Details of all first and
second degree relatives (FDRs/SDRs), as reported by the
interviewee, were recorded in a structured proforma. A
comprehensive manual search of records of births, deaths,
and marriages held at the General Register Office for
Scotland was performed, in order to verify, correct, and
extend pedigree information reported at interview in prep¬
aration for record linkage.
Data for all relatives were systematically linked to Scottish
Cancer Registry data held by the Information and Statistics
Division (ISD) of the Scottish Executive. The Scottish Record
Linkage System links all records relating to hospital
discharge, cancer registration, and cause of death for each
individual, and represents a comprehensive resource for
identifying cancer incidence in a given population group.
Using techniques based on the principles of "probability
matching" developed by Ncwcombe," such records arc linked
via patient specific identifying information with a false
positive rate of less than l%.'°~2° Our own internal assessment
of colorectal cancer ascertainment is that the false negative
rate is also of this order. The same methodology can be
applied to linking research data containing personal identi¬
fiers with the health information held by ISD. Surname,
forename, sex, date of birth,-and postcode are commonly
used to match records, and our data set contained all but the
latter of these. Record linkage served not only to validate
reports of cancer but also to identify previously unidentified
cases. Confidence intervals (CI) were calculated using an
approximation based on inverting an appropriate score test
statistic,21 which compares favourably with exact methods for
our data.22
Ethics approval for the recruitment and interview of
patients and controls was granted by the Lothian Local
Research Ethics Committee. The record linkage process was
subject to approval from the Privacy Advisory Committee
responsible for advising ISD on the release of patient
identifiable data. All linked data remained at ISD throughout
the analyses to ensure confidentiality.
RESULTS
Mean age of the 199 colorectal cases at the time of interview
was 64.0 years. There were 86 females and 113 males, who
had a total of 3290 relatives included in the database. One
hundred and ten relatives were reported to be resident
outside Scotland, and the nurse constructing the pedigrees
classified a further 251 as "untraceable". Mean age of the 133
controls was 64.2 years at the time of interview. There were
60 females and 73 males with a total of 2347 relatives. In all
there were 107 relatives who were reported to be resident
outside Scotland and 91 were deemed to be untraceable.
Individuals who have neither died nor developed cancer will
not be matched through record linkage, and so it is
impossible to distinguish these individuals from those who
cannot be traced. Hence all 3290 relatives of cases and 2347
relatives of controls were included in the subsequent record
linkage and analysis, regardless of apparent "traccability".
Knowledge of family members' health and occurrence
of all types of cancer
Interviewees were asked to state their knowledge as to
whether a given relative was alive, and regarding the medical
history of relatives, including any history of cancer. The
proportion of relatives for which the interviewees were able
to provide any health related information is shown in table 1.
Table 1 also details the responses given by interviewees for all
relatives found to have any type of cancer by linking with
central records.
In the majority of instances where a cancer was not
correctly reported, the interviewee either had no knowledge
of the health of the relative in question or was unaware that
they had developed any type of cancer. However, in some
cases a cancer was reported but the site was incorrect or
unknown. An indication of the extent to which this occurred
is provided by the sixth column in table 1, which states the
proportion of affected relatives reported to have had any form
of cancer.
Reporting of colorectal cancer cases
There were a total of 148 confirmed cases of colorectal cancer
in FDRs or SDRs, of which 62 were reported correctly by the
interviewee. Mean age at onset of cases that were correctly
reported was 63.3 years (95% CI 60.5, 66.1), a value
significantly different from the mean age of 70.2 years
(95% CI 67.8, 72.5) for cases that were not correctly reported.
This observation is not unexpected as cancer affecting more
elderly relatives is less likely to be discussed within families.
The suggestion that early onset cases are more likely to be
reported accurately at interview is of clinical interest as such
cases arc more significant in terms of indicating increased
genetic risk. A separate trend towards more accurate
reporting in recent years was evident, although not statisti¬
cally significant. Summary statistics associated with the
accuracy of reporting of colorectal cancer in relatives are
presented in table 2.
The data in table 2 demonstrate substantial underreporting
of colorectal cancer in relatives. In both cases and controls,
sensitivity of reporting in FDRs is approximately 50-60%,
implying that a large proportion of cancers in FDRs go
unreported. The poor sensitivity of reporting is even more
striking in SDRs, with the majority of cases in SDKs of cases
and controls not being reported at interview. The very high
estimates of specificity and negative predictive value primar¬
ily reflect the fact that in absolute terms colorectal cancer
affects only a small proportion of the population. However,
even small effects on these parameters may have important
implications for genetic risk assessment and resource
allocation. For all relative groups, estimates of positive
predictive value were in the range 60-70%, indicating that
approximately one third of reports of individual colorectal
wvAv.gutjnl.com
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cancer cases arc not confirmed using cancer registry data. The
sensitivity of reporting of colorectal cancer compared with
other common cancers is shown in table 3. As no differences
were observed between eases and controls in terms of the
accuracy of family history reporting, all consultands have
been grouped together.
Estimates of sensitivity for colorectal cancer were broadly
comparable with the other common cancer types listed in
table 3, although numbers were small. However, it is
noteworthy that breast cancer was more frequently reported
than the other internal cancers in FDRs. This may reflect the
more enigmatic presentation of visceral malignancy and the
social stigma associated with bowel cancer in particular.
Practical implications of inaccurate or incomplete
reporting of family history
From a clinical perspective it is important to determine the
validity of interviewee reporting as a means of identifying
families that arc eligible for colonoscopic surveillance and/or
genetic testing. Various guidelines exist to help determine the
extent of family history that warrants such interventions, but
for illustrative purposes we have applied family history
criteria adopted by the British Society of Gastroenterology
and the Association of Coloproctology of Great Britain and
Ireland (two FDRs with colorectal cancer, or one FDR
diagnosed under 45 years).' Using these family history
criteria, we identified a group of interviewees who merited
colonoscopic surveillance. We then re-evaluated the risk
categorisation of these individuals based on validated family
history data following record linkage.
Again, cases and controls were considered together. In
order to gauge the overall impact of inaccurate or incomplete
reporting on surveillance recommendations, cases and con¬
trols were considered simply as consultands, rather than
eases meriting postsurgical surveillance following their own
personal history of colorectal cancer. At interview, five of the
interviewees reported a family history that met criteria
indicating a need for surveillance. However, only two of
these five families were confirmed by record linkage to meet
these criteria, giving an overall positive predictive value of
0.400 (95% CI 0.118, 0.769). In addition, four further
consultands who did not report a family history of colorectal
cancer fulfilling criteria actually did have such a family
history based on record linkage data. Therefore, only two of
six consultands who should have been recommended for
surveillance were identified at interview, suggesting that the
sensitivity of interview in terms identifying appropriate
individuals for surveillance is 0.333 (95% CI 0.097, 0.700).
DISCUSSION
This study has quantified the accuracy of reported family
history of cancer in two important groups of people—namely,
those with colorectal cancer and those from the general
population. Because we confirmed eases reported to have
colorectal cancer and also identified eases that had not been
reported by the interviewee, we have been able to system¬
atically assess overall accuracy of reported family history of
large bowel malignancy.
Using this approach we have determined the accuracy of
reporting of colorectal cancer in a large data set comprising
332 interviewees and 5637 first and second degree relatives.
We showed conclusively that substantial underreporting of
cancer family history is evident in reports made at interview.
In this study, the family history documentation was optimal
as a trained genetics nurse conducted interviews during a
lengthy consultation at the interviewee's home. Reporting
inaccuracies may be more extreme where family history is
taken in a busy gastroenterology, surgical, or general practice
clinic.
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Table 3 Sensitivity of interview as a means of identifying familial cancer cases, by site
No of cases correctly Sensitivity of interviewee
Site Relative group No of cases* reported report (95% CI)
Colorectal FDR 70 39 0.557 (0.441, 0.668)
Colorectal SDR 78 23 0.295 (0.205, 0.404)
Breast FDR 28 21 0.750 (0.566, 0.873)
Breast SDR 37 11 0.297 (0.175, 0.458)
Bronchus and lung FDR 66 37 0.561 (0.441,0.674)
Bronchus and lung SDR 67 10 0.149 (0.083, 0.2531
Stomach FDR 30 12 0.400 (0.246, 0.5771
Stomach SDR 64 11 0.172(0.099, 0.2821
'Where more than one primary cancer occurred at the same site, it was not possible to determine whether the
interviewee was aware of both of these tumours. Therefore, where metachronous primary cancers occurred, only
the first is considered.
FDR, first degree relatives; SDR, second degree relatives; 95% CI, 95% confidence interval.
A comparable approach to assessing accuracy of reporting
of colorectal cancer, which includes identification of unre¬
ported cases as well as checking the accuracy of cases
reported at interview, has been employed in one previous
study.' This study estimated the sensitivity of reporting a
family history of colorectal cancer in FDRs as 0.65 (95% CI
0.39, 0.85) for colon cancer cases and 0.81 (95% CI 0.54, 0.95)
for controls, and the authors concluded that subjects were
able to accurately report family history.' However, this
previous study did not consider SDRs, and no information
is provided regarding the total number of relatives involved.
Furthermore, the focus of this paper was on validation of an
epidemiological study. The observed values for sensitivity of
reporting may be less acceptable for genetic risk assessment
where the objective is to determine the need for clinical
intervention, particularly given the wide confidence intervals.
In general, there is a distinct lack of quality data regarding
the accuracy of reporting of family history of colorectal cancer
at interview, and the impact of inaccuracy and under¬
reporting on genetic risk assessment has not been evaluated.
The current study is thus highly relevant, particularly given
the current increase in public demand for information on
genetic risk.
We did not observe any difference in the accuracy of family
history reporting in cases compared with controls. Similarly,
age and sex of interviewee had no significant effect on
accuracy. Clearly, the accuracy of reporting of family history
by colorectal cancer cases is an important consideration as
cancer occurrence is frequently the first point of contact with
a particular family. This study addresses the hypothesis that
individuals who have had colorectal cancer may be more
likely than controls to provide false positive reports of the
condition in their relatives. However, we found no evidence
to support this hypothesis as there were 21 false positive
reports among 199 cases compared with 11 false positive
reports among 133 interviewed controls.
Table 1 shows that interviewees could provide no useful
information for approximately half of all SDRs but did have
some knowledge of the health status of all but approximately
5% of FDRs. This consistent disparity suggests that many
instances in which cancer in SDRs goes unreported arc due to
lack of contact with relatives, rather than ignorance of
diagnosis in a known family member. The observation that
positive predictive value is similar in FDRs and SDRs lends
further support to this notion. Clearly, one would expect that
interviewees would have greater knowledge about FDRs, and
would be more likely to receive and maintain knowledge of a
cancer diagnosis from such close family. Disparity between
FDRs and SDRs is evident throughout this study, and is
consistent with findings from other published studies.7~'°
There is some potential for bias within this study but we
feel that the effect of such bias is minimal. The total
proportion of potential participants who declined to take part
in the study, or did not respond to a letter of invitation, was
less than 20%. False positive and false negative rates were
low for the record linkage process that we used, emphasising
the overall validity of our approach. Spouses of cases may be
more aware of their own family history of colorectal cancer
than the general population, although any such effect would
only apply to a small proportion of control subjects. Some
mismatching may have occurred, and a proportion of
relatives, probably approximately 10%, may have been
untraceable. This latter effect would theoretically lead to an
underestimation of the positive predictive value. However, no
cases and only one control subject reported colorectal cancer
in a relative reported to live abroad or deemed to be
untraceable, and consequently this effect will have little
influence on the reported results.
The accuracy and completeness of cancer registry data
itself is a crucial consideration for any study that uses such a
resource to validate or confirm diagnoses. The Scottish
Cancer Registry was initiated in 1958, and ascertainment
was considered to be suboptimal prior to 1968. Although
ascertainment of any registry is unlikely to reach 100%,
methods of ascertainment have steadily improved since this
time, and the Scottish Cancer Registry is considered to be
reasonably complete in recent years and to compare
favourably with other registries." An evaluation of the
accuracy of colorectal cancer registration data found that
while misclassifications do occur at a low level, such data
exhibit a high degree of accuracy." Colorectal cancer cases
occurring prior to the availability of an effective cancer
registry were only identified by this study if this malignancy
was recorded as a cause of death. Again, this is unlikely to
introduce systematic bias, but may have resulted in a slight
underestimation of the positive predictive value. Overall,
therefore, we consider record linkage with the Scottish
Cancer Registry to constitute a reliable and valid means of
determining the actual cancer experience of our study
subjects. The intermediate use of central records to confirm
or correct reported information and to extend knowledge of
pedigrees was essential to ensure that study data were of
sufficiently high quality for record linkage.
From a clinical perspective, the information provided aboul
the family as a whole is more important than the accuracy of
individual reports. The observation in this study that only
two of six families who actually met surveillance criteria were
identified at interview is a particular concern, implying that
reliance on interview data in a clinical context could result in
many families who actually meet criteria for significant
family history being overlooked. Conversely, of five families
reported at interview to meet the chosen criteria, only two
were confirmed by record linkage to meet this classification.
In practice, such an effect could lead to surveillance being
wvAv.gutjnl.com
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applied unnecessarily. While the numbers involved are too
low to provide a conclusive assessment of the clinical utility
of family history information reported at interview, our
results illustrate that incomplete or inaccurate interviewee
reporting could have a substantial impact on genetic risk
assessment.
The appropriate family history criteria for offering genetic
counselling, colonoscopic surveillance, or genetic testing is
the subject of much current debate, and is likely to remain so.
The findings of our study are highly relevant to this
discussion, as they suggest that family history information
obtained by interview may be misleading, and that verifica¬
tion of both positive and negative interviewee reports should
be conducted whenever possible.
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Appendix A6 Contingency Tables for Reporting of Colorectal
Cancer
(i) First degree relatives of Cases
Confirmed
Yes No
Reported Yes 30 13 43
No 23 1256 1279
53 1269 1322
Sensitivity = 0.566 (95% CI = 0.433,0.690)
Specificity = 0.990 (95% CI = 0.983,0.994)
Positive Predictive Value = 0.698 (95% CI = 0.549,0.814)
Negative Predictive Value = 0.982 (95% CI = 0.973,0.988)


























Sensitivity = 0.271 (95% CI = 0.166,0.410)
Specificity = 0.996 (95% CI = 0.992,0.998)
Positive Predictive Value = 0.619 (95% CI =
Negative Predictive Value = 0.982 (95% CI =
0.388,0.837)
= 0.985,0.996)












Sensitivity = 0.529 (95% CI = 0.310, 0.738)
Specificity = 0.995 (95% CI = 0.989,0.998)
Positive Predictive Value = 0.643 (95% CI =
Negative Predictive Value = 0.992 (95% CI =
Sensitivity = 0.333 (95% CI = 0.192,0.512)
Specificity = 0.995 (95% CI = 0.991,0.995)
Positive Predictive Value = 0.667 (95% CI = 0.417,0.848)
Negative Predictive Value = 0.985 (95% CI = 0.976,0.990)
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Appendix A7 Conceptual Model of Cascade Genetic Testing
The objective of this appendix is to present the conceptual model in the form of the
diagrams created and associated text. It is not feasible to display every element of the
conceptual model in this manner, but the following appendix does represent an
accurate and largely complete version of the conceptual model.
A7.1 Use Case View
A7.1.1 Overview
The use case view has been split into several "packages" in order to facilitate the
organisation and logical presentation of the model. The screenshot shown in figure
A7.1 illustrates the packages created, both in the browser view and in diagrammatic
form.
Figure A7.1 Overview of Packages Created in Use Case View
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Genetic Testing Test Results
For Help, press F1
The "Scot" actor is the only actor that is not included in a specific package, and is
therefore shown in the overview diagram. This actor represents any member of the
Scottish population that interacts with the cascade genetic testing system.
A7.1.2 Epidemiology Team Package
This package is designed to define the actors that are involved in actually running the
cascade genetic testing system.
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Genetic Nurse Coordinator Genealogist Lab Worker
A7.1.2.1 Actor: Epidemiologist
This actor is a generalised form of any member of the epidemiology team. The
epidemiology team is defined as anyone involved the ascertainment of potential index
cases, the genetic testing process, or the tracing and ascertainment of relatives of
index cases.
A7.1.2.2 Actor: Coordinator
The "coordinator" has the ultimate responsibility for overseeing the process of
ascertainment and genetic testing. It is the coordinator to whom at-risk individuals
will be referred, and to whom test results should be provided.
A7.1.2.3 Actor: Genetic Nurse
This actor is responsible for the initial interview (appointment) with an at-risk
individual, and also for taking a blood sample and sending it to the LabWorker.
A7.1.2.4 Actor: Lab Worker
The LabWorker is responsible for genetic testing, from the point they receive a
sample to the point where they provide the test results to the coordinator.
A7.1.2.5 Actor: Genealogist
Not a real person, but provides a useful way ofmodelling the process of tracing




The ascertainment package contains the actors and use cases involved in the process
of identifying Scots who are eligible to participate in the cascade genetic testing
system, and including them in the system subject to consent.




(from Use Case View)
Cancer diagnosis Registry Manager
Cancer registration
AscertainConsent Coordinator Update EC waiting list
(from EpidemiologyTeam)
Update genetic nurse waiting list
A7.1.3.1 Actor: Doctor
This actor is representative of all health professionals involved in the identification of
colorectal cancer cases. In reality, this would comprise GPs, Coloproctologists,
Pathologists etc, but for the purposes of the model system one actor is sufficient. The
main tasks of this actor are to diagnose new colorectal cancer cases and provide the
relevant details of these cases to the registry manager.
A7.1.3.2 Use Case: Cancer Diagnosis
Documentation: This use case is initiated when a "Scot" is diagnosed with colorectal
cancer. Details of this diagnosis are passed on to the Registry Manager. The actual
process of cancer diagnosis could be modelled (and indeed was in early versions), but
this is not necessary for the purposes of the model.
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Figure A7.4 Sequence Diagram: Cancer Diagnosis
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Figure A7.5 Collaboration Diagram: Cancer Diagnosis:
2: diagnose
>
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Flow ofEvents: Cancer Diagnosis
1.1 Preconditions
A colorectal cancer must have developed in the "Scot" in question. This will occur




The Use Case begins when a Scot presents to the healthcare system with colorectal
cancer. This may be a symptomatic self-referral to a GP, an emergency presentation at
a hospital, or the outcome of a screening program such as Faecal Occult Blood
Testing; the detail is not relevant to the model. Similarly, diagnoses made at post¬
mortem are included at this stage, since all tumours should be reported to the cancer
registry regardless of the clinical situation.
The "Doctor" actor will process the personal and clinical information relating to the
case and will make an official diagnosis of colorectal cancer. This information will
then be passed on to the registry manager.
1.3 Sub-flows
1.4 Alternative flows
N.B. Since the actual occurrence of colorectal cancer is essential to initiate this use
case, alternative diagnoses are not considered in the model.
E-l: The tumour is mis-diagnosed. The individual in question will not be registered as
having colorectal cancer at this point, although they may re-present at a later stage.
E-2: The tumour is diagnosed correctly, but details are not passed on to the registry
manager. The individual in question will not be registered as having colorectal cancer
and will take no further part in the model system.
A7.1.3.3 Actor: Registry Manager
The Registry Manager is the hypothetical person responsible for maintaining the
cancer registry. This is sufficient for the model system, but is an over-simplification
of reality, in which the process ofmaintaining and updating the Scottish Cancer
Registry is complex and involves many different individuals and groups.
A7.1.3.4 Use Case: Cancer Registration
Documentation: This use case describes the creation of a colorectal cancer registry
(beginning with no entries since all "Scots" are assumed to be cancer-free when the
cascade genetic testing system is initiated). The registry will record new cases, and the
Epidemiology Coordinator will have access to this resource to identify individuals
who are aligible for cascade genetic testing.
This process ensures that the epidemiology coordinator becomes aware of each
potential index case that is eligible for the cascade genetic testing programme,
regardless ofwhether the patient themselves have any contact with the system.
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Figure A7.7 Collaboration Diagram: Cancer Registration
Flow of Events: Cancer Registration
1.1 Preconditions
The "CancerDiagnosis" Use Case must have successfully completed.
1.2 Main Flow
Information relating to a new colorectal cancer case is processed by the registry
manager. This data is then added to the Scottish Cancer Registry.
1.3 Sub-flows
1.4 Alternative flows
E-l: The relevant information is not added to the Scottish Cancer Registry, or is
entered wrongly. This would be an extremely rare occurrence due to clerical error. In
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this event, the colorectal cancer case would not be recorded and the individual
concerned would take no further part in the system.
A7.1.3.5 Use Case: Update EC Waiting List
Documentation: The epidemiology coordinator will have access to the Scottish
Cancer Registry and will update the waiting list of eligible colorectal cancer cases
from this source.
Figure A7.8 Sequence Diagram: Update EC Waiting List
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Flow ofEvents: Update EC Waiting List
1.1 Preconditions
The Cancer Registration use case must be working correctly, and a new colorectal
cancer case must have occurred.
1.2 Main Flow
The Coordinatorwill access the Scottish Cancer Registry and obtain information on
each new colorectal cancer case. They will apply the age limits specified for the
cascade genetic testing system. If a colorectal cancer case is identified as falling
within these limits, the S-l: Add to Waiting List sub-flow is initiated. If the case is
above the upper limit, the S-2: Exclude From System sub-flow is followed.
1.3 Sub-flows
S-l: Add to Waiting List
Personal and clinical data relating to this individual are collated and they are added to
the EC waiting list.
S-2: Exclude From System
The case in question is not added to the EC waiting list, and takes no further part in
the system.
1.4 Alternative flows
A7.1.3.6 Use Case: Ascertainment Consent
Documentation: The "Consent" use case is a vital one, and can be adapted to several
similar situations in the model. At various stages in the model system, the "Scot" in
question will be asked to give their consent to proceed to the next stage. The
probability that this consent will be forthcoming will be defined by an "Acceptance"
look-up table. The principal stages at which consent must be obtained are as follows:
(i) Ascertainment: Consent to participate in the system by attending an interview with
the genetic nurse
(ii) Recruitment: Consent to undergo genetic testing
(iii) Tracing Relatives: Consent to allow family members to be contacted in
connection with the cascade genetic testing programme
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Figure A7.10 Sequence Diagram: Ascertainment Consent
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Flow ofEvents: Ascertainment Consent
1.1 Preconditions
The "Ascertain Invitation" use case must have been completed successfully.
1.2 Main Flow
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This use case is begun by a "Scot" who has developed colorectal cancer, upon receipt
of an invitation letter from the Coordinator asking them to participate in the cascade
genetic testing programme by attending an interview with a genetic nurse. The Scot in
question will study the information pack and then consider whether to take part. They
will then complete a "consent form" specifying their decision. If they agree to take
part the S-l: Accept sub-flow will be applied, if they do not the S-2: Decline sub-flow
will be used.
This protocol (invitation - information - consideration - decision) is written on the
assumption that the approach will be made by mail, but it is equally valid if contact is
made through health care professionals (e.g. research nurses). In either case, the
"consent form" represents an expression of desire, or otherwise, to participate, and is
not necessarily a formal or legal form.
1.3 Sub-flows
S-l: Accept
The Scot is prepared to participate in the next stage of the cascade genetic testing
system (i.e. attend a genetic nurse interview), and completes a consent form to that
effect.
S-2: Decline
The Scot does not wish to participate in the next stage of the cascade genetic testing
system, and completes a consent form to that effect.
1.4 Alternative flows
E-l: The Scot does not respond to the invitation. This can occur at any stage, as there
is no guarantee that a definitive decision will be reached at interview. In this scenario
the individual in question is assumed to have declined the invitation and accordingly
takes no further part in the system.
A7.1.3.7 Use Case: Update Genetic Nurse Waiting List
Documentation: This use case is initiated by the epidemiology coordinator. When an
eligible colorectal cancer patient accepts an invitation to participate in the cascade
genetic testing system (this acceptance does not necessarily include genetic testing),
the epidemiology coordinator will add their name and details to the genetic nurse
waiting list. The genetic nurse will have access to this list and will use it to identify
interviewees and arrange appointments with them.
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Flow of Events: Update Genetic Nurse Waiting List
1.1 Preconditions
The "Consent" Use Case relating to the ascertainment of colorectal cancer cases must
have executed; i.e. the Scot in question must have given consent to attend an
appointment with a genetic nurse
1.2 Main Flow
This use case begins when the Epidemiology Coordinator identifies a colorectal
cancer case that meets the criteria for genetic testing, and has consented to attend a
genetic nurse interview. Relevant data on this individual, including name, date of
birth, date of diagnosis etc. must be collated and processed, and then recorded in the





The recruitment package includes all use case and actors involved with the process of
recruiting an eligible Scot to the cascade genetic testing programme, and offering
genetic testing.
Figure A7.14 Recruitment: Use Case Diagram









Update non specific waiting list Update specific waiting list
A7.1.4.1 Use Case: Recruitment Interview
Documentation: This use case describes the process of an interview with a Scot who
is eligible for genetic testing, as conducted by a GeneticsNurse. The Scot may be a
potential index case or a relative of a known mutation carrier.
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Figure A7.15 Sequence Diagram: Recruitment Interview
2- 2













Figure A7.16 Collaboration Diagram: Recruitment Interview
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Flow ofEvents: Recruitment Interview
1.1 Preconditions
The Update genetic nurse waiting list use case must be working correctly, and there
must be at least one new entry on this list.
1.2 Main Flow
The use case is initiated by the genetic nurse. Details of an eligible Scot are obtained
from the genetic nurse waiting list. The genetic nurse will then arrange a time and
venue for the interview, and the Scot in question will attend this appointment. During
the interview, more information will be provided to the Scot about the cascade genetic
testing programme, and they will be invited to participate further by undergoing a




E-l: The Scot does not attend the interview. Another appointment will usually be
made, and if that is not attended the individual in question will be removed from the
genetic nurse waiting list and will take no further part in the system.
E-2: The Scot decides not to attend the interview and informs the genetic nurse of
this. Either another appointment will be made, or they will be removed from the
genetic nurse waiting list, according to their wishes.
A7.1.4.2 Use Case: Recruitment Consent
Documentation: The "Consent" use case is a vital one, and can be adapted to several
similar situations in the model. At various stages in the model system, the "Scot" in
question will be asked to give their consent to proceed to the next stage. The
probability that this consent will be forthcoming will be defined by an "Acceptance"
look-up table. The principal stages at which consent must be obtained are as follows:
(i) Ascertainment: Consent to participate in the system by attending an interview with
the genetic nurse
(ii) Recruitment: Consent to undergo genetic testing
(iii) Tracing Relatives: Consent to allow family members to be contacted in
connenction with the cascade genetic testing programme
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Figure A7.18 Collaboration Diagram: Recruitment Interview
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Flow ofEvents: Recruit Consent
1.1 Preconditions
The "Recruit Invitation" use case must have been completed successfully.
1.2 Main Flow
This use case is begun by a "Scot" who has developed colorectal cancer, upon being
invited to undergo genetic testing by a genetic nurse. The Scot in question will study
the information pack (i.e. obtain and process the relevant information from the genetic
nurse) and then consider whether to take part. They will then complete a "consent
form" specifying their decision. If they agree to take part the S-l: Accept sub-flow
will be applied, if they do not the S-2: Decline sub-flow will be used. The "consent
form" represents an expression of desire, or otherwise, to participate, and is not
necessarily a formal or legal form.
1.3 Sub-flows
S-l: Accept
The Scot is prepared to participate in the next stage of the cascade genetic testing
system (i.e. undergo genetic testing), and completes a consent form to that effect.
S-2: Decline
The Scot does not wish to participate in the next stage of the cascade genetic testing
system, and completes a consent form to that effect.
1.4 Alternativeflows
E-l: The Scot does not respond to the invitation. This can occur whether the invitation
is made by post or in person, as there is no guarantee that a definitive decision will be
reached at interview. In this scenario the individual in question is assumed to have
declined the invitation and accordingly takes no further part in the system.
A7.1.4.3 Use Case: Obtain Sample
Documentation: this use case describes the process of obtaining a blood sample from
a recruit, in order to conduct genetic testing. The DNA sample is originally obtained
at the recruitment stage by the genetic nurse. It is then passed on to the Lab Worker,
who will perform the appropriate genetic test.
458












Flow of Events: Obtain Sample
1.1 Preconditions
The S-l: Consent to Testing sub-flow of the Recruitlnterview use case must have
executed, and the S-l Accept sub-flow of the RecruitConsent use case must also have
been successfully completed.
1.2 Main Flow
The Scot will supply a blood sample for the purpose of genetic testing.
1.3 Sub-flows
1.4 Alternative flows
A7.1.4.4 Use Case: Update Non-Specific Waiting List
Documentation: This use case is initiated by the genetic nurse. When a potential index
case (i.e. a colorectal cancer patient who meets the specified criteria for inclusion in
the cascade genetic testing system) accepts the invitation to undergo genetic testing,
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their details will be placed on this waiting list and the blood sample that they provided
willbe sent to the Lab Worker. The non-specific test, or "mutation analysis" will then
be performed in due course, with the time-scale dependent on the specified time
needed to perform such a test and the resources available.

















Figure A7.22 Collaboration Diagram: Update Non-Specific Waiting List
: Lab Worker
Flow of Events: Update Non-Specific Waiting List
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1.1 Preconditions
The S-l: Accept sub-flow of the Consent use case must have executed in the context
of recruitment of a potential index case by a genetic nurse (i.e. a Scot with colorectal
cancer must have consented to undergo genetic testing). The Obtain Sample use case
must also have completed.
1.2 Main Flow
The Genetic Nurse will update the relevant Scotlnformation with information
obtained at the recruitment interview. The updated information will then be added to
the non-specific waiting list. The blood sample will also be sent to the LabWorker.
1.3 Sub-flows
1.4 Alternative flows
N.B. Since this use case is controlled entirely within the cascade genetic testing
system it will be assumed to operate correctly.
A7.1.4.5 Use Case: Update Specific Waiting List
Documentation: This use case is initiated by the genetic nurse. When a relative of a
known mutation carrier accepts the invitation to undergo genetic testing, their details
will be placed on this waiting list and the blood sample that they provided will be sent
to the Lab Worker. The specific test will then be performed in due course, with the
time-scale dependent on the specified time needed to perform such a test and the
resources available.
Figure A7.23 Sequence Diagram: Update Specific Waiting List
A A
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Figure A7.24 Collaboration Diagram: Update Specific Waiting List
Flow of Events: Update Specific Waiting List
1.1 Preconditions
The S-l: Accept sub-flow of the Consent use case must have executed in the context
of recruitment of a relative of a known mutation carriers by a genetic nurse (i.e. such a
relative must have consented to undergo genetic testing). The Obtain Sample use case
must also have completed.
1.2 Main Flow
The Genetic Nurse will update the relevant Scotlnformation with information
obtained at the recruitment interview. This updated information will then be added to
the specific test waiting list. The blood sample will then be sent to the LabWorker.
1.3 Sub-flows
1.4 Alternative flows
N.B. Since this use case is controlled entirely within the cascade genetic testing
system it will be assumed to operate correctly.
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A7.1.5 Genetic Testing Package
This package contains all use cases and actors involved in the process of conducting a
genetic test.
Figure A7.25 Use Case Diagram: Genetic Testing Overview
Update non specific waiting list
(from Recruitment)







A7.1.5.1 Use Case: Conduct Test
Documentation: The process of conducting the required molecular analyses. For
relatives of known carriers this will consist of a test for a specific mutation. For
suspected index cases this will consist of the analysis protocol defined as part of the
model. These two options will have very different test characteristics (sensitivity etc.),
and should probably be recorded in the flow of events as two distinct sub-flows.
Details of these analyses will vary according to the variables set by the model.




















Flow ofEvents: Conduct test
1.1 Preconditions
The main flow of the Send Sample use case must have completed
1.2 Main Flow
The molecular analyses will be undertaken by the LabWorker. When the
BloodSample in question has come from a potential index case, the S-l "Mutation
Analysis" sub-flow will be performed. When it has come from a relative of a known
index case the S-2 "Specific Test" subflow will be performed.
1.3 Sub-flows
S-l: Mutation Analysis
When the BloodSample is from a suspected index case with no known carrier
relatives, mutation analysis will be carried to investigate whether or not a mutation is
present. The required AnalysisProtocol, and the associated test parameters, will be
defined by the user of the model.
S-2: Specific Test
When the Blood Sample is from a relative of a known mutation carrier, the only test
required will be a simple PCR-based test to determine if the relative has the same
mutation. If they do not it will not be necessary to conduct more detailed mutation
analysis: the individual will be classified as test negative. Because of the simple
nature of this test, sensitivity and specificity will be very high, but flexibility in this
respect should be built into the model regardless.
1.4 Alternative flows
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A.7.1.6 Test Results Package
This packages contains actors and use cases relating to the processing and
communication of genetic test results






Update genealogist waiting list
A7.1.6.1 Use Case: Present Results
Documentation: In this use case, the results referred to are the actual product of
molecular analysis. This includes the actual sequence ofDNA, plus the results of any
other relevant tests that may be applied in the specific protocol used by the model
system. Obviously, the most important information will be details of any potential
mutations.
(from EpidemiologyTeam)
Figure A7.29 Sequence Diagram: Present Results
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Flow of Events: Present Results
1.1 Preconditions
One of the sub-flows of the Conduct Test use case must have executed (i.e. a Scot
must have undergone genetic testing).
1.2 Main Flow
The molecular data arising from the genetic test will be collated, processed, and
presented to the Co-ordinator. The co-ordinator will then interpret the results and will
record the molecular data in a Molecular Database.
1.3 Sub-flows
1.4 Alternative flows
A7.1.6.2 Use case: Communicate Genetic Risk
Documentation: This use case describes the communication of the genetic testing
results to the tested individual, their coloproctologist, and the genealogist responsible
for tracing relatives, if appropriate.
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Figure A7.31 Sequence Diagram: Communicate Genetic Risk
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Flow ofEvents: Communicate Genetic Risk
1.1 Preconditions
The Present Results use case must have been successfully completed.
1.2 Main Flow
The coordinator will study the molecular data arising from a genetic test, and will
assign a test result on this basis. If a pathogenic mismatch repair gene mutation is
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evident, the S-l "assign carrier status" subflow will be performed. Ifno such mutation
is found, the S-2 "reassure" sub-flow will be performed.
1.3 Sub-flows
S-l: Assign Carrier Status
The molecular data indicates that the Scot in question carries a MMR gene mutation.
The Scot will be informed of this and offered genetic counselling and clinical
surveillance. They will also be eligible for the next stage of the cascade genetic testing
system, i.e. relative tracing.
S-2: Reassure
The molecular data does not indicate the presence of a MMR gene mutation. The Scot
in question will therefore be reassured in this regard. It should be emphasized that
failure to find a mutation does not necessarily mean that they, or their family, are not
at increased genetic risk. Family history information etc. must also be taken into
consideration when making decisions regarding clinical surveillance. However, the
Scot will be considered mutation-free for the purposes of cascade genetic testing, and
will take n further part in the system.
1.4 Alternative flows
E-l: The test may be inconclusive, in which case it will be repeated or the S-2 sub-
flow will be applied with added emphasis on the possibility of the Scot being at
increased genetic risk.
A7.1.6.3 Use Case: Update Genealogist Waiting List
Documentation: This use case is initiated by the epidemiology coordinator. When a
MMR gene mutation carrier is identified (positive genetic test), the epidemiology
coordinator will add this information to the genealogist waiting list. The genealogist
will have access to this list and will use it to identify interviewees and arrange
appointments with them.




















Flow ofEvents: Update Genealogist Waiting List
1.1 Preconditions
The S-l: Assign Carrier Status sub-flow of the Communicate Genetic Risk use case
must have been successfully completed.
1.2 Main Flow
This use case begins when a new mutation carrier has been identified, and is initiated
by the Coordinator. Relevant data on this carrier, including name, date of birth, details




A7.1.7 Relative Tracing Package
This package is concerned with process of identifying relatives of a newly identified
mutation carrier who are eligible for genetic testing.
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Figure A7.35 Use Case Diagram: Relative Tracing
o





Scot Tracing consent Genealogist
Validate family info
(from Use Case View) (from EpidemiologyTeam)
Update EC waiting list
(from Ascertainment)
A7.1.7.1 Use Case: Trace Consent
Documentation: The "Consent" use case is a vital one, and can be adapted to several
similar situations in the model. At various stages in the model system, the "Scot" in
question will be asked to give their consent to proceed to the next stage. The
probability that this consent will be forthcoming will be defined by an "Acceptance"
look-up table. The principal stages at which consent must be obtained are as follows:
(i) Ascertainment: Consent to participate in the system by attending an interview with
the genetic nurse
(ii) Recruitment: Consent to undergo genetic testing
(i) Tracing Relatives: Consent to allow family members to be contacted in
connenction with the cascade genetic testing programme
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Flow of Events: Tracing Consent
1.1 Preconditions
The "Recruit Invitation" use case must have been completed successfully.
1.2 Main Flow
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This use case is begun by a "Scot" who has developed colorectal cancer, upon being
invited to undergo genetic testing by a genetic nurse. The Scot in question will study
the infonnation pack (i.e. obtain and process the relevant information from the genetic
nurse) and then consider whether to take part. They will then complete a "consent
form" specifying their decision. If they agree to take part the S-l: Accept sub-flow
will be applied, if they do not the S-2: Decline sub-flow will be used. The "consent
form" represents an expression of desire, or otherwise, to participate, and is not
necessarily a formal or legal form.
1.3 Sub-flows
S-l: Accept
The Scot is prepared to participate in the next stage of the cascade genetic testing
system (i.e. allow contact with relatives), and completes a consent form to that effect.
S-2: Decline
The Scot does not wish to participate in the next stage of the cascade genetic testing
system, and completes a consent form to that effect.
1.4 Alternative flows
E-l: The Scot does not respond to the invitation. This can occur whether the invitation
is made by post or in person, as there is no guarantee that a definitive decision will be
reached at interview. In this scenario the individual in question is assumed to have
declined the invitation and accordingly takes no further part in the system.
A7.1.7.2 Use Case: Validate Family Info
Documentation: This use case is concerned with the further investigation and
validation of relative information, using such death records, registry entries and
medical notes as may be used under ethical regulations.
Figure A7.38 Sequence Diagram: Validate Family Info
o
... : Familv : Central










Figure A7.39 Collaboration Diagram: Validate Family Info







Flow ofEvents: Validate Family Info
1.1 Preconditions
The S-l: Assign Carrier Status sub-flow of the communicate genetic risk use case
must have been completed, and the Update Genealogist Waiting List use case must
working correctly (i.e. a new mutation carrier must have been identified and
information on this carrier must have been passed to the genalogist).
1.2 Main Flow
Using the central records such as records ofbirths, deaths and marriage, the
genealogist will undertake to extend and verify the family history information
provided by the Scot in question at the genetic nurse interview. Based on all
information sources available under ethical regulations, the genealogist will then
construct a pedigree for that individual.
1.3 Sub-flows
1.4 Alternative flows
1: process 2: link
> : Family >
History
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A7.2 Logical (Class) View
A7.2.1 Class Diagrams
Figure A7.40 Overview of Logical View
Figure A7.41 Class Diagram: DataLists Package
5
Scot








Figure A7.42 Class Diagram: PeopleData Package
o
Scot
(from Use Case View)
A





Figure A7.44 Class Diagram: Participation Package
Invitation
Scot











Figure A7.45 Class Diagram: Tests Package




















The classes used in the conceptual model, along with their attributes, operation and
documentation, are presented below. Documentation was written for many attributes
and operations, but was not used consistently, and is therefore not presented in this
appendix.










Documentation: This class refers to all centrally held records in Sotland, including
details ofbirths, marriages, deaths and health-related information. Because these
databases can be linked by ISD they can be treated as one souce of information, or







Documentation: This database contains all molecular results of genetic testing, linked






Documentation: This class refers to the Scottish Cancer Registry, which will provide





Documentation: This is a boundary class, that has the capability to maintain the
cancer registry. This is a vital feature of the model, but in real life will take place










Documentation: This class provides the capacity to update waiting lists and present
information on waiting lists and times to the system for display in the GUI.
















Documentation: This class represents the personal information on all "Scots" who are


















Documentation: This class contains, for each genetic test performed, the resulting
molecular data. This may include sequence data, or the results of various other tests.






Documentation: This class contains the specifications for inclusion criteria for the
following groups: 1. Referrals, 2. Relatives







Documentation: This class represents an invitation to participate in the next stage of





Documentation: This class represents the information provided for participants about
the cascade genetic testing programme. In reality, this will be provided at counselling
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sessions as well as printed material, but for the purposes of the model it can be








Documentation: This class represents any interview that takes place during






Documentation: A member of the consent form class will represent the
communication of a Scot's decision regarding whether or not to progress to the next
stage of the cascade genetic testing system. This may be done as an actual form, or by







Documentation: This class comprises all the blood sample objects relating to each





%?\ab techniques : Long
Oapply()
Documentation: This class contains all relevant information on the parameters of the
test being applied. These include sensitivity and specificity, and will be entered via




Documentation: This class is the subset ofAnalysisProtocol that is concerned with
testing for specific mutations in relatives of known earners.Attributes and Operations
are defined at the higher AnalysisProtocol level.
Mutation Analysis
MutationAnalysis
Documentation: This class is the subset ofAnalysisProtocol that is concerned with
mutation analysis in suspected index cases. Attributes and Operations are defined at
the higher AnalysisProtocol level.










Documentation: This boundary class enables the results of genetic testing to be
displayed by the system.





Documentation: This class contains the pedigree information for each individual who
has undergone genetic testing. By definition of the cascade screening process, these
pedigrees will overlap considerably, so it may not be necessary to have a specific file
for every carrier. However, the relevant data should be obtainable.
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Appendix A8 Acceptance Rates Look-up Table
Age Sex Relationship Probability of Probability of Probability of Probability of
group Allowing Attending Genetics Accepting Pre- Allowing
Contact Nurse Interview symptomatic Relative Contact
test
0-4 M Pat ent 0.90 0.90 0.90 0.90
5-9 M Pat ent 0.90 0.90 0.90 0.90
10-14 M Pat ent 0.90 0.90 0.90 0.90
15-19 M Pat ent 0.90 0.90 0.90 0.90
20-24 M Pat ent 0.90 0.90 0.90 0.90
25-29 M Pat ent 0.90 0.90 0.90 0.90
30-34 M Pat ent 0.90 0.90 0.90 0.90
35-39 M Pat ent 0.90 0.90 0.90 0.90
40-44 M Pat ent 0.90 0.90 0.90 0.90
45-49 M Pat ent 0.90 0.90 0.90 0.90
50-54 M Pat ent 0.90 0.90 0.90 0.90
55-59 M Pat ent 0.90 0.90 0.90 0.90
60-64 M Pat ent 0.90 0.90 0.90 0.90
65-69 M Pat ent 0.90 0.90 0.90 0.90
70-74 M Pat ent 0.90 0.90 0.90 0.90
75-79 M Pat ent 0.90 0.90 0.90 0.90
80-84 M Pat ent 0.90 0.90 0.90 0.90
>85 M Pat ent 0.90 0.90 0.90 0.90
0-4 F Pat ent 0.90 0.90 0.90 0.90
5-9 F Pat ent 0.90 0.90 0.90 0.90
10-14 F Pat ent 0.90 0.90 0.90 0.90
15-19 F Pat ent 0.90 0.90 0.90 0.90
20-24 F Pat ent 0.90 0.90 0.90 0.90
25-29 F Pat ent 0.90 0.90 0.90 0.90
30-34 F Pat ent 0.90 0.90 0.90 0.90
35-39 F Pat ent 0.90 0.90 0.90 0.90
40-44 F Pat ent 0.90 0.90 0.90 0.90
45-49 F Pat ent 0.90 0.90 0.90 0.90
50-54 F Pat ent 0.90 0.90 0.90 0.90
55-59 F Pat ent 0.90 0.90 0.90 0.90
60-64 F Pat ent 0.90 0.90 0.90 0.90
65-69 F Pat ent 0.90 0.90 0.90 0.90
70-74 F Pat ent 0.90 0.90 0.90 0.90
75-79 F Pat ent 0.90 0.90 0.90 0.90
80-84 F Pat ent 0.90 0.90 0.90 0.90
>85 F Pat ent 0.90 0.90 0.90 0.90
0-4 M FDR 0.90 0.90 0.90 0.90
5-9 M FDR 0.90 0.90 0.90 0.90
10-14 M FDR 0.90 0.90 0.90 0.90
15-19 M FDR 0.90 0.90 0.90 0.90
20-24 M FDR 0.90 0.90 0.90 0.90
25-29 M FDR 0.90 0.90 0.90 0.90
30-34 M FDR 0.90 0.90 0.90 0.90
35-39 M FDR 0.90 0.90 0.90 0.90
40-44 M FDR 0.90 0.90 0.90 0.90
45-49 M FDR 0.90 0.90 0.90 0.90
50-54 M FDR 0.90 0.90 0.90 0.90
55-59 M FDR 0.90 0.90 0.90 0.90
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